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ABSTRACT 
Background: Hospital drug formularies are developed in order to support safe, 
effective and cost-effective prescribing. Their utilisation is based on the 
assumption that prescribers and other users will follow guidance outlined within 
them. The role of formulary users’ attitudes has been largely overlooked in the 
research literature. The nature and impact of attitudes to formularies on 
influencing prescribing practice have not been fully investigated. This study 
seeks to address this issue through a local practice based research project.  
Objectives: To determine the attitudes and experiences of users and key 
stakeholders with the utilisation of a new formulary at a local hospital trust. 
Methodology: Semi-structured interviews were conducted exploring the views 
of doctors, pharmacists and non-medical prescribers. An online self-completion 
questionnaire was sent to all key stakeholders. In addition prescribing data was 
also extracted from the Pharmacy computer system to assess impact of the 
new formulary. Data collection was thus split into two phases with modifications 
made to the formulary based on preliminary findings and emerging themes.  
Results: The local formulary symbolises a ‘critical split’ in the approach to 
resource management and patient care. Pharmacists are ‘closely bound’ to the 
formulary, relying on it for retrospective decision-support and ultimately seen to 
improve pharmacists’ autonomy while prescribers consider it to be over-
rationalisation eroding their professional autonomy. Although the quantitative 
data in this study demonstrates a statistically significant improvement in doctors’ 
perceptions of using the formulary, the distinct divide between doctors’ and 
pharmacists’ attitudes towards the formulary remained. Prescribing data 
extracted showed no significant impact of the formulary on prescribing practice.  
Conclusion: The study confirms the existence of deeper sociological 
constructs, particularly concerning autonomy and professionalism. Doctors 
claim an ability to manage uncertainty during patient consultations while 
pharmacists claim to be drug ‘experts’. The monopoly on drug knowledge is 
therefore contested ground. This study concludes that both the formulary and 
the pharmacy profession need to be more influential, and embrace a more 
‘humanised-bureaucracy.’ It is recommended that pharmacists build on a new 
philosophical union with the formulary and focus on asserting their claim and 
dominance on the monopoly of drug knowledge.  
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Chapter 1 
Introduction 
 
1.1 Overview 
Section 1 comprises Chapters 1, 2 and 3. Chapter 1 broadly addresses the 
political and clinical context in which prescribing is carried out within the United 
Kingdom (UK) and briefly introduces the rationale for the present study. 
Chapters 2 and 3 will explore some of the less salient characteristics of the 
prescribing arena while drawing on practice-based examples from the author's 
own professional experience as a Senior Formulary Pharmacist at East and 
North Hertfordshire NHS Trust. It is hoped that these practice-based examples 
will help illustrate key concepts and articulate the practice-based problem that 
underpins the rationale for the research. Since these examples were originally 
the subject of critical reflections, they will be presented in the first-person 
narrative in order to maintain authenticity.  
Section 2 will then turn to the study itself beginning, in Chapter 4, with a 
description of the 'Prescribing Guide', a new hospital drug formulary at East and 
North Hertfordshire NHS Trust.  
 
1.2 Medicines in the National Health Service  
Expenditure on the National Health Service (NHS) has risen consistently since it 
was established on 5th July 1948. In its first full year of operation, the 
Government spent £11.4bn on the NHS. Sixty years later, in 2008/9, spending 
on health in the UK witnessed an approximate ten-fold increase to over £100bn 
far outpacing the rise in both Gross Domestic Profit (GDP) and total public 
expenditure (Harker, 2011; NHS Choices, 2011).  
While the NHS has recently enjoyed “record levels” of investment, it would 
appear the tides are now changing. Amidst new and pressing health challenges 
plus increasing demands, the previous Government had announced “the rate of 
growth will not be as great from now on and for the foreseeable future” (DH, 
2008, page 23). Compounding the situation further, the current economic 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 17 
 
recession has also taken its toll on public finances. As a result of these factors, 
the NHS is now, instead, required to produce ‘efficiency savings’ in the region of 
£20bn by the end of 2013/14 (Hughes and Thorp, 2010; BBC, 2010).  
In the emerging picture then, it is not so surprising that a principal concern of 
many NHS organisations is whether or not they will finish the year within budget 
(Malson and Wang, 2009). The impact on the NHS means even greater 
rationing of limited resources – a largely undesirable situation yet necessary.  
It is often cited that within the NHS, the prescription of medicines is the most 
frequent therapeutic intervention and therefore constitutes a significant cost 
burden to the allocated healthcare budget (NPC, 2011; Picton and Quinn, 
2011). For instance, in 2010, the overall NHS expenditure on medicines alone 
was £12.9 billion, with a 31.7% spent solely on hospital prescriptions – a 
significant increase (30.9%) in hospital prescribing from the previous year (The 
NHS Information Centre, 2010). As Jenkings and Barber (2004) explain, since 
the use of medicines represents the area of healthcare for which the most 
scientific evidence exists, it is therefore also subject to control using the 
principles of scientific rationality and represents the current era of ‘evidence-
based medicine’.  
 
1.3 The rise of evidence-based medicine 
In addition to and indeed as a consequence of being the principal therapeutic 
intervention, the ‘quality’ of drug prescribing has been called a “foundation 
stone” for high quality patient care (NPC, 2011). The importance of quality here 
could be clarified in terms of Cribb and Barber’s (1997) notion of ‘good 
prescribing’. In summary this refers to a combination of: “what the patient 
wants”; the “greater good” – referring to a consideration of ‘cost’ in a national 
utilitarian system such as the NHS; and the “technical / rational”, that is, the 
scientific measurement of specific features of medicines – a reference to the 
‘evidence’ of clinical effectiveness (Barber, 2004, page 450).  
The term ‘evidence-based medicine’ was popularised after Sackett et al’s 
(1996, page 71) notable definition of the term: 
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 “Evidence-based medicine is the conscientious, explicit, and 
judicious use of current best evidence in making decisions about 
the care of individual patients. The practice of evidence based 
medicine means integrating individual clinical expertise with the 
best available external clinical evidence from systematic research.” 
 
The use of robust evidence-base is now, to a great extent, considered a 
hallmark of good quality prescribing (NPC, 2011b). Whether clinical guidelines 
originate from independent Medical Royal Colleges or from the National 
Institute of Health and Clinical Excellence (NICE)1 – an arms-length body of the 
Government – evidence-based medicine invariably informs these guidelines 
and provides a rationale for decision-making. The prescriber’s ‘choice’ to 
prescribe a particular medicine is – as a result of this relatively new evidence-
based medicine ‘movement’ – now subject to being “judged against evidence 
accumulated in the world’s literature” (Maxwell, 2005, page 331).  
At the point of prescribing however, the arduous tasks of first ‘familiarising one’s 
self with-’, and second ‘summoning’ the required evidence-based decision-
making, has been discussed before (Allen and Harkins, 2005). Excessive 
guidance especially in the form of unfiltered and non-localised information only 
complicates matters further (Maxwell, 2005). As a partial solution, local 
decision-making concerning prescribing and the rationing of drugs and the drug 
budget is more and more supported by the concept of ‘medicines management’, 
a process by which a wide range of medicines-related activities are co-
ordinated throughout the NHS.  
 
1.4 The medicines management strategy 
Ninety-seven percent of hospitalised patients are prescribed medicines and 
82% are prescribed four or more different preparations (Healthcare 
Commission, 2007). Clearly there is a need to ensure the appropriate, effective 
prescription, administration and ongoing management of medicines. The Audit 
                                                          
1
 The National Institute of Health and Clinical Excellence (NICE) is one of the Department of 
Health’s arms length bodies. NICE provides guidance  and makes recommendations to the 
NHS on new and existing medicines, treatments and procedures. It also sets quality standards 
of healthcare that people can expect to receive. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 19 
 
Commission (2001, page 5), in their original review a decade ago, defined 
medicines management as: 
 “the entire way in which medicines are selected, procured, 
delivered, prescribed, administered and reviewed to optimise the 
contribution that medicines make to producing informed and 
desired outcomes of patient care.” 
 
The previous Government released, in two phases, the Medicines Management 
Framework which enabled trusts in England to conduct self-assessments 
establishing current practices and highlighting where improvements were 
necessary. In addition, the initiative looked to clarify to Trust Chief Executives 
and Chief Pharmacists, their responsibilities regarding the use of medicines 
within their trusts and the related health economy (DH, 2003). One such 
responsibility and focus is on the rigorous application of a local ‘hospital drug 
formulary’ – widely recognised as “the cornerstone of effective medicines 
management” (Khan, 2002; Audit Commission, 2001, page 16). 
 
1.5 Formularies as key medicines management tools 
The Medicines Management Framework emphasised that “formularies should 
not be lists of drugs stocked but working documents incorporating national and 
locally agreed prescribing policies and guidelines” (DH, 2003, page 8).  
To implement formularies and to “maximise the health and economic outcomes 
achieved via drug use”, it is considered “pivotal” by the World Health 
Organisation (WHO), for hospitals to operate under a specific model (Tan et al, 
2005, page 527). This model manifests in practice as local, multi-disciplinary 
Drug and Therapeutics Committees (DTC), responsible for promoting rational 
use of medicines including the control of the introduction of new medicines 
within a specific prescribing locality (Williams and Bryan, 2007).  
The previous Government had established a specific objective for formularies 
and medicines management initiatives: “to promote therapeutic consistency 
across the local health economy” (DH, 2003, page 8). The significance of the 
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‘local health economy’ can be understood through the following statistics: in 
1994 the Audit Commission estimated that one prescription issued from 
secondary care directly resulted in seven or eight in primary care (Prosser and 
Walley, 2005). More recently, secondary care is reported to influence up to 40% 
of the drugs prescribed in primary care (Hill, 2005). In light of this, to provide 
seamless care at the primary / secondary care interface, establishing ‘joint 
formularies’2 is conceptually ideal. However, in the numerous cases where this 
is not a feasible reality, inclusion of Primary Care Trust (PCT) representation on 
secondary care DTCs is vital in order to develop comprehensive and 
representative formularies. Along with other measures such as effective 
discharge planning, these services can all lead to appropriate use of finances, 
less wastage of medicines and improving patient care (NPC, 2002).  
As Hill (2005, page 441) states, through primary and secondary care 
collaboration, the aim of the local formulary is to produce a “greater familiarity 
with a limited range of drugs” which itself facilitates safe, effective and economic 
prescribing. This collaboration involves multidisciplinary engagement, that is, a 
bringing together of the specific skill sets of different professional practitioners 
not only across the care sectors but particularly in secondary care, where new 
drug therapies are often initiated. 
 
1.6 The relationship between formularies and healthcare professions 
In the secondary care setting, doctors, pharmacists and nurses, through various 
roles each contribute to the medicines management strategy. Doctors with full 
registration who hold a licence to practice may prescribe all medicines. While 
interprofessional collaboration is widely sought and encouraged, doctors often 
work from their own limited lists of medicines, referred to as ‘personal 
formularies’ or ‘evoked sets’ (Robertson et al, 2001; Denig and Haaijer-
Ruskamp, 1983). Such personal preferences will at times inevitably be at odds 
with locally developed hospital formularies. Groves et al (2002) advise formulary 
                                                          
2
 A joint formulary is developed for users in both and primary and secondary care. It typically 
involves clinicians forming specific ‘working groups’ in order to systematically develop individual 
sections of the formulary. A key aim is to develop greater consistency in prescribing across the 
primary / secondary care interface and minimising errors associated with the transition of 
patients from one sector to the other.  
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managers to pursue strategies to influence ‘adoption’ of locally approved 
medicines to these evoked sets and similarly the ‘relinquishment’ of non-
preferred medicines.  
Turning now, from prescribers to “recognised” drug experts (DH, 2008, page 
27), ‘clinical pharmacists’ were first identified, by the Nuffield Report in 1986 
and then in a 1988 Health Circular, as being able to provide important 
pharmaceutical advice and promote cost-effective prescribing (Fitzpatrick et al, 
2001). Formularies soon became a practical medium to capture this advice as a 
way of improving prescribing practice (Khan, 2002). Pharmacists’ participation 
on ward rounds has been shown to reduce medication errors and prescribing 
costs (Fertleman et al, 2005). In the 2008 White Paper, ‘Pharmacy in England’, 
the Government stated that already highly trained pharmacists had greatly 
expanded their clinical knowledge and expertise (DH, 2008). The introduction of 
the ‘Consultant Pharmacist’ post symbolises the specialist aspirations that 
clinical pharmacists are developing in both clinical and managed service roles 
(DH, 2005).  
Armed with such expertise on medicines, pharmacists’ primary role is to 
optimise drug therapy either at the point of prescribing, or by liaising with 
prescribers at a later opportunity or through developing medicines management 
services such as the formulary. Schumock et al (2004, page 557) explain, “the 
effectiveness of strategies to control the quality and cost of medication use is 
largely dependent on the ability to alter the selection of medications”. The 
authors go on to discuss how clinical pharmacists, doctors and formulary 
committee members are each themselves influenced by a range of factors that 
affect their individual, independent decision-making processes (Schumock et al, 
2004).  
In summary, although these healthcare professionals are involved in delivering 
various aspects of the same overarching medicines management agenda, each 
profession is also engaged in some manner of perpetual adaptation and 
development resulting from furthering professional aspirations or due to various 
other factors including socio-economic, cultural developments and technological 
innovations (McDonald et al, 2010). 
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1.7 The overlooked role of attitudes in formulary development 
In the current literature, there are only a few reports of multidisciplinary 
engagement in preparing and operating hospital drug formularies (Sutters, 
1990; Tugwell et al, 1984). The literature is replete with often opposing and 
disgruntled sentiments arising from within the medical professional community 
(Kwan, 2005; Goodwin, 2003; Rucker and Schiff, 1990; ISMP, 2005). While 
there are reports of potential “misconceptions” associated with formularies 
(Rucker and Schiff, 1990, page 59; ISMP, 2005), there are no ‘in depth’ 
critiques of the potential origins of such attitudes towards formularies or where 
perspectives are divergent. Instead only rudimentary descriptions, often framed 
as complaints about an allegedly ‘restrictive’ nature of formulary operation are 
aired. Any studies in the field that ‘do’ aim to investigate the impact of 
formularies have focused exclusively on the ability of formularies to reduce drug 
expenditure (Pearce and Begg, 1992; Petrie and Scott, 1987). Furthermore, the 
historical overview of formulary evolution, presented in Chapter 3, demonstrates 
that thus far the attitudes and perceptions of key stakeholders have not been 
incorporated into the design, implementation and operation of formularies.  
Chapters 2 and 3 will use practice-based examples to illustrate how such 
attitudes and perceptions of key stakeholders manifest in local prescribing 
practice – often with specific reference to the local formulary. Critically, 
alongside these examples, established change management principles and 
broader sociological understandings will assist in the analysis of key cases.  
 
1.8 Summary of Chapter 1 
This chapter introduces some of the fundamental, more readily discernible 
aspects connected with drug therapy in the UK. For instance, the significant 
cost pressure that prescribing brings to the overall NHS expenditure was 
illustrated. The ‘movement’ known as evidence-based medicine was defined 
and understood as a means to effectively control the quality of prescribing 
based on the application of scientific rationality.  
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The notion of medicines management, a largely government-driven initiative, 
was also introduced. Seamless care at the primary / secondary care interface 
can be facilitated through the rigorous application of a hospital drug formulary, 
which is widely recognised in both government and non-government 
publications, as the ‘cornerstone’ of effective medicines management. 
This chapter briefly introduces the rationale for the current practice-based study 
which is further explored using practice-based examples in Chapters 2 and 3. 
Essentially attitudes and perceptions towards formularies have thus far been 
neglected and overlooked. Although relatively simplistic and anecdotal reports 
are present in the current literature, no in depth studies have been designed to 
investigate the origins and impact of such attitudes on formulary operation.  
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Chapter 2 
The Professional Arena 
 
2.1 Introduction 
This chapter will begin with a detached exploration of the relevant principles of 
sociology with an increasing focus on ‘professionalism’ in the healthcare arena. 
Practice-based examples are then presented to illustrate how such principles 
can be drawn upon to understand the interactions between healthcare 
professionals involved in drug therapy. 
Secondary care prescribing typically takes place within highly complicated, 
resource-constrained and localised settings. Central to this complexity are the 
ways in which professional predispositions and attitudes impact on specific 
aspects of the prescribing process. In many cases markedly different 
approaches to patient care taken by doctors and pharmacists often fuel 
considerable debate. The nature of debate often varies from a highly inclusive, 
skill-mixing and collaborative approach to one of damaging disagreement, 
conflict and on occasion, outright rejection of recommendations made by those 
perceived to be the ‘other’. The sociological framework facilitates an initial 
understanding of how doctors and pharmacists interact around issues 
concerning prescribing practice.  
 
2.2 Sociology of professionalism 
Sociology is an academic discipline involving the scientific study of the human 
world, whole societies and social groups (Taylor et al, 2003; Giddens, 2009). 
One area of sociological enquiry – the ‘academic’ study (distinguishing from 
more ‘colloquial’ use) of the ‘professions’ – has drawn considerable debate over 
many decades. For the purposes of the present research, the definition outlined 
by Macdonald (1995, page 1) will be adopted, that is, professions as: 
“occupations based on advanced, or complex, or esoteric, or arcane 
knowledge”. 
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Since the early nineteenth century, a number of perspectives in sociology have 
been formulated that – despite advocating distinctly unique tenets – display 
varying degrees of overlap and have sought to understand the interactions 
between social structures and individual behaviours. 
 
2.2.1 Sociological perspectives used to understand the professions 
In the mid-twentieth century, ‘functionalism’ provided an early model to 
conceptualise the division of labour and occupational groups in modern society. 
This perspective endorses the view that society operates through a degree of 
interdependence on groups of individuals performing different tasks much like a 
living organism is dependent upon the functioning of various physiological 
systems (Taylor et al, 2003; Giddens, 2009). Functionalism supported the 
‘attribute’ or ‘trait’ approach to defining professions, listing features of an 
occupation that would raise its status to that of a profession (Table 1).  
A 1960s variation of functionalist theory, ‘structural-functionalism’, stressed in 
particular how socially functional traits ultimately led to ‘social cohesion’ 
(Giddens, 2009). Structural-functionalists attributed the stability of the “most 
important features of our society to...the smooth functioning of the professions” 
(Parsons, 1939, page 457). In fact, Macdonald (1995, page 2) describes ‘praise’ 
for the professions, at the time, as reaching a level of “uncriticality that is hard to 
credit”.  
1. A profession determines its own standards of education and training 
2. The student professional undergoes an extensive training and socialisation 
process 
3. Professional practice is legally recognised by some form of licensure 
4. Licensing and admission is regulated by members of the profession 
5. Most legislation which affects a profession is shaped by that profession 
6. A profession has high income, power and status, and can demand higher 
calibre entrants 
7. The professional is relatively free from lay evaluation 
8. The norms of practice enforced by the profession are often more stringent than 
legal controls 
9. Members of a profession have a powerful sense of identification and affiliation 
with their occupational group 
10. A profession is likely to be a lifetime occupation 
  
Table 1. Attributes of an ‘ideal’ profession (Taylor et al, 2003) 
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An alternative sociological perspective known as ‘symbolic interactionism’ has 
also been employed in the understanding of the professions (Macdonald, 1995; 
Giddens, 2009). Typically studies focus on individual and group interactions, 
language and meaning (Giddens, 2009). Research revealed that qualities once 
thought to be purely professional in nature, such as altruism, service and high 
ethical standards were now being described as present in all members of 
society. The ‘traits’, originally used to define professions, were deemed 
ideological in nature and even ‘mythological’ as Macdonald (1995, page 4) 
writes: 
 “Trainee physicians were portrayed as developing cynicism rather 
than altruism, doctors appeared as wielders of power, not servants 
of the social good...” 
 
It was this school of thought that gave birth to the ‘power’ approach to study the 
professions. Freidson describes the process by which the State grants 
professions the license and mandate to control their work ultimately manifesting 
as ‘dominance’ over kindred occupations and thereby preventing interference or 
supervision (Macdonald, 1995).  
At this juncture, an important division in sociological thought ought to be 
clarified. Particularly with functionalism, there was an emphasis on ‘consensus’ 
within society. For instance, Durkheim posited that in order for society to have a 
continued existence, the significant institutions – for example, the political 
system, educational system, and the professions – must work in harmony with 
one another and thus implies a general consensus (Giddens, 2009). The 
‘conflict theorists’ criticise and reject this assumption. The alternative 
perspective they express focuses on the ‘divisions’ in society and as a result, 
demonstrate the existence of issues around power inequality and struggle. 
Therefore, different groups of individuals essentially pursue interests relevant to 
themselves and thus the potential for conflict with other groups is always 
present (Giddens, 2009).  
Marxism, a notable conflict theory, is concerned with the relationship between 
producer and consumer of professional services (Harrison and McDonald, 
2008). The extent to which the producer can control this relationship and 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 27 
 
subsequently benefit from it are of interest. With reference to the medical 
profession’s autonomy, Marxian thought has, for instance, led to theories of 
medicine being subordinated to demands and requirements of ‘production’ in 
order to maximise capitalists’ profits (Harrison and McDonald, 2008). Critics of 
this view argue that the medical profession:  
 “cannot be equated with... proletarianisation3...since proletarians 
do not have supervision over others, do not have some space for 
decision making, do not realise mental rather than manual work, 
and do not have skills that need to be credentialed by the state” 
(Navarro in Harrison and McDonald, 2008, page 48). 
 
The thesis of ‘proletarianisation’ of the medical profession has also been 
dismissed by others (Freidson, 1985; Elston, 1991). In particular, Britten (2001), 
through her analysis of ‘prescribing autonomy’, concludes that while 
government intervention ‘has’ eroded doctors’ clinical freedom, the medical 
profession – nevertheless – “continues to dominate the clinical agenda and the 
responsibilities of other healthcare workers”. 
In the late 1960s, part of the sociological community, again, shifted focus from 
trying to ‘define’ professions to understanding the ‘circumstances’ in which 
people in an occupation attempt to turn it into a profession (Taylor et al, 2003). 
In 1977, Magalí Larson conceptualised the ‘professional project’ (Macdonald, 
1995). 
 
2.2.2 The ‘professional project’ 
Larson’s model – formulated on the basis of preceding works illustrating 
‘professional prestige’ and the involvement of the State – depicts how the 
interplay of a range of key factors leads to an occupation rising to the status of 
profession (Figure 1). The ‘professional project’ states that the ultimate goal for 
an occupation seeking professional status is ‘social closure’. Max Weber 
described this as an endeavour to become “a legally privileged group” where 
                                                          
3
 Proletarian – "connected with ordinary people who earn money by working, especially those 
who do not own any property" (Oxford University Press, 2011). 
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the occupation aims for a closed monopoly with “closure of social and economic 
opportunities to outsiders” (Macdonald, 1995, page 28).  
Therefore, according to Larson’s interpretation, professions are essentially 
monopolies of ‘specialist knowledge’ and thus of the professional status which it 
brings. If those who possess relatively ‘abstract’ knowledge are able to form a 
group and begin to standardise the dissemination of this knowledge, they will 
then be able to enter a ‘regulative bargain’ with the state (Macdonald, 1995). 
The state endorses the creation of a monopoly by allowing this group of 
individuals the ability to restrict access to their knowledge and thus control their 
market, all resulting in upward social mobility4.  
 
 
 
** Content removed for copyright reasons ** 
 
Reference: 
Macdonald KM. (1995). The Sociology of the Professions. London. SAGE 
Publications Ltd. (Page 32). 
  
 
 
 
Figure 1. Larson’s conceptualisation of the ‘professional project’ (adapted from Macdonald, 
1995 p32). 
 
 
 
 
 
 
                                                          
4
 Social mobility – in studying social stratification, social mobility refers to the movement of 
individuals and groups between different socio-economic positions. Those who gain in income 
or (professional) status are said to be upwardly mobile (Giddens, 2009). 
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2.2.3 Specialist knowledge as the essence of professionalism 
Taylor et al (2003) describe how occupations that aspire to attain a privileged 
status tend to present their knowledge-based services as esoteric and thus 
establish a ‘social distance’ from those served by them creating ‘mystification’ 
with their work.  
An important element of specialist knowledge, in terms of its application in 
practice, is ‘abstraction’. Abbott concluded that professional service routinely 
entails diagnosing, inferring and treating the problem presented – “the purely 
professional act” being inference (Macdonald, 1995, page 164). Therefore, the 
professional “believes what he is doing”, as Freidson describes it, even with 
uncertain chances of success (Taylor et al, 2003, page 117). However to 
exercise effective professional judgment, an equilibrium needs to be reached, 
between extreme abstraction and extreme concreteness.  
In 1970, Jamous and Peloille famously proposed the I/T ratio to express the 
‘degree’ of professionalism that an occupation possesses (Harrison and 
McDonald, 2008). A ‘true’ profession will score highly for indetermination (I), 
which represents personal judgement. Technicality (T) – knowledge that is 
codified, would be minimal. In order for a profession to remain at its privileged 
position in society, its work must not become rationalised and routinised, thus 
maintaining a high I/T ratio (Taylor et al, 2003). Freidson describes the “zone of 
discretion” as a key feature of medical practice explaining that even rank-and-
file doctors exercise more discretion over their work compared to other 
healthcare professionals (Crinson, 2007). In today’s world, however, knowledge 
is increasingly becoming codified and thus more accessible to the laity – this is 
widely recognised as a significant threat to the professions (Macdonald, 1995; 
Crinson, 2007). 
 
2.2.4 The Iron Cage of bureaucracy and its implications for professionalism 
Freidson (1994) states society involves the interaction of two radically different 
modes of organisation: ‘bureaucratisation’ and ‘professionalisation’. Robert 
Merton famously described the “dysfunctions of bureaucracy” noting that 
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bureaucrats are typically trained to adhere to predefined rules and procedures, 
essentially practicing ‘rigidity’, and lack any encouragement to use their own 
judgement (Giddens, 2009, page 787). What is of interest, as Macdonald (1995) 
explains, is that bureaucratisation may in fact be antithetical to professionalism 
insofar as it is fast becoming a dominant force in modern society and 
increasingly subsuming professionals into mere managerial roles. Weber 
notably stated, almost as an epilogue, that bureaucracy constituted an ‘Iron 
Cage’ from which we (society) cannot escape (Taylor et al, 2003). He was the 
first to document society’s tendency to move away from traditional beliefs such 
as religious customs and superstitions, instead embracing rational, instrumental 
calculations in an attempt to increase efficiency and to account for future 
consequences of their actions (Giddens, 2009). The advancement of science 
along with bureaucracy, Weber collectively termed ‘rationalisation’. Some now 
identify rationalisation – in its effort to systematically measure and control 
medical work – as a challenge to the continuing dominance and clinical freedom 
of the medical profession with healthcare systems (Crinson, 2007).  
 
2.3 Professionalism in healthcare 
In a typical NHS hospital a number of different occupations fulfil specific duties, 
without which, overall functioning would not be met, exemplifying the original 
tenets of functionalism. Table 2 shows some occupational definitions as they 
appear on the ‘NHS Choices’ website. 
Occupation Definition as appearing on ‘NHS Careers’ (2010) 
Doctors diagnose symptoms and recommend treatment in patients 
Pharmacists 
are experts in drugs and medicine and can be involved in all 
aspects of their use, preparation, discovery and development and 
the monitoring of effects 
Pharmacy 
technicians 
prepare and deliver drugs, store incoming drugs and make up 
sterile preparations 
Nurses 
works in a variety of settings to directly provide and manage the 
care directly of individual patients 
Physiotherapists 
treat the physical problems caused by accidents, illness and 
ageing, particularly those that affect the muscles, bones, heart, 
circulation and lungs 
Porter 
move patients between different departments and wards in safety 
and comfort and transport complex and valuable equipment that 
may need expert handling 
 
Table 2. Some occupations commonly found in hospitals (NHS Careers, 2010). 
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 Albeit a short description, the medical profession appears to completely 
engage in ‘inferential’ activity, that is, the “purely professional act” described by 
Abbott (Macdonald, 1995, page 164). For pharmacists, there is reference to the 
‘expertise’ they possess for “drugs and medicine”, thus a monopoly is implied 
however use of the word “preparation” alludes to somewhat technical activities. 
Pharmacy technicians are entirely defined in terms of their technical duties: 
“delivery”; “make up”. In Practice-based example 1, the role of doctors and non-
medical prescribers in prescribing practice is contrasted against the input of 
pharmacists. 
Practice-based example 1 
During a routine ward visit I was approached by a specialist Pain Nurse and 
requested to order the non-formulary drug, ‘Versatis (lidocaine) plasters’ for an 
elderly patient suffering from severe postherpetic neuralgia (PHN). The Elderly 
Care Consultant, under whose care the patient had been managed, had 
referred this aspect of the patient’s care to the Pain Team that consisted of an 
anaesthetist and two specialist Pain Nurses (non-medical prescribers). On 
reviewing the patient’s drug chart I noted that the patient had also been 
prescribed amitriptyline, gabapentin and opioid analgesics (morphine-based 
pain killers). I was aware that in many past cases of a similar nature, the 
established NICE guidelines for diabetic neuropathy are usually adopted for the 
pharmacological management of PHN. Therefore, other treatment options 
available were carbamazepine, duloxetine and capsaicin cream (all formulary-
approved items). An alternative to the requested, high-cost and non-formulary 
Versatis plaster was EMLA cream (another lidocaine-based product). On 
discussing these options with the Pain Nurse, the matter was escalated to the 
Elderly Care Consultant and the Anaesthetist. My Line Manager (Directorate 
Pharmacist for Formulary and Medicines Management) was contacted by the 
Anaesthetist and I was approached by the Elderly Care Consultant and the Pain 
Nurses during the subsequent ward visit (‘witnessed’ by the consultant’s team 
of doctors). Both consultants and Pain Nurses took notably resistive stances 
against the two pharmacists. They argued that they had in fact taken “all 
aspects of the patient’s care into account” and thus were able to make an 
“informed decision” and criticised pharmacists for being “all about cost” and 
unable to think about “the patient’s quality of life”. The Pain Nurses argued that 
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EMLA cream would not be pragmatic for ward nurses to apply and would be 
inconvenient for the patient since it would need to be applied far more 
frequently than the Versatis Plaster.  
Eventually EMLA cream was ‘reluctantly’ prescribed and supplied (with 
damaging consequences for the relationship between the formulary 
pharmacists and the Pain Team).  
 
In this incident the diagnostic expertise and inferential activity of prescribers 
(both consultants and non-medical prescribers) is illustrated. In addition, a 
strong defensive stance is also seen to be taken against forces that – counter to 
this ‘inferential activity’ – supported the adherence of established guidelines and 
local policy. Although such local protocols were ultimately enforced, 
pharmacists in this example appear to be greatly out-numbered and their 
advocacy of ‘cheaper’ formulary-approved alternatives roundly condemned. 
Both nursing and the medical profession are, through such ‘strength in 
numbers’, in a position to both defend their professional territory as well as 
expand their influence over new areas. In 2009, the estimated number of 
registered doctors was approximately 230,000; the number of nurses was 
estimated to be at least 400,000; and the estimated number of pharmacists 
approximately 45,000 (Chemist and Druggist, 2009). 
 
2.3.1 The medical profession 
Medicine has achieved a particularly prestigious status within society. Previous 
authors have gone as far as to state that the very interest in professionalism is 
an indication of how medicine is perceived by society (Jotkowitz and Glick, 
2009). Practice-based examples 2 and 3 embody aspects of such prestige for 
the medical community particularly where ‘expertise’ and ‘seniority’ are 
perceivable attributes. In example 2 the pharmacist appears to have a greater 
regard for the consultant’s decision to prescribe a non-formulary drug than she 
has for the decisions represented in the local formulary. Similarly example 3 
shows junior members of the medical team displaying a greater ‘allegiance’ for 
the ‘expertise’ of the consultant than for the Trust formulary. From both practice 
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cases, it appears that the concept of ‘social distance’ – as outlined by Taylor et 
al (2003) – may exist between consultants and those of kindred occupations or 
those subordinate to them in other ways (junior doctors). 
 
Practice-based example 2 
In the out-patients section of the Pharmacy department, an allocated 
pharmacist ‘clinically screens’ each out-patient prescription ensuring each drug 
is prescribed appropriately in terms of clinical accuracy (dose, frequency, 
duration of treatment etc.), safety (side effects, contra-indications) and locally 
acceptable (formulary-approved, most cost-effective option etc.). On this 
occasion, a junior pharmacist had clinically screened an out-patient prescription 
written by a consultant. The drug prescribed was Movicol – officially a ‘non-
formulary’ drug however stocks were routinely maintained in the Pharmacy 
department for restricted use in palliative care patients (an approved use). Once 
the prescription had been dispensed, I was ‘final checking’ before handing out 
to the patient and questioned the junior pharmacist as to its appropriateness. 
The junior replied, “I know this consultant, he always gets what he wants...I’m 
sure he knows more than me”. I encouraged the junior pharmacist to challenge 
the prescription and recommend a formulary-approved alternative provided the 
patient was not receiving palliative care.  
 
 
Practice-based example 3 
During a routine ward visit, I approached a Senior House Officer (SHO, now 
called FY2) regarding a drug that she had just prescribed. The drug was 
esomeprazole – the Trust’s third-line proton pump inhibitor (PPI), used for 
duodenal / gastric ulcers or gastro-oesophageal reflux disease (GORD). The 
doctor was immediately dismissive and very reluctant to continue the 
conversation. I explained there are other options that should be considered in 
the first instance and later also explained my position at the Trust (Senior 
Formulary Pharmacist). The SHO maintained her stance and asserted that in 
fact “my consultant told me to prescribe this so you can’t go higher than that”. I 
eventually offered to speak to the consultant and enforced a switch to 
omeprazole (the Trust’s formulary-approved first-line PPI). 
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It is widely cited that the medical profession has always maintained a close 
relationship with the State (Freidson, 1994; Macdonald, 1995; Elston, 1991). 
According to Weber’s notion of ‘social closure’ and certainly Larson’s 
conceptualisation of professional status, it is because of this relatively unique 
relationship that medicine has enjoyed a significant degree of autonomy to 
practice without interference and supervision. In fact the distinct feature of 
professionalism in modern western society is that members of a specialised 
occupation are able to control their ‘own’ work (Freidson, 1994). However, 
medicine has, rather anomalously, been able to extend this form of control 
beyond their own profession. Operating through the General Medical Council 
(GMC) and the British Medical Association (BMA) it was able to convince the 
government of the day to delay licensure to other occupations (Harrison and 
McDonald, 2008). The medical profession’s relationship with the state, 
described by Klein (1990, page 700) as a “mutual dependency”, evidently 
manifested as dominance over kindred occupations reflecting the core element 
of the aforementioned ‘power approach’ to understanding the professions.  
Practice-based example 4 reveals the apparent ‘discomfort’ experienced by 
doctors when attempts are instead made to control ‘their’ work for example, 
prescribing. Most notably the consultant displays an apparent rejection of the 
‘formulary concept’ altogether, uncovering tensions that are directed at the 
pharmacy profession. 
 
Practice-based example 4 
As an initial step in the development of the local hospital drug formulary, I sent 
out individualised lists of formulary-approved drugs to all consultants at the 
Trust. Drug lists displayed traffic lights for each drug depicting whether the drug 
is first-line (green), second-line (amber) or third-line (red) at the Trust (for 
example omeprazole, lansoprazole and esomeprazole, respectively). In 
response I received a telephone call from the Trust’s Lead Gastroenterologist 
who angrily objected to the development of a “standardised list to put on the 
computers”. He claimed that a “pharmacist-led formulary” will be “restrictive to 
practice” and that “clinical decisions made in front of individual patients cannot 
possibly be put into formularies”. I realised that one of my underlying 
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assumptions concerning the development of the local formulary was partially 
flawed. I had assumed that although consultants may not agree with a 
perceived ‘restrictive’ theme of formularies, they would at least support the 
underlying ‘purpose’ and ‘rationale’ for formularies. The consultant made clear 
that many of the ‘current’ traffic lights would need to change because he was 
“not prepared” to prescribe some drugs second-line or third-line but instead as 
and when he saw fit.  
 
Similarly Klein (1990, page 700) exposes the “tensions” and the “repetitive cycle 
of confrontation” between the medical profession and the State representing a 
somewhat distinct interpretation of this relationship in the literature. In particular, 
he cites two key areas that have caused “frustrations and resentment” between 
the two (Klein, 1990, page 700). Firstly, finance: doctors are concerned with 
their own pay as well as the availability of funds for more resources. Secondly, 
autonomy: government ministers can only achieve their priorities if they develop 
ways to influence clinical decision-making particularly concerning issues such 
as lengths of patient stay and drug expenditure (Klein, 1990).  
It was due to government recognition that GP numbers were starting to decline 
as fewer newly qualified doctors wished to purse general practice as a career, 
that the GP contract was renegotiated in 2003 and came into full effect in April 
2004 (Kmietowicz, 2006; Batty, 2003). The negotiations involving the BMA and 
the government’s NHS Confederation led to ‘out-of-hours’ care for patients 
being removed from the contract for a 6% cut in pay and through a new system 
to incentivise GPs and improve quality, the Quality and Outcomes Framework 
(QOF), GPs saw their earnings increase by approximately 30% (BBC, 2007; 
Kmietowicz, 2006). A BMA ballot at the time revealed that 80% of GPs 
supported the deal (Batty, 2003).   
However, the ‘repetitive cycle of confrontation’ between the profession and 
government ‘does’ appear to continue in more recent times as well. The NHS 
Confederation Chief Executive has recently alluded to the fact that the 
aforementioned removal of ‘out-of-hours’ care from the GP contract may have 
contributed to rising pressures on A&E departments (Lind, 2013). In fact the 
Health Secretary, Jeremy Hunt, has indicated that the contract needs to be 
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rewritten in order to once again include GP responsibility for “signing off” 
patients’ care out-of-hours. In response, the BMA has recently declared it has 
no confidence in the Health Secretary (Lind, 2013b). 
Britten (2001) outlined the three key challenges to the medical profession’s 
clinical autonomy. Referring specifically to ‘prescribing’, she discusses the 
impact of state interventions; the rise of a well-informed and educated patient 
population; and the challenge represented by other healthcare professionals. 
Pharmacists and nurses are either encroaching on the medical profession’s 
“exclusive right” to prescribe or, as in the case of pharmacists, are gradually 
being given more responsibilities with respect to the oversight of medication 
supply (in community pharmacy) as well as monitoring GPs’ prescribing through 
the work of ‘primary care pharmacists’. Britten in particular focuses on the 
theses of (a) ‘proletarianisation’ of the medical profession (mentioned in Section 
2.2.1) that is, subordination to the state or (b) the ‘deprofessionalisation’ of the 
medical profession arising from patient demand. Although acknowledging the 
impact of such influences on the autonomy of doctors, Britten notably concludes 
that while the prescribing arena is a “battleground on which the cause of clinical 
autonomy is defended”, the medical profession ultimately dominates the clinical 
agenda and neither of these theses can be applied in absolute terms to the 
medical profession. She does, however, allude to the notion that given the ever 
changing NHS, the advancing of prescribing rights and, critically, the continued 
involvement of the state, that doctors’ “clinical freedom will continue to be 
eroded” echoing Weber’s prediction of increasing rationalisation in society. 
   
2.3.2 The pharmacy profession 
The founding aims of the Pharmaceutical Society in 1841 were to: 
 “unite the profession into one body, to protect its members’ 
interests and to advance scientific knowledge.” 
 
Pharmacy obtained State licensure and then set up a register in 1852, 
restricting the practice of pharmacy to examined and registered people 
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(Harrison and McDonald, 2008; RPS, 2011). However since this time, notable 
'threats' to the profession have emerged.  
Building on the idea of rationalisation introduced by Max Weber, George Ritzer, 
an American sociologist, coined the term ‘McDonaldisation’ (Taylor et al, 2003). 
He believed that the policies and practices of fast-food restaurants (such as 
‘McDonald’s’), including highly efficient, routinised production and delivery, were 
now observable in other sectors of society including healthcare. This is evident 
in frustrations expressed by hospital pharmacists who seem to allude to a divide 
between their professional work and the demands of “bureaucrats” (PJ, 2009, 
page 586). One hospital pharmacist stated: 
 “We are probably at the stage where the governance aspect of our 
role is so great that we spend too much time doing paperwork...we 
just want to get on and do our job.” (PJ, 2009, page 586). 
 
 
Similar sentiments are illustrated in Practice-based example 5. Activities that 
contribute to ‘highly efficient, routinised production’ that characterises 
‘McDonaldisation’ are prioritised in the Directorate Pharmacist’s working 
agenda. The pharmacist expresses frustrations about not being able to practice 
as a “proper pharmacist” and the “limited clinical input” he routinely has for 
patients.  
 
Practice-based example 5 
During the early stages in the development of the new hospital drug formulary, I 
tried to arrange meetings with: consultants; specialist pharmacists (Directorate 
Pharmacists); and myself (Senior Formulary Pharmacist).  
For the gastroenterology chapter, after repeated attempts, such a meeting 
never transpired. In this case, it soon became apparent that there was in fact a 
breakdown in the relationship between the Directorate Pharmacist and the 
gastroenterologists. For the routine, bimonthly directorate meetings the 
consultants demanded an array of drug data to be extracted from the pharmacy 
computers – this was an established role within the remit of the Directorate 
Pharmacist who consistently failed to produce the data. On enquiring, the 
Directorate Pharmacist informed me that he was consistently “swamped” by 
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excessive paperwork (such as that required for directorate meetings) and extra 
ward rounds which meant that he had very little time “to be a proper pharmacist” 
for his patients and therefore carried out the bare minimum of ward-based 
duties, often hastily, and with “limited attention to detail” and “limited clinical 
input”. 
 
Hospital administrators typically support initiatives that seek to improve labour 
efficiency and reduce costs and do not necessarily support individual 
professional aspirations (Novek, 2000). The contribution to directorate meetings 
expected of the Directorate Pharmacist (Practice-based example 5) was the 
provision of drug data – any ‘expertise’ that pharmacists may possess was not 
sought by consultants.  
It would appear that the notion of ‘mutual dependency’ stated to exist between 
the medical profession and the state does ‘not’ exist – at least not to the same 
extent – between the pharmacy profession and the state. Instead, some 
hospital initiatives such as automation of dispensing have been commended by 
the Department of Health since it has been shown to “improve productivity, 
improve waiting times and reduce errors” while also advising “there is much that 
can be done to increase efficiency in the supply of medicines” (DH, 2008, page 
80).  
 
Practice-based example 6 
I had secured the support of Directorate Pharmacists for the compilation of 
clinical content for individual sections of the new hospital drug formulary. 
However, many Directorate Pharmacists consistently failed to provide me with 
the required information by mutually agreed deadline dates. I approached the 
Directorate Pharmacist for ‘Chapter 12: Ear, nose, and oropharynx’. She 
explained that her only problem was a severe lack of time to focus on clinical 
activities. She viewed contributing to the development of the hospital formulary 
as a ‘clinical’ role and expressed an enthusiastic desire to be involved by 
applying her critical appraisal skills to drug evaluation and by liaising with Ear, 
Nose and Throat (ENT) consultants in order to develop consensus-driven 
algorithms for common conditions claiming to have developed a good rapport 
with her medical counterparts. However, she was frustrated by the amount of 
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time she was required to spend around the “repetitive supply function” both on 
the wards and in the Pharmacy dispensary. She expressed concerns about 
being regarded by other professions as a “glorified technician” and about “losing 
professional credibility”.  
 
As with Practice-based example 5, example 6 also depicts a somewhat passive 
discontent with the status quo and with established ‘professional’ arrangements. 
Jamous and Peloille’s notion of the I/T ratio can be used to explain some 
aspects of this scenario. Professions tend to lose credibility at either extremes 
of abstractness or concreteness (Macdonald, 1995). The Directorate 
Pharmacist from the above example may regard the application of “her critical 
appraisal skills to drug evaluation” and development of “algorithms for common 
conditions” as activities that involve the exercise of judgement and 
‘indeterminacy’. However, it is clear that the pharmacist characterises her actual 
role as highly ‘technical’ in nature and resented the professions’ subsequent 
portrayal to other healthcare professionals.  
The ‘technical’ duties or over-rationalisation of pharmacy work depicted in 
example 6 is concerned with the ‘supply’ side of medicines management. 
Practice-based example 7 now illustrates an apparent divide in the approach to 
the ‘prescribing’ side of medicines management. Here, while pharmacists, in 
particular those in senior management, adopt a far more rationalised and 
codified approach to compiling prescribing advice for the new hospital drug 
formulary, many doctors instead appeared to support an opinion-oriented 
approach. Taylor et al (2003, page 117) summarise: “in order to remain 
exclusive to the members of the profession itself, its work must not become 
routinised or rationalised”. In example 7, the work of pharmacists – through the 
need to strictly adhere to guidelines and protocols – may be regarded as 
becoming routinised and rationalised.  
 
Practice-based example 7 
Novel features of the new ‘online’ hospital drug formulary were ‘Consultant 
buttons’ and ‘Pharmacist buttons’. It was originally hoped that consultants and 
Directorate Pharmacists would submit prescribing advice statements that would 
be accessible via these ‘buttons’ online. Such advice was expected to help 
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users in selecting the most appropriate treatment options for their patients since 
local ‘experts’ were providing their rationales for drug therapy.  
During meetings set up with consultants, in a large number of cases they 
frequently declined to provide such statements citing the sheer complexity of 
patient diagnosis and treatment. In other cases consultants often provided short 
paragraphs that clarified exactly how they chose one drug over the other. This 
sort of advice was invariably provided without references to any specific clinical 
studies or trials and nor did it refer to established guidelines such as NICE or 
Royal Colleges.  
At a routine meeting with the Chief Pharmacist and the Directorate Pharmacist 
for Formulary / Medicines Information, the comments submitted by consultants 
were criticised for being “isolated opinions” and lacking justification based on 
“established evidence” or “guidelines and protocols”.  
A sharp contrast in the approach to drug therapy and medicines management 
between the two groups of professionals was visible. Subsequent attempts to 
obtain ‘evidence-based’ statements from consultants failed as they were 
reluctant to spend time collating literature.  
As a result ‘Consultant buttons’ do not appear in the final version of the 
formulary. Instead, ‘Pharmacy buttons’ have been developed consisting of 
references to corresponding evidence-base.  
 
Pharmacists’ desires to relinquish responsibilities concerning technical duties 
and thus transitioning to more clinical roles have been expressed before 
(Plumridge, 1981; Novek, 2000). One significant development in recent times 
has been pharmacist (and nurse) supplementary and independent prescribing. 
It was the Department of Health’s commitment to improving access to 
medicines – outlined in ‘A Vision for Pharmacy in the new NHS’ in 2003 – that 
was the principal driving force behind the apparent fragmenting and dilution of 
the prescribing monopoly into the hands of ‘allied’ healthcare professionals. The 
medical profession took a particularly reactionary stance frequently voicing 
disapproval (BBC, 2005; Guardian, 2007; Martin, 2007). Doctors had deemed 
the recent development as “irresponsible and dangerous” and claimed that 
“patients will suffer” (BBC, 2005). Concerns about inadequate pharmacist and 
nurse training were often compared, publicly, to the “five or six years of training 
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every doctor has undertaken” and which results in the “highest level of care and 
prescribing...provided by a fully trained doctor” (Hall, 2011).  
 
Practice-based example 8 
A number of meetings I had arranged with consultants (in order to develop the 
clinical content for the hospital drug formulary) were particularly noteworthy. For 
example, on asking one of the Trust’s Cardiologists about developing an 
algorithm for the pharmacological management of arrhythmias (abnormal heart 
rhythms), she responded with, “I don’t think a pharmacist should be doing that 
at all, it should be a doctor.” She also questioned the need for such an algorithm 
and emphasised that, “that’s what we’re [Cardiologists] here for.”  
Similar opposition to the idea of developing such guidance was witnessed from 
the ENT consultant asked to help in developing a flow chart for the steroid 
preparations for nasal conditions. The Trust Ophthalmologist expressed his 
opposition to the development of a glaucoma algorithm. The Trust 
Dermatologist reacted particularly defensively to suggestions of rationalising the 
drug options or basal cell carcinoma (BCC). He further added, “who are we 
doing this for?...I don’t need to be policed by members of the formulary group 
[DTC].” 
 
From the perspective of the conflict theories, issues of ‘jurisdiction’ and 
monopoly over knowledge and practice help to explain both doctors’ reactions 
to non-medical prescribing and the seemingly defensive stance taken by 
doctors in Practice-based example 8. Macdonald (1995, page 15) states: 
 “It is the content of work and the control of work and the 
differentiation of work, which give rise to internal occupational 
divisions and to conflict with other occupations, conflict over 
jurisdiction.” 
 
In example 8, consultants may perceive pharmacists and the local DTC as 
encroaching on their professional territory with added attempts to rationalise 
their work. 
Pharmacists have also displayed similar protective dispositions over the control 
of their work. Novek (2000), for instance, examined the impact of automation on 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 42 
 
professional demarcations in three Canadian healthcare facilities. The study 
revealed that automation, in fact, reinforced professional demarcations with 
pharmacists attempting to maintain control over at least the ‘ordering’ aspect of 
the dispensing process, resisting doctors, nurses and even pharmacy 
technicians. The author concludes that pharmacists, in reality, perceived 
automation as a threat to their jobs and control of their drug expertise (Novek, 
2000). 
The government wishes to empower pharmacy technicians in order to facilitate 
more efficient healthcare delivery (DH, 2002). New legislation means regulation 
of pharmacists and pharmacy technicians is now under the same system as the 
demarcations between the two occupations blur, allowing pharmacy technicians 
the opportunity to expand into roles such as: taking medication histories; 
checking patients’ own medication; checking discharge medication (Nathan, 
2009; DH, 2002).  
Much of the literature discussing the professionalism of pharmacy relates to 
pharmacy’s more traditional place, that is, in community pharmacy. As Bush et 
al (2009) state, community pharmacies, due to their retail environment, will 
operate successfully only so long as they remain profitable. This inevitably 
causes internal unease within the professional between, on the one hand, the 
desire to provide a health service, and thus functioning as a ‘true’ profession, 
and on the other hand, the fundamental requirement to produce higher profit 
margins (Bush et al, 2009). Community pharmacists have been unable to 
capitalise on even state-sponsored professional reform, such as Medicine Use 
Reviews (MUR)5, partly due to the relative importance given to income targets 
over and above engaging with new services (McDonald et al, 2010). The 
Marxist perspective is applicable here with the pharmacist assuming the role of 
the producer and the patient as the consumer. Striving to achieve maximum 
profits, the community pharmacist runs the risk of being viewed as a ‘capitalist’ 
first, rather than a member of a profession whose sole focus is the patient’s 
welfare.  
                                                          
5
 Medicine Use Reviews (MUR) - is an Advanced service and is part of the NHS Community 
Pharmacy Contract. Undertaken by a pharmacist, it is a structured review that helps patients to 
better manage their own medication. It specifically targets the 'use' of patients' medication and 
helps to identify any potential issues e.g. side effects and provides feedback to the prescriber 
when necessary (PSNC, 2012).   
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Further studies in community pharmacy have shown that GPs’ attitudes towards 
pharmacists could also have mitigating effects on the professional status of 
pharmacy (Edmunds and Calnan, 2001; Hughes and McCann, 2003). Any 
accommodating attitudes expressed by GPs towards expanding community 
pharmacists’ roles are often tempered by GPs also displaying dominating 
dispositions attempting to ‘limit’ and ‘exclude’ pharmacists from clinical activities 
(Edmunds and Calnan, 2001). One study that attempted to capture the 
dynamics of collaboration between community pharmacy and general 
medicines found those GPs who appear to be disinterested in collaboration with 
community pharmacists express concerns about the perceived lack of training 
of pharmacists suggesting limited confidence in their ability (Bradley et al, 
2012). The study also shows the commercial aspect of community pharmacy 
was viewed “negatively and with suspicion” by some GPs.  
Specifically, Wilcock and Harding (2007) found GPs in general expressed 
“negative views” about community pharmacy-conducted MURs. Although 60% 
of GPs stated they ‘generally’ found pharmacists’ recommendations useful, only 
one-fifth considered the recommendations to be a priority. Similarly, the New 
Medicine Service (NMS), introduced to community pharmacies in England in 
2011, was set up to improve adherence to new medicines in patients with long 
term conditions. A study recently revealed that barriers to implementation of the 
NMS included a perceived lack of interest and awareness  by GPs despite 
briefings from local PCTs (Wells et al, 2013). Exploring pharmacists’ views and 
experiences, the study showed participants were concerned by the “lack of GP 
enthusiasm for pharmacy services”.  
Practice-based example 9 describes a consultant’s continued attempts to resist 
pharmacist interference with his drug decision, analogous to Edmunds and 
Calnan’s (2001) observations in primary care. Once the decision is enforced the 
consultant displays further frustrations towards the established bureaucratic 
procedure to prescribing non-formulary drugs.  
 
Practice-based example 9 
In the out-patients section of the Pharmacy department, a junior pharmacist 
clinically screened an out-patient prescription for azithromycin (an antibiotic) for 
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a patient suffering from bronchiectasis (a respiratory condition). The use of 
azithromycin in this way was considered non-formulary use and therefore not 
permitted at the Trust. The junior pharmacist had initially contacted the 
consultant to challenge the prescription however quickly succumbed to the 
demands of the consultant and thus (against established protocol) permitted the 
supply of a non-formulary drug. At the checking stage of the dispensing 
process, a second pharmacist (senior) brought the prescription to my attention. 
A brief review of the literature demonstrated weak evidence for the rationale 
and place in therapy for azithromycin in bronchiectasis with only case reports to 
support its use. After discussing the case with the original junior pharmacist, I 
then contacted the consultant to recommend an alternative or suggest 
reviewing the patient again. The consultant explained that this ought to be a 
decision made by an “expert”, that is, a professional who understands the 
patient’s individual circumstances. The patient had previously been tried on 
standard therapy for bronchiectasis and is only now responding to azithromycin 
(reduction sputum volume). In this case, after discussing with the Chief 
Pharmacist, it was agreed that as per formulary protocol, the consultant 
complete the necessary paperwork (‘fast-track’ application) for ‘one-off’ use and 
provide supporting material that justifies its use in practice. 
The reaction from the consultant was now more disapproving. He felt that his 
expertise was being questioned and that such a decision should not include the 
Pharmacy department or necessitate “bureaucratic” procedures. It appeared as 
if the consultant viewed the role of the pharmacist to comprise of no more than 
‘supply’ and in particular ‘without’ the need to critique his decision.  
 
While the medical profession is considered to have achieved a particularly 
elevated status in society, cases such as those described in Practice-based 
example 1 and 9 in fact demonstrate an awkward and uneasy dominance of 
‘rigid’ protocols and procedures that appear to be enforced by pharmacists. 
Since – as Macdonald (1995) states – bureaucratisation may be antithetical to 
professionalism, pharmacy’s status as a ‘true’ profession is at risk.  
Morgall and Almarsdóttir (1999) assert that pharmacy in Iceland has ‘lost’ its 
monopoly and outline three reasons for this: political encouragement to 
increase competition between the community pharmacies; political desire to cut 
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the total health budget; and internal divisions within the pharmacy profession 
itself. Certain elements discussed in the literature above appear to share some 
of the fundamental features of Morgall and Almarsdóttir’s (1999) findings. 
Perhaps there are lessons to be learnt from such studies if the professional 
status is, at the very least, to remain protected, if not enhanced.  
 
2.3.3 Established models to understand the doctor-pharmacist interaction 
A number of investigations have previously sought to explain, in particular, the 
factors affecting prescribing decisions (Brown et al, 1999; Groves et al, 2002; 
Greenfield et al, 2005; Plumridge, 1983; Armstrong et al, 1996). Although a 
professional agenda has not been openly explored in this field of prescribing 
research, there are, nevertheless, nuanced allusions to occupation-oriented 
thought processes involved in selecting one drug over another. Some of these 
investigations have focused on the interactions between doctors and 
pharmacists proposing models to understand their outcomes and interpret how 
they ultimately impact on drug selection. This section introduces the 
‘collaborative working relationship’ model, the ‘challenge model of change’ and 
‘Game Theory’. 
Doucette et al (2005) used the ‘Collaborative Working Relationships’ (CWR) 
model to guide an investigation of the influences on collaborative care between 
doctors and pharmacists. The model states that a number of variables affect the 
development of collaborative working and can be categorised into either: 
‘individual’, ‘context’ and ‘exchange’ characteristics. Using the CWR model, and 
data collected through a survey, the investigation revealed three variables were 
significantly associated with collaborative care between doctors and 
pharmacists: the context variable, ‘professional interaction’; and the exchange 
variables, ‘trustworthiness’ and ‘role specification’.  
The interaction between the consultant and various members of the Pharmacy 
department in Practice-based example 8 and 9 may have benefited if the 
findings from Doucette et al’s (2005) investigation were adopted. ‘Role 
specification’, for example, refers to the expectations each practitioner may hold 
about the other “based on past experiences, stereotypes and educational 
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backgrounds” (Doucette et al, 2005, page 571). The authors state that when 
pharmacists and doctors “jointly determine specific roles, the relationship is 
more likely to be collaborative.” It appears, according to this model, that 
consultants are unaware of the nature and quality of contribution that 
pharmacists are capable of making.  
Practice-based examples have so far demonstrated that individual healthcare 
professions will inevitably offer contrasting approaches to drug therapy. Given 
such differences, 'collaboration' can still yield clinically desirable outcomes. 
Armstrong et al (1996) explored GPs’ reasons for changes in their prescribing 
behaviour theorising the ‘challenge model for change’ to explain behaviour 
change that followed a conflictual clinical event. The authors state that while 
some changes in prescribing habits occur through “a gradual accumulation of 
cues” (medical literature, conferences, and consultants’ letters), this model 
highlights change that results from “immediate challenge” typically as a 
consequence of pharmacist intervention. The model emphasises the “very lack 
of preparedness that caused the rapid reassessment of prescribing policy” in 
GPs, thus averting potential “clinical disasters” (a dangerous drug interaction 
and a dangerously large dose of drug) (Armstrong et al, 1996). Practice-based 
example 10 describes a case to which this model can be applied to interpret the 
interaction. Upon the pharmacist’s intervention, the Specialist Registrar is 
subjected to a scenario where there is ‘immediate challenge’, he is arguably 
lacking ‘preparedness’ (unfamiliar with established Trust ‘Tramadol Guidelines’) 
and thus forced to engage in ‘rapid reassessment’ of his prescribing choice. 
Through ‘collaboration’, an alternative way forward is agreed upon. According to 
this model however, had the doctor been familiar with all aspects of the 
prescribing scenario, he may not have conceded to such a reassessment of his 
drug selection. 
 
Practice-based example 10 
While covering a colleague’s ward, I noticed the drug ‘tramadol’ newly 
prescribed on a patient’s drug chart. Tramadol is an opioid analgesic (pain 
killer) restricted at the Trust owing to its potential for dependence, side effects 
and interactions with various other drugs and higher cost. The established 
‘Tramadol Guidelines’ at the Trust recommend ‘codeine’ is used in the first 
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instance and to try laxatives if codeine causes constipation – if this combination 
fails, then tramadol is a suitable alternative.  
Since the Specialist Registrar (senior doctor under whose care the patient was 
managed), was present on the ward, I decided to approach him and discuss the 
potential switch to codeine. After making him aware of the current guidelines, 
the Registrar maintained his determination to use tramadol since he had 
experience of prescribing it successfully in previous patients. In addition the 
doctor reminded me of the patient’s presenting complaint (reason for admission 
to hospital) and co-morbidities so did not want to further complicate the patient’s 
care by having to manage constipation as well. 
Wanting to enforce the guidelines while also appreciating the patient’s clinical 
condition, I proposed switching to codeine for the time being and if the pain is 
not reduced within a 24 hours period, to switch to tramadol (thus minimising the 
risk of developing constipation and subsequent management). The Registrar 
readily agreed with this and was grateful for the understanding and flexibility 
shown.  
 
Another model to study the interaction between individuals is known as ‘Game 
Theory’. Myerson (1997, page 1) defines it as the study of “conflict and 
cooperation between intelligent rational decision-makers”. One version of Game 
Theory supports the belief that ‘cooperation’ is, in fact, never a rational strategy. 
This idea is best explained through the famous 'Prisoner's Dilemma' game 
outlined in Appendix 17. Central to Game Theory is the notion of the 'Nash 
equilibrium' (Appendix 17) achieved when the interacting parties strategise 
'against' each other instead of cooperating. 
In the present context of professionalism we shall attempt to apply Game 
Theory to understand the professional scenario depicted in Practice-based 
example 10 in which a pharmacist challenges a doctor's drug choice. The 
scenario’s potential outcomes are illustrated in Figure 2. Once the pharmacist 
has outlined the identified issue to the doctor, the pharmacist can opt to 
'cooperate' (C) by only mentioning the issue but too easily willing to acquiesce 
upon the doctor's insistence. This option represents a lack of professional 
assertiveness, perhaps of the nature seen in the junior pharmacist depicted in 
Practice-based example 2.  
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The second option available to the pharmacist is to 'defect' (D), that is, to insist 
on having their recommendation enforced. As a contrast to the first option, here 
the pharmacist pursues a 'self-interested' professional engagement. Since the 
pharmacist in example 10 displays an intention to both enforce established 
guidelines as well as incorporate the patient’s specific situation into the clinical 
decision, the pharmacist could be argued as displaying ‘indeterminacy’ and 
exercising ‘inferential’ activity. Additionally, rather than be subordinate to the 
doctor, the pharmacist asserts a professional dominance through the exercise 
of clinical judgement based on his specialist knowledge.  
A similar pair of options can be outlined for the Specialist Registrar who can 
'cooperate' (C) in much the same way as the pharmacist by avoiding conflict 
and yielding to the expertise of the pharmacist. Conversely, the doctor could 
vigorously insist on maintaining his original drug selection (D). In example 10, 
this insistence is a result of having acquired previous successful experience 
with the drug (tramadol).  
As with the Prisoner's Dilemma (Appendix 17), the Nash equilibrium occurs 
when both parties choose to defect (D, D), in other words when both doctor and 
pharmacist wish to engage in professional 'non-cooperation', each attempting to 
assert professional dominance. The reason for this is because if either 
healthcare professional chooses to 'cooperate' they immediately run the risk of 
the other choosing to 'defect' thereby asserting their professional dominance 
over them. In Practice-based example 10, it can be argued that both 
professionals opted to ‘defect’ and engage in professional activity. While the 
doctor determinedly argued the case to maintain the initial drug choice, 
tramadol, the pharmacist enforced a switch to codeine albeit temporarily and 
with a view to switch (back to tramadol) if it failed as a first-choice option. 
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Figure 2. Game theory and the doctor-pharmacist interaction 
based on Practice-based example 10. 
 
2.4 Summary of Chapter 2  
A broad understanding of some established sociological perspectives were 
discussed in this chapter. Using this understanding, both the medical and 
pharmacy professions were subjected to broad historical and sociological 
critiques. The medical profession has been shown to have maintained a unique 
relationship with the state, which has enabled it to have delayed the social 
mobility of a number of other occupations. This dominance over kindred 
occupations, as well as a state-backed monopoly over a specified domain of 
knowledge has been defined as key characteristics of the professions, of which 
medicine has often been stated to be the highest manifestation.  
Although one can point to various articles in the literature reporting successful 
collaboration between the medical and pharmacy professions, pharmacists 
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continue to pursue their own professional agenda, and wish to embrace more 
clinical roles. The wider recognition of the pharmacist as the ‘drug expert’ has 
opened doors for the profession to independently prescribe in all sectors of 
healthcare as well as engage in more clinically-oriented services in community 
practice.  
The hospital drug formulary is another commonly developed tool designed to 
influence drug prescribing and impacts on all healthcare professionals involved 
in drug therapy. Chapter 3 will now explore the origins of formularies, their 
contemporary manifestations as well as ideal implementation strategies and 
techniques.  
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Chapter 3 
Formularies and Change Management 
 
3.1 Introduction 
This chapter will now turn to a closer exploration of the ‘hospital drug formulary’, 
introduced in Chapter 1. Described as the “cornerstone of effective medicines 
management” (Audit Commission, 2001, page 16), formularies are seen by 
many as a solution, but by others as ‘solely’ cost-motivated and are sceptical as 
to its true benefits to patient care. This chapter explores the evolution of 
formularies in order to shed light on how its purpose and remit have evolved 
over time. 
The methods used to develop and implement formularies are said to be pivotal 
to their successful uptake. Since the introduction of a formulary into established 
prescribing practices represents ‘change’, an understanding of the relevant 
change management strategies and tactics will be examined. Such strategies 
help to uncover a variety of factors that can either facilitate the change process 
or serve as resistance. Often ‘attitudes’ of key stakeholders, whether for or 
against formularies, can serve as formidable influences, particularly in the 
domain of drug therapy.  The last section of this chapter will discuss what is 
known of these attitudes as they appear in contemporary literature. 
As with Chapter 2, practice-based examples will be used to illustrate key 
concepts discussed, and reflect on their existence in practice.   
 
3.2 Hospital drug formularies 
 
3.2.1 Historical overview of formularies 
In the UK, the closest ancestor to present-day formularies is the National War 
Formulary (Figure 3). It was compiled in 1939, at the start of the Second World 
War, by the British Medical Association (BMA) and the Pharmaceutical Society 
of Great Britain at the request of the Minister of Health – indicating early 
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government influence (FAME, 2005). Up to this point, formularies had always 
been more about production than prescribing. From this point on, however, an 
additional intent was for formularies to provide for “the strictest economy in 
prescribing” (Swansea Museum, 1995). 
Following the end of the war and the formation of the NHS, in 1949 the British 
National Formulary (BNF) came into being and was updated every three years 
until 1976. The pharmaceutical industry penetrated prescribing practices far 
more than the BNF due to intensive marketing and regular publications. The 
split in influence was estimated at 80% versus 20%, respectively (FAME, 2005). 
In an attempt to counter this influence, the BNF was redesigned in 1981 as a 
comprehensive prescribing tool, no longer selective about medication, but 
giving information about all medicines available in the country. Additionally, 
more information was included on the prices of medicines, and was designed as 
a handbook to fit into a coat pocket for ward use (FAME, 2005). Perhaps for the 
first time, for the pharmaceutical industry, the formulary concept became a 
threat to profitability. While the BNF now provided national drug guidance there 
was, however, a parallel development of local hospital initiatives. 
Hospitals have long since operated within their own set of priorities and 
budgetary constraints. The awareness of increasing costs of drug therapy in 
addition to governmental control, led to the development of hospital policies in 
the 1950s. DTCs were formed in the early 1970s due to the increasing number 
and diversity of medicines and eventually led to the development of specific 
drug policies (FAME, 2005). Now DTCs are considered by the WHO as “one of 
the pivotal models to promote rational use of medicines” (Tan et al, 2005, Page 
527).  
As we have seen in Chapter 2, the rise of ‘specialist knowledge’ – particularly 
that associated with the pharmacy profession – has had implications for the way 
medicines-related healthcare is delivered. It was the Nuffield Report in 1986 
that first brought to prominence the importance of pharmaceutical advice. 
Formularies soon became a practical medium to capture this advice as a way of 
improving prescribing practice (Khan, 2002).  
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3000 BC 
3000 BC – Sumerian clay tablet discovered in Nippur, Iraq 
(oldest known example of a formulary)  
 
1400 1498 – European pharmacopoeias 
 
1700 
 
1700s – Hospital pharmacopoeias 
1800 
 
Late 1800s – new understanding of pharmacology and 
standardisation of potency of active ingredients  
1930 
 
1939 – National War Formulary produced at request of 
Minister of Health by British Medical Association and 
Pharmaceutical Society of Great Britain 
1940 
 
1949 – British National Formulary (BNF) born and updated 
every three years 
 
1950 
 
1950s – greater awareness of increasing drug costs and 
more government control  
1960 
 
Pharmaceutical industry maintains a far greater influence on 
prescribing than BNF (80% Vs 20%) 
1970 
 
Early 1970s – Drug and Therapeutic Committees (DTC) 
formed, specific drug policies produced 
1980 
 
1981 – BNF reborn as a comprehensive prescribing tool, 
includes prices, designed as a handbook 
1985 
 
1986 – Nuffield Report recognises importance of 
pharmaceutical advice and is soon incorporated in to local 
hospital formularies 
1990 1993 – advent of Internet and World Wide Web (WWW) 
1995 
 
1996 – Sackett et al (1996) define evidence-based medicine 
(EBM) 
 
1999 – National Institute of Health and Clinical Excellence 
(NICE) set up 
 
2000s 
 
2001-2003 – Medicines Management Framework launched 
by government – Chief Executives and Chief Pharmacists 
now allocated responsibility of enhancing local hospital 
formularies and meeting newly defined standards 
 
2007 - Healthcare Commission reviews 173 trusts – 
electronic and web-based formularies with hyperlinks to 
clinical guidelines promoted 
 
2008 – government publishes its review of the NHS 
promising greater control and choices for patients – new 
implications for prescribers 
 
2010 
 
2010 – NHS Constitution becomes law giving a legal right to 
all patients in England to drugs and treatments 
recommended by NICE 
 
Figure 3. Key milestones in formulary evolution. 
While such professional involvement has influenced the evolution of the 
formulary, it has also been subject to varying degrees of government control 
EMPHASIS ON 
PRODUCTION 
EMPHASIS ON 
PRESCRIBING  
(e.g. cost, efficacy) 
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(Sutters, 1990). In 2001, the Department of Health launched the Medicines 
Management Framework offering trusts an opportunity to review their medicines 
management systems (DH, 2003). The ‘weakest area’ was identified as lack of 
senior management involvement and awareness of medicines management 
issues. As a result, the second wave of the Medicines Management Framework 
outlined specific good practice standards increasing the responsibility of 
managers. With this came a clear notion of the government’s minimum 
standards for medicines management strategies and expectations for a working 
formulary (discussed in Section 3.2.2).  
Many formularies now include detailed prescribing information and treatment 
guidelines that individual hospitals use as a mechanism for advising restrictions 
agreed by DTCs. They provide prescribing direction from a remote source that 
claims validity and authority, many accessible at the point of care (Healthcare 
Commission, 2007). Practice-based example 11 illustrates how such 
compilations are encouraged by senior management. 
 
Practice-based example 11 
After discussions with the Chief Pharmacist, in order to represent local 
prescribing policies more accurately, I was tasked with extracting and 
summarising decisions made about individual drugs from DTC meetings and 
incorporating them into the formulary.  
During the lengthy process of reviewing the previous ten years worth of DTC 
decisions I realised that, in fact, the formulary is essentially a ‘vehicle’ by which 
the DTC’s decisions are conveyed and are made accessible to users at the 
Trust. It is also, in effect, a ‘repository’ of a wide range of information.  
The Chief Pharmacist and my Line Manager (Directorate Pharmacist for the 
Formulary and Medicines Management) were notably supportive of the initiative 
to incorporate ‘all’ DTC decisions in this way.   
 
Today, formularies are still evolving, now expanding across care sectors. It is 
estimated, for instance, that up to 40% of primary care prescribing may be 
influenced by secondary care (Furniss, 2000). Patients can often be discharged 
on medicines from a hospital formulary that are not necessarily on individual 
general practice formularies (in primary care), leading to undue changes in 
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medication (Crowe, 2002). In 2002, the emergence of Strategic Health 
Authorities (SHA) had reinforced attempts to merge prescribing practices across 
the two sectors (FAME, 2005). In their efforts to tackle cost pressures and 
encourage more consistent prescribing across this interface, chief executives 
from PCTs and hospitals often turn to the development of ‘joint formularies’ as a 
viable solution (Duerden and Walley, 1999; Furniss, 2000). Setting up a forum 
with representation from both local hospital trusts and PCTs have been critical 
to the success of many formulary projects (Crowe, 2002). 
Prior to any collaborative endeavours to establish a formulary, it seems sensible 
to first establish a consensus on the philosophy behind the formulary, a broad 
clarification outlining the purpose, in short, a ‘working definition’. 
 
3.2.2 Working definition for a formulary 
Plumridge et al (1984) and Sutters (1990) both define the hospital formulary in 
terms of two major objectives. First, the intention to improve the quality of drug 
therapy through rational prescribing, achieved by restriction of inferior drugs and 
indirectly through the educational content in formularies. Second, cost control, 
which can be enhanced by the use of cheaper alternative agents as displayed 
in the formulary. Other definitions follow a similar pattern, an initial focus on 
quality or evidence-based prescribing then turning to minimising the 
unjustifiable prescribing of expensive drugs, and cost containment (Khan, 2002; 
Petrie and Scott, 1987).  
The aforementioned, Medicines Management Framework in 2003 mandated a 
particular standard that formularies should achieve and outlined, in effect, the 
government’s view on a ‘definition’ for formularies: 
 “Formularies should not be lists of drugs stocked but working 
documents incorporating national and locally agreed prescribing 
policies and guidelines. Where possible, formulary systems should 
be developed to promote therapeutic consistency across the local 
health economy.” (DH, 2003, page 8) 
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In the United States (US), where an insurance-based health service currently 
operates, the American Society of Hospital Pharmacists (ASHP) share a 
somewhat similar perspective and introduced guidelines for hospital formularies 
more than thirty years ago (ASHP, 1978). Their recently revised US definition of 
a drug formulary also mentioned that it represents the “clinical judgement of 
physicians, pharmacists, and other experts” (ASHP, 2000). Others have also 
incorporated a multidisciplinary theme to their wording, often emphasising the 
“peer-controlled process” involved in production (Rucker, 1982, page 465), 
which may encourage a more collaborative approach to formulary management 
and compliance.  
Some definitions, however, are less ‘diplomatic’ in their wording. Pearce and 
Begg (1992, page 191) begin their review of formularies with the words “The 
limited list or formulary concept…”, implying that the term ‘limited list’ and 
‘formulary’ are synonymous, hence the implication that the formulary ‘is’ a 
limited list. Many prescribers are suspicious of the purpose of a formulary 
anyway, they are often not convinced that the choice of drug is determined by 
evidence-base rather than cost (Kwan, 2005). Use of the words “restricted lists” 
and “required to adhere” have often been used to describe formularies 
(Duerden and Walley, 1999, page 435).  
Similar interpretations of formularies and their perceived mode of operation are 
described in Practice-based example 12. Pharmacists with attitudes from both 
sides of the spectrum are seen. On the one hand pharmacists support 
formularies being used to ‘guide’ drug selection while other pharmacists favour 
formularies being designed and utilised to ‘enforce’ drug decisions made by the 
local DTC.  
 
Practice-based example 12 
Prior to the development of the new hospital drug formulary at East and North 
Hertfordshire NHS Trust, I gave an initial presentation to the entire Pharmacy 
department that addressed the underlying principles behind establishing a new 
local formulary.  
I discussed, at length, the emphasis on guidance and not policing prescribing. A 
number of interesting responses were observed. There were some pharmacists 
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who clearly agreed that as pharmacists we should convince prescribers of 
appropriate prescribing through a ‘discussion’ of the evidence-base and the 
knowledge of the pharmacology of drugs. There were others who, while 
supporting the underlying approach of presenting evidence, also maintained 
that the formulary should be used to “enforce” the decisions made by the local 
DTC. Words used included “hammer home”, “not allowed” etc. 
Towards the end of the presentation, I discussed the possibility of the new 
hospital formulary being called the ‘Prescribing Guide’, as a way of distancing 
the new service from the ‘restrictive’ connotations of the past. Once again, while 
there was an overall favourable consensus for the potential moniker, there were 
voices that expressed concerns about a ‘Prescribing Guide’ being consulted but 
ultimately ignored since it will be perceived to be “only guidance”. 
 
However, contrasts also seem to exist in just how strictly formularies are 
intended to govern prescribing. In the US, the idea of ‘open’ and ‘closed’ 
formularies has been discussed: 
  “Open formularies allow physicians to prescribe most medications 
without penalty and... are viewed as guides to prescription 
practices. Closed, or restrictive, formularies limit the number of 
drugs that are stocked...they are usually more costly.” (Lanser, 
2002, page 52) 
 
Lanser’s (2002) conclusion is that by incorporating elements of both models and 
operating along a continuum between the two, patients and healthcare 
organisations are most likely to benefit. Although in the US a different funding 
system for medicines and healthcare operates, Lanser’s reasoning in 
advocating a balance between ‘flexibility’ and ‘constraint’, is certainly 
noteworthy and relevant to the UK’s NHS model. 
 
3.2.3 Formulary formats 
Formularies have also evolved considerably in format and content over recent 
years. Early American and Australian studies revealed a high proportion of 
formularies rated poorly in terms of content, compilation, size and binding, for 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 58 
 
example, a high percentage were larger than pocket-size (Rucker and Visconti, 
1976; Plumridge et al, 1984). Although the nationwide BNF was ergonomically 
designed, local formularies were not designed with the user’s convenience in 
mind.  
Over the decades, with the advancement of technology, formats and content 
have transformed. In 1993, a review of various aspects of formulary 
management at major acute and general UK hospitals revealed that 95% of 
formularies were now pocket-sized and, in fact, the number of hospitals 
operating a formulary had increased to 90% over three decades (Joshi et al, 
1994). Recently a more comprehensive review of medicines management at 
173 acute and specialist NHS trusts in England revealed that of the 152 trusts 
that had a formulary (again approximately 90%), 86 were paper-based, 111 
were stored in an electronic format and 56 had a web-based design (Healthcare 
Commission, 2007). With the growing interest in web-based versions of 
formularies, recent developments involve the introduction of diagnosis-based 
guidance that supports the selection of medicines. It is hoped clinical guidelines 
conveniently linking to and from the formulary will drive best practice in 
prescribing. 
 
3.2.4 Formulary compliance 
Compliance may be described as “the practice of obeying rules or requests 
made by people in authority” (Oxford University Press, 2009). With respect to 
hospital formularies, the ‘authority’ is the local DTC, and the ‘rules and requests’ 
are the drug decisions which are ultimately represented in the local formulary. 
Superficial reasons for limited use and therefore compliance include poor 
design, presentation, and structure. Furthermore, the underlying ‘performance’ 
of a formulary is said to depend as much on the approach to implementation as 
the design and content (Tugwell et al, 1984).  
However, data specifically on formulary compliance is either lacking or 
outdated. There are only vague indicators of compliance, most notably the 
extent of non-formulary drug usage (Sutters, 1990; Tugwell, 1984; Khan, 2002) 
as well as the volume of generic drug prescribing compared to brand-based 
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prescribing (Feely at al, 1990). The early reports on hospital formularies 
focussed more heavily on the financial benefits that they can bring than 
anything else (Pearce and Begg, 1992; Petrie and Scott, 1987).  
There is, nevertheless, published work on hospital guidelines (rather than 
formularies per se) that do reveal interesting findings. For instance, the 
prevalence of inappropriate prescribing has been consistently highlighted 
concluding that ‘education’ is key to optimising the prescribing carried out by, in 
particular, junior doctors (Shetty et al, 1999; Humphries et al, 1997). As one 
might expect a direct relationship exists between appropriateness of drug 
therapy and improved patient outcomes (DeVito and John, 1985).  
Since the early formularies were simple lists and historically DTCs and 
Pharmacy and Therapeutics committees (the US equivalent of DTCs) were 
primarily concerned with cost minimisation, any form of restriction presented to 
prescribers in today’s world, by way of a formulary, is often met with varying 
degrees of hostility (Goodwin, 2003; Kwan, 2005; Gosalakkal, 2005). Practice-
based example 13 illustrates such hostility towards formularies and, in 
particular, the antipathy towards their role in cost-minimisation.  
 
Practice-based example 13 
While developing ‘Chapter 7: Obstetrics, gynaecology and urinary tract 
disorders’ for the new hospital drug formulary, I arranged a meeting with a Trust 
urologist. I had stipulated prior to the meeting that it will be an opportunity to 
discuss the allocated traffic lights to formulary-approved drugs and develop 
algorithms to aid potential users. However, after the first ten minutes, it quickly 
became clear that the urologist, although actively participating, was instead far 
more interested in listing ‘new’ drugs that he would like to have stocked in the 
Pharmacy department, in effect attempting to bypass the established review 
process that usually takes place when new drugs are requested. In addition, he 
appeared to list the desired drugs without any regard for my opinions as to their 
merits. 
I reaffirmed the intentions laid out for the meeting. We began by discussing 
drugs approved for urinary incontinence. A new drug, solifenacin, had recently 
been approved at the Trust for this indication but it had been agreed that it 
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would, effectively, be a fourth-line option. Far more defensive now, the urologist 
asserted that he would “always” prescribe solifenacin as a first-line agent for his 
patients because in his “experience” and “in practice” patients do not tolerate 
the first-line agents well so rather than “waste their time and mine” he would 
prefer to prescribe a drug that he “knows” will be effective and tolerated. I 
decided to discuss the trial evidence with the consultant, some of which I was 
familiar with. The consultant, nevertheless, maintained his defiant stance, 
reinforcing his reasons for preferring solifenacin over other options. At this point, 
I decided to discuss the cost implications of solifenacin against those of its 
alternatives. From previous experience I was conscious of expecting some 
potential retaliation however, on this occasion the consultant did not react 
aggressively. Instead there was a clear sense of withdrawal from further 
discussions. The consultant asserted solifenacin as his preference once again, 
but quite visibly refrained from further active participation in discussions. The 
remainder of the meeting was rather more subdued and largely unproductive 
owing to the consultant’s lack of participation.  
 
Sutters (1990, page 59) talks of the need to develop “voluntary compliance” but 
adds that this can only be achieved if prescribers develop a sense of ownership 
and sympathise with the objectives of the local formulary. 
Collaborative workings across PCTs and within acute hospitals have been 
documented by the National Prescribing Centre (NPC). Various cross-sector, 
medicines management initiatives are described with some highlighting the 
relative successes of formulary implementation (NPC, 2007). Focus has 
explicitly been on minimising the use of non-formulary drugs or drugs restricted 
to designated departments and specialists. However, once again, there are only 
vague and discreet references to either formulary ‘compliance’ or ‘adherence’. 
 
3.2.5 Personal formularies 
Doctors are said to often prescribe from ‘personal formularies’ which often 
remain in constant conflict with local hospital formularies. Robertson et al (2001, 
page 333) describe the concept of the personal formulary as: 
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 “...generally not written down, has developed as a matter of habit 
rather than rational thought, and has been shaped by colleagues, 
patients and experience.”  
 
Denig and Haaijer-Ruskamp (1992), present a similar depiction of what they call 
the ‘evoked set’ – a small set of possible treatments that a doctor might 
consider for a specific condition. They state the “drug choice process” that the 
doctor engages in is thus reduced to a single step, that is, the selection of a 
drug from their “limited set” and can be taken “without further active thinking” 
(Denig and Haaijer-Ruskamp, 1992, page 9).  
Hence, the idea of the evoked set suggests that a therapy that is unfamiliar to 
the prescriber will not be prescribed. As Groves et al (2002) advise, for 
formulary managers it is critical to be able to influence the adoption and 
relinquishment of drugs to and from the evoked set and the subsequent 
maintenance of the status quo. Miller (1973) classifies the process through 
which an individual passes from first hearing about an innovation (a new drug) 
to actually using it as the ‘adoption process’. New drug adoption, in particular, is 
said to be influenced by ‘attitudinal’ changes of individuals and organisations 
(Groves et al, 2002). Documented influences to adoption are: perceived 
attributes of the drug, communication channels, nature of the social system and 
the extent of promotional efforts by ‘change agents’, that is, those who seek to 
influence the drug decisions of prescribers, typically pharmacists in a hospital 
setting and the pharmaceutical industry (Groves et al, 2002; Miller, 1973). 
Practice-based example 14 describes an interaction between a doctor 
prescribing from within his ‘evoked set’ and a pharmacist advising on a 
formulary-approved drug. 
Sophisticated interventions made by the pharmaceutical industry to influence 
prescribers are also recognised (Stone, 2006). A technique known as ‘academic 
detailing’ uses the principles of social marketing to achieve behavioural change, 
particularly prescribing behaviour (Cutts and LaCaze, 2003). The broader 
strategy known to be employed by the pharmaceutical industry is to establish 
the new drug into doctors’ personal formularies as early as possible and “attain 
top-of-mind physician awareness, and ultimately maintain the product’s first-
choice status” (Groves et al, 2002, page 187).  
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3.3 Change management  
 
3.3.1 The relevance of change management  
Change within any organisation is both a necessity and inevitable. Change can 
result from: the arrival of a new leader; adoption of new technology; or the 
launch of a new product or service (Harvard Business, 2003). It is this last case 
that this paper is concerned with, that is, the implementation of a new product – 
a formulary – and its functioning as a new service within an acute hospital.  
Change management is a wide ranging discipline. An appreciation of the key 
change management concepts can facilitate a better understanding of the 
environment in which local formularies operate, including the attitudes that have 
thus far been identified. This section will therefore examine some of the issues 
Practice-based example 14 
A new SHO at the Trust newly prescribed ‘diclofenac’ (an anti-inflammatory pain 
killer) for an elderly patient on my ward. For the purposes of investigation, I 
questioned him on his rationale for choosing diclofenac over other anti-
inflammatories. He explained that since he had qualified as a doctor he has 
routinely prescribed diclofenac simply because it was the first-line agent at his 
first work placement. In response to using ibuprofen, he felt uncomfortable to 
change it since he had greater experience with diclofenac.  
In order to provide an adequate ‘learning experience’ I directed him to the 
Trust’s new Prescribing Guide showing ‘ibuprofen’ as the first-line agent. I also 
demonstrated that there was in fact an evidence-based rationale (available 
through the ‘Pharmacist button’) for example the Commission on Health 
Medicines (CHM) considers ibuprofen to carry the lowest risk of GI adverse 
effects and trials show ibuprofen is as effective as diclofenac for the 
management of osteoarthritis and rheumatoid arthritis.    
The doctor agreed to prescribe ibuprofen first-line in future.  
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surrounding formularies using change management theory to understand the 
origins, positioning and implications of these issues.  
 
3.3.2 The change agent  
In instigating an effective change management project, an essential 
requirement is the appropriate allocation of a ‘change agent’. Paton and 
McCalman describe three core attributes that this individual must possess. 
Firstly, emphases on personality – the ability to listen, empathise and display 
people-oriented skills. Secondly, the change agent requires both ‘analytical and 
diagnostic skills’. In other words, they can identify and solve problems and 
effectively facilitate the change process. Thirdly, the change agent would be 
better equipped if they had previous experience in implementing the change in 
question. The implication is that having experience informs decision-making 
since the change agent has a somewhat ‘revealed’ insight of the entire change 
situation (Paton and McCalman, 2000).  
The Formulary Pharmacist has been identified by previous authors as the sole 
individual involved, in some manner, at every stage of formulary development 
(Sutters, 1990), from conception, to preparation, to implementation and 
eventually maintenance and updating (Khan, 2002). While other authors 
mention, rather vaguely, working groups, formulary teams or the oversight 
provided by local DTCs, it is invariably the Formulary Pharmacist who ultimately 
coordinates and steers the process of formulary development, manoeuvring 
around difficulties thus constituting a significant aspect of their working remit 
(Bochner et al, 1996; Joshi et al, 1994; Hill, 2005). Practice-based example 15 
outlines a case of overcoming such difficulties including those arising as a result 
of limitations in the Formulary Pharmacist himself. It is the change agent’s 
responsibility to portray the change as an opportunity rather than a threat or 
crisis. Paton and McCalman (2000) explain that when those affected by the 
change feel part of a team and working towards common goals, delegated 
aspects of change will be viewed as common to all involved.  
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Practice-based example 15 
After meeting with three gastroenterologists for the development of ‘Chapter 1: 
Gastrointestinal system’, I realised I was in many ways deficient as I was unable 
to confidently and broadly discuss the use of drugs in this chapter. While I could 
provide details as to the cost of medication and the volume of use, ‘clinically’ I 
was certainly lacking.  
Directorate Pharmacists had previously expressed an enthusiasm for the 
project however were unable to commit to helping on chapter development 
citing lack of time. In my capacity as ‘change agent’ I devised a way of 
simplifying the process of contributing to chapter development. I constructed 
‘chapter development packs’ that required Directorate Pharmacists to fill in 
minimal information. By portraying their contribution as a useful ‘opportunity’ to 
re-familiarise with drugs relevant to their own directorate (clinical speciality), this 
solution was overall a success.  
 
During multidisciplinary approaches to producing drug policies or indeed 
sections of formularies-in-development, it has been noted that the medical and 
pharmacy profession often resort to different drug selection philosophies. 
Doctors often base their opinions on personal experience with drugs while 
pharmacists make more use of critically evaluated published data (Tugwell et al, 
1984). The incident described in Practice-based example 13 is a quintessential 
example of this. Sutters (1990, page 72) consequently underlines the 
importance of the Formulary Pharmacist being able to competently “reconcile 
and influence the prescribing views and needs of clinicians where opinions are 
divergent.” The first two attributes described above are in play in such 
circumstances, that is, being able to sense and diagnose problems from the 
perspective of the audience and motivating people to change are critical roles 
and have been similarly identified by other authors (Harvard Business, 2003).  
 
3.3.3 Planning the stages of change 
Beneficial effects of formularies are notoriously short-lived (Hemeryck et al, 
1996). If potential improvements in quality of prescribing are to be sustained, 
formulary implementation should ideally incorporate a wide range of ‘continuous 
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interventions’ (Feely et al, 1990; Joshi et al, 1994; Hill, 2005). For instance, 
NICE advocates the use of educational forums such as training courses to 
facilitate the implementation of change (NICE, 2007). There is also a lively 
debate in the literature regarding the value and impact of large-scale didactic 
meetings (such as lectures) in bringing about behavioural change (Oxman et al, 
1995; Charlton, 2006). Various formulary development projects are described in 
the literature in depth, however there is no ‘one-fits-all’ model that has been 
recommended.  
The Formulary Pharmacist thus requires a ‘global’ strategy’. Buchanan and 
McCalman (1989) established the ‘Perpetual Transition Management’ model 
that outlines four interlocking processes that must take place in order to 
implement and sustain organisational changes (Figure 4).  
Sutters (1990) and Tugwell et al (1984) both conduct their formulary 
development work in a stepwise fashion establishing a clear purpose behind 
each stage. Tugwell et al (1984) describe an early focus on articulating an 
essential reason – analogous to the ‘Trigger layer’ (Figure 4) – and then 
progress to a broad vision. The authors outlined the initial problems as: 
increasing drug expenditure and; a large unchecked number of drugs to choose 
from which represented an unreasonable burden on medical and pharmacy 
staff and was deemed unsafe.  
** Content removed for copyright reasons ** 
 
Reference: 
Buchanan DA, McCalman J. (1989). In: Paton RA, McCalman J. (2000). 
Change Management: A guide to effective implementation. 2nd ed. London. 
SAGE Publications Ltd. (Page 11).   
 
 
Figure 4. Perpetual Transition Management model (adopted from Buchanan and McCalman, 
1989). 
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The  Perpetual Transition Management model encourages the change agent to 
recognise that they need to carefully articulate the vision for the change being 
implemented with the purpose of instilling a sense of “shared perception” (Paton 
and McCalman, 2000, page 28). Tugwell et al (1984) do just this: they clarify 
their ‘Guide to the Prescribing of Medicines’ is intended for the ‘non-specialist’ 
while laying out a list of specific planned benefits to be gained from its 
instigation. The authors claim successful implementation of their hospital 
formulary with “tentative estimates” of compliance being “well over 90%” 
(Tugwell et al, 1984, page 318). It may be reasonable to conclude that such a 
“successful” project is due to an approach that resembles the Perpetual 
Transition Management model – perhaps a ‘clarity’ brought about by separating 
the entire change process into manageable layers. 
The predicament for the Formulary Pharmacist in Practice-based example 16 is 
that he is in danger of not achieving the ‘shared perception’ among those crucial 
to the success of the formulary. The “palpable sense of apathy” suggests 
attitudes are in play and requires a modified approach to gaining favour from 
Directorate Pharmacists.  
Practice-based example 16  
Once the underlying design of the new online hospital formulary had been 
agreed with the Chief Pharmacist and my Line Manager, the concept was 
presented at the next Directorate Pharmacist meeting. There was instant 
support and enthusiasm for the project. However, once it was made clear each 
chapter will be allocated to the corresponding Directorate Pharmacist (for 
example ‘Chapter 1: Gastrointestinal system’ for the specialist pharmacist in 
gastroenterology), there was a palpable sense of apathy – a noticeable change 
in attitudes were observed. When Directorate Pharmacists were prompted to 
voice their opinions, they stated that they were already overwhelmed with other 
duties under their specialist remit and this would further constrain their times 
spent on the wards and elsewhere.  
I was conscious of not presenting the ‘change’ as a threat, rather an opportunity 
to optimise future activities particularly streamlining the process of drug therapy 
and pharmacist interventions on the ward level. These points seemed to 
resonate with many of the Directorate Pharmacists.  
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Prior to the end of the meeting, a commitment was made between the 
Directorate Pharmacists and me to share the workload and to help facilitate the 
development of the formulary. 
 
3.3.4 Characterising the nature of the change 
After having conducted a thorough examination of formularies in Section 3.2, a 
further analysis can now be made concerning the underlying ‘nature’ of the 
change that formularies represent. Paton and McCalman (2000) describe the 
‘change spectrum’ as a way of categorising the nature of a change into either 
‘hard’, ‘soft’ or ‘flexi’ (Figure 5). Using the TROPICS test the change agent can 
categorise a change situation (Paton and McCalman, 2000). This test focuses 
specifically, on seven key factors that need to be considered in order to 
accurately classify the change situation (see Table 3).  
** Content removed for copyright reasons ** 
 
Reference: 
Paton RA, McCalman J. (2000). Change Management: A guide to effective 
implementation. 2nd ed. London. SAGE Publications Ltd. (Page 24).   
 
Table 3. The TROPICS test to define the change situation (Paton and McCalman, 2000).  
Although the Formulary Pharmacist, in his / her role as change agent, oversees 
the entire formulary development, they do not act alone. A variety of key 
personnel are brought together contributing to both clinical and administrative 
aspects of the formulary (Crowe, 2002; Duerden and Walley, 1999). Mobilising 
several pharmacists, doctors and managers in order to first take part, and then 
attempting to manage individual preferences and viewpoints suggests a highly 
people-oriented and complex change situation for the Formulary Pharmacist to 
contend with. 
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Figure 5. Locating change on the change spectrum. 
Depending largely on the level of sophistication of the formulary as well as the 
comprehensiveness of the project, this assessment of the change scenario 
could vary drastically. If the remit for a formulary development project was 
similar to the 56 web-based formularies outlined in the Commission for 
Healthcare and Audit (2007), and comprised diagnosis-based guidance 
supporting the selection of medicines, the change agent could, quite 
conceivably, interpret the entire change as leaning towards ‘soft’ complexity. In 
other words, all the factors outlined in the TROPICS test are subject to being ill-
defined, obscure or problematic, requiring various forms of input to make the 
change more manageable. For example, ‘perceptions’ and ‘interest’ are 
particularly difficult to categorise since formularies have been deemed 
“educational” and “a necessity” by some (Petrie and Scott, 1987, page 919), 
while others openly perceive them as “restrictive” and solely cost-motivated 
(Kwan, 2005, page 515).  
Although involvement of a wide range of stakeholders encourages ownership 
and enables a formulary to be “much more readily accepted” by eventual users 
(Tugwell et al, 1984, page 313), a major obstacle to even a partially shared 
perception are the often conflicting view points of different individuals (Paton 
and McCalman, 2000). Many of the practice-based examples in Chapters 2 and 
3 illustrate such opposing dispositions and confirm the existence of often 
Soft / complex 
Hard / mechanistic 
People / 
system 
interface 
increasing 
Flexi / grey 
100% 
100% 
0% 
Complexity and variability of the  
change environment increasing 
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powerful attitudes and perspectives. The “solution methodology” – as Paton and 
McCalman (2000, page 23) put it – for such a scenario requires adequate 
management of ‘people’ rather than simplistic oversight of technical, mechanical 
or systems-oriented processes.  
 
3.3.5 Understanding the drivers and resistors to change  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thus far a disoriented array of factors influencing the design and introduction of 
formularies demonstrably exists. The application of Kurt Lewin’s ‘force field 
analysis’ – a major contribution to change management theory – can help 
examine in a basic yet illustrative and useful manner, the forces for and against 
Equilibrium 
Driving forces Restraining forces 
Government standards outlined in 
‘Medicines Management Framework’ 
mandate formulary development 
Dissatisfaction amongst DTC and 
senior pharmacy management, with 
current prescribing practice 
Web-based formulary will 
reduce cost of production 
and ease updating 
Specialist pharmacists 
providing expertise for each 
chapter (‘champions’) 
Support from staff who 
perceive the change as 
‘internally generated’ 
Agreed support from IT in setting 
up the web-based formulary 
Extensive marketing: agreed 
support from Public Affairs, leaflets, 
posters, teaching sessions 
Formulary will bring 
down drug costs 
Formulary will become single 
and convenient source of all 
drug-related information 
‘Misconceptions’ (within 
medical profession) of remit 
and purpose of the formulary 
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Budget: constrained budget 
limits degree of innovation 
and marketing opportunities  
Resistance amongst doctors who 
see the formulary as a threat to 
their prescribing autonomy 
Lack of support from staff who 
perceive the change as 
‘externally generated’ 
 
Limitations of the ‘problem owner’ 
Inadequate clinical evidence 
available to ‘clearly’ justify 
every formulary decision 
Pharmaceutical Industry 
(medical sales representatives) 
promoting non-formulary drugs 
Skilled workforce: inadequate 
number of pharmacists to 
compile chapters or assist with 
constructing entire formulary  
Time: pharmacists (including FP) 
overwhelmed with ward, 
dispensary and directorate duties 
Practice-based example 17: 
A force field analysis of driving and restraining forces impacting on the development and 
implementation of the hospital drug formulary at East and North Hertfordshire NHS Trust 
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the change (Paton and McCalman, 2000). Practice-based example 17 
graphically presents some of these forces, demonstrating that if the restraining 
forces are not minimised, ‘equilibrium’ (at the very least) is likely and change will 
not successfully come about. The goals, therefore, are to strengthen driving 
forces while weakening the restraining forces thus propelling the change 
through. The value behind producing a force-field diagram in this manner is that 
the change agent is encouraged to consider the position of surrounding power 
sources and how they affect the change in question (Paton and McCalman, 
2000). 
The Formulary Pharmacist may not be able to introduce many new driving 
forces, instead, it may be more feasible to simply focus efforts on 
‘strengthening’ existing drivers. Boddy and Buchanan suggest a variety of ways 
to reduce the uncertainty associated with the change situation, for example, 
nurturing “coalitions of support” and recognising “power bases” (Paton and 
McCalman, 2000, page 50). Such measures thus make use of ‘existing’ 
organisational structures, mobilising them to facilitate and benefit the change 
process. Sutters (1990, page 60) follows a similar approach: 
 “A formulary will only be used if it is supported by an authoritative 
and respected body and if there is wide ownership and sympathy 
with its objectives.”  
 
Sutters (1990) further clarifies, in particular, the pivotal role of an effective 
chairman of the local DTC. She concludes that this individual must be 
respected, have “credibility with other medical staff” and that “it can be of 
political and practical importance if the chairman also holds a senior office in the 
[sic.] medical school.” Having the support of such a well-known advocate, 
championing the formulary to medical doctors – a large proportion of potential 
users – would constitute a significant driving force.  
A vital understanding associated with the application of force-field analysis is 
that driving forces are likely to be stronger when there is a feeling of ownership 
combined with the knowledge that one ‘controls’, or at least, has influence over 
the change environment (Paton and McCalman, 2000). Such a ‘feeling of 
ownership’ would suggest attitudes and opinions of stakeholders are particularly 
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relevant and that their appropriate management is a core component of 
realising ‘people-dependent’ driving forces and minimising restraining forces 
resulting from resistance.   
 
3.3.6 Attitudes and perceptions resulting in resistance to change 
Attitudes are hypothetical constructs and cannot themselves be observed, they 
can only be inferred from other responses that ‘can’ be observed such as what 
the individual says about how they feel towards an ‘attitude object’ (Davey, 
2004). One of the definitions of an ‘attitude’ provided by Zimbardo and Lieppe 
(1991, page 378) is as follows: 
 “...an evaluative disposition toward some object. It is an evaluation 
of something or someone along a continuum of like-to-dislike or 
favourable-to-disfavourable.”  
 
We have already seen a similar ‘continuum-based’ approach in the TROPICS 
test discussed above. It is attitudes that are ‘at work’ behind factors such as 
‘perceptions’ and ‘interests’ that contribute to the overall classification of the 
nature of change into either ‘hard’ and mechanistic or ‘soft’ and therefore 
complex. The ‘source’ of change, also considered under the TROPICS test, 
should likewise be understood in terms of its impact on attitudes. Paton and 
McCalman (2000) identify a number of attitudinal responses that arise from the 
organisational or individual view of the ‘perceived’ source of change (Table 4). 
They also state: 
 “Externally-generated change produces the greatest degree of 
negative feedback from those affected. A department, section or 
individual will regard external change as being any development 
forced upon them from outwith their own environment” (Paton and 
McCalman, 2000, page 27). 
 
“Passive resistance” often results from such perceptions of the source of 
change and can be defined as “non-commitment to goals” that does not 
sabotage the entire program but certainly does not help productive progression 
(Harvard Business, 2003, page 76). Indeed the Directorate Pharmacists in 
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Practice-based example 16 initially display such a ‘passive resistance’ and 
distanced perspective towards the formulary – once again, perhaps evidence of 
externally generated views. Similarly in Practice-based example 4 the 
consultant gastroenterologist may also regard the formulary as externally 
generated change. Devising appropriate methods to manage this form of 
resistance will, needless to say, be high on the Formulary Pharmacist’s agenda.  
** Content removed for copyright reasons ** 
 
Reference: 
Paton RA, McCalman J. (2000). Change Management: A guide to effective 
implementation. 2nd ed. London. SAGE Publications Ltd. (Page 27).   
 
Table 4. Attitudinal responses attributed to perceived source of change (Paton and McCalman, 
2000). 
 
3.4 Attitudes impacting on formularies  
The Formulary Pharmacist needs to be cautious in attempts to engage a 
supportive attitude amongst doctors since past attempts have focused on 
demonstrating the financial benefits that formularies can bring (Goodwin, 2003; 
Feely et al, 1990; Petrie and Scott, 1987). Such emphasis on cost-effectiveness 
alone can actually be counterproductive and wider benefits need to be 
highlighted (Watkins et al, 2004).  
Instead, the ‘impartial’ change agent, needs to ensure that views of affected 
parties are understood, countered or incorporated where appropriate (Paton 
and McCalman, 2000). Groups of individuals, particularly managers, will 
inevitably present their “own brand of common-sense”, possibly based on 
specific perceptions and attitudes, and as such is recognised as a “major 
obstacle” to the formation of a ‘shared perception’ (Paton and McCalman, 2000, 
page 28). As Practice-based example 18 shows, faced with such a scenario, 
the change agent needs to assert their claim to a more complete and accurate 
understanding of the change environment in order to eliminate detrimental 
‘brands of common-sense’.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 73 
 
Practice-based example 18 
The Chief Pharmacist maintained a distanced oversight of the entire formulary 
development process and at various junctures either approached me directly or 
my Line Manager. During the development of the individual chapters, she again 
intervened and requested a meeting with me. Mentioning her own supervisor, 
and clarifying that instigating a Trust formulary was one of her ‘objectives’ for 
the next year ahead, she began to discuss deadline dates for individual chapter 
completion. I maintained that all chapters are being worked on simultaneously 
by individual teams of collaborators and rather than launch each chapter in 
succession (on to the Trust Intranet), it would be far more productive to employ 
a large-scale all-embracing implementation of the entire service. After much 
discussion (over the next few days and weeks) she conceded and the 
‘Prescribing Guide’ was launched with a wide ranging implementation strategy. 
 
Perhaps most crippling to the instigation of a new hospital drug formulary, is 
resistance that manifests as ‘opposition’ to the formulary concept itself. 
Typically, when stakeholders connected to the change process perceive that 
their “specialised skills will be rendered less valuable” resistance should be 
expected (Harvard Business, 2003, page 74). For example, formularies, 
typically developed by hospital pharmacies, have often been deemed an 
imposing force with a solely cost-driven motive (Vickers, 1987; Kwan, 2005). In 
particular, Kwan (2005, page 515), a medical doctor, alleges his drug choices 
are “determined not by evidence but cost per tablet” and describes his 
prescribing being “governed by a strict hospital formulary”. Goodwin (2003, 
page 11) takes issue with “restrictive” formularies which he believes are based 
on a “naive interpretation” of therapeutic equivalence and, due to their 
restraining impact on clinical innovation, “may slow the advance of medical 
science without even achieving the only goal that could possibly justify such 
restrictions – cost control.” DTCs have been criticised too and charges of being 
“neither explicit, transparent nor based on scientific rigour”, have not escaped 
the literature (Walker et al, 2006, page 21). Whether this represents a skewed 
interpretation of reality or not, the potential for conflict between proponents of 
the formulary and those who oppose it is evidently high. 
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In the United States (US), two studies 15 years apart, claim to have identified 
some of the reasons for the diminished potential of formularies (Rucker and 
Schiff, 1990; ISMP, 2005). In 1990, Rucker and Schiff (page 930) document 
specific assertions made by doctors attending US Pharmacy and Therapeutics 
(P&T) Committees as they discussed the addition of new drugs to the formulary. 
Examples include: “formulary sacrifices patient care to cost control”; 
“widespread use equals drug of choice”; “specialist knows best”; and “education 
requires experience with a multitude of drugs”. Rucker and Schiff (1990, page 
928) describe these statements as “misconceptions” and “myths and 
misinformation”. These results were reproduced in similar formulary 
deliberations 15 years later (ISMP, 2005). These findings necessitate further 
exploration of the attitudes of ‘all’ key stakeholders of the formulary. 
In the US they have an insurance-based health service, one would think 
business-like financial imperatives would have mandated considerable 
investigation into optimum methods of managing conflicting attitudes – perhaps 
methods that draw upon the interesting disclosures revealed by Rucker and 
Schiff.  
 
3.5 Summary of Chapter 3  
This chapter has shown that the setting within which formulary development 
and implementation takes place is highly complicated, comprised of political 
influences, interventions from the pharmaceutical industry as well as doctors’ 
personal drug preferences. NHS organisations, in the current economic climate, 
provide unpredictable infrastructures of support and limited available resources. 
Since the instigation of a convincing formulary to be used by healthcare 
professionals constitutes the introduction of significant change to established 
prescribing practices, an adequate management of this change is essential. The 
Formulary Pharmacist must accept a new role, one of ‘change agent’ and 
‘problem owner’. In doing so, they will be wise to embrace the change 
management concepts and models discussed in this chapter. Such concepts 
can assist the change agent to better understand both the change as well as 
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the change environment and thus tailor the process of change to fit the 
variables that constitute their working environment. 
Formularies have been shown to evoke a range of perceptions and attitudes 
from different groups of people, some of which have been characterised as 
‘misconceptions’. There is no evidence that current formularies have been 
designed with a firm grounding in the concepts discussed in either Chapter 2 or 
Chapter 3. Although some successes have been reported, a formulary carefully 
crafted with the application of these concepts in practice needs to be developed 
and investigated. Chapter 4 will introduce the ‘Prescribing Guide’, a hospital 
drug formulary developed and implemented at the East and North Hertfordshire 
NHS Trust in 2009.  
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SECTION 2 
The practice-based project 
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Chapter 4 
Development of the Prescribing Guide 
 
4.1 Introduction 
This chapter now turns to the hospital drug formulary currently operating at the 
East and North Hertfordshire NHS Trust and known locally as the ‘Prescribing 
Guide’. Working within the confines of available resources, the Prescribing 
Guide was launched in 2009. A brief overview of the setting in which the 
development process took place will be described along with the features and 
benefits that the Prescribing Guide was designed to deliver.  
As Chapter 3 illustrated, over recent decades in particular, formularies have 
come a considerable way with respect to their purpose, remit, content and 
scope. To further progress formulary evolution, a new direction appears to be 
related to acquiring a deeper understanding of the attitudes and perceptions of 
users. What is of particular interest is exactly where these attitudes appear to 
be divergent and why at times the formulary may represent an apparent source 
of conflict and embitterment. Therefore, once the Prescribing Guide was fully 
developed and implemented, it was subjected to a wide ranging service 
evaluation exploring its impact on prescribing practices including users’ 
experiences and perceptions. The chapter closes by detailing the aims and 
objectives for this study setting the scene for Chapter 5 which will then focus on 
the adopted methodology. 
 
4.2 East and North Hertfordshire NHS Trust 
The East and North Hertfordshire NHS Trust consists of two District General 
Hospitals (DGH): the 480-bed Lister Hospital based in Stevenage; and the 350-
bed QEII in Welwyn Garden City (East and North Herts NHS Trust, 2011a, b).  
Although both sites provide pharmacy services, overall management for the 
entire pharmacy department is based at the Lister Hospital. A single Principal 
Pharmacist oversees the management of the Trust’s approved list of drugs as 
well as the Medicines Information service.  
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In its recent past, the Trust has not operated a formulary, whether in paper 
format or in any manner of electronic versions that have been available for over 
a decade. Clinical guidelines, policies and algorithms have been available either 
as hard copies disseminated across-site to relevant consultants, senior nurse 
managers and pharmacists, or, more recently, via the Trust’s Intranet. Queries 
from various healthcare professionals are often resolved by contacting the 
Medicines Information pharmacists within the pharmacy department. Further 
details about specific restrictions applying to Trust approved medicines has 
always been accessible – albeit restricted to pharmacy staff – from the 
pharmacy computers used for labelling dispensed items to fulfil prescriptions 
from prescribers and drug chart requests from nurses.  
As with most hospitals in the UK, the Trust operates a conventional DTC 
comprised of consultants, the Chief Pharmacist, senior pharmacists, nurses, 
PCT pharmacists and GPs. This committee meets bimonthly and discusses the 
addition of newly requested and reviewed drugs for addition to the Trust’s 
approved list. The employment of a Senior Formulary Pharmacist in 2006, 
solely dedicated to the aforementioned ‘approved list of drugs at the Trust’, 
facilitated the conception, design, compilation and eventual implementation of a 
new, web-based formulary to be accessible from the Trust Intranet to all 
healthcare professionals at the Trust. This formulary was locally marketed as 
the ‘Prescribing Guide’.  
 
4.3 The Prescribing Guide 
When developing a hospital formulary, to merely adopt an existing one would 
lack local perspectives and ownership (Hill-Smith, 1996). Therefore, from the 
design of individual features now present in the Prescribing Guide to the 
overarching strategy behind its construction, the Formulary Pharmacist has 
drawn on a number of established sources and disciplines. For instance, a 
comprehensive review of contemporary formularies was initially conducted. This 
involved a thorough literature search of published formulary development 
projects (Chapter 3), and a paralleled effort to communicate with other 
Formulary Pharmacists (Appendix 1). These communications culminated in 
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actual site visits to a large London teaching hospital and a DGH of comparable 
size to the Lister Hospital. The insights essentially provided the rationale for the 
development approach and for allegedly ‘successful’ formulary features. 
The decision to discard the overt use of the term ‘formulary’ in favour of 
‘Prescribing Guide’ was a deliberate attempt to move away from negative 
connotations associated with the former. The latter may also have an affinity 
with the notion of ‘abstract’ knowledge since the aim for this service was to 
‘guide’ rather than ‘direct’ prescribers to evidence-based and cost-effective 
options.  
Similarly, some effective change management models were also assimilated in 
the design approach. For example, as we saw earlier, the change agent would 
be better equipped and perhaps more competent if they had previous 
experience in implementing the change in question. Since the Formulary 
Pharmacist was deficient in this area of expertise, the primary reason to carry 
out a ‘pilot’ was to generate an awareness of the dynamics involved in 
implementing such a change and to what extent the surrounding infrastructure 
of support and resources can be called upon. The pilot included the 
development of a single chapter in its entirety, that is, from design to 
compilation to eventual launch on to the Trust Intranet. As Paton and 
McCalman (2000) advise, pilots provide the greatest opportunities to test 
assumptions, procedures and help to increase future acceptance of the change. 
Furthermore, a strong change agent – one with previous experience in his / her 
arsenal of skills – can be regarded as a strong driving force, and a weak change 
agent, at best, a weak driving force and at worse, in effect, a restraining force.  
The pilot chapter, ‘Chapter 1: Gastrointestinal system’ was completed and 
launched in October 2006. Subsequent improvements to this chapter and work 
on the remaining 14 chapters were split into two phases. Phase I, finalised in 
November 2007, saw the development of the entire structure for the website 
and engaged both senior pharmacists and consultants around agreeing the lists 
of approved drugs to be visible to the end-user. In January 2009, the final 
product was launched to the entire Trust completing Phase II. The more 
substantive Phase II, involved the input of clinical content by orchestrating a 
network of links to various sources of drug information. The Prescribing Guide 
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attempts to employ a diagnosis-based guidance that supports the selection of 
medicines by diagnosis and clinical guidelines. The Healthcare Commission 
(2007) states that such functions should drive best practice in prescribing. 
Table 5 lists some of the key features the Prescribing Guide offers to healthcare 
professionals involved in medicines management at the Trust. Appendix 2 
further includes 'User Guides' developed for all users as well as the 
presentation slides used in the 'Teaching Sessions' that accompanied the 
launch of Phase II. Throughout the entire website, the new online formulary 
provides consistent referencing to the electronic BNF (eBNF). Each drug 
monograph is hyperlinked to its corresponding page on the eBNF website thus 
providing basic guidance for each drug such as: licensed dose; frequency; 
cautions and contra-indications; side effects etc. The Prescribing Guide also 
incorporates guidance from NICE by providing links to many of the technology 
appraisals and clinical guidelines at NICE’s website. Other established 
evidence-based websites are also accessible via hyperlinks integrated within 
‘Pharmacist buttons’ and ‘Consultant buttons’. These ‘buttons’ were designed 
primarily to build ownership as they present specific guidance offered by the 
participating healthcare professional.  
Similar links to the National Patient Safety Agency (NPSA) are also available, 
thus highlighting common drug safety concerns that have received national or 
international attention. Through simple and easy-to-update graphical displays, 
the Prescribing Guide also aims to bring to the attention of prescribers and 
other users, the cost of medicines.  
In the current evidenced-based era superimposed on an environment with 
limited resources that require careful allocation, the Prescribing Guide aims to 
facilitate safe, clinically effective and cost-effective use of medicines at East and 
North Hertfordshire NHS Trust. Nevertheless, as the previous chapter has 
outlined, introducing a new formulary faces many challenges to its 
implementation and subsequent compliance. The Prescribing Guide has indeed 
encountered various degrees of resistance and obstacles. Limited man-power 
and resources have meant delays and setbacks while difficulty in obtaining 
consensuses between consultants as well as between members of different 
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professions (doctors and pharmacists) have invariably complicated individual 
chapter development.  
Key features of the Prescribing Guide 
 List of all approved drugs stocked by the Pharmacy department 
 Information about formulary status
6
 (‘traffic light system’) 
 Links from each drug to the electronic BNF 
 Health Topics section that supports ‘diagnosis-based guidance’ 
 Quick Index – enables searching by drug name or class 
 Graphical representation of drug costs 
 Pharmacist button, Consultant button  
 Links to NICE and other established evidence-based website (e.g. SIGN, MeReC, 
electronic medicines compendium, Medical Royal Colleges) 
 Links to NPSA 
 Drug administration support (e.g. IV Medusa Guide, Policy for swallowing difficulties) 
 Internal links: for example, Trust Guidelines, specialist-approved algorithms, DTC 
decisions (including minutes) 
 Internal links to forms for requesting new drugs and guidelines for the review process 
 The ‘Pharmacy Bulletin’ 
 
Table 5. Key features of the Prescribing Guide. 
 
4.4 The present study of the Prescribing Guide 
The formulary, as a concept, has developed from a recipe for medication to an 
established mechanism for encouraging the evidence-based prescription of 
drugs specifically promoted on the grounds of safety, efficacy and economy. In 
all of this evolution, with formulary development projects, there seems to have 
been an assumption that prescribers and other users generally adopt advice, 
follow guidance, and refer- or defer- to the content.  
Given the extensive history demonstrated along with the fact that most hospital 
pharmacies maintain a local formulary, as indicated in the Healthcare 
Commission’s (2007) review, it seems anomalous that the literature offers 
remarkably little about the attitudes and perceptions to formularies and how 
they may impact on prescribing practices and formulary compliance.  
Rucker and Schiff’s (1990) ‘alleged misconceptions’ – so far identified only in 
the US – and the somewhat sporadically documented negative attitudes 
                                                          
6
 Formulary status – refers to the decision made by the DTC after reviewing a new drug 
application submitted by either a Trust Consultant or the Pharmacy department. Examples 
include ‘approved’, ‘not approved’, ‘restricted to specific consultants (specialties)’, ‘restricted to 
specific conditions’ and ‘unlicensed’. The new Prescribing Guide offers a visual representation 
of formulary status via ‘traffic lights’: ‘green’, ‘amber’ and ‘red’. 
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towards formularies, may constitute formidable restraining forces although not 
much is known of them. These attitudes may serve to limit the potential 
influence and support that the Prescribing Guide could provide to all healthcare 
professionals involved in drug therapy. Tugwell (2000, page 59), on the other 
hand, expresses a rather more optimistic view. His encouraging claims that 
pharmacists’ services including formularies on the Intranet can help provide 
“better and faster services and more comprehensively”, need to be explored.  
The next chapter in the formulary’s evolution should centre on an exploration of 
the briefly documented attitudes that seem to materialise once a new formulary 
has been implemented, perhaps revealing exactly ‘where’ and ‘why’ the 
opinions are divergent. The recently introduced Prescribing Guide at East and 
North Hertfordshire NHS Trust can facilitate this research. 
If the experiences and perspectives of users are explored and the Prescribing 
Guide subsequently modified in order to meet their needs and the needs of the 
Trust, it could – potentially – serve as a powerful prescribing tool at the Trust 
with scope for wider dissemination.  
 
4.5 Aims and objectives 
The aim of this study is to determine the attitudes and perceptions of users and 
other key stakeholders about the recent development and implementation of the 
new Prescribing Guide and ensure that it is developed in a manner that meets 
the needs of users within the Trust.  
The objectives for this study are: 
1. To explore the perceptions of stakeholders who use the Prescribing 
Guide with regard to its purpose and on-going use within the Trust 
2. To identify key features of the Prescribing Guide that are working well 
and where difficulties or issues are occurring 
3. To describe the various influences on local prescribing practices and how 
the Prescribing Guide affects such practices 
4. To compare the experiences of using the Prescribing Guide from the 
perspectives of different healthcare professionals 
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5. To adapt or modify the Prescribing Guide based on the insights gained 
through objectives 1-4 and explore subsequent changes in attitudes and 
perceptions 
6. To make final recommendations to ensure that hospital drug formularies 
continue to evolve in order to meet the needs of the organisation and 
users  
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Chapter 5 
Research Approach  
 
5.1 Introduction 
Within social research, a variety of research instruments can be employed. 
Without a careful exploration of the strategic advantages and disadvantages of 
each one, the research is unlikely to yield meaningful results and conclusions. 
This chapter thus provides a justification for the chosen research design taking 
into account the resource-constrained environment within which the research 
will be conducted.  
To begin with, a philosophical stance on the acceptability of knowledge will be 
outlined and its relevance for social research discussed. The chapter then turns 
to a discussion of the merits of adopting an action research model and a mixed 
methods design, that is, one that incorporates both quantitative and qualitative 
research instruments. In particular, the explicit focus on the ‘link’ between 
different research instruments, namely, the notion of ‘triangulation’ is 
highlighted. 
Qualitative data was obtained using semi-structured interviews while primary 
quantitative data was generated through widespread deployment of online self-
completion questionnaires. The chapter also addresses the ethical issues 
associated with conducting such research and finishes on a discussion of the 
attempts made at ensuring rigour within research.  
 
5.2 Epistemological stance  
Epistemology is a branch of philosophy concerned with the theory of knowledge 
(Green and Thorogood, 2004). The claim to have produced knowledge is 
defined by the researcher’s selection and justification of a particular 
epistemological tradition. Broadly speaking the epistemologies of ‘positivism’ 
and ‘interpretivism’ have dominated this area of philosophical discourse. 
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Proponents of positivism support the view that the methods used to study the 
natural sciences should be applied to study social reality (Bryman, 2004). 
Positivism is characterised by a focus on ‘empiricism’. This is the belief that 
phenomena are observable only through experiment and confirmed by the 
senses. Quantitative purists maintain that science, and therefore knowledge, 
ought to be considered separately from society and thus remain neutral, value-
free and not ‘contaminated’ by subjective or political view points (Green and 
Thorogood, 2004).  
The doctrine of ‘interpretivism’ surfaced in the early 1960s as the contrasting 
epistemology, shifting the emphasis to 'understanding' rather than ‘experience’. 
Therefore phenomena that form the subject of study in the natural sciences, for 
example atoms, plants or planets do not “make sense of their place in the 
world” – humans beings, clearly, do (Green and Thorogood, 2004, page 12). 
Interpretivism thus holds that since humans are complex and unpredictable, 
their behaviour cannot be determined in a 'law-like' manner. It instead 
encourages grasping the ‘social reality’ by basing your own understanding on 
the understanding and interpretations of others acting within the social world – 
an “empathic understanding” (Bryman, 2004, page 13; Green and Thorogood, 
2004).  
Potential users of the Prescribing Guide will each hold their own interpretations 
of the social world around them, that is, the domain of drug therapy. It is the 
subjective, empathic understanding of these key stakeholders that is the crux of 
this study. Taking the interpretivist’s stance and through the deployment of 
appropriate research instruments, the role of the researcher is to grasp the 
meanings behind their behaviours and actions in relation to the Prescribing 
Guide and prescribing practice.  
 
5.3 Literature review 
The previous chapters have addressed topics beyond the field of healthcare, 
such as sociology and change management. However, it is the specific 
literature search with respect to hospital drug formularies per se that will be 
outlined here.  
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The primary area of interest was formulary development and implementation. 
Concepts closely related to this core area of interest were formulary 
compliance, adherence and documented attitudes towards formularies which 
rarely formed the central subject matter of any individual papers identified. In 
addition, the broader area of medicines management was explored focusing on 
formularies as the tool used to optimise drug therapy. As the literature revealed 
a number of references to government policy and frequently implied political 
influences, related Internet searches were also conducted.  
The initial searches were confined to published dates between 1995 and 2011, 
however an examination of the relevant reference sections of many papers 
necessitated further literature searches going back to as far as 1978. Although it 
is highly unlikely that the findings of any studies from such a time period will be 
transferable to modern day settings, a historical understanding of the evolving 
purpose and remit began to emerge which was considered useful. Additionally, 
much of the literature concerning hospital formularies is concerned with 
initiatives in the US where a private, insurance-based health service is 
established. American formularies are part of drug benefit plans for which 
patients themselves are financially responsible. Selected literature from this 
background was, nevertheless, accepted where it was considered that the focus 
is on developing, maintaining or implementing safe, clinically effective and 
economic formularies.  
Many of the search terms, if identified as ‘word-stems’, were truncated 
appropriately to widen the search. For example the search term ‘formular$’ was 
entered to search for both ‘formulary’ and ‘formularies’. Boolean search 
techniques (using ‘AND’, ‘OR’, ‘NOT’) were incorporated into the search to 
broaden or narrow the exploration where appropriate.  
 
A literature search was conducted (Appendix 3) using the following search 
terms: 
 Formulary (broadened to ‘hospital’ and / or ‘drug’ formulary) 
 Formulary development / implementation / management 
 Formulary compliance / adherence 
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 Medicines management 
 Prescribing practice / behaviour / attitudes 
 Obstacles / resistance in healthcare 
 Doctors / pharmacists / non-medical prescribers 
The following databases were searched: 
 MEDLINE  
 EMBASE  
 Pharmline – recently incorporated under National electronic Library of 
Medicines, (NeLM) 
 The Allied and Complementary Medicine Database (AMED) 
 Cumulative Index to Nursing and Allied Health Literature (CINAHL) 
In addition, specific journals were also searched: 
 British Medical Journal (online search) 
 Pharmaceutical Journal (online search) 
And also websites: 
 Department of Health 
www.dh.gov.uk  
 NPSA 
www.npsa.nhs.uk  
 
5.4 Overarching research strategy 
The overarching research strategy for this study was based primarily on the 
action research model. This approach advocates closer ties between social 
theory and the solving of immediate social problems with an underlying aim of 
improving practice. Action research has been used in a variety of settings 
(including health and social care) typically where organisational development is 
central to investigation (Tanna, 2005; Green and Thorogood, 2004).  
The following key characteristics of action research, outlined by Denscombe 
(2007) are particularly suitable for the evaluation of the Prescribing Guide: 
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 Practically orientated – focus is on difficulties arising in routine practice. 
 Change – concerned with altering an aspect of current practice based on 
insights from users of the service. 
 Cyclical process – initial findings generate insights that trigger the 
change in practice. The service is then further evaluated and the 
subsequent findings can potentially lead to another change, always 
perfecting the service in keeping with the needs of key stakeholders of 
the service (Figure 6). 
Encourages participation – both in the actual implementation of change and 
with the design and focus of the research, practitioners are typically active not 
passive in the research process. This essentially ‘democratises’ the research.  
 
** Content removed for copyright reasons ** 
 
Reference: 
McNiff J, Whitehead J. (2008). All you need to know about Action Research. 
London. SAGE Publications. (Page 9).   
 
 
Figure 6. An action-reflection-cycle (McNiff and Whitehead, 2006) 
 
Chapter 3 illustrates that formularies are not ‘crystallised’ end-products but are 
instead evolving. An action research approach was therefore adopted in order 
to empower ‘stakeholders’ so that they can steer this ongoing development, 
manifesting in practice as ‘change’ to the service. Therefore after obtaining the 
views and perceptions of the Prescribing Guide from users (study objective 1), 
the study involved ‘applying’ these perceptions (study objective 5) by translating 
them into tangible modifications made to the Prescribing Guide. Once the 
modifications were made and a period of time was given to communicate the 
changes to all potential users, the Prescribing Guide was then subjected to 
another phase of evaluation, completing the action-reflection-cycle (Figure 6). 
Action research also encourages stakeholders’ views about study design to be 
taken into account. Therefore, six stakeholders, including the Chief Investigator, 
were originally identified and invited to participate as official ‘Stakeholders’ 
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attending ‘Stakeholder Meetings’. These were held on three occasions in order 
to discuss and validate initial findings and emerging themes presented to them 
and discuss modifications to the Prescribing Guide.  
To ensure that a representative sample of stakeholders was consulted, it was 
considered important to include the participants listed in Table 6. Essentially this 
was an attempt to merge as many categories of healthcare professionals as 
possible in order to maintain feasibility and ease coordination of meetings. After 
experiencing a number of refusals to participate in Stakeholder Meetings, an 
eventual total of four was accepted primarily because all of the categories 
outlined in Table 6 were subsumed within these four stakeholders.  
List of participants considered important for Stakeholder Meetings 
 Formulary pharmacist 
 Purchasing pharmacist 
 Ward pharmacist 
 New Drugs and Formulary (NDF) Committee member 
 Consultant doctor 
 NMP (a nurse or pharmacist) 
 
Table 6. Participants for Stakeholder Meetings. 
 
 
5.5 Qualitative research instruments 
 
5.5.1 Consideration of qualitative research instruments 
A qualitative research instrument was considered essential in order to explore, 
in depth, the attitudes, perceptions and experiences of users of the Prescribing 
Guide. The subject of discussion in this section will be: focus groups, 
ethnography and qualitative interviews, since these research instruments can 
facilitate significant exposure to ‘key players’ closely linked to the phenomena 
under investigation, that is, users of the Prescribing Guide.  
Focus groups are a qualitative instrument whereby a small group of people, 
moderated by the researcher, discuss “attitudes, perceptions, feelings and 
ideas about specific topics” (Denscombe, 2007, page 178). Although this 
appears to be an insightful research method, the difficulties in co-ordinating 
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meetings is likely to be particularly troublesome (Bryman, 2004). In addition the 
researcher is unlikely to have as much control specifically over the groups’ 
proceedings than, for instance, with individual interviews. In particular, as 
Bryman (2004) describes, the researcher may have problems dealing with 
reticent speakers and those who wish to dominate the debate. Another problem 
is the propensity of participants to express “culturally expected views” in focus 
group scenarios rather than in individual interviews (Bryman, 2004, p360).  
Ethnography requires the researcher to spend considerable time in the ‘field’, 
among the people whose perceptions and indeed actions are being studied 
(Denscombe, 2007). The four recognised roles that the researcher can assume 
are presented in Table 7.  
** Content removed for copyright reasons ** 
 
Reference: 
Bryman A. (2004). Social Research Methods. 2nd Edition. Oxford. Open 
University Press. (Page 301).   
 
Table 7. The various roles of ethnographers (adopted from Bryman, 2004). 
 
The advantage of such research, particularly in the present context of studying 
the Prescribing Guide, is that it is based on ‘direct observations’ rather than on 
second-hand statements obtained from interviews. Such an approach allows 
‘holistic’ explanations to be constructed with a focus on “behind the surface 
events” as the researcher acquires a degree of self-awareness not achievable 
in other qualitative research instruments (Denscombe, 2007, page 72).  
Turning to interviews, these can vary from structured, semi-structured to 
unstructured. In reality, qualitative interviews will operate along the continuum of 
semi-structured and unstructured allowing the interviewee the freedom to 
“speak their minds” and uncover complex issues (Denscombe, 2007, page 
178). Researchers are also able to demonstrate accuracy since data can be 
checked for relevance during the interviews themselves (Denscombe, 2007).  
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Conducting interviews, as Denscombe (2007, page 173) puts it, is an “attractive 
proposition” for any qualitative researcher since it presents the interviewee with 
an opportunity to disclose their views and experiences once a theme or topic 
has been introduced. Certain issues simply will not be amenable to observation 
and only through asking and following up with further probing questions can the 
‘truth’ be uncovered (Bryman, 2004). Rucker and Schiff’s (1990) study of 
formulary ‘misconceptions’ was based on such observations (at Pharmacy and 
Therapeutics Committee meetings). However, the attitudes and opinions 
outlined in Chapters 2 and 3 will instead require deeper probing and elucidation 
in order to understand the social reality of key stakeholders of the Prescribing 
Guide.  
Furthermore, it was considered impractical to follow doctors around on their 
ward rounds waiting for them to use the Prescribing Guide and then attempting 
to observe their experiences with it, as ethnography would require. Ethnography 
is also recognised as having a greater potential for ethical problems concerning 
intrusions of privacy, particularly in the healthcare setting, where sensitive 
patient information is exposed (Denscombe, 2007). For this reason gaining 
informed consent from research subjects is also problematic.  
 
5.5.2 Semi-structured interviews 
Thus, one-to-one interviews with a semi-structured format were employed. In 
order to maintain clear areas of focus, interview topic guides (Appendix 4) were 
developed for doctors, pharmacists and NMPs. The interviewer maintained 
flexibility with the order in which the topics were considered and asked follow up 
questions in order to probe issues for greater clarity and understanding. The 
emphasis was for the interviewee to elaborate on particular aspects of 
prescribing practice and the Prescribing Guide. Lasting approximately 30 
minutes, interviews were audio-taped, transcribed verbatim and then subjected 
to content analysis. Non-verbal and para-linguistic communication was also 
documented providing clarity on points of emphasis made by the interviewee.  
Qualitative interviews can take up time and may involve travel. Within 
organisations operating with limited resources, such as a DGH, conducting a 
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pilot study to ensure feasibility is encouraged (Denscombe, 2007). For this 
reason, a senior pharmacist and a consultant were interviewed to ensure the 
chosen research instrument was in fact viable.  
In the substantive study, interviews were carried out during two phases, each 
time over a period of approximately one month and were thought of as 
‘reconnaissance’ or ‘fact-finding’ phases. The first wave of interviews was 
carried out in Week 5-8 of the study. Provisional analysis of emerging themes 
was presented to a group of 'Stakeholders' (Section 5.4) and through 
discussions, agreed modifications were made to the Prescribing Guide. The 
second wave of interviews, during Week 20-23, continued to explore users’ 
experiences of the Prescribing Guide but now in the light of any modifications 
made to the service during Week 11-19. Thirty interviewees were selected in 
total with fifteen interviewed in Week 5-8 and the remaining fifteen in Week 20-
23. Particular attention was given to interview a similar category of participants 
in both instances. Each healthcare professional was contacted by telephone, a 
participant information sheet (Appendix 5) was then sent and a consent form 
(Appendix 6) signed just prior to the start of the interview. 
In order to ensure a representative sample of users and stakeholders of the 
Prescribing Guide were selected, it was considered important to include the 
participants listed in Table 8. The ‘purposive sampling’ technique was used to 
select participants. In this form of sampling participants tend to be chosen 
deliberately as they are recognised as having a special contribution to make 
(Denscombe, 2007). Ultimately, purposive sampling attempts to “establish a 
good correspondence between research questions and sampling” (Bryman, 
2004, page 333). As Denscombe (2007) clarifies, it very much depends on the 
underlying goals of the study. If the overall aim is to generate generalisable 
findings, then a representative sample (based on random sampling) is required. 
If, however, the primary aim is to produce in-depth insights, exploring attitudes 
and experiences, the recommendation is to select key players based on the 
knowledge and experience of the researcher (Denscombe, 2007; Thompson 
and Walker, 1998). 
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List of participants considered important for semi-structured interviews 
 Junior doctor (FY1, FY2) 
 Senior doctor (Registrar) 
 Senior doctor (Consultant) 
 Medical doctor (Consultant) 
 Surgeon (Consultant) 
 Consultant on the NDF Committee 
 Junior Pharmacist 
 Senior Pharmacist (Chief or Deputy Chief Pharmacist) 
 Senior Pharmacist (Directorate) 
 Clinical Governance Pharmacist 
 Formulary Pharmacist 
 Purchasing Pharmacist 
 I.T. Pharmacist 
 Pharmacist on the NDF Committee 
 NMP (a pharmacist) 
 NMP (a nurse) 
 
Table 8. Participants for semi-structured interview. 
 
5.6 Quantitative research instruments 
 
5.6.1 Consideration of quantitative research instruments 
The combining of qualitative and quantitative research instruments within a 
single study is often referred to as the ‘mixed methods’ approach. Although 
semi-structured interviews were conducted to investigate the attitudes and 
perceptions of the Prescribing Guide ‘in depth’, it was considered that an 
appropriately positioned quantitative element would corroborate these findings 
as well as provide a more comprehensive picture to the entire context 
(Thompson and Walker, 1998; Denscombe, 2007). In addition the sample 
population for semi-structured interviews is typically small and open to the 
criticism of being unrepresentative. Use of wide scale surveys can compensate 
for this recognised weakness. The combination of two different research 
approaches in this way is known as ‘methodological triangulation’. Triangulation 
is particularly successful if “markedly different” approaches are employed in 
order to allow the researcher to see things from as widely different perspectives 
as possible (Denscombe, 2007, page 135).  
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Quantitative research instruments are capable of allowing a broad, objective 
examination of the impact and influence of the Prescribing Guide. Of the 
quantitative research instruments available, ‘surveys’, including short structured 
interviews, self-completion questionnaires and observations, can produce a 
large amount of data in relatively short time and at relatively low costs – a 
pivotal advantage in an environment of finite resources (Denscombe, 2007). 
The ‘structured’ interview lends itself to the quantitative research philosophy 
which typically involves asking participants questions over which there has been 
tight control regarding the wording. The range of answers that are on offer are 
‘standardised’ and thus make subsequent data analysis relatively easy 
(Denscombe, 2007). However, when data of such nature is desired, structured 
interviews are more expensive and far more time consuming than postal or 
online self-completion questionnaires.  
Although in many ways the self-completion questionnaire and the structured 
interview are very similar (Bryman, 2004), if the researcher wishes to collect 
simple and relatively uncontroversial facts, then Denscombe (2007) 
recommends self-completion questionnaires are a far more cost-effective 
method. In addition to being cheaper and quicker to administer, they present a 
convenience to participants since they are able to complete and return the 
questionnaire at their leisure (Bryman, 2004). This does however point to the 
“most damaging limitation” of surveys by postal questionnaire – namely low 
response rates (Bryman, 2004, page 135). Bryman (2004) describes how this 
introduces the risk of bias since those who choose not to respond may differ in 
their perceptions and attitudes to those who have. For instance, those not 
responding to a questionnaire investigating the Prescribing Guide may not, in 
fact, be advocates of the formulary system or may have had conflicts with 
pharmacists attempting to enforce the decisions of the New Drugs and 
Formulary (NDF) Committee7 that are reflected within it. Bryman (2004) 
discusses several steps to improve response rates, summarised in Table 9. 
 
 
                                                          
7
 New Drugs and Formulary (NDF) Committee – is effectively the local Drug and Therapeutics 
Committee (DTC) at East and North Hertfordshire NHS Trust 
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** Content removed for copyright reasons ** 
 
Reference: 
Bryman A. (2004). Social Research Methods. 2nd Edition. Oxford. Open 
University Press. (Page 136-137).   
  
 
Table 9. Steps that can be taken in order to improve response rates to self-completion 
questionnaires (adopted from Bryman, 2004). 
 
5.6.2 Self-completion questionnaires 
An online self-completion questionnaire was thus designed and deployed as 
part of the study. Since it was emailed to a large number of potential users at 
the Trust via administrative staff, it was considered particularly useful as it 
eliminated the need for the researcher to meet with participants directly, 
ultimately saving time while having ‘accessed’ a significant proportion of the 
entire population. 
Questionnaires were sent out during Week 5-7 and Week 20-23 in order to 
coincide with both waves of semi-structured interviews and together comprised 
two comprehensive reconnaissance phases. Separate questionnaires were 
designed for dissemination to doctors, pharmacists and NMPs (Appendix 8). 
The majority of questions sought to obtain information about the Prescribing 
Guide and prescribing practices that is clear, relatively brief and 
uncontroversial. 
Designed using SurveyMonkey8, the questionnaires were made available via a 
hyperlink sent by email to doctors, pharmacists and NMPs. Accordingly, 
medical, pharmacy and nursing administration and secretarial staff were 
                                                          
8
 SurveyMonkey™ – is an online professional survey tool that allows researchers to create 
customised questionnaires and embed them as hyperlinks in emails. It collects, stores and 
provides quick graphical representations of the data produced. 
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approached to assist in the delivery of the questionnaires. As with the previous 
research instrument, during Month 1, the feasibility of using questionnaires was 
also tested. For this reason, five doctors, four pharmacists and one NMP were 
identified, purposefully, in order to test for feasibility.  
‘Implied consent’ was accomplished by sending a covering letter (Appendix 9) 
as part of the email communication. Consent was understood by participation 
and return of the questionnaire. It was not possible to identify those who had not 
responded, therefore follow-up reminders (along with the original hyperlink to 
the online questionnaires) were periodically sent to improve response rates. 
All returned questionnaires were checked to ensure there were no mistakes in 
data entry by the respondent. Almost all raw data obtained from the 
questionnaires was in the form of ordinal data, which is to say they were in 
categories that were already in order. The range of answers on offer were 
therefore ‘standardised’ and thus made subsequent data analysis relatively 
uncomplicated (Denscombe, 2007). Relationships between selected variables 
were assessed using contingency tables and Chi-squared analysis. Variables 
were compared both ‘across’ questionnaires (for example, doctors’ frequencies 
of using the Prescribing Guide in questionnaire 1 against frequencies stated in 
questionnaire 2) as well as ‘within’ questionnaires (for example, relationships 
between healthcare professionals and other variables). These findings are 
presented in Chapter 7.  
 
5.6.3 Prescribing trends and formulary adherence 
Denscombe (2007) states that social surveys need not focus solely on people. 
Empirical research can be based on documents for example newspapers, 
company reports and committee minutes to name a few (Denscombe, 2007). 
The Pharmacy computer system at the Trust was quickly recognised as being 
able to provide significant prescribing statistics dating back to previous years. 
This was considered an effective and reliable method of tapping into the 
Prescribing Guide’s impact on prescribing practice. 
This provided an opportunity to retrospectively extract information about the 
volume of total approved and unapproved ‘non-formulary drug' dispensing (and 
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therefore prescribing) taking place over the previous 12 month period so as to 
clearly show any impact the launch of the Prescribing Guide may have had. 
Similarly, formulary adherence was also monitored by extracting specifically 
targeted drug 'issues' (volume) and their associated 'expenditure' (cost) from 
the Pharmacy computer system. These drug categories were pre-selected 
during discussions at the first Stakeholder Meeting in Month 1. During the 
second and third Stakeholder Meetings, these findings were discussed in the 
light of other findings obtained from the semi-structured interviews and the self-
completion questionnaires.  
Once again, as part of a feasibility analysis, during Month 1 data was extracted 
in order to determine the level of complexity and the likely time required for total 
data extraction. Although this pilot was conducted on a small-scale (extracting 
only one month of data) the task was considered to be long and arduous. 
However, corresponding graphical presentations illustrated prescribing trends 
clearly and were deemed worthwhile. Senior management thus allocated the 
researcher time within the existing remit as Senior Formulary Pharmacist to 
complete the task. 
The Pharmacy computer system provided a facility to easily convert the 
extracted statistics into Microsoft Excel spreadsheets. Subsequent graphical 
presentations have been able to display prescribing trends. Bar charts showing 
volume of prescribing are superimposed with line graphs showing 
corresponding cost. This data is presented in Chapter 7. 
Statistics such as these are amenable to computer storage and analysis and 
are considered “hard facts around which there is no ambiguity” (Denscombe, 
2007, page 228). An important advantage here is that provided the source is 
made clear (Pharmacy computer) those reviewing the study can be assured of 
the ‘credibility’ of this form of data since it is open to public scrutiny.  
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5.7 Analysis of qualitative research data 
 
5.7.1 Discussion of approaches to qualitative data analysis  
The most popular approaches to the analysis of qualitative research are 
‘grounded theory’ and ‘phenomenology’ (Denscombe, 2007; Clissett, 2008). 
Both approaches adopt the interpretivist stance in which the researcher is 
concerned with human interactions and acquiring an understanding of ‘real life’ 
situations.  
Grounded theory above all emphasises the importance of linking empirical 
fieldwork (in practice) very closely to any explanations that may be offered. This 
is typically achieved by continuing to undertake data collection throughout the 
entire course of the research and then systematically formulate theories from 
analysis of the emerging data (Denscombe, 2007). There is a constant effort 
made to refine the study as the specific nature of the problem begins to emerge 
(Clissett, 2008). In this sense, grounded theory does not submit to the charge of 
being speculative or based on abstract theory since there is constant attention 
to empirical data. However, it does represent a significant disadvantage, namely 
the inability to plan the research with any great precision (Denscombe, 2007). 
The grounded theorist will not be able to specify at the outset the exact nature 
of the sample population since the sample itself ‘emerges’ as the theory 
emerges. Such an approach is immediately problematic for a busy DGH in 
which healthcare professionals will often be unable to commit to research 
initiatives at short notice. 
Turning to phenomenology, its founding principle is that “experience should be 
examined in the way that it occurs, and in its own terms” (Smith et al, 2009, 
page 12). Unless researchers step outside their ‘natural attitude’, owing to their 
predilection for order, they invariably seek to place initial understandings within 
a “pre-existing categorisation system” (Phillips-Pula et al, 2011). Instead, the 
‘phenomenological attitude’ enables one to identify the ‘essence’ of human 
experience where the focus is on the subjects’ ‘lived experiences’ thus revealing 
their values, perceptions, meanings and beliefs (Starks and Trinidad, 2007). 
The central feature of phenomenology consists of the ‘epoche process’. This 
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means ‘bracketing’ the researcher’s presuppositions, beliefs, expectations and 
predispositions about the phenomenon under investigation. This may be 
classed as a drawback of phenomenology since the feasibility of truly 
suspending common sense in this way is doubtful (Denscombe, 2007). 
However, Hycner (1985, page 281) clarifies that this “in no way means that the 
phenomenologist is standing in some absolute and totally presuppositionless 
space”. Smith et al (2009) and Hycner (1985) both explain such an extreme is 
neither expected nor possible, respectively, and that the researcher needs to be 
reflective, self-conscious and attempt to moderate the impact of 
presuppositions. Grounded theory similarly encourages the researcher to adopt 
an ‘open mind’ without a “rigid set of ideas that shape what they focus on” 
(Denscombe, 2007, page 90; Clissett, 2008).   
Furthermore phenomenology “celebrate(s)” the possibility of “multiple realities” 
(Denscombe, 2007, page 79). Clearly such grounds for analysis is particularly 
conducive to the present study of the Prescribing Guide in which the ‘lived 
experiences’ of doctors, pharmacists and NMPs are to be explored. Indeed, 
even this form of “pre-existing categorisation” (into ‘healthcare professionals’) is 
to be ‘bracketed’ since the individual interviewee could provide insights from a 
variety of standpoints for example, healthcare professional, manager, junior or 
senior practitioner. Grounded theory, in sharp contrast, is often criticised by 
interpretivists for claiming to provide the one ‘correct’ account of reality that is 
“not open to alternative interpretation” (Denscombe, 2007, page 105). While 
phenomenology’s critics (positivists) claim that its subjective focus lacks 
scientific rigour, it has previously been applied successfully in healthcare 
research in order to gain greater insights and improve collaboration between 
healthcare professionals (Hughes and McCann, 2003).  
The present study is concerned with obtaining authentic descriptions of the 
‘lived experiences’ of key stakeholders for which the phenomenological 
approach was considered most suitable. Its congruence with interpretivism and, 
unlike grounded theory, its ability to permit a well planned research makes 
phenomenology an attractive option for the present study of the attitudes and 
perceptions to the Prescribing Guide.  
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5.7.2 Generating codes and thematic analysis 
Semi-structured interviews were audio-taped and transcribed verbatim. Each 
transcript was first assigned a unique serial number for reference purposes and 
read repeatedly in order to capture the ‘essence’ of accounts given. 
Phenomenological ‘bracketing’ of presuppositions must take place particularly 
during the reading and transcription process in order to first achieve a sense of 
the whole interview – a ‘gestalt’ (Hycner, 1985).The raw data was then 
subjected to a consistent process of analysis which incorporated the following 
four steps: 
 
1. Coding – significant units of data were labelled with a code to clearly and 
transparently represent facts emerging from the raw data. 
2. Categorising the codes – based on their relationships, codes were grouped 
into specific clusters.  
3. Identify themes – emerging themes and patterns were identified that 
communicated the ‘essence’ of stated experiences and perceptions about 
the Prescribing Guide.  
4. Develop concepts – the steps described above facilitated the discovery and 
identification of otherwise obscure concepts and allowed the researcher to 
arrive at generalisable statements.  
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5.8 Timescales for the study  
Timescales for each element of the study are outlined in Table 10 and Figure 7.  
Week 
Pilot 
study 
Stakeholders 
Meetings 
Reconnaissance phase 
Modifications Semi-
structured 
interviews 
Questionnaires 
Formulary 
adherence / 
prescribing 
trends 
1 
Testing of 
research 
instruments 
(small-scale) 
First Meeting   
 
Ongoing 
monitoring of non-
formulary and on-
formulary drug 
prescribing 
 
 
Previous 12 
months formulary 
adherence data 
and prescribing 
trends to be 
prepared for 
presentation at 
second the 
Stakeholder 
Meeting 
 
 
2     
3     
4     
5   
First wave 
First wave 
 
6    
7    
8     
9      
10  Second Meeting    
11     
Modifications to 
Prescribing Guide 
made after 
discussion with 
stakeholders in 
Week 10.  
 
Includes 
appropriately 
communicating 
any changes to 
the service to all 
users. 
 
12     
13     
14     
15     
16     
17     
18     
19     
20   
Second wave Second wave 
 
21    
22 
Study suspended for 10 week period 
Due to a significant change in the researcher’s personal circumstances, it 
was necessary to suspend the study for a period of ten weeks. Since this 
suspension occurred after the agreed modifications were put into place and 
users at the Trust had already been appropriately updated, it was considered 
that this break from the study would have had little effect on the overall 
findings. 
 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32   Second wave 
(resumed) 
Retrieval resumed   
33      
34       
35  Third Meeting     
 
Table 10. Timescale for the study. 
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Figure 7. Flow diagram outlining stages in study. 
Stakeholder Meeting 1 
Stakeholder Meeting 2 
Qualitative data 
analysis 
Pilot study 
Modifications made to 
Prescribing Guide 
Coding scheme established  
First wave of  
data collection 
Self-completion questionnaires  
Semi-structured interviews  
Data extraction  
Preliminary analysis for 
Stakeholder Meeting 2 
Second wave of  
data collection 
Self-completion questionnaires  
Semi-structured interviews  
Data extraction  
Preliminary analysis for 
Stakeholder Meeting 3 
Use of independent coder to 
refine codes and code definitions  
63 themes identified and 13 
Generalised Statements made  
Quantitative data 
analysis 
Statistical analysis of data from 
questionnaires using Chi 
squared testing  
Data extracted represented 
diagrammatically  
Stakeholder Meeting 3 
Discussion & 
Conclusions 
Week 1 
Week 1-4 
Week 5-7 
Week 20-23 
Week 5-8 
Week 11-19 
Week 10 
Ongoing 
(Week 1-21) 
Week 8-10 
Week 33-35 
Week 20-23 
Ongoing 
(Week 1-21) 
In-depth 
analysis of raw 
data took place 
after  the study 
period (i.e. after 
Stakeholder 
Meeting 3) 
Week 35 
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5.9 Research ethics 
 
5.9.1 Local Research Ethics Committee (LREC) approval for study 
Since the study would involve collecting data directly from individuals and in 
addition would require healthcare professionals to give up their time for various 
aspects of the study, ethical approval from the Local Research Ethics 
Committee (LREC) was sought. The researcher attended the Committee’s 
meeting on 22nd April 2009 in order to answer any specific questions and 
provide further clarity.  
On 29th April 2009 the Hertfordshire Research Ethics Committee sent a letter 
(Appendix 10) confirming that, in fact, the study was not strictly speaking 
‘research’, and instead fell into the category of ‘service evaluation’. Therefore, 
after final confirmation was secured from the East and North Hertfordshire NHS 
Trust’s Clinical Governance office, the study was commenced.  
 
5.9.2 Ethical issues in the study 
Although no ethical review was considered necessary by the Hertfordshire 
Research Ethics Committee, an ethical dimension to the research had already 
been built in to the design of the study. How these ethical considerations were 
incorporated into the present study of the Prescribing Guide will be briefly 
outlined in this section.  
To ensure that there was no risk of deception or misrepresentation, efforts were 
made to ensure all participants were fully informed of the clear purpose of the 
evaluation. For the semi-structured interviews and Stakeholder Meetings, 
participants received a participant information sheet (Appendix 5) fully 
explaining the purpose of the evaluation and the Chief Investigator’s contact 
details if they would like to view the findings of the final report. Since the self-
completion questionnaires were Internet-based, a ‘covering email’ (Appendix 9) 
was sent with similar information.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 104 
 
Consent of the interviewee is necessary and has become an important aspect 
of research ethics (Denscombe, 2007; Bryman, 2004). A consent form 
(Appendix 6) was therefore signed prior to starting an interview or meeting. 
These documents clearly stated that participation is voluntary and the 
participant is free to withdraw at any time. The participant information sheets 
explain that the researcher intends to audio-tape interviews and that any 
material produced will be subsequently analysed and may be published in a 
scientific peer-reviewed journal. For questionnaires, implied consent was 
considered appropriate by sending participants the aforementioned covering 
email. Consent was understood by participation and return of the questionnaire. 
The covering letters and emails, participant information sheets and consent 
forms stated explicitly that any participant details will be kept in strict 
confidence. During the interviews and Stakeholder Meetings, no patient health 
records or personal information will be generated from this evaluation. 
Those who contribute to the research should be no worse off, that is, harmed, at 
the end of their participation than they were when they started. One way this 
was ensured is by adhering to the interview topic guides with no deviance 
outside the remit of this research.  
 
5.10 Steps taken to ensure rigour in research analysis 
 
5.10.1 Rigour in qualitative data analysis 
Established ‘good practice’ guidelines that help to ensure rigorous analysis in 
qualitative research have been incorporated into the data collection and 
analysis of the present study. Lincoln and Guba (1985) suggest four key criteria 
that help contribute to the trustworthiness of qualitative research: credibility; 
transferability; dependability; and confirmability. How each of these concepts 
were incorporated into the present study will be discussed below. 
Credibility is concerned with the ‘truth’ of interpretations (Green and Thorogood, 
2004) and to the extent that researchers can demonstrate their data is accurate 
and appropriate (Denscombe, 2007). To mitigate the charge that data is a result 
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of absolute subjective interpretation, a number of measures can be incorporated 
into data analysis. For example, the primary purpose of the ‘Stakeholder 
Meetings’ was to provide a means of validating provisional findings and 
emerging theories from qualitative data. It is recognised that ‘respondent 
validation’ would have been ideal, as Green and Thorogood (2004, page 193) 
put it, this is the “ultimate mark of credibility”, however this approach was 
rejected for two reasons. Firstly on attending the LREC meeting, significant 
concerns about the amount of time taken to conduct semi-structured interviews 
were raised on more than one occasion. The researcher was reminded that the 
site of the study was a busy DGH and that healthcare professionals to be 
interviewed would no doubt be already under significant time constraints. 
Secondly, recruitment of interviewees was particularly difficult as many potential 
participants declined to be involved citing time constraints as the reason. Many 
of those that did eventually agree sacrificed tea breaks and lunch times to 
accommodate the research. For these reasons, the identified Stakeholders 
comprising: a senior clinical pharmacist; a consultant doctor; a senior NMP; and 
the Senior Formulary Pharmacist were considered to provide adequate 
feedback and validation of preliminary findings.  
Methodological triangulation also increases the credibility of qualitative analysis. 
Triangulation through the use of both qualitative and quantitative research 
instruments has been discussed earlier. Another claim to triangulation arises 
from the inclusion of different categories of stakeholders namely doctors, 
pharmacists and NMPs. It was anticipated that different attitudes, perceptions 
and experiences would be revealed thus providing a wider context for making 
interpretations about the Prescribing Guide and its potential impact on 
prescribing practices.  
In addition, during data analysis, deliberate attempts were made to ‘test’ 
emerging theory by searching for disconfirming evidence or deviant cases and 
then making attempts to account for them (Green and Thorogood, 2004). As 
Denscombe (2007) states this approach is related to the argument that good 
research is not just concerned with verification of findings but with their 
falsification as well. This is what Lincoln and Guba (1985) have termed 
‘confirmability’ – the ability to keep an ‘open mind’ and being willing to consider 
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alternative explanations. This is closely related to the concept of ‘reflexivity’ 
which is discussed in the next section (Section 5.10.1.1) and a reflexive account 
has been presented in Appendix 11. Simple counts of relevant events or 
statements in order to increase the reader’s faith in interpretations have also 
been carried out, ultimately defending against the charge of ‘anecdotalism’, 
(Green and Thorogood, 2004).  
We turn now to ‘generalisability’, a term more commonly employed in 
quantitative research. Since qualitative research typically deals with small 
sample populations, Lincoln and Guba (1985) instead developed the notion of 
‘transferability’. This concept is concerned with the extent to which qualitative 
findings ‘could’ be transferred to other instances, rather than with an 
expectation that findings ‘are’ likely to exist in other instances, as is the case in 
quantitative research (Denscombe, 2007). In order to achieve a justified degree 
of transferability, the following approaches were taken for this study. The reader 
has been presented with relevant information and details in order to make 
comparisons with other instances. For example Chapter 4 has attempted to 
provide the reader with a clear picture of the organisation within which the 
research was conducted, as well as relevant details about the Prescribing 
Guide. The practice-based examples in Chapters 2 and 3 further contribute to 
the readers understanding of (a) the nature of the environment from which 
participants were selected to take part in the research; and (b) the dynamics of 
local formulary operation. Furthermore, attention to producing ‘rich’ and ‘thick’ 
descriptions has been a key underlying theme to the research from the outset. 
Thick descriptions imply ‘multi-layered’ insights often from different perspectives 
for instance pharmacists’ views about the Prescribing Guide contrasted against 
those of doctors.  
Additionally, the inclusion of raw data within the analysis allows the reader to 
make their own judgements as to the reliability of interpretations (Green and 
Thorogood, 2004). For this reason, Chapter 6 has included relevant extracts 
from interview transcripts ensuring adequate context is provided rather than 
short statements.  
Green and Thorogood (2004) discuss the issue of ‘transparency’, which 
concerns providing a clear account of procedures. While this chapter has 
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discussed the chosen research instruments, Chapter 6 will describe in further 
detail the lengthy process of coding and theme generation. Providing such 
detailed information acts as a “proxy for being able to replicate research” 
(Denscombe, 2007, page 298).  
‘Dependability’ concerns the question “if someone else did the research would 
he or she have got the same results and arrive at the same conclusions?” 
(Denscombe, 2007). Use of an independent coder (discussed in more detail in 
Section 6.5.1.) was employed in order to help minimise the charge of 
subjectivity as a second individual selected from the academic field would 
facilitate cross checking of coding strategies and interpretation of data.  
 
5.10.1.1 Reflexive analysis of researcher’s personal narrative 
From the outset it was also recognised that the researcher himself is a part of 
the process of producing the data. Whereas in positivistic studies, efforts are 
made to ensure the researcher is largely ‘invisible’, in qualitative research the 
strategy is to instead account, explicitly, for subjectivity (Green and Thorogood, 
2004). Bryman (2004) describes ‘reflexivity’ as a “greater awareness and 
acknowledgement of the role of the researcher as part and parcel of the 
construction of knowledge”. The researcher’s own values – which are 
essentially a form of preconception – can influence a number of points in the 
process of research. In the present study, these issues are of particular 
importance since the researcher was also employed by the Trust as a Senior 
Formulary Pharmacist. As mentioned in Section 4.2, this role was pivotal in the 
development and implementation of the local Prescribing Guide at East and 
North Hertfordshire NHS Trust. During this process, the researcher made 
contact with numerous doctors, pharmacists and non-medical prescribers who 
were all ultimately potential participants to semi-structured interviews or 
Stakeholder Meetings or respondents to the online self-completion 
questionnaires. Specific effort was made to avoid selecting participants for 
interviews or Stakeholder meetings who had been actively involved in compiling 
the clinical content for the Prescribing Guide. Nevertheless, members of the 
pharmacy department and those routinely attending the local DTC meetings 
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(consultants and senior pharmacists) were at least ‘known’ to the researcher 
prior to the research taking place. 
Since objectivity and impartiality can thus be called into question, a reflexive 
account of the researcher’s self and their impact on the research has been 
included exploring how personal experiences and values might have influenced 
interpretations (Appendix 11). This has proven particularly conducive to the 
phenomenological approach taken to analyse the qualitative data. As Hycner 
(1985) suggests, a way of ensuring that presuppositions have indeed been 
‘bracketed’ is for the researcher to initially list the presuppositions that they are 
consciously aware of. It is noteworthy that the reflexive account highlights in 
particular, the involvement of the researcher in previous encounters with 
doctors where there have been varying degrees of disagreement and 
divergence – a topic that is repeatedly raised by participants in the semi-
structured interviews (Chapter 6). Similarly, in the capacity of the Trust’s Senior 
Formulary Pharmacist, the researcher has alluded to a positionality of ‘drug 
expert’.  
In addition, as Denscombe (2007) advises, “personal experience linked to the 
research topic” have been made available in the practice-based examples 
outlined and discussed in Chapters 2 and 3 which should help the reader to 
understand the routine work of the researcher.   
 
5.10.2 Rigour in quantitative data analysis 
Quantitative research findings need to be both ‘reliable’ and ‘valid’ 
representations of the concepts being investigated. Reliability is concerned with 
the consistency of measures (Bryman, 2004). Threats to reliability, particularly 
in questionnaires include using ambiguous questions or two many questions 
where the respondent is likely to lose interest (UKMI, 2011). A good level of 
reliability is achieved if the questionnaire was capable of producing the same 
data on more than one occasion (Denscombe, 2007). Since this study would be 
deploying the same self-completion questionnaires on two separate occasions 
(Week 5-7 and Week 20-23), two ‘check questions’ were deliberately inserted to 
test for consistency (Denscombe, 2007). These questions were not considered 
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to be directly related to the phenomenon under investigation and therefore, 
even in the light of modifications made to the Prescribing Guide, respondents 
with similar profiles were expected to give similar answers. In addition, Greco et 
al (1987) suggest another approach to ensure a questionnaire’s internal 
consistency. They recommend looking for logical patterns within answers to 
different questions. This approach was adopted and is discussed in greater 
detail in Chapter 7. 
Validity, put simply, is concerned with whether the measure of a concept really 
measures that concept (Bryman, 2004). The researcher attempted to ensure 
validation of quantitative data by ‘checking the data’ for errors arising from 
incorrect data entry by respondents (Denscombe, 2007). In many cases such a 
task can be laborious. However the questionnaires used in this study were 
completed online and electronically submitted using SurveyMonkey. This online 
resource provided a facility to set each question as a ‘required field’ so if a 
respondent had overlooked a question, he / she was instantly presented with 
another opportunity to provide an answer.  
Additionally, the validity of quantitative research instruments is often assessed 
by determining whether the findings can be generalised to other similar settings 
(Denscombe, 2007). Chapter 8 provides a discussion of the findings and 
compares this to the existing body of literature, particularly where 
questionnaires or other forms of survey have been used to investigate hospital 
drug formularies. However, it is important to note that in this study 
questionnaires were deployed primarily to corroborate findings emerging from 
semi-structured interviews and to provide a more comprehensive overall 
understanding of the Prescribing Guide and its likely impact on prescribing 
practice.  
 
5.11 Summary of Chapter 5 
This chapter has attempted to provide a clear and explicit account of how the 
chosen research instruments were deployed throughout the course of the study. 
The principal component of the research is the findings from the qualitative 
research. As the aims and objectives of the study outline, the attitudes, 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 110 
 
perceptions and experiences of users using the Prescribing Guide have been 
extracted using semi-structured interviews. Alongside this, online self-
completion questionnaires have been developed in order to corroborate 
qualitative findings and have helped in providing a broader, more 
comprehensive context to this primary data. Formulary adherence and 
prescribing trends that were extracted from the pharmacy department’s 
computer have been more difficult to interpret but, nevertheless, provide further 
insights into the nature of prescribing practices. 
Chapter 6 will now turn to the qualitative research data that has been subjected 
to an extensive and rigorous analysis.  
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Chapter 6 
Findings – Qualitative Data 
 
6.1 Introduction 
This chapter is the first of two that present the study’s findings. Chapter 7 will 
analyse the quantitative findings from the online questionnaires and describe 
the prescribing data extracted from the Pharmacy department’s computer 
system. The present chapter focuses on the qualitative data arising from the 
semi-structured interviews. Since both Chapters 6 and 7, at various points, refer 
to the ‘modifications’ made to the Prescribing Guide, in the interests of greater 
clarity, this chapter begins by addressing these modifications at the outset.  
In total, 34 semi-structured interviews were conducted. Although the 
phenomenological approach has been discussed in the previous chapter as has 
a broad overview of the thematic analysis, this chapter describes how the 
‘coding scheme’ was first independently validated and then used to generated 
‘units of meaning’ represented by an extensive number of codes. The vast 
majority of the chapter is spent on the presentation of 63 themes identified from 
the coded interview transcripts. These themes were further analysed in order to 
derive a number of ‘generalised statements’.  
 
6.2 Modifications made to the Prescribing Guide 
In this chapter the qualitative data set from both the first and second wave of 
semi-structured interviews will largely be presented together, however, notable 
differences will be highlighted when necessary and references to modifications 
will occasionally be made.  
Two phases of reconnaissance or ‘fact-finding’ were conducted. The purpose of 
this approach was in order to introduce ‘change’, a central element of action 
research. After having discussed provisional findings (emerging from the first 
phase of reconnaissance) at the second Stakeholder Meeting, specific 
modifications were discussed, agreed and then implemented.  
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The modifications listed in Appendix 12 can be classified into three broad 
categories of change recommended by participants of semi-structured 
interviews and respondents to online questionnaires. These categories concern: 
(1) prescribing guidance; (2) awareness and / or training; (3) features available 
on the Prescribing Guide. The implementation and realisation of these 
modifications contributes to the study’s objective 5. 
 
6.3 Pilot interviews 
 
6.3.1 Recruitment of pilot interview participants 
The purposive sampling technique was used in the study to identify and select 
potential participants for semi-structured interviews. During Week 1-4 two 
individuals were similarly chosen to participate in pilot interviews in order to test 
the research instrument’s feasibility considering the local pressures and 
resources. Another key advantage of the pilot was to ensure that the researcher 
would acquire some experience with conducting semi-structured interviews 
particularly in being able to remain impartial and refrain from asking leading 
questions. 
The researcher was employed at the Trust as a Senior Formulary Pharmacist 
and thus was familiar with most consultant doctors and all pharmacists 
operating at the Trust. For this reason, the researcher was in a position to select 
participants based on their potential insights and any ‘special’ contribution they 
may have to make. It was considered more appropriate, for the purposes of the 
pilot interviews, to select ‘senior’ participants since they would be more likely to 
elaborate on the issues addressed in the interview topic guides (Appendix 4). 
Therefore, one consultant doctor (CD1) and one senior pharmacist (SP1) were 
selected and have been included in Table 11 (Section 6.4).  
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6.3.2 Reflections on the conduct of pilot semi-structured interviews 
The pilot interviews were transcribed and reviewed repeatedly whilst listening to 
the original recording. The transcripts demonstrate that all original topics were 
addressed generating passages of discussion that could be appropriately 
subjected to thematic analysis. Therefore the interview topic guides were 
retained and used during subsequent semi-structured interviews.  
However, during the first pilot interview with CD1, the interviewer did use 
leading questions on two specific occasions. On both occasions, CD1 
fortunately appeared to not be influenced by such suggestive questions.  
Since it is essential to minimise any preconceptions and presuppositions for a 
true phenomenological stance, the interviewer modified his approach by making 
a more concerted effort to ‘bracket out’ such knowledge. The interviewer 
conducted the second pilot interview without any leading questioning.  
During the second pilot interview, the venue chosen was a small pharmacy 
office beside a noisy out-patients’ waiting area. Although the noise did not 
disrupt the discussion between the participant and the interviewer and the 
digital dictaphone was sensitive enough to pick up the entire conversation, there 
were sections that were difficult to transcribe and required repeated listening 
and review in order to confirm the exact words used. Once again, this was a 
useful experience leading to the interviewer placing the dictaphone more 
strategically and ensuring the venues chosen were quieter where possible.  
In summary, the pilot interviews proved to be useful, yielding interesting 
findings. Owing to their successful execution and insight from the participants 
the transcriptions were included in the larger qualitative data interpretation.  
 
6.4 Conducting the semi-structured interviews 
Although 32 semi-structured interviews (including pilot interviews) were 
originally planned, two extra interviews were also permitted on the advice of the 
Stakeholders. The first supplemental interview was with the Chief Pharmacist 
who had declined to participate however after discussions with the researcher’s 
supervisor and the Stakeholders, the researcher continued to pursue this 
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individual due to potentially unique insights. The second additional interview 
followed the presentation of emerging themes at the second Stakeholder 
Meeting. All four Stakeholders felt that the perceptions of the one NMP, during 
the first wave of semi-structured interviews, were particularly interesting and felt 
that there should be more NMP interviews. The NMP-Stakeholder suggested a 
potential participant and provided contact details. Table 11 lists all 34 semi-
structured interviews conducted during this study. An example interview 
transcript has been provided in Appendix 18. 
After the 10 week suspension in the study (Table 10), the interviewer resumed 
data collection in Week 32. Three semi-structured interviews were conducted by 
telephone. For each of these participants, consent forms were sent to the 
participants prior to the agreed interview dates. Telephone interviewing carries 
with it, its own unique set of advantages and limitations. While they can prove to 
be far cheaper to conduct and save having to travel long distances (as in the 
researcher’s case), interviewers obviously cannot engage in observation 
(Bryman, 2004). Therefore non-verbal cues such as signs of puzzlement and 
unease or occasions in which the participant uses gestures of emphasis will not 
be discernible. However, the necessity to rely on telephone interviewing as an 
alternative did not appear to have caused any significant detriment to the study 
since the participants’ perceptions and views were recorded and analysed 
without any perceived ambiguity. 
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No. Participant Code Duration Venue Date 
Phase 1 of semi-structured interviews: 
1 Consultant Doctor 1* CD1 37mins Consultant’s office June 2009 
2 Consultant Doctor 2 CD2 37mins Consultant’s office June 2009 
3 Consultant Doctor 3 CD3 34mins Consultant’s office July 2009 
4 Consultant Doctor 4 CD4 45mins Consultant’s office July 2009 
5 Registrar Doctor 1 RD1 33mins Doctor’s office on ward June 2009 
6 Registrar Doctor 2 RD2 32mins Doctor’s office in clinic June 2009 
7 Registrar Doctor 3 RD3 31mins Doctor’s office on ward July 2009 
8 Junior Doctor 1 JD1 29mins Pharmacy office June 2009 
9 Junior Doctor 2 JD2 33mins Pharmacy office July 2009 
10 Junior Doctor 3 JD3 33mins Pharmacy office July 2009 
11 Senior Pharmacist 1* SP1 46mins Pharmacy office June 2009 
12 Senior Pharmacist 2 SP2 35mins Pharmacy office June 2009 
13 Senior Pharmacist 3 SP3 41mins Pharmacy office June 2009 
14 Senior Pharmacist 4 SP4 39mins Pharmacy office July 2009 
15 Senior Pharmacist 5 SP5 28mins Pharmacy office  July 2009 
16 Junior Pharmacist 1 JP1 37mins Pharmacy office June 2009 
17 Junior Pharmacist 2 JP2 32mins Pharmacy office June 2009 
18 NMP 1  NMP1 38mins NMP’s office June 2009 
Phase 2 of semi-structured interviews: 
19 Consultant Doctor  CD5 29mins Consultant’s office October 2009 
20 Consultant Doctor  CD6 36mins Consultant’s office December 2009 
21 Consultant Doctor  CD7 34mins Consultant’s office December 2009 
22 Registrar Doctor  RD4 28mins Doctor’s office on ward December 2009 
23 Registrar Doctor  RD5 27mins Doctor’s office on ward December 2009 
24 Registrar Doctor  RD6 27mins Doctor’s office on ward January 2010 
25 Junior Doctor JD4 34mins Doctor’s office on ward October 2009 
26 Junior Doctor JD5 22mins Telephone call arranged December 2009 
27 Junior Doctor  JD6 28mins Telephone call arranged January 2010 
28 Senior Pharmacist  SP6 38mins Pharmacy office October 2009 
29 Senior Pharmacist  SP7 34mins Pharmacy office October 2009 
30 Senior Pharmacist  SP8 34mins Telephone call arranged January 2010 
31 Senior Pharmacist  JP3 24mins Pharmacy office October 2009 
32 Junior Pharmacist  JP4 28mins Pharmacy office  October 2009 
33 NMP 2 NMP2 28mins Doctor’s office on ward October 2009 
34 NMP 3 NMP3 38mns NMP’s office October 2009 
 
Table 11. Semi-structured interviews conducted during study (* pilot interviews). 
 
6.5 Coding and thematic analysis 
 
6.5.1 Independent coding for validation of coding scheme 
Independent coding was also sought out for the analysis of the qualitative data. 
The process was considered to have provided further credibility to the 
qualitative data analysis.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 116 
 
First a ‘coding scheme’ was established based on a description of Glaser and 
Strauss’s original ‘grounded’ approach to data analysis (Miles and Huberman, 
1994). Recommended for the more inductive researcher, it encourages more 
open-mindedness and contextual-sensitivity. In contrast to other coding 
approaches, this coding scheme did not support developing a ‘prefabricated 
start list’ of codes instead allowing the “data to get well molded [sic.] to the 
codes that represent them” (Miles and Huberman, 1994, page 58).   
Once the coding scheme had been discussed and agreed with the researcher’s 
doctorate supervisor, it was applied to CD1’s interview transcript, generating a 
list of codes along with their code definitions. An independent coder, identified 
from within the academic field, then provided their own interpretations of the 
interview transcript. Once the researcher and the independent coder reviewed 
each other’s contributions, they were then in a position to identify areas of 
congruence; where they differ; and also discuss codes that had been deemed 
ambiguous. This resulted in the refinement of codes and code definitions which 
could then be applied to the remaining interview transcripts.  
 
6.5.2 Presentation of themes 
The analysis of the entire qualitative data set for the study generated a number 
of codes which were then categorised into ‘clusters’ (Appendix 13). Themes 
were then derived from further patterns identified between the clusters and 
codes. These themes are presented in Sections 6.6 to 6.9 below. The sections 
have been organised according to the order in which the topics appear in the 
original interview topic guides.  
All sixty-three themes appear in the following sections, numbered, in black and 
bold face. Table 12 outlines how the themes in each section are linked to the 
study’s original aim and objectives. 
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Section Aim and Objectives 
6.6 Perceptions of the hospital drug formulary and DTC Objectives 1 and 2 
6.7 Perceptions of the Prescribing Guide Objectives 2 and 4 
6.8 Influence on local prescribing practices Objective 3 
6.9 Interactions between key stakeholders and the working 
dynamics within which the Prescribing Guide functions 
Objectives 1, 3 and 5 
 
Table 12. Linking qualitative findings to study’s aim and objectives. 
 
6.6 Perceptions of the hospital drug formulary and DTC 
 
1. Formularies ensure management of constrained financial resources 
The wider budgetary benefits and implications of hospital drug formularies were 
clearly identified, particularly by pharmacists, as one of the principal reasons for 
their existence. A senior pharmacist and manager stated one of the purposes of 
the local formulary was:  
 “...to control prescribing, to support the PCT as well in controlling 
their prescribing.”  
SP5 Interview No.15 
Doctors and pharmacists both expressed a similar awareness of limited 
‘available resources’ and an NHS in which there is a finite budget. The 
implications of this financially constrained healthcare setting on the local 
availability of drugs are clearly understood by most participants.  
 
2. Pharmacists more likely to speak about formularies in terms of clinical 
benefits to patients 
Participants were in general able to elaborate thoroughly, and without the need 
for further probing, about how the formulary is intended to help impact on 
prescribing practices. Pharmacists were more inclined to first state how 
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formularies are likely to be clinically beneficial to the patient within practice and 
then mentioned a cost-effectiveness strategy. 
Senior pharmacists, particularly managers, were quick to point out that the 
formulary ensured ‘cost-effective’ prescribing as opposed to ‘cost-containment’ 
alone.  
 
3. Doctors insistent on formulary being adaptable  
Other participants, notably more doctors, while providing an overall supportive 
sentiment for formularies often supplemented this support with a somewhat 
‘conditional’ undertone. For example, one consultant stipulates the need for 
formularies to be “adaptable” and the need for “room to manoeuvre”.  
Only one senior pharmacist displayed similar views asserting the need for the 
formulary to be able to adapt in “certain situations”. This pharmacist routinely 
visited many wards as part of her role and was an experienced member of the 
pharmacy department involved in training junior pharmacists. She often spoke 
from experience and justified the need for flexibility within the formulary.  
 
4. Pharmacists unaware of restrictive language 
A number of participants articulated the view that formularies were in fact 
devices of control and impose restrictions on prescribing practices. Some 
pharmacists, though not overtly expressing any formal support for a ‘restrictive 
approach’ per se, routinely used words such as “ought to” and “enforce”.  
One senior pharmacist manager who oversees the purchasing department 
described scenarios in which the prescribing of certain non-formulary drugs or 
second-line options were not routinely challenged by pharmacists. She 
complained “there isn’t a rigid <<emphasis>> system” (SP4 Interview No.14).   
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5. Doctors perceive formulary as restrictive  
In sharp contract were doctors’ views. The majority of doctors far more overtly 
described the formulary as a means to limit, restrict and ultimately control 
prescribing. In addition, with many of these statements there were a number of 
allusions to a perceived cost-motivated element to formularies.  
  “To keep the prices down <<smiles>>. Oh, I think a very distant 
second is umm, good practice...it’s restrictive rather than helpful.”  
CD4 Interview No.4 
 
NMPs interviewed stated that the formulary was to ensure appropriate 
prescribing and ensuring drugs were chosen on the basis of their evidence-
base and cost-effectiveness. One NMP did however stress that the formulary is 
a “guideline” and felt it should not interfere with clinical judgment.  
 
6. Formulary restrictions generate opposition and resistance 
Continuing with the theme described above of ‘control’ and ‘restrictions’, the 
interviews also revealed far more ‘assertive’ versions of such views about the 
formulary concept. These views often appeared to result in some form of 
‘outright’ opposition towards the formulary’s existence. In one interview with a 
medical registrar, initially supportive comments, on further probing by the 
interviewer, diminished to a more resistive stance, stating that the formulary is 
in fact “wrong” to “force” doctors to change their drug choices (RD3 Interview 
No.7). 
Many doctors described frustrations around the local imposition of excessive 
guidelines and reviews in prescribing practice. Duplicating reviews and writing 
guidelines locally were deemed “wasting a lot of time” (CD 6 Interview No.20).   
Two doctors in particular described how they usually attempt to overcome the 
perceived restrictions of the hospital formulary. Faced with such restrictions, 
rather than ‘capitulate’ to it, doctors effectively bypass the hospital formulary 
and the pharmacy department and involve the patient’s GP in obtaining the drug 
in question for the patient. 
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7. Prescribing practice should include being able to experiment with 
drugs and gain experience 
It seemed that doctors may also oppose the existence of the formulary on the 
grounds that they should be free to gather experience by prescribing a wide 
range of drugs.  
Notably, one senior pharmacist also expressed a similar view. He stated that 
formularies, through limited availability of drugs, can “stifle innovation” because 
drugs are not being used beyond “stringent” clinical trial settings (SP3 Interview 
No.13). 
 
8. Only pharmacists and DTC members able to elaborate on DTCs’ 
importance and role 
Many of the views regarding the local DTC seemed to mirror those of the 
formulary. Participants, in particular pharmacists, referred to clinical 
effectiveness, evidence-based medicine, patient safety and cost-effectiveness 
routinely. Those participants who were members of the DTC were better able to 
elaborate on its functions and purpose. Registrars on the whole were familiar 
only with the existence of a local DTC who at best could only vaguely outline its 
purpose.  
 
9. Doctors regard DTC as primarily concerned with cost-containment 
CD5 when discussing the DTC, further implies that it exists to support 
pharmacists in their role to control prescribing. Although he asserts that the 
DTC is “obviously very important” he also adds: 
 “...so I mean it is, it’s rather a policeman’s role I’m afraid to say, 
sorry <<laughs>>...”  
CD5 Interview No.19 
 
His seemingly apologetic stance may imply that he feels he has revealed a 
sentiment that may offend pharmacists or is contentious.   
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Junior doctors on the other hand, particularly in the first wave of interviews were 
unaware of the Trust’s DTC. After the modifications (Appendix 12) were 
implemented and new doctors were spoken to about the DTC’s purpose at their 
induction training and leaflets were handed out explaining how it operates, two 
out of the three junior doctors during the second wave of the interviews were 
able to, at least vaguely, recall the DTC’s function. One junior doctor displayed 
a frustrated tone when the DTC was being discussed in the interview describing 
it as “a lot of red tape” (JD6 Interview No.27). 
 
10. Pharmacists tend to justify the cost-motivation behind the DTC 
Pharmacist participants also tended to mention a cost-motivated element to 
DTCs, but here there was a frequently observed effort to contextualise the cost-
orientation and in effect, justify the ‘cost-effectiveness’.  
Conversely, it should be noted that there were ‘sceptical’ views even among 
members of the pharmacy department who were critical of the DTC’s intentions 
(for example JP3).  
 
11. Doctors regard the DTC as excessively bureaucratic 
Many consultants and registrars expressed the view that the DTC represented a 
bureaucratic system of controlling prescribing. These participants ranged from 
junior to senior doctors and also included members of the DTC. There was a 
sense of ‘resignation’ from many, a pervasive tendency to abandon pursuits 
when faced against the DTC process as it is perceived to be “an uphill battle” 
(RD2 Interview 6). One consultant (CD2) described his time constraints and the 
number of patients he sees routinely and complained that it is too difficult for 
him to “sit down and produce a voluminous application process for things that 
are done and dusted around the world and internationally”.  
The Chairman of the DTC, who was also interviewed (CD3 Interview 3), was 
notably forthcoming about his view that the DTC was indeed bureaucratic. He 
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spoke about the “torturous way in which we appraise drugs” and stated there 
was “a lot of duplication [of drug reviews] unnecessarily”.  
 
12. Pharmacists tend to justify the need for the DTC process 
Of the pharmacists that had discussed aspects of the DTC, many appeared to 
be able to ‘understand’ the frustrations and sympathise with the resentment of 
doctors. Nevertheless, these pharmacists all maintained an apparently 
pragmatic view, going on to justify the rationing of the drug budget and 
asserting that adherence to the DTC was essential for effective medicines 
management.   
 “I think they think they’re giving away some of their autonomy... 
...but at the end of the day you can’t have one consultant have one 
form of treatment and another having another...” 
JP4 Interview No.32 
 
 
13. The formulary perceived as a threat to prescribing autonomy 
Almost all doctors expressed some degree of discomfort with the formulary 
process restricting their prescribing practices. Certainly all consultants, including 
members of the local DTC, maintained such views as well registrars.  
While many of the comments were either obscured or tempered with an overall 
appreciation for the formulary, other consultants took a particularly ‘damning’ 
view. A consultant commenting on the perceived value of formularies to junior 
doctors explained that formularies could in fact harm free and independent 
thinking. Although there was no clear reference to the issue of autonomy, the 
consultant contended:  
 “juniors will tend to see it as an instruction which precludes thinking 
about things...possibly reduces their cerebral activity... 
...so if I became dependent on it, I wouldn’t be able to function 
 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 123 
 
properly without it.”  
CD4 Interview No.4 
The implication is that by relying on the formulary for prescribing decisions, 
junior doctors are unable to develop ‘autonomous’ prescribing practice. Junior 
doctors on the whole appeared to take a more collaborative stance however 
there were more forthcoming participants who took a similar view to their 
superiors. 
Non-medical prescribers corroborated much of the rhetoric from doctors.  
 
14. NMPs feel restricted by their own lists 
NMPs described how they felt restricted in much the same way doctors did. 
According to the three NMPs interviewed, the Trust had imposed a tailored ‘list’ 
to which each NMP was required to adhere to.  
 
6.7 Perceptions of the Prescribing Guide 
15. Prescribing Guide widely welcomed and praised as a new service 
The Prescribing Guide was widely praised for having an innovative design and 
interactive features. As with the perceptions of the formulary concept, once 
again pharmacists were more able to elaborate on the various aspects of the 
Prescribing Guide.   
One senior pharmacist manager stated that in her 10 years of being at the 
Trust, the Prescribing Guide “was the best thing that has come out of the 
Pharmacy department” (SP6 Interview No.28). Whether participants had 
expressed an earlier resentment towards the formulary concept or not, all 
participants, except one (CD7 Interview No.21), to some extent complimented 
the Prescribing Guide. CD7 appeared notably dismissive about the new service 
asserting her established drug expertise.  
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Other doctors however, as with pharmacists were nevertheless impressed with 
the available version of the Prescribing Guide. When senior doctors were asked 
whether the Prescribing Guide met their expectations of what a local hospital 
formulary should offer its users, most participants stated it was better than their 
expectations. 
 
16. Managers concerned with impact data 
Some participants did, however, demonstrate a level of doubt and suspicion 
regarding the actual use and impact of the Prescribing Guide. Noticeably, the 
two participants to express this scepticism most bluntly were a senior 
pharmacist manager and a consultant who were both senior members of the 
DTC.   
  “...I’m very anxious to know if the quantitative research shows that 
it has changed prescribing habits... 
...the Trust wants to know whether they’ve got value for money out 
of it...” 
SP5 Interview No.15 
 
 
17. Vague conjecture regarding a perceived impact of the Prescribing 
Guide 
Throughout the interviews there was a sense of ‘perceived impact’ rather than 
anything particularly tangible that participants could point to. Many pharmacists 
for instance, were aware that the Prescribing Guide was now part of the 
doctors’ induction training programme and they may have been making 
assumptions about the impact of the service based on this knowledge.  
Among doctor participants there was again, rather vague conjecture regarding 
the perceived, potential impact of the Prescribing Guide. Doctors speculated 
that the Prescribing Guide was likely to be influencing specifically junior doctors’ 
prescribing and not at the consultant level. Consultant Doctor 5 (CD5 Interview 
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No.19) also stated that the Prescribing Guide will have “increased patient 
safety”, although once again he seemed to have derived this statement only 
from speculation rather any distinct examples that he could point to in practice. 
 
 18. Resorting to the Prescribing Guide needs to become ‘habit’ 
A number of doctors also mentioned that they were actively introducing the 
Prescribing Guide to colleagues in their teams. Two registrars in particular 
described the importance of “making an effort” (RD5 Interview 23) and to 
“hammer it home” to their junior doctors because “often they need a helping a 
hand and the Prescribing Guide offers so much” (RD4 Interview 22).   
There was also a sense that in order for the Prescribing Guide to have a 
sustained impact on practice, referring to it as a primary resource would need to 
become a “habit” or part of “routine” activities over time.  
  “...it’ll get into our habits and collective consciousness eventually.” 
CD5 Interview No.19 
 
 
19. Prescribing Guide is currently more supportive to junior doctors rather 
than an immediate source of drug information 
Many pharmacists pointed out that currently the Prescribing Guide was 
probably “more supportive” (JP3 Interview 31) to junior doctors rather than a 
first port of call. This was confirmed by corroborating statements made by junior 
doctors. 
Following the modifications made to the Prescribing Guide, some pharmacists 
and doctors did make comments about a perceived improvement in the level of 
awareness of the Prescribing Guide as a result of now being included in the 
new junior doctors’ induction training:  
 “...in my, you know, the induction for new junior doctors, it’s quite 
high up as an influence and it’s going up for sure... 
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...I mean when I spoke to them yesterday, they were like ‘oh yeah I 
know how to use that’ so the awareness is there now for sure.” 
SP7 Interview No.29 
 
Participants described, often in some detail, instances of using the Prescribing 
Guide. Many of these descriptions take the form of verbal diaries that help to 
understand where it appeared to be useful.  
 
20. Prescribing Guide now primary source of drug information for most 
pharmacists 
Pharmacists were, on the whole, more readily able to describe various 
experiences of using the Prescribing Guide. A number of pharmacists stated 
that their primary source of information was now the Prescribing Guide in order 
to check whether a prescribed drug was stocked at the Trust.  
 “Right, for me, I would be looking at formulary status so looking at 
the Prescribing Guide as my number one thing because...I would 
rather than using my personal opinions and using sort of like past 
experience, I would rather be looking at what is laid down as sort of 
rules and regulations so I would be looking to use that.” 
JP2  Interview No.17 
 
 
21. Pharmacists and doctors differ in consideration of formulary status of 
drug 
Pharmacists stated that inappropriate or incorrect prescribing would typically be 
challenged “retrospectively” (SP4 Interview No.14). Although many pharmacists 
aspired to be able to challenge prescriptions “at the point of prescribing” (SP7 
Interview No.29) while being part of doctors’ ward rounds, they felt that owing to 
limited available resources, the reality meant that they had no other resort other 
than to identify errors ‘after’ prescribers had already selected and prescribed the 
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drug. Faced with such a reality, pharmacists stated they would use the 
Prescribing Guide accordingly:  
  “...like, if a doctor prescribed something but now you can say ‘you 
can’t have it’ and he’s like ‘well why not’...you can say ‘here look, 
this is the Prescribing Guide and it is such and such line’.” 
SP1  Interview No.11 
 
This does however highlight a significant difference between the pharmacists’ 
approach to drug therapy and the prescribers’ approach. Pharmacists not only 
manage prescriptions ‘after’ drug selection has already been made, but also, 
typically approach the ‘appropriateness’ of the drug by checking its formulary 
status. Conversely, doctors often do ‘not’ incorporate the formulary status of a 
drug into the selection process and often cite the patient’s well being as the 
primary driver for drug choice. Therefore the need to consult the Prescribing 
Guide in the ‘first’ instance, that is, ‘prior’ to drug selection was seen to be 
noticeably absent in doctors.  
 “...doctors don’t think about the formulary in the same way you 
do...doctors only really think about the patient hey?” 
CD6  Interview No.20 
 
 
22. Prescribing Guide facilitates pharmacists’ retrospective challenging of 
prescribed drugs 
All pharmacists stated that they would typically use the Prescribing Guide 
during their routine dispensary duties to screen in-patient drug charts and out-
patient prescriptions. Once again, this represented a tendency to retrospectively 
analyse drug prescribing. Nevertheless, pharmacists seemed to find the 
Prescribing Guide useful in this setting since it provided convenient access to 
the BNF, NICE and other guidelines and links to the DTCs drug decisions. Four 
pharmacists referred to challenges they made individually regarding the 
inappropriate prescribing of solifenacin, a ‘red’ traffic light drug (third-line) being 
prescribed, against the DTC decision as a first-line choice. They all described 
how the Prescribing Guide was successfully used to inform their challenges 
during each encounter with the corresponding prescribing doctors. 
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Of the doctors, only a single registrar claimed to use the Prescribing Guide in a 
similar fashion to pharmacists screening in the dispensary, that is, available at 
the desk in her out-patient clinic:  
  “...I’ll bring it up for every clinic...so I’ll open up typically Kodak, ICE 
and the Prescribing Guide so that I can just check stuff as I’m 
seeing patients.” 
RD1 Interview No.5 
 
 
23. Access to Prescribing Guide thwarted by limited computer terminals 
A number of pharmacists explained that use of the Prescribing Guide on the 
wards, as opposed to in the Pharmacy dispensary, was less achievable due to 
limited accessibility to computer terminals. Doctors and NMPs corroborated 
these claims.  
 
24. Access to Prescribing Guide thwarted by time constraints 
One senior pharmacist did however contend that accessibility was not as much 
a barrier as was the limitation placed on the amount of time made ‘permissible’ 
to each pharmacist on their ward. Another senior pharmacist made the following 
comments regarding junior pharmacists in the department: 
 “they feel under pressure you know they just don’t have the time to 
spend on each patient, you know they might make a difference for 
one patient, but then they’ve still got twenty-nine to deal with in 
umm, a umm very short space of time on the ward, umm you often 
just end up making the supply and that’s about it...” 
SP8  Interview No.30 
 
This was corroborated by a number of pharmacists, particularly juniors. Junior 
doctors felt similar time constraints prevented them from using the Prescribing 
Guide as frequently as they perhaps might intend to. JD5 stated he used the 
Prescribing Guide to access the eBNF adding that he routinely lacks the time to 
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be able to browse through the “outside reference sources” that have been made 
available via links.  
 
25. Prescribing Guide not appropriate for specialists (use value) 
Consultant doctors and some registrars stated they were familiar with the drugs 
they routinely prescribe and therefore did not feel the need to consult the 
Prescribing Guide. Many did however mention that they may use it for drugs 
that they are not familiar with as the quote illustrates below: 
 “...so for umm, respiratory, I’m fairly on board with what I’m doing 
and I’m fairly certain I’m aware of all the evidence I would need to 
practice...but certainly for the more general medication outside my 
own area of expertise, yeah sure, I’d consider it in that situation.” 
RD5  Interview No.23 
 
NMPs appeared to share the opinions of doctors. They all asserted a level of 
confidence in their own drug ‘lists’ and thus felt no immediate need to consult 
the Prescribing Guide since they would not be prescribing ‘outside’ their area of 
expertise. NMP3 stated she accessed it regularly only to check local stock and 
formulation availabilities. NMP1 (a pharmacist), stated that she routinely used 
the Prescribing Guide only for screening prescriptions in the Pharmacy 
dispensary – therefore solely in the capacity of a pharmacist. Interestingly 
though, as an NMP, she too felt confident in her area of expertise (anaemia in 
renal patients) and asserted that she was able to function as a prescriber 
without the need for additional support from the Prescribing Guide.  
 
26. Prescribing Guide praised for its comprehensive inclusion of a wide 
range of information sources within one local website 
As stated in the previous subsection, participants in general praised various 
aspects of the Prescribing Guide. Pharmacists emphasised in particular: the 
traffic light system of organising the drugs; links to external websites; the 
apparent ease-of-use; and links to drug decisions made by the local DTC.   
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The majority of NMPs and doctors also praised individual features of the 
Prescribing Guide. In particular, many doctors stated that inclusion of links 
specifically to the eBNF was “quite a good touch and obviously crucial” (RD4). 
Doctors commented on the “easily recognisable setup” referring to the BNF-
style breakdown of chapters and subsections.   
There was widespread appreciation for the availability of clinical guidelines and 
other prescribing guidance. Both junior professionals as well as seniors 
described the value this feature offered. 
 
27. Prescribing Guide on occasion supplanting advice of colleagues 
Similarly doctors identified how on occasions the Prescribing Guide can serve 
as an alternative to contacting their senior colleagues or the ward pharmacists 
for advice.  
 “Oh well I think it’s fantastic especially for us umm, junior doctors, 
it’s a way of as I said, umm knowing what’s the first-line options 
available to you without having to contact the reg or the 
consultant...” 
JD5  Interview No.26 
 
 
28. Prescribing Guide provides an awareness of local availabilities and 
priorities 
Participants from each of the healthcare professions stated that the Prescribing 
Guide was useful in making users aware of the local stock availabilities, local 
preferences through traffic light systems and local guidelines. The emphasis 
here is clearly on the ‘localised’ insight that the Prescribing Guide can bring to 
prescribing practices. Once again, senior practitioners – pharmacists and 
doctors – made the case for this local insight being most useful for ‘juniors’ at 
the Trust.  
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29. Prescribing Guide has educational value 
There were also numerous references to the educational value that the 
Prescribing Guide brings to practitioners. SP1 spoke of how the Prescribing 
Guide was used in a junior pharmacist’s formal training exercise. Other 
participants referred to a more subtle, indirect educational function that the 
Prescribing Guide served through regular use. 
 “...with all the links that go beyond the Trust, especially to the 
juniors, because ultimately it is educational, it is something that 
people can easily click around on and just become familiar with the 
drugs used at this particular hospital...” 
RD4  Interview No.22 
 
 
30. Traffic light system causes confusion 
Although participants praised the traffic light system for its visual, graphic 
representation of first-line and second-line drug options, there were a number of 
participants, notably pharmacists, who felt confused by the ‘red’ traffic light.  
 “...I can remember what green is, amber I can probably, I’m never 
sure if red is restricted or not allowed because I think if it’s not 
allowed at all, it’s not there...I sometimes have to think about that 
so maybe if I think that, others would too.” 
SP5  Interview No.15 
 
JP1 also describes an incident in which doctors were frustrated at seeing a drug 
classified as ‘red’ and assuming that indicated it was a ‘non-formulary’ status 
and thus unavailable when in fact this was not the case.  
 
31. Prescribing Guide contains more information than is needed 
A few participants spoke about the perceived comprehensiveness of the 
Prescribing Guide as further compounding the already time constrained 
atmosphere.  
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 “I’ll tell you another thing, I mean, you ask me a negative, I know 
that you’re attaching guidelines...the down side to that is that I find 
the juniors wanting to check so many guidelines, I mean three 
hours to screen a prescription, I think to myself we can’t be doing 
that.” 
SP5  Interview No.15 
 
CD4 similarly referred to the Prescribing Guide as “encyclopaedic”. He further 
cited requirements on doctors “being asked to do more and more in shorter 
time” as a reason why using the Prescribing Guide was “relatively not 
productive in clinic”. CD4 stated that information sources can often reduce the 
“cerebral activity” of doctors and using a “computer program which tells you 
what it [the drug for a patient] is” can hinder the development of a competent 
and autonomous medical professional. There appears to be an implication here 
that the Prescribing Guide ‘may’ provide guidance for the clinical management 
of the patient that is inappropriate and that the doctor should engage the 
required thought process to be able to discern this for them self. 
 
32. Doctors concerned with patient’s impression of them using the 
Prescribing Guide 
Doctors also raised the issue of the patient’s perspective with regards the 
Prescribing Guide. They contended that not only was it impractical to move 
away from the patient’s beside in order to consult information sources but 
particularly in the out-patient clinic setting, “it is still very obvious to the patient 
that you’re looking though the book about them” (CD1 Interview No.1).  
 
33. Recommendation to ensure more up-to-date links to local and national 
guidelines 
All categories of participants stated more guidelines would encourage them to 
use the Prescribing Guide more. One registrar suggested listing the appropriate 
clinical management of common scenarios that he encountered in his speciality 
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for example the drug management of a patient being admitted for a routine 
angiography.  
Guidance was also noted to take the form of advice from specialists for example 
Directorate Pharmacists. SP3 stated that these senior clinical specialists ought 
to be more responsible for updating their corresponding chapters and even 
conceded that he, himself, should contribute more too. Pharmacists made a 
number of recommendations, often very specific and concerning their own area 
of expertise.  
An important feature of ‘guidance’ was seen to be its ‘timely’ relevance. Many 
participants, across all healthcare professionals, stated that guidance should be 
kept up-to-date.  
 “You know for me if I knew that it wasn’t updated more than once 
each year then I wouldn’t want to look at it again...” 
CD2 Interview No.2 
 
 
34. Practitioners are interested in local DTC’s drug decisions  
Particularly pharmacists stated they felt the summarised decisions available 
through links on the Prescribing Guide were useful in informing their 
discussions with doctors. However, one consultant still took issue with a 
perceived lack of transparency of the DTC: 
 “What I feel about the New Drugs and Formulary Committee is that 
I don’t see any transparency...so from there the NDF Committee is 
like a black box, so doctors just don’t like black boxes...  
CD2 Interview No.2 
 
 
35. Recommendations to improve functionality of Prescribing Guide 
Participants also pointed to specific features that could improve the functionality 
of the Prescribing Guide. Locating specific drug information on the site proved 
to be troublesome for some participants. In some cases, these participants 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 134 
 
recommended developing a search bar to ease search and navigation or to 
develop the ‘How to use’ section better with more descriptive detail.  
Other features that individual participants mentioned included developing a 
designated area on the home page, effectively a ‘notice board’ with “today’s 
message” (SP5 Interview No.15) consistently promoting “regular problems” in 
local prescribing practice.  
 
36. Recommendation to increase training and awareness 
A common recommendation was to ensure there was adequate training offered 
to all potential users particularly junior staff. SP4 (Interview No.14) stated, “you 
assume you know it but you don’t until you go to the training session” adding 
“we have to make sure that our juniors are familiar with, that they’ve been to the 
teaching sessions”.  
Other similar calls to ensure adequate training also came from members of the 
DTC who considered it “high on the agenda” (CD3 Interview No.3). Junior 
doctors and registrars equally stressed the importance of training as well as 
raising awareness through vigorous promotion particularly in the month of 
August since this is when new junior doctors join the Trust.  
 
6.8 Influence on local prescribing practices 
37. Doctors highly influenced by their senior colleagues 
Doctors indicated there was a strong tendency to either directly follow the 
instructions received from their senior colleagues or to make independent 
decisions that are also ultimately based on the ‘preferences’ of their seniors or 
mentors. 
This high regard that junior doctors appear to have for senior members of their 
team was also widely recognised by pharmacists who could cite various 
instances of observing such behaviour. 
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38. Pharmacists less influenced by senior colleagues 
A smaller proportion of pharmacists, discussing their influences, tended to 
mention the advice of senior colleagues ‘after’ other influences, such as local 
Trust guidelines, whereas doctors notably mentioned their senior colleagues as 
significant influences often ‘before’ other factors. 
 
39. Doctors more likely to access primary sources of evidence-based 
medicine compared to pharmacists in routine practice 
Doctors, particularly consultants and registrars cited evidence-based medicine 
as an influence and often clarified by specifying “actual key papers” or “meta-
analysis which is pure evidence, scientific evidence” (CD2 Interview No.2). 
Often doctors would refer to particular websites or other sources of information 
that provide them with up-to-date evidence-based drug information. 
Pharmacists rarely mentioned evidence-based medicine alone as an immediate 
influence. No pharmacist spoke about checking clinical trial data from primary 
sources of evidence as doctors did, unless it was for a review they were 
carrying out for the DTC. Instead pharmacists mentioned broader sources of 
drug information like NICE and local Trust guidelines where evidence-based 
medicine had already been incorporated. Additionally, pharmacists often 
mentioned ‘clinical evidence’ as essential for appropriate prescribing in other 
contexts, for example, when describing interventions made. 
 
40. Through experience pharmacists are more likely to develop an 
understanding of drug usage rather than individual clinical outcomes 
The quote below highlights how pharmacists often demonstrated a knowledge 
of drug usage patterns rather than clinical outcomes with drug usage. Here the 
pharmacist refers to previous experience of seeing drugs being prescribed 
against protocol. Based on this experience she feels she is able to foresee a 
similar scenario occurring, in this case with Movicol – a restricted drug identified 
as consistently being prescribing outside agreed protocol. 
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 “...I see Movicol as being a creeping tide and I’ve been here 
before, I saw lactulose go from, like that <<clicks 
fingers>>...Movicol might be fantastic and maybe we should have it 
but we shouldn’t let it creep in...” 
SP5 Interview No.15 
 
Some pharmacists claimed that they are not able to ‘access’ a ‘complete’ insight 
of drug therapy. For example SP1 stated that pharmacists, in general, were not 
attending doctors’ ward rounds and were not reading patients’ clinical notes. 
She felt that pharmacists were therefore far detached from knowing how 
recently prescribed medication has affected the patient’s clinical condition.  
 
41. Doctors develop experience of individual clinical outcomes  
Doctors frequently made references to previously seen “caseload” (JD1 
Interview No.8) or “experience” (CD4 Interview No.4). One consultant when 
describing an incident in which he made a life-saving intervention stated: 
 “...I don’t think you can know about the sort of algorithm there is 
somewhere in my frontal lobes, you know there’s umm, 
somewhere in that brain there were, the last thirty-five years some 
connections have been made and they’ve been made because of 
experience not because of sitting down and trying to work out an 
algorithm...” 
CD4 Interview No.4 
 
Although some junior doctors also cited experience as influence, it was more 
pronounced in senior doctors who often appeared to incorporate additional 
elements of confidence and autonomy. 
Pharmacists’ recollections of challenges to doctors’ prescribing corroborated 
much of doctors’ statements regarding their reliance on personal experience.  
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42. NICE useful in time constrained scenarios for pharmacists and junior 
doctors  
Among pharmacists, there was widespread appreciation for NICE and it was 
referred to as a significant influence on pharmacy practice. Doctors and NMPs 
also cited NICE as an influence on their prescribing. However, there was a 
notable difference in the comments made by junior and senior doctors. All six 
junior doctors displayed a tendency to rely on NICE and stated it was 
particularly useful in time constrained situations for instance when on-call. JD2 
when discussing NICE, described how she often feels “out of my depth” and 
needed to rely on “somebody else’s decision”. Senior doctors asserted that 
NICE was useful in principal – often refraining from any further commentary on 
the topic. However consultants and registrars, after prompting, displayed signs 
of scrutiny and in some cases defying NICE’s drug reviews and decisions.  
 
43. Prescribers feel restricted by NICE because it impacts local decision-
making 
Senior doctors in particular, expressed a frustration with the view that NICE was 
primarily concerned with keeping national drug expenditure to a minimum. CD4 
mockingly referred to the organisation as “the National Institute of ‘Cost’-
Effectiveness” stating it is a “terminological inexactitude” to call it ‘clinical 
evidence’. 
Doctors appeared to dismiss NICE on the grounds that it is merely ‘guidelines’ 
and therefore it is not mandatory that doctors adhere to it. CD7 makes an 
interesting allegation – that pharmacists use NICE in order to justify restricting 
doctors from prescribing drugs. 
Many pharmacists were familiar with such sentiments within the medical 
profession thus corroborating their existence. Such feelings of being restricted 
were not confined solely to doctors, NMPs also expressed a similar frustration. 
NMP1 stated that NICE was useful in helping to “keep to the budget” since 
NICE often developed specific prescribing criteria. However, she often felt that 
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some patients falling outside of such criteria would in fact benefit by receiving 
treatment earlier but felt limited by NICE.  
 
44. Formulary regarded as a supportive influence for pharmacists 
The formulary or the local DTC is a recognised influence, acknowledged by a 
number of participants. The formulary was specifically mentioned and discussed 
– unprompted – only by pharmacists.  
 “I suppose the first influence would be whether we have it on the 
formulary, so the formulary is one of the very big influences 
because if it’s not on the formulary I’m not going to be able to 
persuade somebody to prescribe it...” 
SP2 Interview No.12 
 
 
45. Formulary recognised as a restrictive and largely unwanted influence 
on doctors prescribing practices 
Doctors did not list either the ‘formulary’ or the ‘DTC’ as influences. However, 
during discussions with the interviewer on other topic areas, or when directly 
asked to comment on the purpose of the DTC, doctors appeared to indicate that 
the formulary, through its “policeman’s role” (CD5 Interview No.19) prevented 
them from access to a broader range of drugs and thereby constituted an 
influence. 
 
46. Pharmaceutical industry is considered highly biased and 
untrustworthy 
Some participants cited the pharmaceutical industry as a recognised influence 
on prescribing practices. Two consultants stated, for example, “we’ve got 
industry reps and they’re a big influence” (CD3 Interview No.3) or that the 
industry has “an effect of bringing that particular drug to the top of your list” 
(CD2 Interview No.2).  
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It is notable that on all occasions, doctors and pharmacists displayed a degree 
of suspicion and caution in speaking about this particular influence. One 
consultant referred the interviewer to a recent talk at the Trust in which the 
guest speaker discussed allegations of the pharmaceutical industry withholding 
important information regarding side effects: 
 “...I think the pharmaceutical industry is playing dirty...” 
CD6 Interview No.20 
 
 
47. Junior doctors and pharmacists often adopt ‘stepwise’ approach to 
drug therapy 
All categories of participants at some point displayed a tendency to ‘rely’ on 
decisions made elsewhere. This was particularly pronounced among junior 
doctors and both junior and senior pharmacists. Pharmacists, in general, 
appeared to imply that the use of Trust guidelines and the recent Prescribing 
Guide, enabled them to, effectively, ‘read and repeat’ drug information 
presented in a ‘stepwise’ manner. 
SP1 expressed her dissatisfaction with this overreliance and strict adherence to 
guidelines. She was particularly concerned about the lack of pragmatism 
evidenced by pharmacists. Doctors often reinforced this notion of pharmacists 
relying heavily on guidelines. This often manifested when doctors expressed 
frustration over being unable to prescribe certain drugs unless – as the 
pharmacists insist – the required ‘protocol’ had been strictly adhered to.  
Among the medical participants, however, there was clear evidence that junior 
doctors were similarly reliant on a “stepwise approach” to drug therapy often 
presented in guidelines.  
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48. Pharmacists operate independently therefore more likely to require 
decision-support tools 
SP7 stated that pharmacists look at the Prescribing Guide and “repeat what it 
says”. When asked to elaborate on this statement she clarified that pharmacists 
rely “less on senior colleagues” and more on “paperwork”. Clearly the 
pharmacist argues that since pharmacists typically operate on a very individual 
basis, they require other forms of ‘back up’ to supplement their routine clinical 
activities.  
In contrast, among doctors, most consultants and registrars instead asserted 
their ability to be able to unravel a patient’s complex problems and discern the 
appropriate therapeutic interventions without the need for ‘decision-support’. 
Other than junior doctors, only one senior doctor, a medical registrar appeared 
to take a different view and felt, favourably, algorithms and “standardised” 
treatment regimens were becoming more prominent (RD4 Interview No.22).  
 
6.9 Practitioner-oriented dynamics within which the Prescribing Guide 
functions 
49. Doctors recognised as open to collaboration provided it is on their 
terms 
A number of both junior and senior pharmacists clearly expressed the opinion 
that doctors were “on the whole” (SP4) collaborative and willing to work with 
pharmacists. 
 “...most team doctors are willing to working alongside a pharmacist 
in a very open...they don’t like being told not to do something 
unless there’s something else that they feel is as good.” 
SP2 Interview No.12 
 
The quote above does, however, include an apparent contradiction. SP2 seems 
to indicate that doctors’ collaboration may, in fact, be contingent upon receiving 
input from pharmacists that they ‘approve of’ and find useful.  
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Doctors also acknowledged pharmacists as “very useful” (RD2) and often stated 
that they hoped for more involvement. CD2 described working with a 
pharmacist by saying: 
 “...I’d turn to her and say okay you tell me what are the interactions 
here...and she would have her BNF out and she would look at that, 
so, it’s good you know, because that is what multidisciplinary is all 
about...” 
CD2 Interview No.2 
 
Although this statement may be intended to be complimentary there is an 
implication that the consultant would wish to utilise a potential pharmacist 
attending his ward round in a manner that one might expect a junior doctor to 
be utilised. In addition there is the assumption that the pharmacist would ‘rely’ 
solely on the BNF for their knowledge.  
 
50. Junior doctors more likely to adopt a collaborative approach than 
senior doctors 
Some pharmacists were also able to express notable differences between junior 
and senior doctors. One senior pharmacist stated that junior doctors are more 
“malleable” and familiar with “the kind of bureaucratic process within pharmacy” 
whereas consultants came from a “they know best...school of thought” (SP3). 
Pharmacists and doctors also stated that junior doctors were likely to appreciate 
structured guidelines and sources like the Prescribing Guide as decision-
support tools.  
Similar views about the hierarchy within the medical profession were echoed by 
some doctors as well as NMPs. A medical registrar, once again, appeared to be 
able to recognise the attitude of some consultants and in addition the expertise 
and value of the pharmacist. RD4 (Interview No.22) stated that some 
consultants take it as “an affront when a pharmacists questions them”.  
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51. NMP expertise is recognised in multidisciplinary environment 
Non-medical prescribers felt that they were largely accepted by doctors and 
were often relied upon for their expertise. One senior pharmacist and a single 
junior doctor elaborated on very specific incidents in which NMPs were of 
particular use and support to them. It ought to be noted, however, other than 
NMPs themselves, no other participants were able to point to positive 
contributions from NMPs. 
 
52. Pharmacists feeling marginalised by prescribers 
Pharmacists expressed frustrations over incidents in which they felt they had 
been overlooked and marginalised in some way. For example, SP1 described 
an incident concerning a drug review she had prepared to present at a DTC 
meeting. She discovered after the meeting that the consultant who had 
requested the drug (for permanent use at the Trust) had in fact previously 
already discussed the merits of the drug with the Chair of the DTC bypassing 
the pharmacist carrying out the review.  
Pharmacists, while commenting on other issues, also appeared to imply – 
perhaps not consciously – other manifestations of being sidelined or 
marginalised. For instance, a common area of concern among pharmacists was 
the failure to address prescribing problems at the point of prescribing and 
instead having to retrospectively intervene and challenge doctors prescribing.  
Another example of pharmacists feeling similarly marginalised and 
disconnected is illustrated below in a comment made by a junior pharmacist 
about non-medical prescribing for pharmacists: 
 “...I think we’ve only got one non-medical prescriber in pharmacy, 
there are so many nurses prescribers <<emphasis>>...it sort of 
bugs me to think that pharmacists shouldn’t have at least a say in 
what to prescribe but a nurse prescriber can override them.” 
JD3 Interview No.31 
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53. Prescribers are subject of pharmacists’ scrutiny 
Whether retrospective or at the point of prescribing, on the whole, pharmacists 
claimed that they were capable of scrutinising doctors’ prescribing. In addition, 
pharmacists also raised concerns about the level of influence the 
pharmaceutical industry was having on prescribing practices. Two senior 
pharmacists demonstrated a similar nature of suspicion towards doctors and 
NMPs being targeted and persuaded to use non-formulary drugs.  
 
54. Conflicts between pharmacists and prescribers centre around 
guidelines and experience / judgement (respectively) 
Many pharmacists were able to cite particular incidents in which they felt their 
advice to doctors was not accepted and caused conflict. A number of 
pharmacists frequently described incidents concerning a newly approved drug, 
‘solifenacin’. In many of these cases, although the Prescribing Guide provided 
background information for pharmacists, consultants were still insistent, often 
basing the reason for their choice on successful previous experience with 
solifenacin. Another senior pharmacist described a consultant who tended to 
routinely deviate from local Trust guidelines or agreed policies. In one particular 
incident, the consultant was quoted as referring to pharmacists as “part of the 
Gestapo pharmacy” (SP7 Interview No.29). 
Doctors similarly raised grievances against pharmacists restricting access to 
drugs they wished to prescribe for their patients, often with a sense of outright 
hostility in some interactions between doctors and pharmacists. NMP3 similarly 
commented on what she thought was an inappropriate ‘celebratory’ attitude 
taken by pharmacists towards having enforcing a cheaper drug against the 
recommendation of the Anaesthetic team (including NMP3 who was ‘Pain 
Nurse’). Furthermore, NMP3 described another incident in which her decision to 
deviate from the Trust guideline for pain relief (Analgesic ladder) was 
questioned by a pharmacist. She stressed that as a prescriber and a specialist 
she felt confident in her judgement and asserted that she “could take offence to 
that”.  
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55. Participants reinforcing traditional divides and segregated working 
arrangements 
Participants made many comments about their own roles and how they are 
distinct from the roles of others. In many instances participants, in particular 
doctors appeared to affirm and reinforce their own professional duties, activities 
and role. A consultant, and DTC member, commented on a pharmacist 
discussing potential drug interactions with a patient by saying “I sort of think if 
you want to see the patient you should become a doctor” (CD6 Interview 
No.20). This consultant went on to say, unequivocally, that he sees this as the 
“pharmacist interfering”. One junior doctor made the following comment: 
 “...I wouldn’t try and tell you oh don’t, I don’t know, stop packing 
your pills in some way... 
...if I’m giving tramadol because codeine won’t work for them, I 
don’t like being questioned about that.” 
JD2 Interview No.9 
 
The last quote here, by a junior doctor, not only asserts a level of expertise and 
training that enables doctors to prescribe as they see fit for their patients (in this 
case the doctor is arguing the case for tramadol over the Trust’s approved first-
line agent, codeine), but also depicts her perceived view of a pharmacist’s role 
– “packing your pills”. Similarly other doctors have stated that the pharmacist is 
only responsible for the accurate ‘supply’ of a prescribed drug (for example 
CD3). There is an apparent attempt to distinguish the roles and areas of 
expertise of doctors and of pharmacists.  
Doctors often reinforced their own roles by outright rejections of the perceived 
intrusions by those of other professions. For example, CD3 expressed concerns 
about nurses’ and pharmacists’ prescribing, stating such initiatives are 
“encroaching” on to doctors’ practice (CD3 Interview No.3). 
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56. Pharmacists are considered to be obstructive in prescribing practice 
Similar notions of freedom to prescribe without pharmacy or others interfering 
were widely made by many doctors and NMPs. NMP3 commenting on the 
formulary and pharmacists impacting on their ‘autonomy’ stated: 
 “...I think that a lot of us that are clinical nurse specialists...find 
pharmacists and pharmacy as a whole, a bit of obstructive 
<<lowers voice and leans over>>, umm and that cost-efficiency, 
umm sometimes overrides may be individual patient need at a 
particular time.” 
NMP3 Interview No.34 
 
 
57. Doctors attempt to limit the prescribing powers of NMPs 
Interestingly, however, a number of doctors appeared to be mildly critical of 
non-medical prescribing. While there ‘were’ a few more overtly critical 
comments made about NMPs, most appeared to ‘limit’ and ‘confine’ non-
medical prescribing in some way. For example, doctors of all grades expressed 
either the opinion that NMPs should never initiate medication (only continuation 
and maintenance is acceptable) or that prescribing ‘over-the-counter’ 
medication and ‘simple’ medication like laxatives and painkillers are acceptable. 
 
58. Pharmacists are too algorithm-driven 
There appears to be an acknowledgement by pharmacists that one of their 
routine roles concerns the enforcing and upholding of guidelines. However, 
what appears to be more ‘subtly acknowledged’ by fewer pharmacists is a worry 
that such an approach has a detrimental impact on the potential clinical 
contribution that pharmacists have.  
Other pharmacists, in seemingly stark contrast, used words like “policing” to 
describe the role that pharmacists have with respect to prescribing and further 
complained that pharmacists are, in fact, not “policing” enough. Some senior 
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pharmacists used words, often repeatedly throughout their interviews, such as 
“enforce” (SP3 Interview No.13) referring to pharmacists ensuring that 
guidelines are adhered to by prescribers. This pharmacist had joined the Trust 
relatively recently and often referred to previous experience at a large teaching 
hospital. His previous hospital operated a similar online formulary that had 
additionally adopted a highly extensive algorithm-oriented approach to directing 
prescribing. When asked to comment on the potential for overreliance on such 
tools, SP3 stated: 
 “I think it’s just the way things are going with IT in general so I don’t 
think it’s a problem, not really... and freedom to choose sort of the 
kind of things you want is sort of being eradicated.” 
SP3 Interview No.13 
 
NMP1 made an interesting comment regarding this adherence to algorithms 
and guidelines: 
 “Hmm, yeah, yeah I think because as I’ve said we’re doing weird 
things with cinacalcet now which before I’ve gone no you can’t do 
that and NICE says this and formulary says that and whatever, but 
now I’m like, what can you do with this patient, we’ve got to try 
something.” 
NMP1 Interview No.18 
 
This statement reveals a previous tendency to adhere to guidelines very 
stringently – as a pharmacist – but now, operating as a prescriber, she is 
inclined to confidently deviate from the guidelines for the benefit of the patient.  
 
59. Pharmacists are too preoccupied with the supply function 
Most pharmacists felt they were too preoccupied with the ‘supply’ of drugs and 
that this had an impact on the time they could spend on more clinical activities. 
SP7 stated that this focus on only the supply of medicine is “soul destroying for 
our junior pharmacists”. Junior pharmacists themselves routinely displayed 
dissatisfaction about their present roles and function. 
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There were two pharmacists however who did ‘not’ feel that they were 
overwhelmed by a supply function (SP4 and SP3).  
 
60. Pharmacists lack clinical expertise and opportunity to further cultivate 
a more clinical understanding 
A number of pharmacists expressed a desire to attend and contribute routinely 
to doctors’ ward rounds. SP1 stated that as a result of attending ward rounds, 
there was not only a greater chance of acquiring a “special understanding” 
about how drugs are prescribed, but also stated that pharmacists would “get 
more respect”. 
On prompting, pharmacists revealed their perceptions of their own roles and 
priorities. The ‘frustrations’ concerning the implications of ‘supply function’ on 
clinical input were clear even among senior pharmacist managers who were 
also able to elaborate on the limited resources that further compound the 
problem: 
 
“...we’ve got the University of Hertfordshire just there, and we still 
can’t relieve pharmacists for further specialist training, instead 
they’re stuck in there doing a bunch of supply <<pointing at 
dispensary>>” 
SP6 Interview No.28 
 
 
61. Prescribers claim unique ability to deal with unusual and uncertain 
patient cases  
Doctors routinely mentioned an ability to successfully manage complex patient 
scenarios and deal with uncertainty, particularly by not adhering to existing 
guidelines or any other form of published guidance. CD4 refers to an incident in 
which he seems to imply that he acted on sheer instinct and this resulted in 
saving the patient’s life. The consultant alludes to the fact that as a result of 
different experiences others may have chosen a different treatment option. CD7 
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similarly uses ‘experiences’ to justify the lack of consensus between the 
respiratory consultants at the Trust.  
Doctors laid claim to this ability to manage uncertainty solely for the medical 
profession, excluding pharmacists in particular. Many doctors, both junior and 
senior, tended to mention their years at medical school and training in order to 
justify their ability to discern the most appropriate course of action for patients. 
A consultant, commenting on his ability to deviate from guidelines, also makes a 
similar point: 
 
“...what I’m saying is that I’ve trained <<emphasis and point 
finger>> and that training allows me to say this patient falls out of 
current NICE recommendation.” 
CD1  Interview No.1 
 
Doctors did accept that guidelines, whether local Trust guidelines or national 
guidance such as NICE, was often incorporated into their decision-making 
process. For example, a medical registrar accepted the role guidance plays in 
practice however he stated that often time constraints prevented him from 
covering all of NICE guidelines and therefore also relied on “experience” and 
“own knowledge”.  
 
62. NMPs claim an evolution in clinical understanding that equips them 
with ability to manage ‘uncertainty’ in complex patient cases 
Non-medical prescribers also made claims to a unique ability and a level of 
insight that enabled them to manage ‘uncertainty’ in complex clinical scenarios. 
As with medical doctors, they too demonstrated an impulse to nonconformity 
with guidelines when they ‘felt’ it was appropriate. NMP1 (a pharmacist) made 
the following comments about DTC decisions: 
 
“...I think becoming a prescriber I’m starting to see more the clinical 
side of things, before I was very pharmacy, like yes formulary, cost 
and all that, but now I’m starting to see patients and prescribing 
and stuff, it’s not so clear cut, you’ve got these patients and they’re 
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all individuals and that’s where the formulary might be limiting, the 
formulary’s decision might not be suitable for that one patient. I 
think my opinions might be slightly changing as I’ve become an 
NMP...you slowly start to break your own rules...” 
NMP1  Interview No.18 
She contrasted her previous role as a pharmacist with her current role as a 
‘prescribing pharmacist’ and highlighted the “weird” manner in which she 
exercises “judgement” and can prescribe drugs for her renal patients. 
Amongst NMPs there appears to be an attempt to associate and align one’s self 
with medical doctors.  
 
63. Doctors claim to be the only party who is entirely patient-focused 
Consultants in particular widely maintained that they were predominantly 
patient-focused and that they were not primarily concerned with either the cost 
of treatment options or whether a drug was on formulary or not. Similar 
perspectives are echoed by registrars and junior doctors: 
 
“...I’d rather be in the patient’s best interests, I don’t really care 
about the formulary and about money...I’d rather practice with 
evidence based so even if it’s a couple of pounds more I’d rather 
put the patient’s benefits first.” 
JD2  Interview No.9 
 
Doctors frequently compared their ‘level’ of patient-orientation with that of others 
for example pharmacists or NICE or “the formulary”.  
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6.10 Generalised statements from semi-structured interviews 
Using the themes presented in the previous section, ‘generalised’ statements 
were inferred and are presented here. As an example, Appendix 14 shows how 
the themes were utilised in order to arrive at ‘Statement 5’. 
 
Statement 1  
The Prescribing Guide has been well received at the Trust although limited time 
and local IT problems currently hamper its full potential. It is predominantly 
useful for practitioners who require either decision-support as in the case of 
non-consultant doctors and pharmacists or in reinforcing challenges and 
interventions made by pharmacists. 
Statement 2  
The Prescribing Guide is primarily viewed from four different but in some cases, 
overlapping perspectives: as a control measure; as a necessity and a utilitarian 
service; as means to improve autonomy; as a threat to autonomy. 
Statement 3 
The Prescribing Guide has quickly become the primary source of drug 
information for pharmacists. The following reasons have been identified: (1) 
pharmacists can routinely and easily access the Prescribing Guide from the 
Pharmacy dispensary only struggling with access, as doctors do, with resource 
constraints on the ward level; (2) pharmacists see the value and rationale 
behind the existence and implementation of a local formulary and are prepared 
to defend it; (3) pharmacists invariably work alone so need extra support: (4) 
pharmacists feel too preoccupied with 'supply' adversely affecting the time left 
to research clinical trial data; (5) the Prescribing Guide facilitates the 
retrospective 'checking' of prescribed medication; (6) the design of the 
Prescribing Guide is closely aligned with pharmacists' role so is seen as a 
useful educational tool.  
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Statement 4 
Among doctors, the Prescribing Guide is most useful for non-consultant doctors 
particularly in providing information about local priorities and availabilities and 
when senior colleagues are unavailable. However owing to the following factors, 
the Prescribing Guide struggles to become a core component of doctors' routine 
within prescribing practice: (1) the perceived uniqueness of medical 
professional's role (specifically, a unique patient-focus and an authority based 
on clinical knowledge); (2) local resource constraints; (3) lack of training in 
specific features of the Prescribing Guide and; (4) an underlying distrust for the 
formulary concept.  
Statement 5 
The local formulary symbolises a critical split in approaches to resource 
management and patient care. The formulary is therefore central to many of the 
conflicts that take place within prescribing practice where the opponents take 
varying degrees of either a supportive or opposing view of the formulary 
decisions.  
Statement 6  
Different claims to and manifestations of authority seem to exist in the local 
prescribing arena (often overlapping): formularies and DTC claim resource-
conscious and evidence-based evaluations; NMPs and doctors claim a unique 
patient focus and ability to call upon expert judgement; managers through 
hierarchy; pharmacists through being drug experts.  
Statement 7  
Pharmacists are ‘closely bound’ to the local formulary forming a perpetual and 
ingrained component of their thought process thus are unable to detach the 
formulary from their role in drug therapy. Pharmacists, therefore, very much rely 
on the formulary for pre-structured (often algorithm-driven) decision-support.  
Statement 8 
Pharmacists 'do' wish to develop clinically by involving in clinical activities but 
they feel isolated from the 'real' frontline patient care (at the point of drug 
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selection). This isolation arises from the 'continued subjugation' of pharmacists 
in their environment.  
Statement 9 
The local formulary and pharmacists who advocate adherence to guidelines and 
pre-structured approaches to patient care are seen to challenge and threaten 
traditional roles and activities - both pharmacists' and doctors' roles.  
Statement 10 
Doctors' value unrestricted and unfettered freedom to exercise their own 
judgement for the benefit of the patient and will resist attempts to either mimic 
this judgement or mitigate their ‘valued’ freedom. 
Statement 11 
Doctors consider their role in healthcare to be 'uncorrupted' by resource-based 
influences and perceive their role as entirely patient-focused. While they are 
willing to engage in some discussion regarding drug therapy from the 
pharmacist, they feel it is their prerogative to reject such advice in the capacity 
of, in effect, 'guardians' of patient clinical treatment - they portray themselves as 
'closely bound' to the patient. 
Statement 12 
Junior doctors are more likely to adopt a collaborative approach with 
pharmacists and in the absence of their senior colleagues are willing to 
incorporate tools such as the Prescribing Guide into their prescribing practice. 
However since they are: (1) highly influenced by seniors; (2) consider 
themselves to practice with 'absolute' patient-focus and; (3) further ‘believe’ that 
they possess a unique ability to manage uncertainty, there is a likelihood that 
they will eventually reaffirm the resistive attitudes to being dictated, normally 
held by senior doctors and will thus uphold the same divides and segregated 
working arrangements in prescribing practice.  
Statement 13 
NMPs experience an evolution in clinical thought process learning to apply 
knowledge in a different way than in their previously held posts. They 
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characterise this as an ability to autonomously exercise clinical judgement for 
the patient's good. While they attempt to fully embrace their new role as 
'prescribers' they are frustrated by the DTC's imposition of a 'prescribing list' 
and pharmacy and doctors' attempts to limit their abilities by reinforcing existing 
(traditional) divides. 
 
6.11 Contributions made via Stakeholder Meetings 
Throughout the study, Stakeholder Meetings were held as planned (Table 13). 
The first three meetings in May 2009 involved the researcher with one other 
Stakeholder. It was not considered necessary to coordinate a single meeting 
with all Stakeholders in this instance since the topics covered did not need 
extensive discussion. During the second and third Stakeholder Meetings, all 
four Stakeholders attended and discussed provisional findings.  
Stakeholder 
Meeting 
Stakeholders attending Date 
Duration 
(approx.) 
1 (i) 
Senior Pharmacist and  
Senior Formulary Pharmacist  
May 2009 20mins 
1 (ii) 
Consultant Doctor and  
Senior Formulary Pharmacist  
May 2009 20mins 
1 (iii) 
NMP and  
Senior Formulary Pharmacist  
May 2009 20mins 
2 All July 2009 1hr 30mins 
3 All January 2010 1hr 
 
Table 13. Stakeholder Meetings held during study. 
The second Stakeholder Meeting consisted of a wide ranging discussion 
concerning potential modifications that could be made to the Prescribing Guide 
in an effort to improve the service further. Stakeholders helped to facilitate the 
implementation of many aspects of the modifications. For instance, the 
consultant doctor used his position at the Trust in order to help establish 
‘workshops’ at the Trust’s Grand Rounds providing demonstrations of the 
Prescribing Guide. 
The most significant input that Stakeholders provided was by way of 
discussions and feedback regarding the emerging themes and provisional 
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findings from the qualitative and quantitative data. Notes were taken by the 
researcher during the meetings and have been summarised in Appendix 15.  
 
6.12 Summary of Chapter 6 
This chapter has presented themes that describe existing local attitudes and 
perceptions towards the formulary concept, the Prescribing Guide and various 
aspects of prescribing practice. In addition, the qualitative analysis has also 
identified themes concerning the working dynamics within which the Prescribing 
Guide operates, focusing on the interactions between key stakeholders.  
While there is evidence of collaboration between healthcare professionals, 
participants have revealed that varying degrees of conflict ‘do’ exist. Both 
doctors and NMPs consistently described an ability to apply judgement in 
complex patient scenarios and deal with ‘uncertainty’ in a manner that involves 
deviating from local or national guidelines. Pharmacists were often seen by 
prescribers to be obstructive since they routinely challenged such deviance. 
Pharmacists appear to be 'closely bound' to the formulary concept which may 
symbolise a critical split that exists within prescribing practice. The Prescribing 
Guide is subjected to many of the attitudes that participants maintain about the 
formulary and the DTC. Although the Prescribing Guide ‘does’ appear to be well 
received and is considered by many to be a good contribution to the Trust’s 
overall medicines management strategy, participants have consistently cited 
key resource-oriented limitations that hamper its continued uptake.  
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Chapter 7 
Findings – Quantitative Data 
 
7.1 Introduction 
This chapter will now turn to the quantitative arm of the study. Quantitative data 
have been obtained from two sources. Firstly, online self-completion 
questionnaires were designed and disseminated to all doctors, pharmacists and 
NMPs at the Trust during the two ‘reconnaissance’ phases of the study. 
Secondly there was an ongoing extraction of data concerning formulary and 
non-formulary prescribing from the Pharmacy department’s computer system.  
The questionnaires’ results include bivariate analysis and have thus employed 
inferential statistics. Relationships between dependent and independent 
variables have been statistically analysed using chi-square testing. 
Comparisons are predominantly made between doctors and pharmacists since 
the small sample population of NMPs did not permit valid statistical testing. 
Following modifications made to the Prescribing Guide (Week 11-19), some 
respondents to the second wave of questionnaires responded differently to 
questions about the Prescribing Guide. Many of these observed differences 
were statistically significant and are later incorporated with the qualitative 
themes and generalised statements from Chapter 6. The data extracted from 
the Pharmacy computer system have been represented diagrammatically with 
attempts made to analyse the trends observed.  
 
7.2 Pilot  
As with the semi-structured interviews, during Week 1-4 both quantitative 
research instruments were also tested for practical feasibility. This section 
presents the results obtained from this pilot phase along with initial reflections.   
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7.2.1 Self-completion questionnaires 
Separate questionnaires were designed (using SurveyMonkey™) for 
dissemination to doctors, pharmacists and NMPs (Appendix 8). Although all 
respondents were essentially asked the same questions, it was considered 
good practice to include certain subtle differences to some of the questions’ 
wording owing to the differences in the nature of respondents’ professional 
activities. For example for doctors and NMPs only Question 4 reads: 
 “Please indicate how important you consider each of the following 
factors with respect to its influence on your prescribing practice:” 
 
 
For pharmacists, the same question instead reads: 
 “Please indicate how important you consider each of the following 
factors with respect to its influence on your role in drug therapy:” 
 
 
The second notable difference, also in Question 4, concerns the ‘factors’ that 
influence ‘prescribing practice’ or ‘role in drug therapy’. Doctors were asked to 
rate both ‘pharmacists’ and ‘NMPs’, while pharmacists were specifically not 
asked to rate ‘pharmacists’ and, similarly NMPs were not asked to rate ‘NMPs’. 
The reason for this was because it was presumed that pharmacists and NMPs 
would rate members of their own profession under the factor ‘senior members 
of your profession’ and therefore the further addition of either ‘pharmacist’ or 
‘NMP’ would unnecessarily complicate the questionnaire for the respondent.  
During the first Stakeholder Meeting, initial drafts of the questionnaires were 
presented to Stakeholders who provided input into the design and content. For 
the purposes of the pilot, five doctors, four pharmacists and one NMP were also 
identified at this initial meeting, purposively. 
The questionnaires themselves were made available via a hyperlink sent by 
email. The process of dissemination proved to require little effort particularly 
since the covering email was prepared by the researcher and then forwarded to 
medical and pharmacy administrative staff who then emailed the identified 
respondents. The questionnaires themselves were ‘collected’ and ‘stored’ using 
SurveyMonkey™. After a two week period, follow-up reminder emails were sent 
to increase response rates and proved to be effective. However, of the ten 
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questionnaires sent, two (of the five) doctors did not respond during the entire 
one month pilot phase (Table 14, 15 and 16). 
 
Consultant 
ST3 to SpR 
(Registrar) 
ST1 to ST2 FY1 / FY2 Other 
Number of 
doctors 
1 0 1 1 0 
      
Table 14. Doctors responding to the pilot self-completion questionnaires (n = 3). 
 
 
Band 9 Band 8 Band 7 Band 6 
Pre-reg 
Pharmacist 
Number of 
pharmacists 
0 1 2 1 0 
      
Table 15. Pharmacists responding to the pilot self-completion questionnaires (n = 4). 
 
 
Nurse Pharmacist 
Number of 
NMPs 
0 1 
   
Table 16. NMPs responding to the pilot self-completion questionnaires (n = 1). 
 
Of the eight questionnaires returned and analysed, there were no errors noted 
and all questions were considered to be answered appropriately. The 
researcher also gained sufficient insight and confidence into the functionality of 
SurveyMonkey™. The website allowed individual questionnaires to be browsed. 
Data were transferred with relative ease into Microsoft Excel spreadsheets and 
corresponding graphical representations of the results were thus easily 
obtained.  
 
7.2.2 Formulary data extracted from pharmacy computer 
The second quantitative element involved the extraction of data relating to both 
formulary- ‘approved’ and ‘not approved’ drug issues (that is, number of drugs 
dispensed) from the Pharmacy computer system. During the initial Stakeholder 
Meetings (Week 1), this aspect of the pilot phase was discussed. Two 
Stakeholders in particular, namely the researcher, owing to his capacity as 
Senior Formulary Pharmacist, and the Principal Pharmacist both acknowledged 
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an expected level of complexity was likely to be involved in the data extraction 
process. Therefore, since it was hoped that the more substantive phase of the 
study would target similar prescribing trends over a 12 month period, the 
process of extraction would be piloted in order to test for feasibility (with 
particular attention given to time and man-power involved). It was agreed that 
non-formulary prescribing data over a one month period (from 1st August 2008 
to 1st September 2008) and the ‘statins’ drug class would be targeted for 12 
months. The outcomes of the data extraction are shown in Table 17 and Figure 
8 (page 161). 
 
 
August 2008 September 2008 
No. of non-
formulary 
drugs 
dispensed 
(‘issues’) 
Total  
Approved 
13 27 
Total Not 
Approved 
22 28 
 
Table 17. Total ‘approved’ and ‘not approved’ non-formulary drug prescribing at Lister Hospital 
August 2008-September 2008. 
 
The statistical extraction from the Pharmacy computer system proved to be 
achievable yet time consuming. However, the data produced was considered 
particularly valuable for routine medicines management by senior members of 
staff. Hence a designated time slot was arranged for the researcher, and 
incorporated into their routine formulary work for the Trust, in order to capture 
all the required data.  
The process of data extraction from the Pharmacy computer was a complex 
and arduous task and required appropriate training. This was arranged with the 
IT Principal Pharmacist who devised a method of data collection and provided 
the necessary ‘system permissions’ for the researcher. However, the initial data 
collection and subsequent figures produced were deemed inaccurate due to 
what was considered an error in counts for drug issues. Table 18 shows an 
extract from a Microsoft Excel spreadsheet displaying formulary-approved and 
unapproved drug issues in August 2008. Initially the total ‘approved’ drug issues 
would have been counted as ‘3’ (rows 1 to 3) and total unapproved as ‘9’ (rows 
4 to 12). This was considered inaccurate since many drugs for the same patient 
were inadvertently being counted more than once, as the highlighted rows 
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show. For example, ‘triptorelin’ was approved and then prescribed for Patient B 
on only one occasion (04/08/2008). It appears twice in the data because it was 
dispensed by Pharmacy on two occasions. Similarly, ‘azithromycin’ for Patient 
G is dispensed on four occasions (rows 8 to 11) and since it appears four times 
in the data, it was also ‘initially’ counted four times. Once this error was 
recognised, it was considered fair to count same drugs for same patients (within 
a given month) on only one occasion. Therefore, the total approved was in fact, 
‘2’ and total unapproved was ‘6’.  
 Date Non-formulary drug Approval status Patient 
1 20/08/2008 CILOSTAZOL 100mg TABLETS                 Approved A 
2 04/08/2008 TRIPTORELIN 3.75mg SYRINGE    Approved B 
3 22/08/2008 TRIPTORELIN 3.75mg SYRINGE    Approved B 
4 14/08/2008 AMANTADINE 50mg/5ml SYRUP 150ml Not approved C 
5 30/08/2008 AZITHROMYCIN 250mg CAPSULES              Not approved D 
6 01/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved E 
7 19/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved F 
8 14/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved G 
9 17/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved G 
10 19/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved G 
11 21/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved G 
12 14/08/2008 AZITHROMYCIN 250mg TABLETS               Not approved H 
 
Table 18. Extract from Microsoft Excel spreadsheet illustrating the initial error in total approved 
and unapproved counts.  
 
Data concerning ‘formulary-approved’ drugs were also extracted. As part of the 
pilot’s objective to test for feasibility, prescribing trends for ‘statins’ (simvastatin, 
pravastatin, atorvastatin and rosuvastatin) over a 12 month period were 
produced. Although all drugs are ‘formulary-approved’ the Prescribing Guide 
outlines which should be the first-line option (indicated by a ‘green’ traffic-light). 
Similarly second- and third-line options are also represented (‘amber’ and ‘red’ 
traffic-lights respectively). Using this colour-coding Figure 8 (page 161) 
illustrates the level of adherence to Trust-approved options.  
Although again the process was considerably time consuming, it was deemed 
achievable and following this success, Stakeholders agreed to the following 
drugs (Table 19) being targeted in a similar fashion for the substantive phase of 
the research:  
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Drug class Drugs 
Proton-pump 
inhibitors (PPI) 
Omeprazole; lansoprazole; esomeprazole; pantoprazole 
Laxatives Lactulose; senna; Milpar; ispaghula husk; Movicol 
Statins Simvastatin; pravastatin; atorvastatin; rosuvastatin 
Opioid analgesics Morphine; diamorphine; oxycodone; fentanyl 
Macrolide antibiotics Erythromycin; clarithromycin; azithromycin 
Drugs for urinary 
retention 
Oxybutynin; tolterodine; solifenacin; trospium; duloxetine 
Non-steroidal anti-
inflammatory drugs 
(NSAID) 
Ibuprofen; diclofenac; naproxen 
Prostaglandin eye 
drops 
Bimatoprost; latanoprost; travaprost 
 
Table 19. ‘Formulary-approved’ drug classes agreed to be targeted during substantive phase of 
research. 
 
In summary, the pilot phase proved to be of considerable value particularly in 
assessing the manner of deployment of chosen research instruments and 
finalising the exact method of data collection. In addition, there was also a 
greater clarity regarding the level of man-power and time required for each 
aspect of the study. 
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Figure 8. Statin usage at E&N Herts NHS Trust (July '08 to June '09)  
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7.3 Self-completion questionnaires 
This section will now turn to the self-completion questionnaires sent to all 
doctors, pharmacists and NMPs at the Trust. The results from each element of 
the questionnaire will be presented in turn beginning below with a descriptive 
overview of all respondents, breaking down each profession into rank order and 
clinical speciality.  
Results from Questions 2, 3, 4 and 5 will then be presented. These results 
include bivariate analysis and will thus employ inferential statistics (Bryman, 
2004). First each subsection will seek to establish how dependent variables 
concerning either the Prescribing Guide or prescribing practice (for example 
‘knowing how to access the Prescribing Guide’ or ‘frequency of using the 
Prescribing Guide’) are affected by an independent variable (healthcare 
professional) ‘within’ questionnaires. For example, doctors’ frequency of using 
the Prescribing Guide will be compared to pharmacists’ frequency of using the 
Prescribing Guide. Presented alongside this will be a further analysis of the 
same dependent variable ‘across’ questionnaires. For example, the frequency 
of doctors using the Prescribing Guide prior to modifications to the service will 
be compared to the frequency of doctors using it post-modifications. These 
results have been prepared using contingency tables generated using SPSS9 
and statistically analysed for relationships and associations using chi-square 
(2) testing. Notable results, discussed in the accompanying commentary, have 
been highlighted to assist interpretation. 
In order to simplify the terminology, from this point on, self-completion 
questionnaires prior to modifications will be referred to as ‘QRE1’ and self-
completion questionnaires conducted after modifications will be abbreviated to 
‘QRE2’.  
 
7.3.1 Descriptive overview of respondents 
Respondents were required to provide basic details pertaining to their specific 
role at the Trust. For all healthcare professionals, an indication of seniority 
                                                          
9
 SPSS (Statistical Package for the Social Sciences) – is a program that allows statistical testing 
of data produced in social science studies.  
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(Tables 22, 23 and 24) and clinical speciality (Figures 9, 10 and 11) were 
requested. The principle reason for this was in order to ensure a representative 
sample population was accessed and that the views of all categories of doctors, 
pharmacists and NMPs were taken into consideration in the subsequent 
analysis. The category of respondents in both QRE1 and QRE2 are comparable 
in terms of response rates, seniority and clinical speciality.  
Question 1 provided respondents the additional opportunity to specify any job 
titles or clinical specialities that had not been included as options for 
respondents to select. This category did not reveal any undue anomalies and 
were considered to not adversely affect the results or interpretations. However 
in the interests of increasing transparency, these additional details have been 
summarised in Table 20. 
 
Summary of category: 
‘Other (please specify below)’ 
 Job title Clinical speciality 
Doctors 
Staff Grade; Associate 
specialist; General Surgeon; 
Clinical Fellow 
General surgery; MAU; Community 
paediatrics; ITU 
Pharmacists No additional details 
Manager; Stroke Unit; Dispensary 
only; Medicines Information (MI); 
Nutrition; General surgery; 
Purchasing; Antimicrobials 
NMPs No additional details 
Orthopaedics; Surgery and 
nutrition; cardiac paediatric nurse; 
paediatric diabetes 
 
Table 20. Additional role details provided by respondents. 
Since the method of questionnaire dissemination was via emails, sent out by 
medical and pharmacy administrative staff, the total number of questionnaires 
sent out can be stated. Medical secretaries stated approximately 300 email 
addresses were in their possession and were sent by selecting a ‘group email’ 
option. The pharmacy secretaries stated 40 pharmacist-email addresses were 
routinely used for group emails. For NMPs, the NMP-Stakeholder during the 
first Stakeholder Meeting provided a list of NMPs employed at the Trust and 
their corresponding email addresses and the researcher himself emailed the 
questionnaires to them. Based on these totals, Table 21 outlines the 
respondents to the questionnaires (QRE1 and QRE2) before and after 
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modifications were made to the Prescribing Guide and provides corresponding 
response rates as percentages. 
Clearly the highest response rates can be seen from pharmacists and since 
they are both over 85%, they are considered “excellent” for questionnaires 
(Bryman, 2004, page 135). This may be because the Prescribing Guide had 
been the subject of considerable discussion within the pharmacy department 
during its development phases, particularly among the senior staff. Additionally, 
since the researcher was employed as Senior Formulary Pharmacist, his 
presence in the department was likely to have constituted, in effect, a reminder 
to complete and submit the questionnaires. According to Bryman (2004, page 
135) the NMPs response rates of 52% in QRE2 is considered “barely 
acceptable” and therefore any results from this particular cohort of respondents 
may not completely represent the views of the NMP population at the time.  
 QRE1 QRE2 
 Respondents Response rate Respondents Response rate 
Doctors 181 60% 187 62% 
Pharmacists 39 98% 38 95% 
NMPs 13 68% 10 52% 
 
Table 21. Total respondents to questionnaires with associated response rates. 
Since chi-square statistical analysis was to be employed, ‘expected counts’ are 
computed by SPSS as part of the calculation. Owing to the relatively small 
sample populations of NMPs (QRE1, n=13 and QRE2, n=10), some of the 
‘expected counts’ in the contingency tables computed to below the value of 5. 
This is a requirement of the statistical test and thus leaves those particular tests 
for association invalid. Any potential associations that may be ‘observably’ 
discernible are in fact, statistically insignificant. 
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Table 22. Doctors responding to questionnaires by seniority. 
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Figure 9. Doctors responding to questionnaires by clinical speciality. 
Questionnaire 1 Questionnaire 2 
 Consultant 
ST3 to SpR 
(Registrar) 
ST1 to ST2 FY1 / FY2 Other  
Questionnaire 1 (n=181) 37 (20%) 35 (19%) 33 (18%) 61 (34%) 15 (8%) 
Questionnaire 2 (n=187) 47 (25%) 39 (21%) 36 (19%) 42 (22%) 23 (12%) 
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Table 23. Pharmacists responding to questionnaires by seniority. 
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Figure 10. Pharmacists responding to questionnaires by clinical speciality. 
Questionnaire 1 Questionnaire 2 
 
Band 9 Band 8 Band 7 Band 6 
Pre-reg 
Pharmacist 
Questionnaire 1 (n=39) 0 (0%) 18 (46%) 12 (31%) 6 (15%) 3 (8%) 
Questionnaire 2 (n=38) 0 (0%) 16 (42%) 13 (34%) 7 (18%) 2 (5%) 
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Table 24. Non-medical prescribers responding to questionnaires by profession. 
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Figure 11. Non-medical prescribers responding to questionnaires by speciality. 
Questionnaire 1 Questionnaire 2 
 Nurse Pharmacist 
Questionnaire 1 (n=13) 11 (85%) 2 (15%) 
Questionnaire 2 (n=10) 10 (100%) 0 (0%) 
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7.3.2 Access to the Prescribing Guide 
Question 2 sought to establish the proportion of healthcare professionals who 
knew how to the access the Prescribing Guide from the Trust Intranet to which 
respondents were required to select either ‘Yes’ or ‘No’. A total of 128 (70.7%) 
out of 181 doctors responding to QRE1 were familiar with how to access the 
Prescribing Guide compared to 100% of both pharmacists and NMPs (Table 
25). This difference is statistically significant (2 = 19.71, df = 1, p < 0.001).  
 
Healthcare professional 
Total 
Doctor 
Pharmacist 
& NMP 
Do you know how 
to access the 
Prescribing Guide 
from the Trust 
Intranet? 
Yes 
Count 128 52 180 
% within HCP* 70.7% 100.0% 77.3% 
No 
Count 53 0 53 
% within HCP 29.3% 0.0% 22.7% 
Total Count 181 52 233 
 
Table 25. Contingency table showing how many doctors, pharmacists and NMPs are able to 
access the Prescribing Guide (*HCP=Healthcare professional). 
 
After modifications, responses to QRE2 show that 100% of both pharmacists 
and NMPs still knew how to access the Prescribing Guide. As Table 26 shows, 
a statistically significant increase in the proportion of doctors knowing how to 
access the Prescribing Guide was observed in QRE2 (2 = 6.952, df = 1, p < 
0.01). 
 
Doctors responses 
Total 
QRE1 QRE2 
Do you know how 
to access the 
Prescribing Guide 
from the Trust  
Intranet? 
Yes 
Count 128 154 282 
% within Q’re* 70.7% 82.4% 76.6% 
No 
Count 53 33 86 
% within Q’re 29.3% 17.6% 23.4% 
Total Count 181 187 368 
  
Table 26. Contingency table showing the proportion of doctors who knew how to access the 
Prescribing Guide in QRE1 and QRE2 (*Q’re=Questionnaire). 
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Contingency tables are displayed for the results of Question 2 only, simply to 
demonstrate their use. The data for the remaining questions are described 
solely in the text.  
 
7.3.3 Frequency of using the Prescribing Guide 
Question 3 was concerned with how frequently the Prescribing Guide was 
accessed by target users. The respondent could choose from six categories 
available in rank order. Initially the chi-square test was unable to yield legitimate 
values. This is because the chi-square test makes the assumptions that 80% of 
cells (in the contingency table) have an ‘expected count’ of greater than five and 
that all cells have an ‘expected count’ of greater than one. These expected 
counts are automatically calculated by SPSS. However, the results for Question 
3 ‘violated’ these assumptions since some of the cells in the contingency tables 
were either under five or one. In these circumstances, Marston (2010, page 
119) advises “to collapse some categories to give fewer cells with larger cell 
counts”. However, she warns against ‘illogical’ combining of categories, that is, 
only “adjacent” groups should be combined. Table 27 shows how this was done 
for the categories in Question 3. 
New category Old categories (as they appear in questionnaires) 
Frequent use 
More than once daily; 
Daily; 
Weekly 
Infrequent use 
Monthly; 
Not at all (but previously aware of Prescribing Guide): 
Not at all (NOT previously aware of Prescribing Guide) 
 
Table 27. Original categories for 'frequency of use' were collapsed and amalgamated into two 
categories. 
 
In QRE1, approximately 18% of doctors frequently used the Prescribing Guide 
compared to approximately 69% of pharmacists and NMPs. The difference is 
statistically significant (2 = 50.40, df = 1, p < 0.001). Similar results are 
observable for QRE2 (approximately 44% and 79% respectively) and are once 
again statistically significant (2 = 18.50, df = 1, p < 0.001). 
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Comparing the frequency of using the Prescribing Guide between doctors and 
pharmacists alone, QRE1 reveals approximately 18% of doctors and 
approximately 80% of pharmacists demonstrated ‘frequent use’ of the 
Prescribing Guide. This difference was statistically significant (2 = 58.36, df = 
1, p < 0.001). In QRE2, the difference between doctors (approximately 44%) 
and pharmacists (approximately 95%) was again statistically significant (2 = 
32.14, df = 1, p < 0.001). Doctors demonstrated a statistically significant 
increase in ‘frequent use’, approximately 26% (2 = 29.14, df = 1, p < 0.0001). 
Pharmacists also showed an estimated 15% increase in ‘frequent use’ however 
this result was not statistically significant (2 = 3.96, df = 1, p < 0.047). 
The increase in doctors’ use of the Prescribing Guide is therefore unlikely due 
to chance and can be considered a result of the modifications made to the 
service. It can be deduced that although it is an improvement, the modifications 
to the service failed to secure ‘frequent use’ (‘More than once daily’, ‘Daily’ or 
‘Weekly’) among the majority of doctors. However it can be concluded that with 
on-going interventions (of the sort outlined in Appendix 12), the stated use of 
the Prescribing Guide can measurably increase.  
 
7.3.4 Influences on local prescribing practices  
The questionnaires explored how a series of pre-selected factors influenced 
local prescribing practices. In Question 4, respondents were presented with a 
factor to consider and then, using the rating scale provided, they were required 
to indicate the level of importance they attribute to it with respect to their own 
prescribing practice (in the case of pharmacists, their role in drug therapy). 
The five options available to the respondents ranged from ‘Extremely Important’ 
to ‘Not at all Important’. These were collapsed, as in the previous section, into 
two categories in order to maintain the underlying assumptions of chi-square 
tests (Table 28). 
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New category Old categories (as they appear in questionnaires) 
Important 
Extremely important; 
Very important 
Not important 
Somewhat important; 
Not very important; 
Not at all important 
 
Table 28. Original categories for 'importance of influences' were collapsed and amalgamated 
into two categories 
 
7.3.4.1 Check questions 
As described in Chapter 5, two ‘check questions’ were deliberately inserted in 
order to help demonstrate reliability. In summary, if the questionnaire is able to 
produce the same data on more than one occasion, a good level of reliability is 
achieved. Therefore this section begins with the responses collected regarding 
the importance of two factors on prescribing practice that were deemed to have 
been unaffected by the modifications made to the Prescribing Guide and could 
thus be expected to yield the same data. These factors were: ‘senior members 
of your profession’ and ‘personal experience’.  
Approximately 80% of doctors responding to QRE1 considered senior members 
of their profession an important influence on their prescribing practice. Doctors’ 
response to the same factor in QRE2 was approximately 83%. Similarly, 85% of 
pharmacists responding to QRE1 and 87% of pharmacists responding to QRE2 
considered senior members of their profession an important influence on their 
role in drug therapy. By simple comparison, these results demonstrate a 
consistency between healthcare professional and the importance of senior 
members of their profession on prescribing practice.  
The second factor, ‘personal experience’, produced similar results. 
Approximately 80% of doctors in QRE1 and 75% of doctors in QRE2 
considered their own personal experience important to their prescribing 
practice. Similarly, approximately 90% of pharmacists in QRE1 and 82% of 
pharmacists in QRE2 considered personal experience an important influence on 
their role on drug therapy. Once again the data produced by the same group of 
individuals on two separate occasions was comparable and helps to ensure 
reliability for the questionnaire design. 
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7.3.4.2 The importance given to NICE 
Of the 181 doctors responding to QRE1, 140 (77.3%) consider NICE ‘important’ 
to their prescribing practice compared to all 39 (100.0%) pharmacists who 
consider NICE ‘important’ (2 = 10.59, df = 1, p < 0.01). In QRE2, comparable 
results are observed (2 = 4.92, df = 1, p < 0.05) although 3 (7.9%) of the 38 
pharmacists were categorised under ‘Not important’. It should be noted however 
that these 3 pharmacists had in fact rated NICE as ‘Somewhat important’. 
Owing to the statistically significant nature of the findings here it can be said 
that although a high proportion of both doctors and pharmacists consider NICE 
important for prescribing practices, pharmacists appear to rely on NICE 
guidance far more and more consistently than doctors do. 
 
7.3.4.3 The importance given to the pharmaceutical industry 
In QRE1, 26 (14.4%) of the 181 doctors responding considered the 
pharmaceutical industry ‘important’ to their prescribing practice. This is 
compared to 9 (23.1%) of 39 pharmacists answering the same question. This 
difference is not statistically significant. In QRE2, approximately 16% of doctors 
indicated that the pharmaceutical industry’s was ‘important’ in prescribing 
practice. The proportion of pharmacists in responding to the same question is 
approximately 18%. For both doctors and pharmacists the responses in both 
questionnaires are comparable. It appears that the pharmaceutical industry is 
acknowledged as a source of influence on prescribing practices however an 
evidently large majority of healthcare professionals consistently rate it as ‘not 
important’.  
 
7.3.4.4 The importance given to pharmacists 
Pharmacists were considered important by doctors when it comes to their 
prescribing practice. Taking only the first three categories as they appeared 
originally in the questionnaires, approximately 23% of doctors considered 
pharmacists ‘Extremely important’, 48% selected ‘Very important’ and 26% 
selected ‘Somewhat important’. In QRE2, the results from doctors were notably 
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similar, 28%, 48% and 21% respectively. Using the ‘new categories’ (outlined in 
Section 7.3.4), 71% of doctors in QRE1 and 75% of doctors in QRE2 
considered pharmacists ‘important’.  
Pharmacists were similarly considered influential to the prescribing practices of 
responding NMPs. The responses to QRE1 were as follows: approximately 31% 
considered pharmacists ‘Extremely important’, 31% considered pharmacists 
‘Very important’ and 31% chose ‘Somewhat important’. In QRE2 comparable 
results were obtained from NMPs, 30%, 40% and 30% respectively. Using the 
‘new categories’, 61% of NMPs in QRE1 and 70% of NMPs in QRE2 
considered pharmacists an ‘important’ influence on their prescribing practices.  
 
7.3.4.5 The importance given to the local DTC 
The influence the local DTC had on healthcare professionals’ prescribing 
practice was also explored using the questionnaires. Both questionnaires 
revealed a substantial difference between doctors and pharmacists. In QRE1 
approximately 35% of 181 doctors compared to 87% of 39 pharmacists ranked 
the DTC as important to their prescribing practice (2 = 35.70, df = 1, p < 0.001). 
In QRE2, the difference between doctors and pharmacists was again 
statistically significant: approximately 48% of doctors and 82% of pharmacists 
ranked the DTC as important (2 = 14.21, df = 1, p < 0.001). It can be seen that 
the proportion of doctors increased from approximately 35% to 48%. This 
difference was again, statistically significant (2 = 6.72, df = 1, p < 0.05) 
indicating that such an increase is unlikely to be due to chance. Pharmacists’ 
results from QRE1 and QRE2 were comparable.  
The majority of NMPs also ranked DTCs as ‘important’ to their prescribing 
practices and once again, the responses were comparable across the 
questionnaires: approximately 77% (10 out of 13) in QRE1 and 70% (7 out of 
10) in QRE2.  
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7.3.4.6 The importance given to NMPs 
NMPs at the Trust proved to have relatively little influence on others' prescribing 
practices. In QRE1, 165 (91.2%) of 181 doctors considered NMPs ‘not 
important’ to their prescribing practices compared to 26 (68.7%) of 39 
pharmacists (2 = 16.82, df = 1, p < 0.001). In QRE2, a similar set of results 
were obtained. Approximately 87% of doctors responding to QRE2 considered 
NMPs ‘not important’ to their prescribing practices. Similarly approximately 76% 
of pharmacists also indicated NMPs were ‘not important’ to their role in drug 
therapy. Unlike QRE1, this difference is not statistically significant. Therefore, 
according to QRE1 alone, it appears that NMPs are more likely to influence a 
relatively small proportion of pharmacists in their role in drug therapy rather than 
doctors.  
 
7.3.4.7 The importance given to the Prescribing Guide 
Among the selected influences on prescribing practice, the Prescribing Guide 
itself was also listed for respondents to consider and rank in terms of its 
perceived level of importance. In QRE1 approximately half, 50% of 181 
responding doctors considered the Prescribing Guide ‘important’ compared to 
approximately 90% of pharmacists (2 = 20.42, df = 1, p < 0.001). In QRE2, a 
notably similar proportion of pharmacists, 90%, still considered the Prescribing 
Guide an ‘important’ influence on their role in drug therapy compared to 
approximately 63% of doctors (2 = 10.02, df = 1, p < 0.01). The observable 
increase in the proportion of doctors who ranked the Prescribing Guide as 
‘important’ was statistically significant (2 = 6.17, df = 1, p < 0.05) and thus is 
unlikely a chance occurrence. It can therefore be said with some confidence 
that this increase resulted from the modifications made to the service. 
Pharmacists on the other hand appear to have a 'consistently' high regard for 
the Prescribing Guide perhaps indicating an intrinsic value for such medicines 
management tools. 
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7.3.5 Statements about the Prescribing Guide 
The questionnaire employed a Likert scale to determine the degree of 
agreement or disagreement respondents had concerning a series of statements 
about the Prescribing Guide. Question 5 presented respondents with seven 
categories available for each statement. Once again, as with the previous two 
questions (and as described in Section 7.3.3), these original categories were 
collapsed and amalgamated into two broad categories for the purposes of 
producing two-by–two contingency tables and maintaining the assumptions that 
permit chi-squared analysis (Table 29).  
New category Old categories (as they appear in questionnaires) 
Agree 
Strongly agree; 
Agree; 
Partly agree 
Not agree 
Neither agree or disagree; 
Partly disagree; 
Disagree; 
Strongly disagree 
 
Table 29. Original categories showing 'agreement to statements' were collapsed and 
amalgamated into two categories 
 
7.3.5.1 Responses to the statement ‘The Prescribing Guide is user-friendly’ 
(Statement 1) 
This first statement generated remarkably different views from respondents. Of 
the 181 doctors responding to QRE1, 100 (55.2%) agreed with the statement. 
Pharmacists however responded considerably differently. Thirty-eight (97.4%) 
of the 39 pharmacists agreed that the Prescribing Guide was user-friendly. This 
difference between doctors and pharmacists was statistically significant (2 = 
24.43, df = 1, p < 0.001). Doctors and pharmacists responding to QRE2 showed 
a similar difference in opinion with approximately 63% of doctors and 100% 
pharmacists (2 = 20.22, df = 1, p < 0.001). There is an observable increase in 
the proportion of doctors who consider the Prescribing Guide user-friendly from 
QRE1 to QRE2 however this is not statistically significant. 
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7.3.5.2 Responses to the statement ‘The Prescribing Guide is easily accessible’ 
(Statement 2) 
The second statement for respondents’ consideration concerned the 
accessibility of the Prescribing Guide. As with the previous statement, this 
statement once again elicited notably different views among doctors and 
pharmacists.  
In QRE1, approximately 53% of doctors agreed that the Prescribing Guide was 
indeed easily accessible. This response was compared to approximately 97% of 
pharmacists. The difference is statistically significant (2 = 27.12, df = 1, p < 
0.001). In QRE2, approximately 61% of doctors agree with the statement 
compared 97% of pharmacists (2 = 18.97, df = 1, p < 0.001). The proportion of 
doctors agreeing with the statement before and after modifications was 
comparable, as were the proportions within pharmacists. Therefore no 
statistically significant differences ‘across’ questionnaires were found. 
One plausible reason for so many pharmacists displaying agreement with this 
statement could be due to the fact that they operate on both clinical wards as 
well as within the Pharmacy department. Therefore computers within the 
dispensary and in the many offices within the department provide easy and 
regular access to the Prescribing Guide for pharmacists.  
 
7.3.5.3 Responses to the statement ‘The Prescribing Guide helps me decide 
what to prescribe’ (Statement 3)  
The next statement continues the professional discrepancy between doctors 
and pharmacists. Forty-two percent of doctors responding to QRE1 agreed that 
the Prescribing Guide helps them decide what to prescribe when used. This is 
compared to approximately 92% of pharmacists responding to the same 
questionnaire (2 = 32.51, df = 1, p < 0.001). In QRE2 doctors in agreement 
with this statement increases to approximately 62% while pharmacists remain at 
a comparable 90%. This difference between doctors and pharmacists is again 
statistically significant (2 = 11.05, df = 1, p < 0.01).  
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What is of particular interest is that the almost 20% increase in doctors’ 
agreement for the statement is also statistically significant (2 = 14.02, df = 1, p 
< 0.001).  
 
7.3.5.4 Responses to the statement ‘The Prescribing Guide improves my 
professional autonomy’ (Statement 4) 
In QRE1 approximately 39% of doctors indicated that they agree the 
Prescribing Guide improved their professional autonomy, referring to the ability 
to work independently. Correspondingly, over 60% did not agree with the 
statement. Of pharmacists, approximately 87% agreed with the statement (2 = 
30.29, df = 1, p < 0.001). In QRE2 pharmacists maintained a similar proportion 
in agreement while only approximately 49% of doctors agreed (2 = 20.79, df = 
1, p < 0.001). As with the previous statement, the increase in proportions of 
doctors in agreement was statistically significant (2 = 4.13, df = 1, p < 0.05).  
 
7.3.5.5 Responses to the statement ‘I find the Prescribing Guide confirms my 
own preferences’ (Statement 5) 
This statement was included in the list of influences for respondents to consider 
in order to establish the degree of congruence between healthcare 
professionals’ own initial drug choices (personal formularies) and the options 
presented to them within the Prescribing Guide. In QRE1, only 82 (45.3%) out 
of 181 doctors agreed that the Prescribing Guide confirms their own 
preferences. This is compared to 28 (71.8%) of 39 pharmacists (2 = 9.01, df = 
1, p < 0.01). QRE2 yielded somewhat similar response rates: 47.6% for doctors 
and 60.5% for pharmacists were in agreement with the above statement, 
however this was not statistically significant. The almost 10% decrease in 
pharmacists, although notable, was not statistically significant.  
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7.3.5.6 Responses to the statement ‘I think the Prescribing Guide supports 
evidence-based medicine’ (Statement 6) 
Almost the entire pharmacist sample population in QRE1 (94.9%) indicated that 
they agreed with the statement that the Prescribing Guide supports evidence-
based medicine. This is compared to approximately half the proportion of 
doctors responding to the same statement (50.8%). This difference is 
statistically significant (2 = 25.66, df = 1, p < 0.001). In QRE2 similarly, 60.4% 
of doctors and 97.4% of pharmacists agreed with the same statement and the 
difference was again statistically significant (2 = 19.39, df = 1, p < 0.001). The 
increase in doctors response rates from 50.8% in QRE1 to 60.4% in QRE2 was 
not statistically significant. 
 
7.3.5.7 Responses to the statement ‘The Prescribing Guide is patient-focused’ 
(Statement 7) 
The final statement concerned whether healthcare professionals regarded the 
Prescribing Guide as patient-focused. In QRE1, the majority of doctors, 
approximately 60%, did not agree with the statement. This is compared with the 
large majority of pharmacists (almost 80%) who do agree that the Prescribing 
Guide is patient-focused. This difference is statistically significant (2 = 20.32, df 
= 1, p < 0.001). The response rates to this statement in QRE2 are notably 
similar (approximately 46% for doctors and 79% for pharmacists) and once 
again are statistically significant (2 = 14.18, df = 1, p < 0.001).  
 
7.3.6 Open-ended questions 
The final section of the questionnaires provided respondents with the 
opportunity to prepare and submit their own wording commenting freely on any 
aspect of the Prescribing Guide. Respondents were encouraged to express any 
particular difficulties experienced with the use of the Prescribing Guide or where 
they felt improvements needed to be made. Comments from QRE1 were used 
to help fulfil study objective 5, that is, the comments contributed to the 
modifications made to the Prescribing Guide and the way the service is 
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promoted. The comments from both QRE1 and QRE2 will similarly help to fulfil 
study objective 6 concerning any final recommendations to ensure the 
Prescribing Guide continues to evolve. 
 
7.3.6.1 Comments from first questionnaire 
The comments from all respondents to QRE1 were first tallied according to 
subject matter and are now summarised in Figure 12 (doctors), Figure 13 
(pharmacists) and Figure 14 (NMPs). In order to simplify presentation, each 
figure shows the top 10 comments from each category of healthcare 
professional. A total of 233 distinct comments were made by doctors. The top 
10 comments account for 84% of this total. For pharmacists, Figure 13 shows 
53 of 56 comments and therefore accounts for 95% of comments. Finally in 
Figure 14 all comments from NMPs have been presented.  
A large proportion of respondents chose to make no comments and these are 
presented in the figures. For example, of the 233 distinct comments made by 
doctors, 54 represent ‘No comment’ (Figure 12). Similarly there are proportions 
of pharmacists and NMPs who have also opted not to answer this question 
(Figure 13 and 14).  
In Figure 12, 23 comments have been labelled as ‘Trigger to use Prescribing 
Guide’. The comment refers to a statement made by the respondent that implies 
the questionnaires themselves have been a source of promotion or ‘trigger’ to 
use the Prescribing Guide. This indicates that the promotional campaign 
following the launch of the Prescribing Guide was not sufficiently penetrating 
since respondents did not know of its existence. Such comments were not 
found in responses from either pharmacists or NMPs.  
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Figure 12. A pie diagram showing doctors’ responses to open-ended questions in QRE1. 
Unique to pharmacists' comments were references to the stock kept within the 
Pharmacy department. Five comments were condensed to ‘Increase stock 
details’. Both pharmacists and NMPs requested that the Prescribing Guide be 
kept up-to-date with some pharmacists also remarking that some details within 
the Prescribing Guide were out-of-sync with the Pharmacy computer (these 
comments do not appear in the ‘top 10’ list of comments).   
 
Figure 13. A pie diagram showing pharmacists’ responses to open-ended questions in QRE1. 
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Four of the 13 comments from NMPs indicated that there was ‘No need for the 
Prescribing Guide’ (Figure 14). Owing to the small sample population of NMPs, 
it is difficult to conclude that this is specific to NMPs only. However, no 
pharmacists made such a comment and of the 233 comments made by doctors, 
only one comment of a similar nature was made. 
 
Figure 14. A pie diagram showing NMPs’ responses to open-ended questions in QRE1. 
The remaining comments made by respondents were common within all three 
category of healthcare professionals. For example, increasing clinical guidance 
was a common theme as was increasing accessibility, promotion and training. 
Doctors in particular stressed the need for junior doctors’ Trust induction to 
include a session that provides training on how to access and use the 
Prescribing Guide. 
 
7.3.6.2 Comments from second questionnaire 
The comments from the open-ended question posed to respondents in QRE2 
will be used to make final recommendations. As with the previous section, 
Figure 15 (doctors), Figure 16 (pharmacists) and Figure 17 (NMPs) show the 
top 10 comments made by respondents. From a total of 213 distinct comments 
made by doctors, the pie diagram shown in Figure 15 shows 85% of all 
comments. Pharmacists made, in total 44 comments and NMPs made 10 
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comments, all of which have been represented in their corresponding pie 
diagrams (Figures 16 and 17).  
 
 
Figure 15. A pie diagram showing doctors’ responses to open-ended questions in QRE2. 
 
Figure 16. A pie diagram showing pharmacists’ responses to open-ended questions in QRE2. 
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Figure 17. A pie diagram showing NMPs’ responses to open-ended questions in QRE2. 
Many of the characteristics of the previous comments (in QRE1) were present 
in those made in QRE2. Since the modifications to the service were made in 
order to overcome the limitations identified as a result of the original comments, 
the fact that the same comments have been made again would suggest that the 
modifications were not powerful or extensive enough to completely eliminate the 
originally identified reservations.  
 
7.4 Formulary data extracted from pharmacy computer 
This section will now present the results from the extraction of data from the 
Pharmacy computer system, carried out as an on-going process during the 
entire study period. The first subsection deals with the prescribing and 
dispensing of non-formulary drugs (both ‘approved’ and ‘not approved’). The 
second subsection describes any findings from trends of ‘on-formulary’ drug 
prescribing.  
 
7.4.1 Non-formulary drug prescribing 
As the pilot had shown, data extraction of the nature required for this study, 
proved to be a long and arduous task. Non-formulary drug data over a period of 
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12 months was extracted for both Lister Hospital (Figure 18) and QEII Hospital 
(Figure 19). In both figures the 'blue' trend line represents dispensing (and 
therefore prescribing) of non-formulary drugs that were ‘approved’ by senior 
pharmacy managers and the local DTC. The 'red' trend line indicates non-
formulary drugs that were prescribed, remained unchallenged and subsequently 
dispensed ‘against’ local guidelines or policy. According to local Pharmacy 
procedure, a pharmacist (normally the relevant ward pharmacist) should have 
identified the non-formulary drug in question and intervened by discussing its 
legitimacy with the prescribing doctor. In many cases, recommending an 
alternative (an on-formulary drug listed in the Prescribing Guide) can resolve 
the matter. However in other cases, the requesting doctor may present 
evidence to suggest that their non-formulary choice is in fact clinically superior 
than existing formulary options and thus justified.  
The Prescribing Guide is not expected to have had any impact on total 
approved non-formulary drugs (blue trend line) since these drugs represent the 
involvement of a pharmacist and thus consideration of drugs listed in the 
Prescribing Guide. It was hoped that the prescribing of unapproved non-
formulary drugs (red trend line) would show a decline since doctors and 
pharmacists would refer to the Prescribing Guide and seek out on-formulary 
options for their patients. Both Figures 18 and 19 indicate the point at which the 
Prescribing Guide was launched at the Trust (January 2009). 
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Figure 18. Total 'approved' and 'not approved' non-formulary drug prescribing at Lister Hospital  
August 2008-October 2009. 
Total Approved Total Not Approved 
Launch of 
Prescribing Guide 
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At Lister Hospital, from January to April 2009 the trends for both lines are 
largely unremarkable. During May 2009 a sharp decline in ‘not approved’ non-
formulary drugs can be seen, after which a gradual increase is noted. Also from 
May 2009 a somewhat erratic fluctuation in ‘approved’ non-formulary drugs can 
be observed. The total number of ‘not approved’ non-formulary drugs in October 
2009 is in fact higher than it was in January, when the Prescribing Guide was 
launched indicating no significant impact in this area of prescribing practice.  
It is notable however, that the two trend lines seem to follow a similar pattern in 
their peaks and troughs. For example, during November 2008 and April 2009, 
no drastic changes to the number of issues made for either categories can be 
seen. Similarly in July 2009 and September 2009, both ‘approved’ and ‘not 
approved’ drug issues experience a sharp increase. In order to explore this 
further the original Microsoft Excel spreadsheets extracted from the Pharmacy 
computer were analysed. It was revealed that during 2009, as a result of the 
swine flu pandemic, a large number of antiviral drugs (for example, oseltamivir 
and zanamivir) were issued and many complications of virus were also treated. 
The trends in non-formulary drug prescribing reflects the patient load that the 
Trust was required to contend with. This is entirely consistent with national data 
published by the Health Protection Agency (HPA) who demonstrate peaks in 
both swine flu cases and antiviral prescriptions in and around July and 
September 2009 (HPA, 2011). The antiviral drugs ‘oseltamivir’ and ‘zanamivir’ 
were historically input into the Pharmacy computer as non-formulary drugs so 
their prescriptions to treat swine flu cases at least partly explains the rise in the 
blue trend line. During these periods, an inordinate volume of unapproved non-
formulary drugs were also prescribed. These ranged from other antivirals, 
antibiotics and low molecular weight heparins (LMWHs) such as tinzaparin, to 
name a few. It can be logically concluded that these drugs were prescribed in 
order to treat complications and associated conditions arising from new swine 
flu cases. 
Since both ‘approved’ and ‘not approved’ non-formulary drug prescribing has 
inevitably been confused by the prescribing of such agents, it has become 
difficult to elucidate the true picture of non-formulary drug prescribing after the 
launch of the Prescribing Guide. 
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Figure 19. Total 'approved' and 'not approved' non-formulary drug prescribing at QEII Hospital  
August 2008-October 2009. 
Total Approved Total Not Approved 
Launch of 
Prescribing Guide 
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Figure 19 displays trends in non-formulary prescribing at the QEII Hospital. The 
characteristics of these trends are of a similar nature to those at the Lister 
Hospital. There appears to be a gradual decline in ‘not approved’ non-formulary 
drug prescribing from January 2009 until June 2009. In July 2009 and 
September 2009 ‘not approved’ non-formulary drug prescribing peaks, 
approximately when ‘approved’ non-formulary drug prescribing also peaks. A 
check on the original Microsoft Excel spreadsheet for QEII non-formulary drug 
issues reveals similar antiviral drugs were prescribed during these periods 
however not to the same extent as seen at the Lister Hospital. The peak in 
‘approved’ non-formulary drugs in July 2009 for example is not entirely a result 
of the swine flu outbreak and instead indicates a combination of genuinely large 
number of non-formulary drugs being approved by the local DTC and patients 
being admitted to the Trust who had previously been prescribed drugs that are 
locally considered non-formulary.  
 
7.4.2 Formulary-approved prescribing 
The final aspect of quantitative data in the present study concerns exclusively 
formulary ‘approved’ drug prescribing. In Appendix 16, eight figures show the 
data extracted for a selected series of drug classes. These particular drugs 
were chosen after deliberations during the first Stakeholder Meetings. The 
figures display volumes of drug issues (bars) along with their corresponding 
costs (trend lines) for all drug classes except ‘laxatives’ (Figure B). For this 
class of drug, only cost information has been displayed since the number of 
issues were complicated due to the fact that some laxatives were issued as 
specific millilitres and others as packs (of tablets or capsules) and therefore the 
comparisons would not have been appropriate. For all figures, this particular 
type of data was only available on a retrospective quarterly basis with the 
Prescribing Guide being launched in the quarter, January-March 2009. At the 
time of collection, the last quarter available was April-June 2009.  
In large part, the figures do not show any significant impact of the Prescribing 
Guide on local prescribing practice. In Figure B, the cost of Movicol (a restricted 
laxative at the Trust) peaks in March 2009 and then begins a steady decline 
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over the next three months. Figure C shows a small decrease in the cost of 
atorvastatin (a restricted cholesterol lowering drug) prescribing but no real 
discernible reduction in the volume prescribed. In Figure D, a steady decrease 
in the cost and volume of fentanyl (restrictive opioid painkiller) prescribing can 
be seen over the last three quarters. However this appears to be countered by 
an ‘increase’ in the prescribing of oxycodone (another restrictive opioid 
painkiller) over the same period. In Figure F, the prescribing of solifenacin (a 
recently reviewed and restricted drug for urinary incontinence) appears to have 
declined and then ‘stagnated’ over the last three quarters. All of these, relatively 
small, reductions in the prescribing of restricted drugs offer only a tenuous link 
to the impact of the Prescribing Guide. The figures do not point to any drastic or 
convincing changes to the prescribing of any class of drug and thus no real 
changes to prescribing behaviour. 
Formulary approved drugs have, however, remained the most frequently 
prescribing drugs within each class of drug. For example in Figure A, the 
prescribing of omeprazole remains far more frequent than either lansoprazole or 
esomeprazole (drugs to inhibit gastric acid secretion) and in Figure C, 
simvastatin prescribing is consistently greater than either pravastatin or 
atorvastatin. Once again, since there are no discernible changes after the first 
quarter of 2009, the data does not show any impact of the Prescribing Guide. 
One reason for the lack of a visible difference in the prescribing data is that the 
Prescribing Guide was in fact ‘exposed’ to potential end-users in a basic format 
prior to the research. As outlined in Chapter 4, ‘Phase I’ of the Prescribing 
Guide was launched to the Trust in November 2007. This phase involved 
obtaining consensus from specialist consultants at the Trust and Directorate 
Pharmacists as to the allocated traffic light of each drug in the Prescribing 
Guide. Although there was no clinical guidance available for users at this stage 
of the development process, it is reasonable to conclude that the Prescribing 
Guide may have been used by various healthcare professionals to at least 
check on the formulary status of drugs and the restriction based on the traffic 
light system. Therefore the Prescribing Guide may have ‘already’ impacted 
prescribing practice prior to the study, perhaps on a gradual basis. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 190 
 
Another explanation may concern the resistive attitudes of some doctors who 
wish to prescribe restricted drugs in the manner in which they feel appropriate. 
Generalised Statement 4, outlined in Chapter 6 has outlined specific reasons 
why the Prescribing Guide “struggles to become a core component of doctors’ 
routine within prescribing practice”. This will be discussed further in Chapter 8. 
The figures do help develop an appreciation for the relative costs of formulary 
first-line, second-line and third-line drug options. For instance, in Figure A 
(Appendix 16), the cost of the formulary’s third-line proton-pump inhibitor (PPI) 
esomeprazole, can be seen to be more than half the cost of the formulary’s first-
line agent, omeprazole. What is of interest is that the volume of esomeprazole 
prescribing amounts to a very small proportion of total PPI prescribing. Similar 
pictures emerge in Figure C (statins), Figure D (analgesics), Figure E 
(macrolide antibiotics), Figure F (drugs for urinary retention), Figure G (NSAIDs) 
and Figure H (prostaglandin eye drops). These findings will be discussed further 
in Chapter 8 and help to corroborate claims regarding perceived priorities for 
the Trust, the Pharmacy department and the prescribers.  
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7.5 Summarising findings from self-completion questionnaires  
Figure 20 below highlights the key results from the self-completion 
questionnaires in order to ease further analysis and interpretation. All boxes 1-
12 in the diagram show only statistically significant differences ‘between 
healthcare professionals’. Any statistically significant changes ‘across 
questionnaires’ (from QRE1 to QRE2) have been specifically emphasised (with 
**).  
 
 
Figure 20. Boxes 1-12 summarise key findings from the online self-completion questionnaires  
(** indicates the changes in doctors responses ‘across questionnaires’ are statistically 
significant). 
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7.6 Summary of Chapter 7 
This chapter has presented the quantitative findings for the study. In large part, 
the focus has been on results produced by the online self-completion 
questionnaires. The results illustrate vast differences between doctors and 
pharmacists. Far more pharmacists know how to access the Prescribing Guide 
compared to doctors. Similarly, a considerably greater proportion of 
pharmacists use the Prescribing Guide than do doctors. Following the 
‘modifications phase’, statistically significant increases in doctors' responses 
were noted indicating that the modifications did have some impact.  
Non-formulary prescribing at both hospitals within the Trust was also analysed. 
It may initially be concluded that the Prescribing Guide has had an impact on 
prescribing practices. However, a deeper consideration of the trends and 
corresponding drugs prescribed, along with a wider national consideration, 
reveals that in both hospitals much of the observable trends are due to the 
prescription of drugs for swine flu and its complications. This has partially 
obscured the ability to be able to discern the truth about the Prescribing Guide’s 
impact on non-formulary drug prescribing.  
Formulary approved prescribing data has been appended. In most cases, 
formulary first-line, and second-line agents are ‘rightly’ used to a greater extent. 
These figures provide a unique insight into the volume and corresponding cost 
burden of selected formulary approved drugs. They will further contribute to 
later discussions in the following chapter
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Chapter 8 
Discussion 
 
8.1 Introduction 
The discussion focuses predominantly on the qualitative findings with 
quantitative data being incorporated to help provide more comprehensive 
understanding of phenomena. The phenomenological analysis has facilitated 
the construction of participants' 'lived experiences'. Using established 
sociological and political frameworks and drawing on existing formulary 
literature, attempts are made to contextualise these lived experiences. 
The chapter begins with a reflection on identified study limitations and the 
attempts made to overcome or minimise them. The next section discusses the 
main study findings based in large part on the generalised statements outlined 
earlier. This chapter attempts to adhere to the following narrative: initial 
perspectives of the Prescribing Guide; initial perspectives on the formulary 
concept focusing on the 'critical split'; discussions on the lived experiences of 
doctors, pharmacists and NMPs in prescribing practice. Based on the 
discussions in this chapter, a conceptual model is proposed to optimise both the 
functioning of the future hospital drug formulary and the pharmacy profession.  
 
8.2 Reflections on study limitations 
 
8.2.1 Recruitment of participants and Stakeholders 
A pre-selected list of participants (Table 8, page 92) was compiled. Since any 
agreement to take part in the study may have been an indication of a favourable 
endorsement for the Prescribing Guide, it was therefore recognised that a bias 
may have been introduced by the chosen sampling technique. However, the 
interview transcripts along with subsequent analysis have revealed that a wide 
range of experiences and perceptions exist ranging from positive to negative. A 
similar rationale applies to recruitment of Stakeholders (Table 6, page 88). 
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In addition, the number of Stakeholders recruited was eventually four (including 
the study researcher in the capacity of Senior Formulary Pharmacist). As 
Section 5.4 outlines, difficulties were encountered in being able to recruit the 
originally planned number of six. This is recognised as a limitation to the 
Stakeholder Meetings since a larger number of Stakeholders may provide more 
comprehensive interpretations of the emerging themes presented to them. 
Nevertheless as outlined in Appendix 15, in all meetings lively discussions took 
place. 
 
8.2.2 Analysis of qualitative data 
For the qualitative data analysis, a large number of codes (Appendix 13) were 
eventually produced along with code definitions. These codes have been 
reduced to 63 themes and then to 13 generalised statements. Such a large 
network of information may have been managed using new software such 
NUD.ist (QSR, 2011). However since the researcher felt particularly adept at 
using Microsoft Excel, spreadsheets were used to track codes and themes as 
they were produced. This is a robust and appropriate system of data handling. 
A potential limitation of qualitative analysis concerns the interpretation of the 
data. Only a single researcher conducted the analysis and interpreted 
participants’ 'lived experiences'. It is plausible then that the interview transcripts 
may be interpreted differently by other researchers. In order to address this 
limitation and ensure the quality of the research, the researcher arranged for 
independent coding (outlined in Section 6.5.1) to validate initial codes and code 
definitions. Additionally a reflexive account of the researcher's views on 
formularies and healthcare professionals have been presented (Appendix 11) in 
order for readers to assess for themselves where the researcher's personal 
experiences and values may have influenced analysis. This account was written 
prior to conducting the phenomenological analysis. 
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8.2.3 Stakeholder Meetings 
In total three Stakeholder Meetings were arranged. In Stakeholder Meetings 2 
and 3, provisional findings and emerging themes were discussed. However, 
more substantive qualitative analysis yielding codes, themes and generalised 
statements were not discussed since this analysis was conducted a number of 
months after Stakeholder Meeting 3. A further 'Stakeholder Meeting 4' was 
considered but arranging a meeting at such a later date on balance would not 
have been beneficial since Stakeholders would not in all probability have been 
able to recall the context in which the final analysis was being presented. The 
summaries of the contributions made by Stakeholders (Appendix 15), 
demonstrate that many of the interpretations and discussion points resonate 
with the final themes and generalised statements. 
Stakeholder Meetings were not audio-taped as is the case with the semi-
structured interviews. However during these meetings, extensive notes were 
taken in order to ensure all significant discussion points were captured as 
faithfully and comprehensively as possible.  
 
8.2.4 Semi-structured interviews 
During the semi-structured interviews, environmental factors often contributed 
to loss of sound quality in the audio recording. One example of this was with 
SP1's interview in which the pharmacist's voice could in some segments be only 
faintly heard. This was due to the fact that the venue chosen was a small office 
beside a noisy out-patients' waiting area. Following this experience, the 
dictaphone was placed much closer to the interviewee. However, interviewees 
frequently made statements in which their clarity was obscured either due to 
unexpected environmental factors or because the interviewee's speech was 
muffled.  
One particular study limitation associated with semi-structured interviews 
concerns the 'interviewer effect'. The researcher who conducted the interviews 
was also the Trust's Senior Formulary Pharmacist and was therefore known to 
many of the participants. It is established that what the interviewer's identity 
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'means' to the interviewee is likely to influence their willingness to divulge 
information (Denscombe, 2007). Fortunately, the qualitative data demonstrates 
a wide range of answers were expressed allowing broad understanding of 
participants' attitudes and perspectives. Additionally, the quantitative data 
produced from the self-completion questionnaires has been used to corroborate 
the qualitative findings. Respondents to these questionnaires, submitted 
anonymously, were not affected by an 'interviewer effect' or concerns about the 
Formulary Pharmacist's perception. 
 
8.2.5 Online self-completion questionnaires 
There is a noticeable discrepancy between qualitative and quantitative findings 
in relation to views expressed towards ‘senior colleagues’. According to the 
results of Question 4 in the self-completion questionnaires, pharmacists 
indicated that seniors were 'important' influences to their role in drug therapy. 
However during semi-structured interviews, while discussing influences, most 
pharmacists listed senior colleagues either very late in a list of influences or not 
at all. This discrepancy was discussed at the third Stakeholder Meeting. The 
senior pharmacist-Stakeholder provided a rationale for this discrepancy. He 
stated pharmacists invariably carry out their ward duties alone (unlike doctors 
who work in teams) and so although pharmacists certainly regard their senior 
colleagues as 'important' as indicated in the quantitative data, "they do the best 
they can on their own". Since he was often involved in educating junior 
pharmacists he also added that when pharmacists were unable to resolve an 
issue independently then they "always come up to me or whoever for direction". 
Therefore regarding this issue of senior colleagues, rather than the two sets of 
data conflicting or being discrepant, it would appear that in fact they provide a 
more comprehensive interpretation of pharmacists' regard for their senior 
colleagues. 
There is also recognition that, in Question 5, the notion of 'professional 
autonomy' may have been ambiguous, particularly for doctors. Firstly, it is 
considered that 'autonomy' could be taken to imply the ability to work without 
'any' influences and without the need to rely on support other than the 
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practitioner themselves. Secondly, it could also be regarded as the ability to 
work independent of other individuals but accepting the need to rely on non-
human resources such as the Prescribing Guide. Regardless of this apparent 
distinction, there is a consistent and notable difference between pharmacists 
and doctors.  
 
8.2.6 Quantitative data extracted from Pharmacy computer  
The figures illustrating 'formulary-approved prescribing' (Appendix 16), 
described in Section 7.4.2, have been produced using data up to June 2009. 
This data was available for extraction from the Pharmacy department's 
computer system in quarterly portions only and therefore at the time of final data 
collection, the next three months was not accessible. This is a recognised study 
limitation since the impact of the 'modifications' cannot be commented on. The 
figures in Appendix 16 have, however, provided a useful visual understanding of 
not only the prescribing trends of formulary approved drugs but also highlighted 
the relationship between prescribed volumes and their corresponding costs. For 
example, atorvastatin is the Trust's approved third-line statin (Figure C) and, 
while it is prescribed significantly less than simvastatin (first-line statin), it is far 
more costly. The figures also provide insights into areas in prescribing practice 
that require more clinical interventions from pharmacists for example, 
'diclofenac' prescribing was prescribed more than 'ibuprofen' in the first three 
quarters of Figure G. 
 
8.3 Reflections on findings  
 
8.3.1 Initial perceptions of the Prescribing Guide 
During semi-structured interviews, the immediate comments made about the 
Prescribing Guide were largely positive in nature. However subsequent 
comments were wide ranging – apparently drawn either from experiences of 
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having used the service or from deeper existing attitudes and perceptions to 
such influences in prescribing practice.  
Statements 1 and 2 summarise participants' key perspectives. The Prescribing 
Guide is considered useful for practitioners who seek decision-support, typically 
non-consultant doctors and pharmacists. In addition, pharmacists make 
extensive use of the Prescribing Guide to facilitate the 'retrospective' checking 
of prescriptions and supporting clinical interventions.  
Although Themes 30-32 highlight very specific difficulties with the use of the 
Prescribing Guide itself, it is considered that the issues summarised in Themes 
23 and 24 are more likely to prevent the new service from achieving its full 
potential. In particular, the utilisation of the Prescribing Guide is hampered by 
the limited computer access. Doctors indicated that access to the Prescribing 
Guide was troublesome on the wards. Approximately half of all doctors 
responding to QRE1 agreed that the Prescribing Guide was easily accessible 
compared to almost all pharmacists. This is in keeping with pharmacists' 
statements made during interviews, that is, pharmacists are easily able to 
access the Prescribing Guide from computers within the Pharmacy department.  
 
8.3.2 Key conceptualisations of the Prescribing Guide   
Statement 2 summarises participants' four key conceptualisations of the 
Prescribing Guide. These perspectives are shown diagrammatically in Figure 
21. Although it could be argued that 'Improves autonomy' can be interpreted as 
'Utilitarian' and similarly 'Restricts / threatens autonomy' could be subsumed 
under 'Control measure', based on the findings in this study, it was considered 
that each of the four categories merit individual discussion.  
Schumock et al (2004, page 557) state that the "effectiveness of strategies to 
control the quality and cost for medication use is largely dependent on the 
ability to alter prescribing behaviour". Theme 4 summarises how some senior 
pharmacists (often managers) use restrictive terminology when discussing 
medicines management. This may suggest a lack of 'attitudinal-engagement', 
particularly by managers in attempting to influence prescribing practice, instead 
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there is a resort to restrictive policies. Such individuals may interpret the “ability 
to alter prescribing behaviour”, that Schumock et al (2004, page 557) refer to, 
as more oriented around enforcing controlling measures rather than an 
acknowledgement of prescribers grievances. 
 
Figure 21. Positioning tool representing the four identified conceptualisations of the  
Prescribing Guide (based on Statement 2). 
 
In contrast to such control-oriented approaches, participants who appear to 
have constructed a 'utilitarian' view of the Prescribing Guide, address its 
benefits with specific reference to their ‘own’ personal practice rather than an 
immediate attention given to the Trust's ‘wider’ medicines management 
strategy. In this context, the most common feature of the Prescribing Guide 
mentioned was its comprehensiveness and thus its ability to support drug 
selection – this was particularly prominent among non-management 
pharmacists. Allen and Harkins (2005, page 1768) state that a "critical mass" of 
guidelines can be produced, where "sheer volume" is impossible to be applied 
or even read properly. The Prescribing Guide is similarly seen as a conduit for 
extensive drug knowledge that organises this information so that it is relevant 
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for local priorities and needs. In addition, while serving as a central access point 
for drug information, the Prescribing Guide offers an apparent 'education-in-
practice' for many practitioners.  
Although the Prescribing Guide is adversely affected by a severely time-
constrained setting, it paradoxically holds particularly high use value when 
practitioners are in need of advice quickly. Doctors have, for instance, described 
busy on-call scenarios in which the Prescribing Guide has been helpful and 
similarly pharmacists and doctors have both described using the Prescribing 
Guide as a useful alternative to contacting senior colleagues and having 
obtained information they required immediately.  
The remaining two perspectives concerning 'autonomy' will be discussed later in 
the section as the 'lived experiences' of healthcare professionals are further 
explored.  
 
8.3.3 Rationing and resource management  
Statement 5 outlines a critical 'split' within prescribing practice. The hospital 
drug formulary is central to this ‘split’ which concerns resource management, 
namely the allocation of the drug budget. The importance of the drug budget is 
illustrated by examining the Figures A-H in Appendix 16. Typically, third-line 
agents are used far less that first-line agents yet they cost the Trust a 
substantial amount more than first-line agents. 
During semi-structured interviews, solifenacin (drug for urinary incontinence), 
was often mentioned by a number of pharmacists as an example of a third-line 
alternative inappropriately prescribed as first-line. In all cases, pharmacists 
described that subsequent clinical intervention, including challenging the 
prescriber, proved to be contentious. However, eventually doctors agreed to 
switch treatment to oxybutynin (first-line option). Pharmacists further praised the 
Prescribing Guide for providing all relevant details that essentially facilitated the 
challenge. It is likely that referring to the Prescribing Guide may have 
contributed to the reduction in solifenacin prescribing seen in Figure F 
(Appendix 16) 
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Unauthorised non-formulary drug prescribing (Figures 18, page 185 and Figure 
19, page 187) is also of significant concern since it represents the allocation of 
financial resources to unapproved drugs. 
Appropriate resource management has been an issue in the NHS since its 
creation in 1948 (Harrison and McDonald, 2008, page 10). The Minister of 
Health in 1966, for example, stated that the medical profession when faced with 
“various forms of rationing” react with “frustration and irritation”. It is interesting 
that the sentiments expressed in 1966 can be observed in some of the 
participants interviewed in the present study. Some junior and senior doctors, 
for instance, implied that the drug budget appeared to take greater priority than 
the patient's best interests. Similarly, isolated voices within pharmacist 
participants also described resentment towards the formulary's perceived focus 
on cost-minimisation and lack of patient consideration.  
Today, in a period of increasing fiscal austerity, in which the so-called 
'Nicholson challenge' presents a momentous task for the NHS, appropriate 
allocation of resources is even more crucial (Hughes and Thorp, 2010; BBC, 
2010). The sort of ‘split’ amongst key practitioners symbolised by the formulary 
cannot be conducive to meeting such financial challenges.  
 
8.3.4 The 'critical split' depicted by the formulary 
In its most fundamental manifestation, this split can be seen in participants' 
perceptions of the definition and purpose of the formulary concept. In Chapter 3, 
the current literature was consulted in order to establish a loose consensus on 
the accepted definition of a formulary. Firstly, a focus on improving the quality of 
rational, evidence-based prescribing and; secondly, limiting unjustified use of 
expensive drugs.  
Many participants perceive the formulary essentially as a means of 'stock 
control' and to aid the 'logistics' involved in maintaining a large number of 
approved drugs. In this context, doctors in particular discussed the involvement 
of the Pharmacy department or experiences in which pharmacists were seen to 
cite the formulary. Clearly there is a perception among doctors that the 
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formulary and the pharmacy profession are closely aligned and may therefore 
perceive such initiatives as 'externally-generated' control.  
Doctors also described cost-motivation as a key aspect of the formulary's remit, 
however rather than take a secondary level of priority, cost-minimisation was 
seen to be the primary focus of formulary implementation. This is in keeping 
with doctors’ sentiments found in the literature. 
The quantitative findings provide further light on doctors' impressions of the 
local formulary, that is, the majority of doctors consistently disagreed with the 
statements that the Prescribing Guide was ‘patient-focused’ or ‘supports 
evidence-based medicine’.  
Pharmacists were able to elaborate on the formulary’s purpose and remit much 
more readily resonating well with the themes identified in the literature. Theme 
21 further highlights the different regard that the doctors and pharmacists have 
towards the 'formulary status' of drugs. However there were, among senior 
pharmacists, varying degrees of restrictiveness implied when describing how 
formularies were meant to operate. This echoes Pearce and Beggs' (1992, 
page 191) use of terms such as "limited list" to describe the formulary. At the 
other extreme, two pharmacists expressed a perceived lack of pragmatism 
associated with the formulary and its ‘excessive’ interest in cost-minimisation – 
both these comments consisted of pejorative undertones. 
Another noted observation concerns the apparent cognitive dissonance among 
doctors who early in the interview asserted support for the formulary for its 
service to the 'greater good', yet later, when describing conflicts in prescribing 
practices, appeared to reject the notion of the formulary (or other forces) 
impinging on their freedom to prescribe.  
 
8.3.5 Reflections on the ‘lived experiences’ of doctors in prescribing practice 
In this study, through the application of phenomenological analysis there has 
been an attempt to uncover the 'lived experiences' of participants. Statements 
10, 11 and 12 highlight the key features that attempt to represent the 'reality' of 
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the ‘social world’ as interpreted by doctors. The social world in this context is 
the domain of drug therapy within the Trust. Statement 4 is a further effort to 
isolate and develop those experiences in which the Prescribing Guide tends to 
take central relevance.  
Doctors placed great value on their perceived ability to prescribe freely with little 
or no intrusion from those outside their profession. Any discussions during 
interviews on initiatives that could be seen as limiting this 'freedom' were in 
most cases quickly countered with statements expressing their frustrations and 
unease with such notions (Theme 55).  
In the previous section doctors' views of the underlying purpose and definition 
of the local formulary have been noted. It is such interpretations of the formulary 
that generates an opposition to the way in which the formulary is perceived to 
restrict doctors' autonomy. In much the same way doctors have also referred to 
the work of pharmacists as the "policeman's role" (CD5 Interview No.19). 
Although, as Statement 11 asserts, doctors demonstrate a willingness to 
engage in discussions about appropriate drug therapy, pharmacists are often 
seen as cost-motivated, entirely concerned with enforcing guidelines and in 
some cases considered obstructive. Indeed doctors made attempts to lay out 
clear demarcations that separated the professional territory of the medical 
profession and the perceived territory of pharmacists. 
Elements within the medical profession have previously voiced varying degrees 
of concern about the growing threats to their 'autonomy' as is rather telling from 
Zabawski’s (2002, page 726) provocatively titled paper: “No trespassing! Are 
the Pharmacists Stepping over the Line?”. The author, a doctor, focuses on the 
specialist knowledge the ‘doctor’ possesses (not the pharmacist) and 
particularly highlights pharmacists’ “outright interference with the care that 
doctors are endeavouring to provide” (Zabawski, 2002). As early as 1979, the 
development of clinical pharmacy has been described as “boundary 
encroachment” and “an attempt to extend the boundaries of pharmacy practice 
into the territory of the medical profession” (Eaton and Webb, 1979). 
In Section 2.3.1 we have seen that the medical profession has traditionally been 
in a unique position to be able to exert influence over 'kindred' occupations. This 
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influence and ability to extend control beyond its own profession's jurisdictions 
has been possible due to its unrivalled relationship with the government. Klein 
(1990, page 700) describes a "mutual dependency" between the medical 
profession and the state. With the formation of the NHS, the state became 
dependent on doctors to "run" it. In the early years of the NHS, to ‘promote 
rationing’ of clinical resources was considered politically damaging for all 
political parties. Doctors as a result of the state-backed 'professional autonomy', 
served a political purpose, that is, 'implicit rationing' of resources and 
treatment10. As one of the very early principles on which the NHS was 
constructed, the Minister of Health in 1944 stated the following: 
 “doctors...must remain free to direct their clinical knowledge and 
personal skill...in the way...they feel to be best" (Harrison and 
McDonald, 2008, page 42) 
 
Therefore, the medical profession has been 'historically' empowered by the 
state in order to serve what appear to be political ends, namely the 
management of resources and maintaining the NHS. This early empowerment 
might explain the, perhaps remnant notions of, freedom and autonomy that we 
can see in doctor participants in this study. Statement 11 further describes a 
'prerogative' that doctors appear to allude to. Despite other influences and 
authorities (pharmacists or NICE guidance) that might operate within the 
prescribing domain, since doctors consider themselves to be particularly 'closely 
bound' to patients, they therefore perceive themselves to be in a position of 
authority to adopt or reject drug advice.  
During interviews, doctors presented this patient-focus in a number of ways. 
They either unequivocally asserted that as members of the medical profession 
they are solely patient-orientated, or they made discrediting statements about 
other parties involved in the medicine management process. The pharmacy 
department for example, was frequently deemed to be concerned with stock 
                                                          
10
 Implicit rationing - Harrison and McDonald (2008) explain how 'professional autonomy' was 
supported by the government to allow doctors to match supply and demand as they saw fit. 
Research in 1984 shows doctors tried to make the 'denial of care' seem routine or optimal for 
example if a patient was too old for the clinical age for dialysis, the doctor would inform the 
patient and the relatives that the patient has 'chronic renal failure' and nothing can be done for 
them. The political advantages are that rationing of resources, a difficult subject to face publicly, 
did not need to be addressed by the government of the day. 
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control or surreptitiously engaged in cost-minimisation. There were also clear 
notions that pharmacists lacked the skills required to be patient-focused, 
instead adopting a far more guidelines-centric approach. 
Doctors rejected the notion that pharmacists are also, in addition to themselves, 
in some way 'accountable' for the prescribing of medicines. There was a notable 
effort, ranging from junior doctors to consultants, and from members and non-
members of the DTC, to distance pharmacists' accountability from their own. 
Attempts were made to distinguish between the clinical expertise involved in 
making drug selection 'by doctors' and the technical duties involved in 
dispensing and supplying medicines 'by pharmacists'. 
The reluctance to partake in joint professional ventures or to be regulated in any 
manner by ‘outside’ bodies gives credence to the 'conflict theories' described in 
Chapter 2. Rather than work closely or in Durkheim’s words ‘in harmony’, with 
those of different occupations and so demonstrating a general consensus 
around both patient and professional goals, a significant body of literature 
instead points to a degree of defiance and resentment in the attitudes of 
members of the medical profession as seen in the present study (Gollop et al, 
2004; Degeling et al, 2006).   
Larson's model of the 'professional project' (Figure 1), has portrayed 
occupations as endeavouring to acquire 'social closure'. Central to this model is 
a 'monopoly of knowledge' which according to many sociologists is the "core 
generating trait" of professionalism (Freidson, 1994, page 185). Professions 
have long been criticised for "mystifying their knowledge" (O'Day, 2005 in 
Harrison and McDonald, 2008, page 28). Indeed Theme 61 highlights doctors' 
claims to possess the ability to "deal with uncertainty" (CD3 Interview No.3), 
perhaps a manifestation of 'mystification' within local practice. Doctor 
participants frequently referred to the application of 'clinical judgement' in such 
instances of uncertainty.  
In the findings presented in Chapter 6, we have noted doctors alluding to a 
monopoly over a wide range of clinical expertise. For example, there have been 
references to a perceived monopoly on knowledge of clinical outcomes which 
includes the knowledge of drug therapy (Theme 41), or the monopoly on 
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pathophysiology or the monopoly on diagnostic skills. However, for the 
purposes of the present study, it is the realm of drug therapy that may be seen 
to be an area of competition and contestation also implicit in Zabawski's (2002) 
article and other authors (Goodwin, 2003; Kwan, 2005). In the light of such 
theorising, the rationale behind doctors resisting pharmacists' clinical 
interventions now appears to comprise an additional, perhaps 'ulterior' motive – 
namely the defence of their own professional jurisdiction and monopoly on 
knowledge of drug therapy.  
The medical profession has been described as the dominant profession in the 
healthcare arena where other 'semi-professions' are subordinate (Harrison and 
McDonald, 2008). Freidson (in Harrison and McDonald, 2008) explains 
subordination can take on various forms from doctors giving instructions to 
nurses through to the medical profession influencing the training and licensing 
of other health professions. Pharmacists, however, have a claim to extensive 
training and knowledge specifically concerned with the realm of drug therapy 
hence a monopoly that can, potentially, challenge this aspect of the work of the 
medical profession. This 'contested' ground is further emphasised since drug 
therapy is the most frequent therapeutic intervention with 97% of hospital 
patients prescribing medicines (NPC, 2011b; Picton and Quinn, 2011; 
Healthcare Commission, 2007).  
A number of themes captured notions of a wider distrust that doctors have for 
the local formulary and the DTC. Often deemed to be excessively ‘bureaucratic’, 
the formulary ‘process’ restricts doctors from practicing as autonomous 
practitioners. One medical registrar used a particularly notable metaphor to 
describe the formulary. He stated that it acted like a "big iron door" (RD2 
Interview No.6) discouraging him from engaging in the established review 
process to obtain the drug he wanted to prescribe. Weber famously forewarned 
that bureaucracy constituted an 'iron cage' from which society could not escape 
(Taylor et al, 2003). One interpretation is that this perceived bureaucracy has 
evidently penetrated medical practice at the Trust giving rise to frustrations and 
resistance. 
Section 2.2.4 described organisation through bureaucracy coupled with the 
advancement of science, as 'rationalisation'. This Weberian concept focuses on 
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the application of precise calculation and organisation, involving rules and 
procedures (Giddens, 2009). For example, Themes 8, 10, and 12 outline 
instances in which participants support the 'concept' of rationalising drug 
therapy through establishing effective formularies and local DTCs. Themes 47 
and 48 indicate the conscious adoption of the 'outcomes' of rationalisation, that 
is, algorithms, guidelines for their decision-support value. Conversely, there are 
varying degrees of opposing views, predominantly from doctors and NMPs, 
such as seen in Themes 3, 5, 9, 11, 14, 30, 43 and 45. These themes provide a 
critique of some aspect of rationalisation, whether it is broadly through the 
imposition of the formulary's decisions, recommendations from NICE or from 
specific features in the Prescribing Guide that cause confusion (such as the 
traffic light system). Essentially, through both supportive and opposing voices in 
the present study, the perceived existence of rationalisation of local drug 
therapy is confirmed. 
Rationalisation in healthcare, further impacting on doctors' professional 
autonomy, has been previously recognised with the rise of evidence-based 
medicine (Mykhalovskiy and Weir, 2004; Britten, 2001). As Traynor et al (2010) 
state evidence-based medicine targets “the mystique and privacy of medical 
decision-making” (Traynor et al, 2010, page 1506). Even NICE has been 
implicated as offering “too much guidance” which in effect can be “unhelpful and 
can lead to confusion” (Allen and Harkins, 2005, page 1768). Similar notions 
were expressed in the present study as doctors expressed disapproval about 
unnecessary confusion caused by the duplication of effort when reviewing drugs 
for local consideration at the Trust when national reviews had already been 
published. 
Ultimately rationalisation confines practitioners, seeking to organise work 
"according to the principles of efficiency and technical knowledge" (Giddens, 
2009, page 93). Jamous and Peloille's I / T ratio (described in Section 2.2.3 
Specialist Knowledge) provides an effective means by which to 'measure' the 
degree of professionalism an occupation can claim to.  
Since the content of 'purely' professional work consists of high indeterminacy 
and a rejection of rationalistic confines doctors are reluctant to embrace the 
formulary or its perceived 'agents' (pharmacists). The consequences for the 
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Prescribing Guide, based on this underlying conceptual framework are likely to 
be closely related to the combative stance taken towards the formulary. 
Other recognised contemporary challenges to the medical profession manifest 
as managerialism and the breakdown of professional boundaries (Crinson, 
2007). A 2006 study demonstrated that doctors in particular rejected the notion 
of introducing practices that would facilitate the ‘systemisation’ of clinical work 
(Degeling et al, 2006).  
In a Marxian interpretation where “clinical service” is the “product” of healthcare 
professionals, practice is constantly under the scrutiny of the state in efforts to 
increase efficiency, reduce expenditure and raise standards (Cornett, 2006, 
page 301). For instance, the recently formed Care Quality Commission (CQC) 
states that it “regulates providers of medical and clinical treatment...including 
treatment given in hospitals...” (CQC, 2011). Another recent form of oversight 
and further evidence of government initiatives penetrating healthcare activities 
comes as the Commission for Quality and Innovation (CQUIN) framework. 
Introduced in 2009, the aim of the CQUIN framework is “to secure 
improvements in quality of services and better outcomes for patients, whilst also 
maintaining strong financial management” (Crown, 2012). The framework 
enables commissioners of services to ‘incentivise’ local providers to deliver 
improvements in quality and safety of healthcare while also improving 
efficiency. The four CQUIN ‘goals’ for 2013/14 describe specific quality 
improvement objectives to be incentivised for example, “To reduce avoidable 
death, disability and chronic ill health from venous thromboembolism” (Crown, 
2012). CQUIN ‘indicators’ are measures which determine whether a goal has 
been achieved and in turn, whether the provider ‘earns payment’.  
Improvements specifically concerned with the quality of prescribing and 
medicines management has been led by the ‘Medicines Use and Procurement’ 
workstream which is part of the Department of Health’s Quality, Innovation, 
Productivity and Prevention (QIPP) programme introduced by the previous 
government. The aim is to “ensure that value for money is further enhanced 
while quality of care is maintained or improved” (NPC, 2013). The National 
Prescribing Centre (NPC) has worked closely with the Department of Health to 
identify a range of QIPP therapeutic topics. Once again, these areas come with 
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indicators to monitor performance for example, the QIPP topic ‘Renin-
angiotensin system drugs’, is monitored by the following indicator ‘ACE inhibitor 
% items’11 (NICE, 2012). As early as 2003, the introduction of ‘performance 
indicators’ into clinical care was recognised as a “challenge...to a previously 
guarded aspect of clinical autonomy – the assessment of work performance” 
(Exworthy et al, 2003, page 1493). 
In addition, more emphasis has been given to patient choice and their personal 
needs and preferences. With the advent of the Internet contributing to a 
decrease in the knowledge gap between doctors and patients, patients are 
recognised as becoming increasingly well informed and able to cite sources 
during discussions with doctors (Britten, 2001). Lord Ara Darzi’s review of the 
NHS (DH, 2008b), stated that patients will be given “more rights and control 
over their own health and care”. In the same review, the first NHS Constitution 
was announced. With the NHS Constitution now law under the Health Act 2009, 
all patients in England have a “legal right to drugs and treatment recommended 
by NICE” (PJ, 2010). Research in the UK and abroad has shown the treatment 
is more effective if patients are encouraged to understand, choose and control 
their care (NHS Choices, 2013; Crown, 2011). Patient choices promoted by the 
NHS in England outlined in the new ‘Choice Framework’ for 2013/14 include 
being able to “choose a GP and to change to another if not happy with the 
service received” (Kings Fund, 2011). The relatively recent concept of 
‘concordance’ between the patient and the doctor (introduced by the Royal 
Pharmaceutical Society of Great Britain in 1997) acknowledges in particular, the 
‘patients’ autonomy’ within a consultation (Britten, 2001). The traditional 
paternalistic approach to prescribing and any ‘absolute’ autonomy of prescribers 
could be at threat.  
Given these relatively recent developments in healthcare, it is not surprising that 
some Marxist-influenced writers have suggested professional autonomy is in 
fact largely illusory (Harrison and McDonald, 2008). Instead of dominant 
professions, such as medicine, having secured a high social status by securing 
'elite' approval, as described in Section 2.2.2, these thinkers postulate that in 
                                                          
11 ACE inhibitor % items – this refers to the number of prescription items for ‘ACE inhibitors’ (a 
drug used for high blood pressure, heart failure etc.) as a percentage of the total number of 
prescription items for all drugs affecting the renin-angiotensin system (a hormone system within 
the human body that regulates blood pressure and fluid balance). 
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fact, it is the elite, or the 'capitalist state' that "sanctions ostensible professional 
dominance for its own purpose" (Harrison and McDonald, 2008, page 33).  
Indeed a brief historical overview of political influences on UK healthcare 
reveals a consistent effort to optimise the work of healthcare professionals. 
Already mentioned is 'implicit rationing' that had kept the issue of rationing 
resources away from the political agenda for 30 years since the creation of the 
NHS (Harrison and McDonald, 2008). In recent times various parties in 
government have introduced competition with a view to maximise efficiency 
(Butler, 2010). It would appear by these initiatives that practitioners are 
essentially "agents of control for a powerful state" (Esland, 1980 in Harrison and 
McDonald, 2008, page 33). The recently introduced Health and Social Care Bill 
in which privatisation and competition will be further increased, faced 
overwhelming opposition from the major healthcare professions particularly 
medicine (Adams, 2012). The British Medical Association12 (BMA) raised 
concerns about vast amounts of guidance that were perceived to be 
"constraining clinician-led commissioning within a bureaucratic straitjacket" 
(BMA, 2011). 
The resistance outlined in Statement 10 (against efforts to mimic clinical 
judgement or to mitigate prescribing freedom) now appears to be the result of 
more than simply an 'uncorrupted' patient-focus (Statement 11). Instead, 
doctors perceive their professional jurisdictions to be continuously encroached 
on by converging forces echoing Britten’s (2001) conclusions. The result is a 
‘collective reflex', to protect and defend ‘social closure' for the continued 
maintenance of historically acquired professional status. What appears to 
emerge from the semi-structured interviews is that these reactions are only 
vaguely implied. It is only after relating to the wider political and social literature 
do these motivations become clear and given meaning through context.  
 
 
                                                          
12
 British Medical Association (BMA) - is the doctors' professional organisation established to 
look after the professional needs for its members. The BMA "maintain the honour and interests 
of the medical profession" (BMA, 2012).  
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8.3.6 Reflections on the ‘lived experiences’ of pharmacists in prescribing 
practice  
Generalised Statements 7 and 8 highlight the key features that represent the 
'reality' of the domain of drug therapy within the Trust as experienced by 
pharmacists. Statement 3 focuses on those experiences that directly involve the 
Prescribing Guide.   
One interpretation that the present study makes is the notion that pharmacists 
are 'closely bound' to the local hospital drug formulary. With the formulary 
essentially forming an inherent component of their decision-making process, 
pharmacists invariably incorporate 'ready-made' decisions (often depicted in the 
formulary) in most prescription interventions. This phenomenon appears to 
operate at all levels within the rank and file of the pharmacy profession at the 
Trust. 
There is also a wider portrayal of pharmacists being dependent on pre-
structured decision-support tools. For example, of the influences presented to 
participants in the self-completion questionnaires, the vast majority of 
pharmacists consistently rated NICE guidance and the Prescribing Guide as 
'important' to their practice. Such an apparent dependence, perhaps even 'over-
reliance' on pre-structured decision-support represents the lack of independent 
critique of prescribing decisions that could be offered by a pharmacist. Instead, 
there appears to be a critique that operates characteristically 'through' the 
formulary with pharmacists largely in the capacity of passive 'enforcers' rather 
than active practitioners. Pharmacists typically described the need for 
“paperwork” or the “online Prescribing Guide” to “back them up” instead of 
‘senior colleagues’ as is the case with doctors (SP7 Interview No.29). Indeed, 
we have seen almost all pharmacists in QRE1 indicate that the Prescribing 
Guide helps them 'decide' what should be prescribed. 
Thus, local decisions on drug-related priorities seem to empower pharmacists in 
their routine professional work. In this context pharmacists are, in practice, very 
much localised, deriving much of their contributions to prescribing practice 
'directly' from pre-structured decision-support tools. The concept of 'monopoly of 
knowledge' as outlined in Larson's ‘professional project’ appears to be at the 
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very least limited perhaps even absent since pharmacists rely on guidance that 
has been previously compiled by others (for example national or local drug 
reviews). 
This apparent lack of 'indeterminacy' as depicted by Jamous and Peloille's I / T 
ratio (Taylor et al, 2003), and simultaneous increase in codification and 
'technicality' (due to adoption of pre-structured decision-support) indicates a 
potentially weak claim to professional status and ultimately a cause for 
dissatisfaction for the supposed 'professional'. We have seen in Chapter 2, in 
order for professions to maintain their 'privileged' position in society, their work 
must not become rationalised or routinised. However, this is what appears to be 
happening with pharmacists at the Trust. Weber's concept of the ever 
increasing rationalisation of society is certainly observable here, in the ‘lived 
experiences’ of pharmacists, perhaps to a greater degree than with doctors. 
It could be argued that Merton's definition of bureaucrats seems – to some 
extent – analogous to aspects of pharmacists' routine work, that is, the 
tendency to adhere to predefined rules and procedures, essentially practising 
'rigidity' and lacking any encouragement to use their own judgement (Giddens, 
2009). Although individual pharmacists at the Trust did not articulate frustrations 
in such 'academic' terminology, as members of a 'professional group' there is 
certainly evidence among pharmacist participants of an inherent regard for 
professional expertise and the discomfort of being confined to codified, 
rationalised and predefined guidelines. Furthermore, this 'discomfort' seems 
even more pronounced when these guidelines are perceived to be primarily 
cost-motivated rather than patient-focused suggestive of the 'altruistic trait' often 
noted to be a key characteristic of professions (Macdonald, 1995). 
During semi-structured interviews, pharmacists did frequently imply a claim to 
expert knowledge specific to the confines of drug therapy. Theme 53 for 
example, demonstrated pharmacists' ability to subject doctors' prescribing 
decisions to a level of scrutiny without the immediate need for decision-support 
mechanisms. It is such descriptions that suggest the pharmacy profession may 
actually possess 'theoretical indeterminacy' but lacks the widespread practical 
manifestation of it; we can call this 'practiced indeterminacy'. Britten (2001) 
similarly highlights that although pharmacists exert less professional discretion 
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than doctors, they are responsible for the appropriateness of medication 
supplied to patients. In particular, Britten mentions the ability of pharmacists to 
“monitor” doctors’ prescribing. 
The dominant narrative expressed by pharmacists included varying degrees of 
frustration and resentment about being excessively involved in the 'supply' of 
medicines instead of being encouraged to engage in more clinically oriented 
activities. Although the importance of patients correctly receiving their 
medication was at no point trivialised, the resentment was nevertheless widely 
pervasive amongst all grades of pharmacists. Most aggrieved by a perception of 
excessive focus and time spend on ‘supply function’ were junior pharmacists. 
They often complained about the 'knock-on' lack of clinical development. Indeed 
with JP4 (Interview No.32), there was a sense of resignation and a succumbing 
to current practices by being involved in "just ordering drugs, checking lockers". 
Theme 59 highlights how the emphasis on supply is considered "soul 
destroying" (SP7 Interview No.29) for junior pharmacists. Once again, using the 
I / T ratio, the alleged extensive supply-oriented workload represents a second 
highly 'technical' component to the work of pharmacists and further supports the 
notion of a potentially weak professional claim.  
Section 2.3.2 explored George Ritzer's concept of 'McDonaldisation' and its key 
dimensions: efficiency; predictability; calculability; and control (Taylor et al, 
2003). Along these lines, the 'corporatisation' of community pharmacy has been 
widely debated before (Bush et al, 2009; Taylor et al, 2003), but there are 
aspects of this study’s findings that indicate such principles are being applied to 
hospital pharmacy. Pharmacists in this study have voiced frustrations about 
managers being more concerned about time keeping and ensuring the allocated 
shifts in the dispensary are adhered to, ensuring the "primary focus...dispensing 
and checking" (the supply function), are maintained. As Novek (2000) states, 
hospital administrators support initiatives that improve labour efficiency and 
reduce costs and not necessarily professional aspirations.  
Statement 8 describes this aspect of the ‘lived experience’ of pharmacists as 
the 'continued subjugation' of the pharmacist within local prescribing practice. In 
addition to this, as we have seen in the previous section, is the resistive stance 
taken by doctors towards pharmacists ultimately resulting in the isolation of the 
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pharmacy profession even further from frontline clinical care where decisions 
such as drug selection are made. 
In this way, through various threats to its status and the nature of its routine 
activities, the pharmacy profession has been described as victim of “both 
incomplete professionalisation and deprofessionalisation” (Bush et al, 2009, 
page 305). Guest et al (2008) conducted a survey of 1,996 pharmacists and 
revealed that certain issues concerning pharmacists’ careers became more 
important as their careers progressed. Table 30 shows three ‘career anchors’ 
(or “aspirations” as the authors clarify) in particular and how their perceived 
importance seems to have shifted over the course of time. The three ‘anchors’, 
in the light of the above discussion, reflect issues of a professional nature. In 
particular, anchor two refers to the management of complex situations where, 
perhaps, professional judgement and abstract, indeterminate knowledge would 
be applicable. Anchor three clearly refers to the restrictions to practice freely, 
particularly freedom from management, echoing the attitudes held by 
pharmacist participants in the present study. Incidentally they resonate with 
attitudes held by those of the medical profession described above.  
** Content removed for copyright reasons ** 
 
Reference: 
Guest D, Budjanovcanin A, Oakley P. (2008). Planning the pharmacy 
workforce: what pharmacists want in their jobs and careers – and what they 
have got. The Pharmaceutical Journal. 291: page 598-600.  
  
Table 30. Importance of career anchors when embarking on career and now (adapted from 
Guest et al, 2008b). 
 
Pharmacists both in the present study and in the literature (Waterfield, 2010; 
Cavell, 2009) demonstrate an ‘inherent’ claim, at the very least, to 'expert 
knowledge' and a 'monopoly' on this knowledge derived from extensive training 
during university and pre-registration years. Using the prism of wider political 
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discourse, the apparent use or 'exploitation' of pharmacists’ expertise is further 
elucidated.  
While an array of official government publications concerning the pharmacy 
profession have all highlighted the 'expertise' that this group possesses, there 
are clearly significant cost-oriented objectives expected of it. An independent 
watchdog, the Audit Commission, set up to protect the public purse, cites 
pharmacists as pivotal to reducing the costs in the NHS (Audit Commission, 
2001). In Section 2.3.1 we saw that the government can only achieve its 
priorities if it develops ways to influence clinical decision-making concerning 
issues such as lengths of patient stay and drug expenditure (Klein, 1990). It is 
therefore arguable that any legislation supported by the government that 
introduces changes to professional workings should be critiqued and examined 
in order to understand its true motives. For example, granting independent 
prescribing privileges to pharmacists can now be seen to serve political 
agendas rather than fulfil professional aspirations. Hence, no longer is the 
'mutual dependency', mentioned before (Section 2.3.1), confined between the 
government and the medical profession alone, now the pharmacy profession 
(along with others) is also empowered to "run" the NHS (Klein, 1990, page 700). 
While the need to ration is far more explicit that it was in the past, today, under 
the banner of ‘empowerment’, the means by which professions such as 
pharmacy might be being exploited to serve primarily cost-motivated aims 
remain implicit (DH, 2010; Chemist and Druggist, 2011). 
 
8.3.7 Reflections on the ‘lived experiences’ of NMPs in prescribing practice 
In many regards, during the semi-structured interviews, the most revealing 
disclosures have come from NMP participants. The unique perspectives from 
this cohort of practitioners provided a new and distinct insight of local 
prescribing practices. As Statement 13 outlines, NMPs demonstrated that they 
had 'evolved' as healthcare professionals and on some level experienced a 
'shift' in their thinking towards aspects of patient care as well as towards local 
medicines management strategies such as the formulary. 
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In Theme 62 we saw how the one pharmacist-NMP in the study described the 
transition process of becoming a prescriber as "you slowly start to break your 
own rules" (NMP1 Interview No.18). She described a departure from the original 
"pharmacy", "formulary" and "cost" focused approach to one that is more 
"clinical" and able to legitimise going against Trust guidelines. Clearly the 
implication is that pharmacists 'and' formularies are inherently rigid in practice 
and unable to acquire the 'clinical' insights that prescribers have access to. 
Compared to the previous discussion on pharmacists' ‘lived experiences’, where 
they have essentially been described as 'passive-enforcers', it would appear 
that NMP1 has introduced a greater degree of 'practiced indeterminacy' in her 
routine work, although built on a pharmacist-foundation. 
All NMPs supported the view that every patient is unique and does not "fit into a 
box and into standard procedures" (NMP2 Interview No.33). Just as doctors 
appeared to reject the confines of local guidelines, policies and the formulary's 
restrictions, NMPs all displayed similar sentiments often emphasising the need 
to reject guidelines instead favouring autonomous practice and applying clinical 
judgement. Themes 61 and 62 outline the claim that both doctors and NMPs 
make about being able to manage 'uncertainty' and call upon expert, clinical 
judgement rather than rely on pre-structured, codified decision-support. 
In this way, a number of parallels can be drawn between how doctors practice 
with an evident discomfort for restrictive policies and how NMPs have adopted a 
similar 'anti-bureaucratic' stance. NMPs indicate a perception of conflict with 
'pharmacy'. They implied that pharmacists represent "research" and prescribers 
represent "expertise, knowledge and practice" (NMP3 Interview No.34). We 
have seen now that Larson's ‘professional project’ underlines the desire to 
attain 'social closure'. It would appear that NMPs attempt to create, at the very 
least, 'social distance' from pharmacists by aligning ‘non-medical’ prescribing 
practice with that of ‘medical’ prescribing practice. In terms of the 'split' identified 
in local prescribing practice (Statement 5), it can be reasonably argued that 
NMPs perceive themselves to practice counter to pharmacists.  
A particular point of frustration expressed by all NMPs was the need to adhere 
to a prescribing 'list' (Theme 14). Although NMPs were legally permitted to 
prescribe any drug that they felt was in their area of competence, the Trust's 
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DTC had enforced a restricted list to which they were able to add more drugs 
only through formal submissions pending reviews. Their lists were effectively 
'virtual-formularies' for NMPs. The characteristic frustrations observed in 
doctors' ‘lived experiences’ towards the hospital drug formulary were clearly 
evident with NMPs towards their 'list'. Notably, during the rhetoric towards the 
local hospital drug formulary, amongst both NMPs and doctors there was an 
implied 'confidence' in their 'own' drug selections independent of decisions 
made by the local DTC. 
Therefore, the NMP in the prescribing arena represents an interesting and 
relatively new practitioner. While there 'is' an appreciation of previous non-
medical insights (acquired from previous pharmacy or nursing careers) there is 
also a new embrace of 'abstraction' and 'indeterminacy' in healthcare. The 
instability observable within NMPs towards perceived restrictive policies 
demonstrates the evolution of a more 'humanised' practitioner, particularly 
noticeable with NMP1 – the only pharmacist-NMP in the present study.  
Statement 13 also portrays an apparent opposition to the introduction of 
'decision-making' NMPs. One NMP described an incident in which her drug 
selection was rejected by a senior doctor. The NMP speculated that the doctor 
felt she was "treading on his ground" (NMP3 Interview No. 34) clearly indicating 
that jurisdictional attitudes do exist. In addition, a number of doctors had 
expressed only 'theoretical' support for non-medical prescribing often accepting 
the prescribing of only 'simple' medication. Interestingly, pharmacist participants 
made similar statements about nurse NMPs, but remained supportive of non-
medical prescribing with a pharmacy background. 
 
8.3.8 The Prescribing Guide and the role of healthcare professionals  
Statements 3 and 4 focus on the nature of the 'relationships' that doctors and 
pharmacists had developed with the Prescribing Guide. While Statement 3 
outlines an enthusiastic, determined and in many cases prompt uptake of the 
Prescribing Guide into routine practices by pharmacists, Statement 4 instead 
depicts doctors' apathetic and somewhat reluctant embrace of the new service.  
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These contrasting perspectives are also evident from the quantitative findings. 
Most telling is the response rate to the frequency of using the Prescribing 
Guide. In QRE1, less than a fifth of responding doctors indicated that they 
accessed the Prescribing Guide 'frequently' (compared to approximately 80% of 
pharmacists responding). This figure improved to just under half of all doctors 
responding to QRE2 following the implementation of modifications made to the 
Prescribing Guide however remained significantly lower than pharmacists.  
Doctors did show evidence of embracing the utilitarian function seen through 
significant improvements to perceptions of the Prescribing Guide's 'importance', 
as well as through improved response rates concerning the Prescribing Guide's 
ability to improve 'professional autonomy' and 'helping decide what to 
prescribe'. Conversely, only approximately half of doctors in QRE1 agreed that 
the Prescribing Guide supports evidence-based medicine and similarly just less 
than half of all doctors considered the Prescribing Guide to be 'patient-focused'. 
These findings suggest that subsequent to the modifications phase, although 
the Prescribing Guide's 'utilitarian' function appeared to be more readily 
accepted by doctors, their underlying attitudes towards the Prescribing Guide 
and the formulary concept remained the same. 
Further divergences are also noted concerning specific features of the 
Prescribing Guide. Almost all pharmacists in both questionnaires agreed that 
the Prescribing Guide was 'user-friendly' and 'easily accessible' compared to 
approximately half of all doctors. During semi-structured interviews doctors 
consistently expressed the need for more training on how to use the Prescribing 
Guide and for its inclusion in doctors' induction programmes. Such training was 
therefore arranged as part of the modifications, the apparent increases in 
response rates (observed in QRE2) concerning the aforementioned two 
features were not significant. Time constraints and limited resources (such as 
computer terminals) may have contributed to doctors’ lack of engagement, 
however it is attitudes towards influences that are perceived to restrict and 
rationalise doctors' decisions that are now considered as perhaps more 
formidable 'restraining forces'. It would appear from both qualitative and 
quantitative findings in the present study that for doctors at the Trust, the 
Prescribing Guide is certainly considered as such an influence. The views that 
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participants expressed about the formulary concept appear to be translated 
across and applied instinctively to the Prescribing Guide.  
Rucker and Schiff in 1990, showed that doctors hold a number of views that 
ultimately work against the essential thrust of the formulary concept. The 
findings from this early study, as well as those from the present study indicate 
an inherent distrust for the formulary. There are implications in both studies, for 
instance, that the formulary ‘sacrifices patient care to cost control’ or doctors 
express a clear discomfort with their ‘clinical freedom’ being restricted. Neither 
Rucker and Schiff (1990) nor other authors exploring the impact of formularies 
(Sutters, 1990; Crowe, 2002; Feely et al, 1990; Furniss; 2000; Hemeryck et al, 
1996; Khan, 2002) make any attempts to gather any deeper insights of the 
'users' or key stakeholders. The present study points to a sociological rationale 
for the (apparent) opposition to the local Prescribing Guide.  
During interviews, doctors often alluded to the Prescribing Guide as equivalent 
in purpose and remit to pharmacists. Indeed Khan (2002, page 159) states that 
capturing pharmaceutical advice within formularies is "probably the most 
effective way of improving prescribing practice". Furthermore, generalised 
Statements 3 and 7 in this study imply a similar notion, that is, formularies and 
pharmacists maintain a close working remit. The Prescribing Guide is therefore 
likely to be opposed on the grounds that it is a practical manifestation of both 
the local formulary as well as pharmacists.  
Previous authors have outlined the different drug selection philosophies of 
doctors and pharmacists (Tugwell et al, 1984). This study corroborates such 
statements and further reveals that the approach to resource management 
(typically the prescribing budget) is also a point of divergence between the two 
professions (Statement 5). While the advice of pharmacists is occasionally 
incorporated into prescribing practice, there is also evidence of outright defiance 
of local drug decisions. The quantitative arm of the study illustrates volumes of 
non-formulary drug prescribing in Figures 18 and 19 indicating the nature of 
prescribers' choices. While the 'red trend line' may indicate instances in which 
the prescribers may not have been aware of formulary alternatives, the 'blue 
trend line' is certainly evidence of prescribers consciously insisting on external, 
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non-formulary drug choices for the benefit of patient care. The implication is that 
the formulary, in such instances, needs to be flexible for the sake of the patient. 
Doctors 'do' consider available prescribing guidance but as one doctor stated "in 
the end it's my decision more than anybody else's" (RD5 Interview No.23). This 
sense of 'ownership' over the final 'drug decision' and ultimately the 'knowledge' 
is clearly of paramount importance to doctors. The Prescribing Guide in effect 
'demystifies' this knowledge. The 'inferential activity', outlined in Section 2.2.3 
as the "purely professional act" (Macdonald, 1995, page 164), is perceived to 
be under threat and considered to be under rationalistic, bureaucratic control. 
Through the implementation of the Prescribing Guide, prescribers are alerted to 
the fact that the domain of drug therapy is 'contestable' ground. Doctors in 
particular feel aggrieved because they have traditionally been in the position of 
'paternalistic' care providers where only their recommendations are upheld. The 
Prescribing Guide attempts, in effect, to remove this traditional prerogative.  
Using Larson’s ‘professional project’, the impact of the Prescribing Guide can 
be illustrated diagrammatically as in Figure 22. Since 'monopoly of knowledge' 
is central to the professional pursuit for eventual achievement and subsequent 
maintenance of 'social closure' we can see that the Prescribing Guide currently 
threatens the centrality of the medical profession's ‘professional project’. 
Therefore since the Prescribing Guide does not aid or contribute to the 
‘professional project’ and in fact distorts and destabilises it, the Prescribing 
Guide is, on this higher professional level, rejected. The diagram shows how 
such an influence can lead to 'knock-on' effects weakening relationships with 
the state and diminishes another important aspect of professionalism, 'trust' 
(Figure 22). 
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Reference: 
Macdonald KM. (1995). The Sociology of the Professions. London. SAGE 
Publications Ltd. (Page 32). 
  
 
 
 
 
 
Figure 22. The impact of the Prescribing Guide on the  
medical profession's ‘professional project’ (adapted from Macdonald, 1995 p32). 
Pharmacists' experiences with the Prescribing Guide were distinctly more 
positive in nature as discussed in Section 8.2.1. A large proportion of 
pharmacists agreed with all statements presented to respondents in 'Question 
5' of the self-completion questionnaires. For example, almost all pharmacists 
found the Prescribing Guide to be 'easily accessible' corroborating statements 
made in the interviews. Also pharmacists considered the Prescribing Guide to 
support evidence-based medicine and, similarly approximately 80% of 
pharmacists responding to QRE1 considered it to be 'patient-focused'.  
Ultimately, the Prescribing Guide appears to support pharmacists' prescription 
interventions and retrospective checking of drug decisions. Where doctors 
would rely on their senior colleagues, pharmacists tend now to refer to the 
Prescribing Guide in the first instance before resorting to other sources of 
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information. Indeed, it could be argued that any 'impact' the Prescribing Guide 
has had on prescribing practices is through its use by pharmacists rather than 
other practitioners. However this is not to say that pharmacist participants did 
not identify faults with the Prescribing Guide. To the contrary, some pharmacists 
implied that the Prescribing Guide is 'incomplete' and requires more guidance 
and information for each drug listed (Themes 33-35). 
Pharmacists portrayed in many instances a somewhat deflated and defeatist 
attitude to their role in medicines management – in which they described feeling 
increasingly marginalised and perceived their primary duties concerned with the 
physical 'supply' function rather than the more 'clinical' drug selection. Drawing 
on the findings of this study, for pharmacists to have the sort of impact that they 
aspire to, it would be reasonable to assume that they need to: (a) be aware of 
all local drug decisions and availabilities; (b) possess the confidence to 
approach prescribers (based on adequate drug knowledge) and challenge 
deviant prescribing; (c) maintain enough motivation and enthusiasm to routinely 
engage in drug therapy ‘at the point of drug selection’.  
Using the ‘positioning tool’ introduced in Section 8.2.2, Figure 23, now shows 
how each category of participants can be represented. This diagram is based 
solely on the findings of the present study and discussions thus far. Each 
healthcare profession is portrayed by a corresponding shaded area. An 'ideal' 
characterisation of the Prescribing Guide is also depicted in the diagram 
(yellow) incorporating both the perspectives that the Prescribing Guide 
'improves autonomy' and is 'utilitarian'. It is particularly noteworthy to see that 
pharmacists and this 'ideal' appear to overlap. Although the diagram is purely 
conceptual and based largely on subjective accounts made by participants, it is 
nevertheless grounds on which to build on to optimise both the hospital 
formulary 'and' the pharmacy profession to which we now turn to. 
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Figure 23. Positioning tool portraying how healthcare professionals currently conceptualise the 
Prescribing Guide. 
 
8.4 Implications for pharmacy practice  
 
8.4.1 The 'virtual dystopia' in which pharmacists operate 
As Giddens (2009, page 788) states: "one of the major weaknesses of 
bureaucracy is the difficulty it has in addressing cases that need special 
treatment and consideration". This quote resonates with much of what doctors 
stated about the ability to 'handle uncertainty' and exercise judgement (Theme 
61). The Prescribing Guide in such a context needs to avoid becoming what 
George Ritzer calls an "irrationality of rationality" (Giddens, 2009, page 782). 
Although the rationalisation observable in prescribing practices affects all 
associated stakeholders, from the findings in the present study it can be argued 
that it is evidently far more pervasive and penetrating in the work of pharmacists 
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(through a ‘stepwise’ and structured approach to drug decision-making and a 
perceived disproportionate focus on ‘supply function’). In this 'extreme' sense, 
pharmacists operate in a 'virtual dystopia' characterised by continued 
subjugation, isolation and marginalisation from frontline patient care and are 
perceived to be conducting the work of bureaucrats.  
Pharmacists risk ‘self-deprecating’ the content of their professional work 
through the over-reliance on such pre-structured support. The frustrations that 
pharmacists expressed about the apparent lack of pragmatism that plagues the 
pharmacy profession along with the negative perceptions that prescribers have 
expressed, one could argue there is now an apparent 'dehumanising' element 
to the pharmacy profession itself. The Prescribing Guide arguably works 
towards the fulfilment of administrative ends rather than accommodate 
underlying professional aspirations echoing Merton's concerns. According to 
such theorising, tools such as the Prescribing Guide essentially further 'de-
professionalise' the pharmacy profession.  
Mykhalovskiy and Weir (2004, page 1062) outline the 'humanist' stance which in 
one argument views evidence-based medicine as a form of rationalisation that 
is "done in the name of cost-cutting and efficiency". Even Sackett et al (1996, 
page 71) who constructed the original and widely quoted definition of the 
concept warned that "practice risks becoming tyrannised by evidence". There 
appears to be an apparent call for evidence-based medicine to maintain 'holism' 
and reject the progression towards the "fragmentation and reification" of the 
patient. In describing the relationship between the formal rationality of evidence-
based medicine and the management of 'uncertainty' in practice, Timmermans 
and Angell (2001, page 342) describe the development of "evidence-based 
clinical judgement" – described by the authors as "a combination of evidence 
and clinical experience requiring epidemiological knowledge and interpersonal 
skills". 
While the Prescribing Guide may have been relegated to a mere 'bureaucratic 
tool' or as May et al (2005, page 1022) describe, an example of 
"technogovernance", its future evolution may lie in embracing similarly 
'humanising' strategies and incorporating such strategies into both the 
Prescribing Guide’s content and its underlying philosophical approach to 
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prescribing practices. Although, as defined in Section 4.3, the Prescribing Guide 
was designed to 'guide' not 'direct', it would appear that most doctors as well as 
notable voices within the pharmacy profession also view the Prescribing Guide 
as a 'control' measure.  
Through analysis of the interpretations of study participants, the present 
research confirms the close alignment of pharmacists and hospital drug 
formularies. In relation to this ‘union’, the 'overlap' depicted in Figure 23 can, 
potentially, be exploited in order to serve continuing professional aspirations for 
the pharmacy profession as well as facilitate the formulary's underlying goals of 
ensuring prescribing is safe, clinically effective and cost-effective.  
The Prescribing Guide (and hospital drug formularies in general) may benefit 
from attempting to alter the nature of 'bureaucracy' itself, essentially working 
towards a 'humanised-bureaucracy' or a 'profession-conscious-bureaucracy'. 
The recognition of the pharmacy 'profession' is crucial to this conceptualisation 
since the professions' liberation from excessive bureaucratic shackles could 
facilitate pharmacists' more complete clinical involvement in frontline care. It is 
ultimately an attempt to mobilise 'theoretical indeterminacy' which, as we have 
discussed previously pharmacists evidently possess despite the current lack of 
its ‘practical’ manifestation.  
 
8.4.2 Proposing a new philosophical model for change 
Oxman et al (1995, page 1427) notably stated that there are "no magic bullets' 
when attempting to improve professional practice. This has been confirmed in 
the present study. For example, the study involved the implementation of a 
number of relatively small-scale modifications based on recommendations and 
discussions from users and key stakeholders of the service. Little overall 
benefits materialised. The transition from the 'virtual dystopia' to a far more 
optimised working environment may in fact necessitate broader philosophical 
adaptations to the way pharmacy is practiced. Three mechanisms by which the 
formulary and the pharmacy profession can be more 'humanised' are outlined in 
a theoretical model below.  
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Firstly, the involvement of 'all' pharmacists (in the Pharmacy department) to 
contribute to the clinical content in the local hospital formulary is pivotal. In this 
way an unprecedented level of ownership in the formulary could be 
encouraged, exploiting the already 'closely bound' relationship between 
pharmacists and the formulary that has been presented in this study. Where we 
have seen doctors relying upon senior colleagues within their teams, 
pharmacists can utilise their colleagues' 'expertise' captured in the local 
formulary.  
Secondly, the notion of 'personal formularies', introduced in Chapter 3 (Section 
3.2.5), has a renewed relevance to the proposed model. By incorporating 
Robertson et al's (2001, page 333) definition of the personal formulary, the 
hospital drug formulary may be more accepted and its guidance adopted if it is 
"shaped by patients, colleagues and experience" symbolising a significantly 
'humanised' framework by which to construct and understand formularies. 
Doctors in this study frequently stated that the Prescribing Guide was utilised in 
order to check only local availabilities yet continued to resist the underlying 
guidance offered, implying that doctors had in fact already made the drug 
selection by 'cognitively' accessing their own 'personal formularies'. Drawing 
from this, the hospital formulary can be constructed based on a compilation of 
pharmacists' 'experiences’ with drug therapy in practice combined with critical 
appraisals of "the best available external clinical evidence from systematic 
research" (Sackett al, 1996, page 71). It is important to note that this approach 
to future formulary development, although rejecting excessive bureaucratic 
dehumanisation, ultimately accepts the reality of Weber's prediction, that is, 
rationalisation is ever more pervasive in all aspects and sectors of society.  
This leads to the third factor. The pharmacy profession (to whom the formulary 
in this proposed model is now inextricably linked) needs to adopt a more 
confident, 'competitive' stance in order to establish its place in frontline care. It 
is proposed that a more optimised pharmacy profession in which 'practiced 
indeterminacy' is realised may reconfigure the formulary into providing more 
significant clinical contributions. Chapter 2 introduced ‘Game Theory’ as a 
rationale for an explicitly 'self-interested' approach to professional assertiveness 
particularly in 'conflict' scenarios (typically between pharmacists and doctors) 
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where the monopoly of drug-knowledge is contested ground. In summary, the 
most rational strategy for the pharmacist is to maintain a competitive stance in 
which they assert their profession's dominance and demonstrate ownership on 
the monopoly of drug-knowledge. In Section 2.3.3 it was noted that if the 
pharmacist chooses to unassertively mention a case of perceived 'deviant' 
prescribing, and the doctor instead asserts a more competitive defence of 
his/her drug decision (in Figure 2 this combination ‘C,D’), according to Game 
Theory the pharmacist subsequently looses the 'game'. This is because the 
'pay-off', that is 'monopoly of drug-knowledge' can be seen to 'belong' to the 
healthcare professional who 'fights' or 'competes' for it (Appendix 17). This 
particular pair of strategies is the worst possible scenario for the pharmacist and 
underpins the ‘virtual dystopia’ contributing to pharmacy's 'continued 
subjugation' and 'isolation' from frontline care (Statement 7). 
 
8.4.3 The optimised ‘professional project’ for the pharmacy profession 
In the light of a new philosophical union between the pharmacy profession and 
the local hospital drug formulary, the notion of a 'profession-conscious-
bureaucracy' could support the enhancement of the profession. Figure 24 
depicts a conceptual ‘professional project’ for the pharmacy profession in which 
the formulary is not regarded as a 'threat' to the monopoly of drug-knowledge 
(as in Figure 22, page 221) but instead it could become a significant component 
of pharmacists' practice. The model outlined calls for a genuine mix of: (a) 
'abstraction' in the form of pharmacist-led 'practiced-indeterminacy', and; (b) 
'concreteness' offered through justified rationalisation. Critically, the diagram 
depicts the immediate sequence of 'events' and relationships that are affected 
by such an optimised ‘professional project’. The Weberian concept of ‘social 
closure’ – for the pharmacy profession – is a more realistic scenario.  
As we have seen, the state can act powerfully and in many ways covertly in 
order to realign professional priorities to help deliver a fiscal agenda consisting 
of targets and standards. Perhaps this has contributed to ‘continued 
subjugation’ of the pharmacy profession outlined Statement 8. Rather than have 
its monopoly on drug-knowledge ‘displaced’ or minimised by various threats, the 
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profession in fact may never have truly acquired it in the first place precisely 
because of government dictates. There is a case to lobby the government to 
liberate pharmacy from excessive bureaucratic demands and permit the 
introduction and exercise of judgement based on the specialist knowledge that 
pharmacists have obtained through training. Additionally, and now closely 
related, is the case for pharmacists to lead in the development of formularies in 
the 'humanised' manner described. 
 
 
 
 
** Content removed for copyright reasons ** 
 
Reference: 
Macdonald KM. (1995). The Sociology of the Professions. London. SAGE 
Publications Ltd. (Page 32). 
  
 
 
 
 
Figure 24. The professional project for the pharmacy profession resulting from a new 
philosophical integration of future hospital drug formularies with the pharmacy profession 
(adapted from Macdonald, 1995 p32). 
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Chapter 9 
Final recommendations and conclusions 
 
9.1 Specific recommendations to improve the Prescribing Guide at East 
and North Hertfordshire NHS Trust  
The underlying action research strategy employed by this study advocates 
outlining a new context-specific action-reflection-cycle (Figure 6, page 88) in 
order to 'move in new directions'. The discussion has outlined only a conceptual 
model in which the pharmacy profession and future formulary projects may 
operate more effectively. It is acknowledged that such a paradigm can be 
achieved only through gradual, incremental change. Therefore 
recommendations that are more tangible and feasible for immediate application 
to the Prescribing Guide at East and North Hertfordshire NHS Trust are 
provided below. Changes will need to involve members of the Pharmacy 
department as well as to the Prescribing Guide itself. 
Changes to the Pharmacy department: 
Essentially these initiatives are all aimed at liberating pharmacists so that they 
can have a greater presence in frontline clinical care while 'technical' duties 
(involving repetitive codified tasks) are minimised, and where pharmacists can 
engage in more 'professionally competitive' activities.  
 Reconfigure the Pharmacy department empowering technicians to 
perform supply-oriented (technical) duties on the ward level. Encourage 
more technicians to enrol on to Accredited Checking Technicians (ACT) 
programme freeing up pharmacists from 'checking' responsibilities in the 
dispensary. Greater interactions between senior and junior colleagues 
needs to be promoted particularly on the wards. 
 Senior management (including the formulary team, Chief Pharmacist and 
Chief Executive) should work towards a renewed philosophical approach 
to formulary operation. The notions of 'humanised-bureaucracy' and 
'practiced-indeterminacy' should be incorporated into this philosophy. At 
first this should involve re-examination of the concept of 'clinical 
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judgement' and establish a broad departmental understanding of how to 
approach clinical scenarios in which the 'formulary list' can be 
overridden. Regular training should be provided focusing on how to 
tackle 'deviant cases' in prescribing and to developing assertiveness and 
confidence in applying specialist knowledge when challenging 
prescribers. 
Changes to the Prescribing Guide: 
 Engage all (as many as possible) pharmacists in the clinical compilation 
of the Prescribing Guide. This will result in more pharmacists acquiring 
advanced critical appraisal skills thus facilitating the development of 
informed decision-makers who can exercise 'judgement' in clinical 
scenarios (practiced-indeterminacy). 
 Prescribing Guide is currently lacking guidance for many drugs in each 
chapter. Therefore need a wide ranging campaign that allocates sections 
(or chapter) to 'groups' of pharmacists consisting of senior pharmacists to 
oversee inclusion of clinical content and, junior pharmacists who benefit 
from experience, knowledge and decision-making skills of the senior.  
 Encourage the inclusion of guidance that does not merely 'hyperlink' to 
external information (such as NICE guidance or clinical trial data) or local 
guidelines but incorporates pharmacists' critical appraisals that outline 
the entire review process. This will serve to improve transparency as well 
as educate other pharmacists about sections of the Prescribing Guide 
that they have not been involved in. 
 Need a more comprehensive training programme that clarifies the traffic 
light system to all pharmacists who are encouraged to provide similar 
education to doctors. 
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9.2 Future directions for formulary research 
 The results of this study suggest that neither the local hospital formulary nor 
pharmacists function optimally and are in fact the subject of negative 
perceptions and marginalisation. Although a conceptual model of practice has 
been outlined, further research needs to be carried out to investigate how such 
a model may be practically implemented. Studies should test for feasibility, 
particularly the reconfiguration of the Pharmacy department, as well as 
preliminary quantitative data showing potential impact of this model on drug 
selections and associated interventions. Additionally, since attitudes have been 
shown to constitute formidable restraining forces to the formulary's complete 
realisation, future studies should investigate stakeholders’ attitudes to individual 
elements of the proposed model.  
A somewhat controversial approach portrayed in the proposed model calls for a 
'competitive' stance to be taken during all drug-related interactions with doctors. 
There is a call to embrace and demonstrate ownership over the monopoly of 
drug-knowledge. A qualitative study exploring a small group of pharmacists 
explicitly adopting such a stance could provide revealing insights about the 
consequences for the pharmacy profession. Since such a study would explore 
participants’ subjective accounts, it would benefit from a similar 
phenomenological approach taken in the present study to analyse the 
qualitative data produced.  
In keeping with the action research method, the findings from this study are 
contextually specific but since information rich data has been produced readers 
can assess the degree of transferability themselves in order to apply aspects of 
the findings to their own practice settings. Having said this, the present study 
was carried out at a DGH where the resources needed for practitioners were 
limited contributing to various degrees of frustration. A repeat of this study in a 
larger teaching hospital or a Foundation Trust may reveal different insights. 
Bearing in mind the differences in the underlying infrastructure of support 
available between these two settings, it would be interesting to compare the 
attitudes and perceptions of users and key stakeholders towards a service such 
as the Prescribing Guide.  
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9.3 Final conclusions 
This study has demonstrated the manner in which attitudes and perspectives 
held by users and key stakeholders towards local hospital drug formularies are 
critical to the influence formularies can have on prescribing practices. 
Furthermore it has been revealed that the 'structure' of these attitudes have 
clear sociological themes. Much of this sociology concerns 'professionalism' for 
which a significant body of work exists in the literature. However such concepts 
have not previously been applied to the multidisciplinary healthcare 
environment in order to specifically investigate formularies.  
It has been shown that such underlying sociological constructs appear to 
operate on a deeper, subconscious level, one in which practitioners are often 
unable to articulate their existence directly. Instead, by applying a 
phenomenological analysis to the participants' accounts and ‘lived experiences’, 
such profession-oriented perspectives have been extracted.  
The local formulary is regarded by many participants as a manifestation of 
excessive bureaucracy where its rationalised approach to drug therapy 
threatens the autonomy of prescribers. Sociologists have long established the 
view that bureaucracy may in fact be antithetical to professionalism. It is 
considered that for this reason doctors have expressed significant discomfort 
with the Prescribing Guide.  
Larson's 'professional project' has been in many ways pivotal in understanding 
the overarching professional goal of 'social closure' and the centrality of 
professions claiming a monopoly on specialist knowledge. Along these lines, 
this study has demonstrated that the monopoly on 'drug-knowledge' is 
particularly contested ground. Both pharmacists and doctors have a claim to 
this important aspect of patient care. The findings from this study support the 
view that the pharmacy profession should assert a renewed and more 
determined claim on this monopoly.  
Pharmacists at the Trust are currently thwarted in their attempts at laying claim 
to such a monopoly. Their daily work is instead seen to comprise perpetual 
routinisation and codification. Pharmacists have expressed accounts of 
frustration due to perceived excessive supply-oriented roles. In addition, 
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prescribers (as well as some pharmacists themselves) have described the 
advice and guidance provided by pharmacists to lack pragmatism. Pharmacists 
have been deemed primarily cost-motivated, in effect constituting passive 
enforcers of rationalised, pre-structured guidelines and policies.  
This study has shown that rationalisation adversely affects the pharmacy 
profession to a far greater extent than the medical profession. The sheer 
volume of 'technicality', along with minimalistic exercise of clinical judgement or 
'indeterminacy' potentially reduces the pharmacy profession to the status of 
mere 'occupation'. While pharmacists 'do' possess specialist knowledge, 
acquired through an extensive university degree programme and a 
postgraduate training period, 'practiced-indeterminacy' is rarely seen. This study 
recommends a radical change to the way pharmacy is practiced including a 
significant embrace of the monopoly on drug-knowledge.  
The proposed model defines a unique conceptual integration of the local 
hospital drug formulary with the Pharmacy department. Measures to adopt a 
more 'humanised-bureaucracy' in which clinical judgements are permitted are 
crucial to this model. In addition the liberation of pharmacists from supply-
oriented roles must now be a key priority if the profession and the formulary are 
to operate more optimally. Furthermore, the proposed model also advocates a 
greater ‘competitive’ stance in all drug-related interactions with doctors, 
involving a concerted effort to assert ownership over the monopoly of drug-
knowledge. Perhaps in the spirit of collaborative, interprofessional working, 
‘both’ doctors and pharmacists should possess such a monopoly on drug-
knowledge, however individual professional groups inherently strive for 'social 
closure' and it is in such 'functionalist' modes that they perceive themselves to 
do well for patient care. 
As a 'true' profession, pharmacy has a lot to contribute to patient care. However 
as a mere 'agent of bureaucracy' where it would justifiably be only an 
'occupation' it will have little impact on clinical care but may continue to 
rationalise drug therapy with cost-minimisation remaining a foremost priority. 
 
 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 234 
 
REFERENCES 
Adams S. (2012). BMA calls for ‘active stand’ against health bill. The Telegraph. 
http://www.telegraph.co.uk/health/healthnews/9116604/BMA-calls-for-active-
stand-against-health-bill.html [Accessed 01/05/2012] 
Armstrong D, Reyburn H, Jones R. (1996). A study of general practitioners’ 
reasons for changing their prescribing behaviour. British Medical Journal. 312: 
949-952.  
ASHP. (2000). Principles of a Sound Drug Formulary System.  
http://www.ashp.org/DocLibrary/BestPractices/FormEndPrinciples.aspx 
[Accessed 31/03/2010]. 
ASHP (American Society of Hospital Pharmacists). (1978). ASHP Guidelines for 
Hospital Formularies. American Journal of Hospital Pharmacy. 35: 326-328. 
Audit Commission. (2001). A spoonful of sugar – medicines management in 
NHS hospitals. Wetherby. Audit Commission Publications.  
Barber N. (2004). Designing information technology to support prescribing 
decision making. Quality and Safety in Health Care. 13: 450-454.  
Batty D. (2003). Q&A: GP contract. The Guardian. 
http://www.guardian.co.uk/society/2003/jun/20/politics.theissuesexplained 
[Accessed 26/07/2013] 
BBC. (2005). Nurse prescribing plans opposed. 
http://news.bbc.co.uk/1/hi/health/4424112.stm [Accessed 03/06/2006] 
BBC. (2007). Jeremy Hunt: ‘GPs must be accountable for out-of-hours care’. 
http://www.bbc.co.uk/news/health-22649589 [Accessed 26/07/2013] 
BBC. (2010). Departments pledge to cut costs by billions. 
http://news.bbc.co.uk/1/hi/uk_politics/8586016.stm [Accessed 31/03/2010]. 
BMA. (2011). Why the BMA is opposing the whole Bill. 
http://www.bma.org.uk/images/nhsreformbriefingbmaopposesbilldec2011_tcm4
1-210946.pdf [Accessed 14/01/2012]. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 235 
 
BMA. (2012). About the BMA. http://www.bma.org.uk/about_bma/index.jsp 
[Accessed 23/02/2012]. 
Bochner F, Burgess NG, Martin ED. (1996). Approaches to Rationing Drugs in 
Hospitals – An Australian Perspective. Pharmacoecomonics. 10: 467-474. 
Boddy D, Buchanan DA. (1992). In: Paton RA, McCalman J. (2000). Change 
Management: A guide to effective implementation. 2nd ed. London. SAGE 
Publications Ltd. 
Bradley F, Ashcroft DM, Noyce PR. (2012). Integration and differentiation: A 
conceptual model of general practitioner and community pharmacist 
collaboration. Research in Social and Administrative Pharmacy. 8: 36-46.  
Britten N. (2001). Prescribing and the defence of clinical autonomy. Sociology of 
Health and Illness. 23: 478-496. 
Brown GJE, Dartnell JG, Moulds RF. (1999). Factors Determining Prescribing 
Decisions in a Teaching Hospital Setting. The Australian Journal of Hospital 
Pharmacy. 29: 311-316. 
Bryman A. (2004). Social Research Methods. 2nd Edition. Oxford. Open 
University Press.  
Buchanan DA, McCalman J. (1989). In: Paton RA, McCalman J. (2000). 
Change Management: A guide to effective implementation. 2nd ed. London. 
SAGE Publications Ltd. 
Bush J, Langley CA, Wilson KA. (2009). The corporatisation of community 
pharmacy: Implications for service provision, the public health function, and 
pharmacy’s claims to professional status in the United Kingdom. Research in 
Social and Administrative Pharmacy. 5: 305-318. 
Butler P. (2010). History of NHS reforms: A state of permanent revolution. The 
Guardian.  
http://www.guardian.co.uk/society/2010/jul/09/nhs-history-reforms-health-
policy?INTCMP=SRCH [Accessed 14/01/2012]. 
Cavell G. (2009). Expert pharmacist roles are needed to champion medication 
safety. Clinical Pharmacist. 1:330-331. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 236 
 
Charlton BG. (2006). Lectures are such an effective teaching method because 
they exploit evolved human psychology to improve learning. Medical 
Hypotheses. 67:1261-1265. 
Chemist and Druggist. (2009). Xrayser: is there a pharmacist in the house. 
http://www.chemistanddruggist.co.uk/main-content/-
/article_display_list/2623765/2623761 [Accessed 24/10/2011]. 
Chemist and Druggist. (2011). DH opens debate on ‘responsible pharmacist’. 
http://www.chemistanddruggist.co.uk/news-content/-
/article_display_list/145325/145321 [Accessed 05/06/2011]. 
Clissett P. (2008). Evaluating qualitative research. Journal of Orthopaedic 
Nursing. 12:99-105. 
Cornett BS. (2006). A principal calling: Professionalism and health care 
services. Journal of Communication Disorders. 39: 301-309. 
CQC. (2011). About CQC - What we do. 
http://www.cqc.org.uk/aboutcqc/whatwedo.cfm [Accessed 22/09/2011]. 
Cribb A, Barber N. (1997). Prescribers, Patients and Policy: The Limits of 
Technique. Health Care Analysis. 5: 292-298. 
Crinson. (2007). In: HealthKnowledge. (2011). Health Care: Section 1. The 
Health Professions, Issues of Governance, and the Changing Doctor-Patient 
Relationship. (http://www.healthknowledge.org.uk/public-health-
textbook/medical-sociology-policy-economics/4b-health-care/section8) 
[Accessed 22/09/2011]. 
Crowe S. (2002). What you need to do to establish and benefit from a joint 
formulary. Medicines Management. 2: 20-21. 
Crown. (2011). 2013/14 Choice Framework. London. Crown. 
Crown. (2012). Commissioning for quality and innovation (QUIN): 2013/14 
guidance. February 2013. London. Crown. 
Cutts C, LaCaze A. (2003). What tricks and techniques can be used to influence 
prescribing? Prescribing & Medicines Management. 5: 12-14. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 237 
 
Davey G. (2004). Complete Psychology. London. Hodder and Stoughton 
Educational.  
Degeling P, Zhang K, Coyle B, Xu L, Meng Q, Qu J, Hill M. (2006). Clinicians 
and the governance of hospitals: A cross-cultural perspective on relations 
between profession and management. Social Science and Medicine. 63: 757-
775.  
Denig P, Haajer-Ruskamp FM. (1992). Therapeutic decision making physicians. 
Pharmaceutisch Weekblad. 14: 9-15. 
Denscombe M. (2007). The Good Research Guide for Small-scale Social 
Research Projects. 3rd Edition. Berkshire. Open University Press.  
DeVito JM, John JF. (1985). Effect of Formulary Restriction of Cefotaxime 
Usage. Archives of Internal Medicine. 145: 1053-1056. 
DH. (2002). Pharmacy Workforce – Making the best use of staff to deliver the 
NHS Pharmacy Programme. London. Crown.  
DH. (2003). Medicines management in NHS Trusts: hospital medicines 
management framework. 
http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolic
yAndGuidance/DH_4072184 [Accessed 03/04/2006]. 
DH. (2005). Guidance for the development of consultant pharmacist posts. 
London. Crown.  
DH. (2008). White Paper -  Pharmacy in England. Building on strengths – 
delivering the future. Norwich. The Stationary Office.  
DH. (2008b). High Quality Care For All – NHS Next Stage Review Final Report. 
Norwich. The Stationary Office.  
DH. (2010). Empowering nurses to make a difference.  
http://www.dh.gov.uk/en/Publicationsandstatistics/Bulletins/Chiefnursingofficerb
ulletin/September2010/DH_119676 [Accessed 02/06/2010]. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 238 
 
DH. (2011). Performance data and statistics. 
http://www.dh.gov.uk/en/Publicationsandstatistics/Statistics/Performancedataan
dstatistics/index.htm [Accessed 22/09/2011]. 
Doucette WR, Nevins J, McDonough RP. (2005). Factors affecting collaborative 
care between pharmacists and physicians. Research in Social and 
Administrative Pharmacy. 1: 565-578. 
Duerden M, Walley T. (1999). Prescribing at the Interface Between Primary and 
Secondary Care in the UK. Pharmacoeconomics. 15: 435-443. 
East and North Hertfordshire NHS Trust. (2011a). Lister Hospital. 
http://www.enherts-tr.nhs.uk/our-hospitals/lister/ [Accessed 02/11/2011]. 
East and North Hertfordshire NHS Trust. (2011b). QEII Hospital. 
http://www.enherts-tr.nhs.uk/our-hospitals/qeii/ [Accessed 02/11/2011]. 
Eaton  G, Webb B. (1979). Boundary encroachment: pharmacists in the clinical 
setting. In: Britten N. (2001). Prescribing and the defence of clinical autonomy. 
Sociology of Health and Illness. 23: 478-496. 
Edmunds J, Calnan MW. (2001). The reprofessionalisation of community 
pharmacy? An exploration of attitudes to extended roles for community 
pharmacists amongst pharmacists and General Practitioners in the United 
Kingdom. Social Science and Medicine. 53: 943-955. 
Elston MA. (1991). Chapter 3 - The politics of professional power: medicine in a 
changing health service. In: Gabe J, Bury M, Calnan M. The Sociology of the 
Health Service. New York. Routledge. 58-60. 
Esland G. (1980). In: Harrison S. McDonald R. (2008). The Politics of 
Healthcare in Britain. London. SAGE Publications Ltd. 
Exworthy M, Wilkinson EK, McColl A, Moore M, Roderick P, Smith H, Gabbay J. 
(2003). The role of performance indicators in changing the autonomy of the 
general practice profession in the UK. Social Science and Medicine. 56: 1493-
1504. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 239 
 
FAME. (2005). The FAME Manual 2005 – Working Towards Efficient 
Prescribing and Medicines Management system in Primary and Secondary 
care. Second Edition. London Regional Pharmacy Services. 
Feely J, Chan R, Cocoman L, Mulpeter K, O’Connor P. (1990). Hospital 
formularies: need for continuous intervention. British Medical Journal. 300: 28-
30. 
Fertleman M, Barnett N, Patel T. (2005). Improving medication management for 
patients: the effect of a pharmacist on post-admission ward rounds. Quality and 
Safety in Health Care. 14: 207-211.  
Fitzpatrick RW, Mucklow, SJC, Fillingham D. (2001). A comprehensive system 
for managing medicines in secondary care. The Pharmaceutical Journal. 266: 
585-588. 
Freidson E. (1985). The reorganisation of the medical profession. In: Britten N. 
(2001). Prescribing and the defence of clinical autonomy. Sociology of Health 
and Illness. 23: 478-496. 
Freidson E. (1994). Professionalism Reborn – Theory, Prophecy and Policy. 
Cambridge. Polity Press.  
Furniss L. (2000) Formularies in primary care. Primary Care Pharmacy. 1: 37-
39. 
Giddens A. (2009). Sociology. 6th Edition. Cambridge. Polity Press.  
Gollop R, Whitby E, Buchanan D, Ketley D. (2004). Influencing sceptical staff to 
become supporters of service improvement: a qualitative study of doctors' and 
managers' views. Qual and Safety in Health Care. 13: 108-114. 
Goodwin FK. (2003). Impact of Formularies on Clinical Innovation. Journal of 
Clinical Psychiatry. 64: 11-14. 
Gosalakkal JA. (2005). Letter. Hospital formularies restrict evidence based 
practice. British Medical Journal. 331: 515. 
Greco LD, Walop W, McCarthy RH. (1987). Questionnaire development: 2. 
Validity and reliability. Canadian Medical Association Journal. 136: 699-700.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 240 
 
Green J. Thorogood N. (2004). Qualitative Methods for Health Research. 
London. SAGE Publications Ltd.  
Greenfield S, Bryan S, Gill P, Gutridge K, Marshall T. (2005). Factors 
influencing clinicians’ decisions to prescribe medication to prevent coronary 
heart disease. Journal of Clinical Pharmacy and Therapeutics. 30: 77-84. 
Groves KEM, Fanagan PS, MacKinnon NJ. (2002). Why physicians start or stop 
prescribing a drug: Literature review and formulary implications. Formulary. 37: 
186-194. 
Guardian. (2007). Concern over rights of nurses to prescribe drugs. 
http://www.guardian.co.uk/society/2007/aug/23/health.freedomofinformation 
[Accessed 24/09/2007] 
Guest D, Budjanovcanin A, Oakley P. (2008). Planning the pharmacy 
workforce: what pharmacists want in their jobs and careers – and what they 
have got. The Pharmaceutical Journal. 281: 598-600. 
Hall, C. (2011). Wider prescribing by nurses is too risky, say doctors. 
http://www.telegraph.co.uk/news/uknews/1502725/Wider-prescribing-by-nurses-
is-too-risky-say-doctors.html [Accessed 22/09/2011] 
Harker R. (2011). NHS funding and expenditure – Standard note SN/SG/724. 
Social and General Sciences. House of Commons Library. 
http://www.parliament.uk/topics/Health-financeArchive.htm#SN [Accessed 
03/09/2010]. 
Harrison S.McDonald R. (2008). The Politics of Healthcare in Britain. London. 
SAGE Publications Ltd. 
Harvard Business. (2003). Managing Change and Transition. Boston, 
Massachusetts, USA. Harvard Business School Publishing Corporation. (2003).  
Healthcare Commission. (2007). The best medicine. The management of 
medicines in acute and specialist trusts. London. Healthcare Commission. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 241 
 
Hemeryck L, Chan R, Sabra K, Feely J. (1996) Poor Utilisation and Limited 
Impact of Formularies on Quality of Prescribing by Hospital Doctors. Irish 
Medical Journal. 89:173-4. 
Hill H. (2005). Bridging the gap – joint formularies and leadership. Hospital 
Pharmacist. 12: 441-442. 
Hill-Smith I. (1996). Sharing resources to create a district drug formulary: a 
countywide controlled trial. British Journal of General Practice. 46: 271-275.  
HPA. H1N1 (2009) Pandemic archive.  
http://www.hpa.org.uk/swineflu [Accessed 13/09/2011] 
Hughes CM, McCann S. (2003). Perceived interprofessional barriers between 
community pharmacists and general practitioners: a qualitative assessment. 
British Journal of General Practice. 53: 600-6. 
Hughes CM, Thorp H. (2010). Trends in NHS funding – payment by results. 
Clinical Pharmacist. 2: 201-2.  
Humphries CA, Counsell DJ, Pediani RC, Close SL. (1997). Audit of opioid 
prescribing: the effect of hospital guidelines. Anaesthesia. 52: 745-749.  
Hycner RH. (1985). Some Guidelines for the Phenomenological Analysis of 
Interview Data. Human Studies. 8: 279-303.  
ISMP. (2005). The truth about hospital formularies. Medication Safety alert. 
http://www.ismp.org/Newsletters/acutecare/articles/20050210.asp [Accessed 
03/04/2006]. 
Jenkings KN, Barber, N. (2004). What constitutes evidence in hospital new drug 
decision making? Social Science & Medicine. 58: 1757-1766. 
Joshi MP, Williams A, Petrie J. (1994). Hospital formularies in 1993: Where, 
why and how? The Pharmaceutical Journal. 253: 63-65. 
Jotkowitz AB, Glick S. (2009). Some thoughts on professionalism. European 
Journal of Internal Medicine. 20: 337-338. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 242 
 
Khan F. (2002). Using Medicines Wisely – The place of the formulary in 
medicines management. Hospital Pharmacist. 9: 159-163. 
Kmietowics Z. (2006). New GP contract: modernisation or miscalculation? 
British Medical Journal. 333: 1192. 
Kings Fund. (2012). The quality of GP prescribing.  
http://www.kingsfund.org.uk/sites/files/kf/field/field_document/quality-gp-
prescribing-gp-inquiry-research-paper-mar11.pdf [Accessed 13-07-13]. 
Klein R. (1990). The state and the profession: the politics of the double bed. 
British Medical Journal. 301: 700-701. 
Kwan J. (2005). Letter. Hospital formularies restrict evidence based practice. 
British Medical Journal. 331: 515. 
Lanser EG. (2002). What should your formulary look like? Healthcare 
Executive. 17: 52. 
Lind S. (2013). GP contract set to change as Hunt hands responsibility for out-
of-hours care back to general practice. Pulse. 
http://www.pulsetoday.co.uk/news/political-news/gp-contract-set-to-change-as-
hunt-hands-responsibility-for-out-of-hours-care-back-to-general-
practice/20003067.article#.UfbBeo3qm4g [Accessed 27/07/2013]. 
Lind S. (2013b). Medical profession declares no confidence in health secretary 
Jeremy Hunt. Pulse. 
http://www.pulsetoday.co.uk/news/political-news/medical-profession-declares-
no-confidence-in-health-secretary-jeremy-hunt/20003401.article#.UfbBfY3qm4h 
[Accessed 27/07/2013]. 
Lincoln Y. Guba E. (1985). In: Denscombe M. (2007). The Good Research 
Guide for Small-scale Social Research Projects. 3rd Edition. Berkshire. Open 
University Press.  
Macdonald KM. (1995). The Sociology of the Professions. London. SAGE 
Publications Ltd.  
Malson G, Wang L. (2009). How Stoke-on-Trent is keeping its prescribing 
budget under control. The Pharmaceutical Journal. 282: 615-616. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 243 
 
Marston L. (2010). Introductory Statistics for Health and Nursing Using SPSS. 
London. SAGE Publications Ltd.  
Martin D. (2007). Nurses prescribing medicine would put patients’ health at risk, 
doctor warns.  
http://www.dailymail.co.uk/news/article-477117/Nurses-prescribing-medicine-
patients-health-risk-doctor-warns.html [Accessed 03-06-2006]. 
Maxwell, SRJ. (2005). Evidence based prescribing (Editorial). British Medical 
Journal. 331: 247-248.  
May C, Rapley T, Moreira T, Finch T, Heaven B. (2005). Technogovernance: 
evidence, subjectivity, and the clinical encounter in primary care medicine. 
Social Science. 62:1022-1030. 
McDonald R, Cheraghi-Sohi S, Sanders C, Ashcroft D. (2010). Professional 
status in a changing world: The case of medicines use reviews in English 
community pharmacy. Social Science and Medicine. 71: 451-458. 
McNiff J, Whitehead J. (2008). All you need to know about Action Research. 
London. Sage. 
Medical Sales. (2005). Formularies not always the key. 
http://www.allaboutmedicalsales.com/articles_nhs/formularies_not_always_the_
key_151205.html [Accessed 10/10/2007]. 
Miles MB, Huberman AM. (1994). Qualitative Data Analysis. London. Sage. 
Miller RR. (1973). Prescribing Habits of Physicians. Drug Intelligence and 
Clinical Pharmacy. 7: 492-500. 
Morgall JM, Almarsdóttir AB. (1999). No struggle, no strength: how pharmacists 
lost their monopoly. Social Science and Medicine. 48: 1247-1258. 
Myerson RB. (1997). Game theory - Analysis of Conflict. First Edition. 
Cambridge. Harvard University Press.  
Mykhalovskiy E, Weir L. (2004). The problem of evidence-based medicine: 
directions for social science. Social Science and Medicine. 59: 1059-1069. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 244 
 
Nathan A. (2009). Understanding the Pharmacists and Pharmacy Technicians’ 
Order 2007.  The Pharmaceutical Journal. 282:227. 
NHS Careers. (2010). Careers A-Z. 
http://www.nhscareers.nhs.uk/atoz.shtml [Accessed 02-09-10]. 
NHS Choices. (2011). About the NHS.  
http://www.nhs.uk/NHSEngland/thenhs/about/Pages/overview.aspx  [Accessed 
02-08-11].  
NHS Choices. (2013). Choice in the NHS.  
http://www.nhs.uk/choiceintheNHS/Yourchoices/allaboutchoice/Pages/Allaboutc
hoice.aspx [Accessed 18-07-13]. 
NICE. (2007). How to change practice. Understand, identify and overcome 
barriers to change. London. NICE. 
NICE. (2012). Key therapeutic topics – Medicines management options for local 
implementation. London. NICE.  
The NHS Information Centre. (2010). Hospital Prescribing, 2009: England. The 
NHS Information Centre. The NHS Information Centre.  
NPC. (2002). Medicines management services – why are they so important? 
MeReC Bulletin. 12: 21-24.  
NPC. (2007). Managing medicines across a health community – Making area 
prescribing committees fit for purpose. Liverpool. NPC.  
NPC. (2011). Improving quality in prescribing. 
http://www.npc.nhs.uk/improving_safety/improving_quality/ [Accessed 02-08-
11]. 
NPC. (2011b). Quality in Prescribing. 
http://www.npc.nhs.uk/improving_safety/improving_quality/resources/5mg_quali
typrescibing.pdf [Accessed 02-08-11]. 
NPC. (2013). QIPP.  
http://www.npc.co.uk/qipp/index.php [Accessed 16-07-13]. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 245 
 
Novek J. (2000). Hospital pharmacy automation: collective mobility or collective 
control? Social Science and Medicine. 51: 491-503. 
O’Day R. (2000). In: Harrison S. McDonald R. (2008). The Politics of Healthcare 
in Britain. London. SAGE Publications Ltd. 
Oxford University Press. (2009). “Compliance.”  
http://www.oup.com/oald-bin/web_getald7index1a.pl [Accessed 11/03/2009]. 
Oxford University Press. (2011). “Proletarianisation.”  
http://oald8.oxfordlearnersdictionaries.com/dictionary/proletarian [Accessed 
05/10/2011]. 
Oxman AD, Thomson MA, Davis DA, Haynes RB. (1995). No magic bullets: A 
systematic review of 102 trials of interventions to improve professionals 
practice. Canadian Medical Association Journal. 153: 1423-1431. 
Parsons T. (1939). The Professions and Social Structure. Social Forces. 17: 
457-467. 
Paton RA, McCalman J. (2000). Change Management: A guide to effective 
implementation. 2nd ed. London. SAGE Publications Ltd. 
Pearce MJ, Begg EJ. (1992). A Review of Limited Lists and Formularies – Are 
They Cost-Effective? PharmacoEconomics. 1: 191-202. 
Petrie JC. Scott AK. (1987). Drug formularies in hospital. British Medical 
Journal. 294: 919-920. 
PJ. (2009). Stress and workload for hospital staff. The Pharmaceutical Journal. 
282. 586. 
PJ. (2010). NHS Constitution now law. The Pharmaceutical Journal. 284: 71. 
PSNC. (2012). “MURs: The basics.”  
http://www.psnc.org.uk/pages/murs_the_basics.html [Accessed 05/01/2012]. 
Phillips-Pula L, Strunk J, Pickler RH. (2011). Understanding Phenomenological 
Approaches to Data Analysis. Journal of Paediatric Health Care. 25: 67-71.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 246 
 
Picton C, Quinn C. (2011). Focus on...prescribing. 
http://www.pulsetoday.co.uk/pcarticle-content/-
/article_display_list/12270627/focus-on-prescribing  [Accessed 01/08/2011]. 
Plumridge RJ. (1981). Forecast of the future of hospital pharmacy in Australia. 
American Journal of Hospital Pharmacy. 38: 1469-1472. 
Plumridge RJ. (1983). A Review of Factors Influencing Drug Prescribing (Part 
1). Australian Journal of Hospital Pharmacy. 13: 16-19. 
Plumridge RJ, Stoelwinder JU, Berbatis CG. (1984). Improving patient care and 
pharmacy management: the effect of hospital formularies. Drug Intelligence and 
Clinical Pharmacy. 18: 652-6. 
Prosser H, Walley T. (2006). New drug prescribing by hospital doctors: The 
nature and meaning of knowledge. Social Science & Medicine. 62: 1565-1578. 
QSR International. (2011). N6 (NUD*IST 6) Features and Benefits. 
http://www.qsrinternational.com/FileResourceHandler.ashx/RelatedDocuments/
DocumentFile/90/N6_features_and_benefits.pdf [Accessed 10-02-2011] 
Robertson J, Fryer JL, O’Connell DL, Smith AJ, Henry DA. (2001). Personal 
formularies – An index of prescribing quality? European Journal of Clinical 
Pharmacology. 57: 333-341.  
RPS. (2011). The History of the Royal Pharmaceutical Society.  
http://www.rpharms.com/museum-pdfs/history-of-the-society.pdf [Accessed 22-
10-2011] 
Rucker TD. (1982). Superior hospital formularies: a critical analysis. Hospital 
Pharmacy. 17:465-524. 
Rucker TD, Schiff G. (1990). Drug Formularies: Myths-In-Formation. Medical 
Care. 28: 928-942. 
Rucker TD, Visconti JA. (1976). Hospital formularies: organizational aspects 
and supplementary components. American Journal of Hospital Pharmacy. 33: 
912-917. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 247 
 
Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. (1996). 
Evidence based medicine: what it is and what it isn’t. British Medical Journal. 
312: 71-72. 
Schumock GT, Walton SM, Park HY, Nutescu EA, Blackburn JC, Finley JM, 
Lewis RK. (2004). Factors that Influence Prescribing Decisions. 
Pharmacoeconomics. 38: 557-562. 
Shetty N, Shulman RI, Scott GM. (1999). An audit of first generation 
cephalosporin usage. Journal of Hospital Infection. 41: 229-232. 
Smith J, Flowers P, Larkin M. (2009). Interpretative Phenomenological Analysis 
– Theory, Method and Research. London. Sage Publications Ltd.  
Starks H, Trinidad SB. (2007). Choose your Method: A Comparison of 
Phenomenology, Discourse Analysis, and Grounded Theory. Qualitative Health 
Research. 17:1372-1380. 
Stone AM. (2006). Letter. Prescribing Behaviour and Marketing Practices. 
Psychiatric Services. 57: 419. 
Sutters CA. (1990). The management of a hospital formulary. Journal of Clinical 
Pharmacy and Therapeutics. 15: 59-76.  
Swansea Museum, (1995). Wartime Chemist’s Formulary, Scales & Pill Box. 
http://www.swanseaheritage.net/article/gat.asp?ARTICLE_ID=1875 [Accessed 
17-03-2006]. 
Tan EL, Day RO, Brien, JA. (2005). Perspectives on Drug and Therapeutics 
Committee policy implementation. Research in Social and Administrative 
Pharmacy. 1: 526-545. 
Tanna NK. (2005). Action Research: a valuable research technique for service 
delivery development. Pharmacy World and Science. 27: 4-6. 
Taylor K, Nettleton S, Harding G. (2003). Sociology for Pharmacists. 2nd Edition. 
London. Taylor and Francis. 
Thompson, CB. Walker, BL. (1998). Basics of Research (Part 12): Qualitative 
Research. Air Medical Journal. 17: 65-70. 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 248 
 
Timmermans S, Angell A. (2001). Evidence-based medicine, clinical 
uncertainty, and learning to doctor. Journal of Health and Social Behaviour. 
42:342-359. 
Traynor M, Boland M, Buus N. (2010). Professional autonomy in 21st century 
healthcare: Nurses’ accounts of clinical decision-making. Social Science and 
Medicine. 71: 1506-1512.  
Tugwell AC, Thurston DR, Barrett CW. (1984). Design and preparation of a 
formulary – Guide to the prescribing of medicines. Journal of Clinical and 
Hospital Pharmacy. 9: 311-319. 
Tugwell C. (2000). Taking pharmacy services to a new level with the intranet. 
Hospital Pharmacist. 7: 158-162. 
UKMi. (2011). Data Collection.  
www.ukmi.nhs.uk/filestore/ukmiar/Datacollection.doc [Accessed 18/09/2011] 
Vickers MD. (1987). Drug formularies in hospitals. British Medical Journal. 294. 
1226-1227. 
Walker R, Janknegt R, Scott M. (2006). Evidence based drug formularies. 
European Journal of Hospital Pharmacy Practice. 12: 21. 
Waterfield J. (2010). Is Pharmacy a Knowledge-Based Profession? American 
Journal of Pharmaceutical Education. 74: 1-6. 
Watkins C, Timm A, Gooberman-Hill R, Harvey I, Haines A, Donovan J. (2004). 
Factors affecting feasibility and acceptability of a practice-based educational 
intervention to support evidence-based prescribing: a qualitative study. Family 
Practice. 21: 661-669. 
Wells KM, Thornley T, Boyd MJ, Boardman HF. (2013). Views and experiences 
of community pharmacists regarding the New Medicine Service in England prior 
to implementation. Research in Social and Administrative Pharmacy. 1-14. 
Wilcock M, Harding G. (2007). General practitioners’ perceptions of medicines 
use reviews by pharmacists. The Pharmaceutical Journal. 279: 501-503.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 249 
 
Williams IP, Bryan S. (2007). Cost-effectiveness analysis and formulary 
decision making in England: Findings from research. Social Science & 
Medicine. 65: 2116-2129. 
Zabawski EJ. (2002). “No Trespassing!” Are the Pharmacists stepping over the 
line? Clinics in Dermatology. 20: 726-728.  
Zimbardo P, Lieppe M. (1991). In: Davey G. (2004). Complete Psychology. 
London. Hodder and Stoughton Educational.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 250 
 
APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 251 
 
APPENDIX 1 PRELIMINARY EXPLORATION OF CURRENT APPROACHES TO FORMULARY DEVELOPMENT 
Site Type Formulary    Description of formulary development Feedback Research 
Hospital A   † DGH 
PDF on 
Intranet 
Preferred-list of drugs categorised according to BNF structure; restricted drugs; prices included; no 
EBM guidance; FP contacted consultants from each therapeutic area for opinions; 2 years to 
complete; newsletter produced monthly (if possible) with updates 
“restricted” / “reassured” / 
positive feedback from those 
involved in development 
No formal research 
conducted 
Hospital B DGH 
Web-
enabled 
BNF 
Joint formulary in agreement with PCTs, GPs and hospital consultants / £10,000 cost / outsourced 
production to RPSGB / can be customised to local use e.g. monitor non-formulary drug usage and 
adding new chapters / newsletter to regularly promote formulary / head of each section periodically 
attends DTC 
“quite limited” / “only one 
document per drug link” / 
feedback given via PCTs 
Hit counters indicate 
main users are 
pharmacists for 
screening 
Hospital C DGH 
Web-
based 
Preferred-list of drugs categorised according to BNF structure / coloured coded to indicate restriction 
status / IT department assisted in development of web-based version / non PDF version available 
“Supports our pharmacists, but 
not too sure about doctors” 
No formal research 
conducted 
Hospital D  † 
Large 
teaching 
Web-
based 
Highly interactive, algorithms-based formulary / through series of questions the user is assisted in 
making a clinical decision / belief that prescribers require guidance rather than simply having 
restrictions imposed / each drug hyperlinked to corresponding page on Internet BNF / 18 months to 
put together / FP had special interest in IT and designed web site without help / specialist 
pharmacists (working with consultants) were allocated sections who developed algorithms and 
associated prescribing guidance / monthly Pharmacy Bulletin for updates 
“Only positive feedback has 
been received” 
Hit counters and 
small-scale surveys 
to understand usage 
Hospital E 
Large 
teaching 
PDF on 
Intranet 
Joint formulary for Leicestershire / previously available in a ring binder but now been made available 
as PDF electronically to reduce cost of production / aimed at junior doctors and specialists (outside 
of their field of expertise) / all drugs categorised according to BNF structure / desire to move away 
from list-based design to inclusion of EBM  
“GPs use most frequently” / 
generally positive reviews from 
hospital doctors / maintaining 
cost information is difficult 
Small-scale surveys 
(conducted by 
preregistration 
pharmacists) assess 
extent of adherence 
Hospital F 
Large 
teaching 
PDF on 
Intranet 
Joint formulary / preferred-list of drugs with colours and shapes to represent restrictions / some 
algorithms and prescribing guidance / each section was reviewed and finalised through meetings 
with senior pharmacists and consultants and GPs with a special interest / all sections were approved 
by ADTC / recently introduced a GP-only “eFormulary” in which inputting a diagnosis leads to 
formulary choices / monthly ADTC bulletin with updates 
“Acceptance has been very 
good because its development 
has included widespread 
stakeholder consultation 
throughout” 
Compliance 
routinely monitored 
in primary care by 
hospital pharmacists 
Hospital G 
Large 
teaching 
Web-
based 
Joint formulary / preferred-list with prescribing guidance statements / structure based on BNF / 
drafts for each section originally prepared by FP, then discussed with Working Groups (WG) 
consisting of specialist pharmacist and consultant doctors and GPs / Working Groups reconvene in 
the light of new evidence or when revision is due /  
“Very good acceptance across 
both primary and secondary” 
attributed to multidisciplinary 
approach in development 
Audits measuring 
adherence. 
Improvements 
reported. 
Hospital H FT 
PDF on 
Intranet 
Joint formulary / £0.5 million grant for formulary development and medicines management / “new 
approved prescribing list” / aim was to simplify the formulary, previously operated a paper-based 
formulary consisting of numerous guidelines and algorithms to assist decision making / 3000 paper-
based copies printed as well / ‘subcommittees’ for each section and speciality / senior pharmacists 
heavily involved / traffic light system of availability / 3 page newsletter published every three months 
with updates 
“initial shock because no 
guidelines, initially detrimental, 
but problem with old one was 
there was so many things to 
continuously revise it was not 
feasible in the long run” 
No formal research 
carried out but 
audits will be carried 
in near future to 
streamline the 
service 
 
ADTC = Area Drug and Therapeutics Committee 
BNF = British National Formulary 
DGH = District General Hospital 
DTC = Drug and Therapeutics Committee 
EBM = Evidence-based medicine 
FP = Formulary Pharmacist  
FT = NHS Foundation Trust 
GP = General Practitioner 
PDF = Portable Document Format 
RPSGB = Royal Pharmaceutical Society of Great Britain  
† = Site visits arranged 
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APPENDIX 2 
USER GUIDE (LEAFLET) DESIGNED FOR PHASE II OF PRESCRIBING 
GUIDE 
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PRESENTATION SLIDES FOR TEACHING SESSION ACCOMPANYING THE 
LAUNCH OF PHASE II OF THE PRESCRIBING GUIDE (JANUARY 2009) 
 
East & North Hertfordshire NHS Trust
Prescribing Guide
Launch of Phase II
January 2009
Sandeep Bagga
Senior Pharmacist - Formulary
 
Contents
1. Background
2. Definition
3. Development
4. Traffic light system
5. Clinical content
6. Drivers & barriers to change
7. Implementation
8. Where to find it?
9. Key features and benefits
10. Demonstration
11. Q & A
2
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3
• In 2007, medicines issued in hospital represented 25.7% of 
the total cost of medicines, which was £11.2 billion
• Cost of drugs used in hospitals rose by 12%
• Cost of drugs used in primary care rose by 2.1%
• Cost of drugs prescribed in hospital but dispensed in 
community rose by 4.6%
† The Information Centre. Hospital Prescribing, 2007: England (NHS)
 DRUG COSTS  DRUG PRESCRIBING
Background
 
4
† A Vision for Pharmacy In the New NHS (2003) Department of Health
“Hospital pharmacists are responsible for ensuring medicines 
are used safely, effectively and economically…”
“…active engagement with improving patient safety, the 
implementation of clinical guidelines and NICE guidance, 
and managing the economics of hospital prescribing…”
“In hospital pharmacy, best practice is characterised by 
optimal use of skill mix, information technology, enabling 
pharmacists to devote the bulk of their time to direct patient 
care…”
Background
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5
Formulary –
is a continually revised compilation of the drugs of 
choice, specifically chosen after careful evaluation of 
safety, efficacy, and cost effectiveness, serving as a 
prescribing tool to rationalise drug therapy in clinical 
practice
Too 
restrictive
Only 
about 
cost
Interferes 
with 
clinical 
freedom
Widespread 
use equals 
drugs of 
choice!
The 
specialist 
knows 
best!
MISCONCEPTIONS...?
‘Prescribing Guide’


Definition
 
6
Prescribing Guide’s basic objectives:
1. Specify drugs of choice 
2. Include and identify clearly 2nd line agents
3. Minimise therapeutic duplication
4. Maximise cost effectiveness without compromising 
patient care
OPEN
RESTRICTIVE
Definition
 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 258 
 
7
Development
Phase I – Basic structure
• List of approved drugs
• Design and structure
• Traffic lights system
• Links to electronic BNF
Phase II – Adding the guidance
• Developing each chapter further – justifying traffic lights
• Identifying guidance available
• Trust Guidelines, NICE, NPSA, SPCs, NDF Committee etc.
• Consultant buttons, Pharmacist buttons
• Health Topics
 
8
Think ‘NDF’ – what was approved?
On formulary – accepted 1st line. NDF had accepted 
this on to the formulary for its licensed indication 
and has no ‘restrictions’
On formulary! But – NDF had approved with
restrictions e.g. to be used by specific consultants or 
specific indications (or high cost drugs, or 
unlicensed etc)
On formulary – 2nd line / alternative to the approved 
1st line agent e.g. side effects, contra-indications
Traffic light system
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Clinical Content
• eBNF
• Evidence-based guidance (clinical trials)
• Trust Guidelines
• NICE guidance
• SIGN Guidelines
• Summary of Product Characteristics (SPC)
• Clinical Knowledge Summaries
• NPC / MeReC guidance
• NDF Committee decisions
• IV Medusa Guide
• Guidance from specialist organisations (European Glaucoma 
Society, British Society of Gastroenterologists)
• NPSA
• Cost bars
 
Resistance from 
doctors 
(‘misconceptions’?)
Skilled workforce
Time 
Budget
‘Drug reps’
Those who consider 
it as externally-
generated
change
10
Driving forces Restraining forces
Equilibrium
Triggers for change
Government 
standards
‘Dissatisfaction’
Pharmacists
expertise
IT support
Extensive 
marketing & promotion
Those who consider
it as internally-generated
change
Drivers for change
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• Articles
• Trust Bulletin (regular)
• Grapevine
• Posters & Leaflets
• Wards, corridors, lifts, doctor’s mess!
• Computer monitors
• Desktop icons on ward computers
• Let nurses & doctors know
• Trust Screensavers 
• ‘Word-of-mouth’
• Approach ALL doctors
• Presentations
• Identify ‘champions’ 
Implementation
Preparation
Formulary
Implementation
 
Where to find it?
12
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Where to find it?
13
 
Where to find it?
14
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Where to find it?
15
 
16
Where to find it?
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Chapters
15 chapters
(BNF structure)
Chapter content
(sub-categories) Index bar Health Topics
 
Guidance
Traffic light
Formulary approved drug
+ hypertext link to eBNF
Formulations
available Pharmacist
button
Health Topics
button
Cost 
comparison
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Guidance (cont.)
NDF Committee decisions
Evidence-based guidance 
with links to reference used
Index bar
Summary Statement  Background  Reference
 
Health Topics
Allows user to search by clinical condition or ‘Health Topic’
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Health Topics (cont.)
Approved algorithm Local / national guidelines
Index bar
Formulary approved drugs
 
Demonstration
22
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Demonstration
 
24
Demonstration
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Demonstration
 
26
Demonstration
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Demonstration
 
28
Demonstration
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Demonstration
 
30
Demonstration
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31
Demonstration
 
32
Demonstration
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Demonstration
 
34
Demonstration
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35
Demonstration
 
36
Q&A...
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APPENDIX 3    SUMMARY OF LITERATURE REVIEW 
Reference Title Location 
Literature type / 
study design 
Discussion / Conclusion 
Allen and 
Harkins, 
2005 
Too much 
guidance? 
UK 
Letter to Lancet with 
results of a survey of 
one acute medical 
take in a hospital 
Complains 'critical mass' of guidelines may be reached where sheer volume of documents 
produced will make it impossible for them all to be applied or even read properly. If this was 
the case, then guidelines will cease to be of any use to clinicians. Survey revealed: in an 
acute medical take in hospital, doctors saw 18 patients with a total of 44 diagnoses. 
Guidelines that the on-call doctor should have read, remembered and applied correctly for 
those conditions came to 3679 pages (incl NICE, Royal Colleges and major societies). Takes 
2 minutes to read each page, physician on-call will have to spend 122 hours reading to keep 
abreast of guidelines. The PLURALITY of adivce is unhelpful and can lead to confusion.  
ASHP, 
2000 
Principles of 
a Sound 
Drug 
Formulary 
System 
US 
ASHP 'Endorsed 
Document' - outlines 
principles that have 
been endorsed by a 
number of 
organisations that 
have a stake in 
medicines 
management in the 
US 
Primary goal of the coalition (Academy of Managed Care Pharmacy; Americian Society of 
Health-System Pharmacists; Dept of veterans Affairs; US Pharmacopeia; National Business 
Coalition on Health) was to provide a greater understanding to people about 'formularies'. 
These parties defined as having a stake in designing a formulary system that ensures 
patients have access to "rational, clinically appropriate and cost-effective therapy". Lists set 
of principles for organisations to adapt and adopt which concerns the US drug benefit plans. 
'Drug formulary' defined as "a continually updated list of medications and related information, 
representing the clinical judgement of physicians, pharmacists and other experts in the 
diagnosis and / or treatment of disease and promotion of health."  
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Armstrong 
et al, 1996 
A study of 
general 
practitioners' 
reasons for 
changing 
their 
prescribing 
behaviour 
UK 
Qualitative analysis 
of semi-structured 
interviews. 18 GPs in 
South East London 
interviewed. 
Objective: to explore 
GPs' reasons for 
changes in their 
prescribing 
behaviour.  
Research strategy was to define the nature of the problem before starting to evaluate 
solutions. Instead of a hypothesis-testing experimental design, this approach required 
hypothesis-generating qualitative methods; allowed clinicans' own understandings and 
explanations of their changes in clinical behaviour to become the focus of the research. 18 
GPs took part and interviewed by trained interviewers. Three models of change were 
identified: accumulation model, in which volume and authority of evidence were important; 
challenge model, in which behaviour change followed a dramatic or conflictual clinical event - 
rather than a slow accumulation of cues, here it was the very lack of preparedness that 
caused the rapid reassessment of prescribing policy; continuity model in which change took 
place aganist a background of willingness to change. Behaviour change was reinforced and 
sustained by experiences with individual patients. Multiple factors are involved in GPs 
decisions to change their prescribing habits. Three models for change can be identified which 
have important implications for the design and evaluation of interventions aimed at behaviour 
change.  
ASHP, 
1978 
ASHP 
Guidelines 
for Hospital 
Formularies 
US 
Guidance document 
for formulary 
operation (working 
definition, format, 
content etc.) outlined 
Guidelines on the following: formulary content and organisation (drug lists approved by PTC, 
basic therapeutic information, hospital policies, extra supporting information); format and 
appearance; distribution; how to keep the formulary curren. Largely outdated advice because 
concerns 'printed' formats. The definition of a formulary (provided as "primary objectives") 
they provide is partially relevant to today. 
Barber, 
2004 
Designing 
information 
technology to 
support 
prescribing 
decision 
making 
UK Discussion paper 
The IT system should slot into (be congruent with) a wider vision of 'good prescribing' not 
conflict with it. Good prescribing - what the patient wants; the technical / rationale (area of 
scientific measurement of the drug); the greater good (encourages some consideration of 
societal good - i.e. cost reduction e.g. generic substitutions / use of a formulary). Barber also 
outlines what is meant by 'decision support' - widest possible conception of the term i.e. 
anything which stops bad decisions being enacted or improves the quality of decisions. 
Provides useful definition and discussion regarding 'prescribing decion support systems' i.e. 
target high risk and patients first; work to a patient focus; make it so doctors want to use it 
etc.  
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Bochner et 
al, 1996 
Approaches 
to Rationing 
Drugs in 
Hospitals - 
An Australian 
Perspective 
Australia Discussion paper 
Discusses the issue of rationing and scarcity and the increasing demands / pressures within 
healthcare environments - Australian perspective but relevant to UK debate. Highlights that 
'therapeutic substitution' (defined as dispensing of a particular drug entity in place of a 
theraputically similar, but chemically different drug product) could be as contentious an issue 
as embracing the notion of rationing. Also discusses the role of the DTC and formulary in 
managing scarcity and rationing. Presents (briefly) guidelines on formulary operation and 
highlights the formulary process can be more 'educational' rather than concerned with 
'regulation'.  
Brown et al, 
1999 
Factors 
Determining 
Prescribing 
Decisions in 
a Teaching 
Hospital 
Setting 
Australia 
Survey mailed to 
medical / pharmacy 
staff in hospitals 
Survey tool designed and mailed to all medical (non-surgical) doctors and clinical pharmacy 
staff at two university teaching hospitals. Two clinical scenarios were presented to which 
responses were collate. Scenario 1: greatest weighting given to: efficacy, compliance, 
tolerability, adverse effects then cost and duration of therapy. Scenario 2: efficacy, illness 
severity, drug familiarity and guideline concordance, then cost. Frequency of administration 
was considered less important to prescribers. Therefore prescribing patterns appeared to 
follow expected patterns (e.g. efficacy more important than costs). 
Cribb and 
Barber, 
1997 
Prescribers, 
Patients and 
Policy: The 
Limits of 
Technique 
UK Discussion paper 
Looks at the kind of criteria that are relevant to evaluating prescribing. Outlines the 
components of 'good prescribing' - (1) the right technical properties; (2) what the patient 
wants; (3) the greater good. As a consequence of the above three, the authors define the 
debate around 'good prescribing' to do with technical expertise, professional ethics and 
health philosophy / policy and highlights the significant degree of overlap between the three.  
Crowe, 
2002 
What you 
need to do to 
establish and 
benefit 
benefit from 
a joint 
formulary 
UK 
Feature article 
describing formulary 
development 
Primary Care Organisation develping joint formularies to rationalise prescribing at primary / 
secondary care interface but also to lower costs. Interface Prescribing Group (IPG) was set 
up to help develop the joint formulary. Draft chapters circulated to GPs for comments. 
Editorial committee set up. A5 ring binder format made available to all GPs. Electronic 
version developed for local hospital intranet. The ability to be able to liaise across primary 
and secondary was considered to be particularly valuable.  
Cutts and 
LaCaze, 
2003 
What tricks 
and 
techniques 
can be used 
to influence 
UK 
Feature article 
describing 'academic 
detailing' 
Academic detailing outlined as the method of education that uses the principles of 'social 
marketing' to engage a doctor in a one-to-one discussion. Evidence based exists supporting 
the impact of academic detailing on behavioural change esp. prescribing behaviour. Article 
shows that pharmaceutical industry are thinking about employing sophisticated ('evidence 
based') strategies to impact on prescribing behaviour. 
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prescribing? 
Denig and 
Haaijer-
Ruskamp, 
1992 
Therapeutic 
decision 
making of 
physicians 
Netherlan
ds 
Literature review 
Literature reivew of 'therapeutic decision-making of physicians' - Netherlands - - Drug choice 
process = two steps: (1) generation of a small set of possible treatment options - an 'evoked 
set'; (2) selection of a specific therapy for an individual patient from this evoked set. The 
evoked set may only 'contain' one treatment option for a condition so the choice process is 
then reduced to one step which can be taken without further active thinking. A therapy 
unknown / unfamiliar to the physician will not belong to his / her evoked set. As obvious 
implications for local formulary adoption / adherence.   
DeVito and 
John, 1985 
Effect of 
Formulary 
Restriction of 
Cefotaxime 
Usage 
US Intervention study 
Cefotaxime first assigned to open formulary then placed on formulary restriction. 
Postrestriction use of cefotaxime increased. Cefotaxime was prescribed appropriately in 85% 
of cases during both periods. Findings showed that 'appropriateness of use' was independent 
of formulary restriction.  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 277 
 
DH, 2003 
Medicines 
Management 
in NHS 
Trusts: 
hospital 
medicines 
management 
framework 
UK 
Official government 
publication 
Rosie Winterton (Minister of State) launched the 2nd wave of the Medicines Management 
Framework (MMF) - focus on clinical and cost-effective use of medicines in secondary care. 
(1st wave of MMF gave trusts opportunity to review their MM systems and put remedial 
action plans in place). Standard 1 (S1) - Chief Executive responsible for provision of regular / 
updated assurances of strategic plan for MM; S4 - DTC has multidisciplinary input (outlines 
compulsory members); S8 - a pharmacist should be identified for and integrated into each 
local clinical structure (directorate) to lead on MM; responsibilities should include the 
production of at least quarterly financial reports at directorate, speciality and consultant level; 
S9 prescribers and pharmacists should work together to ensure effective horizon scanning / 
identify future cost pressures; S10 - Chief Executive and Chief Pharmacist consider business 
cases for automated dispensing and upgrading of legacy computer systems to ensure 
integration with electronic patient records; S11 - CE through CP should ensure adequate 
formulary managment stems are in place. Formularies should not be lists of drugs stocked 
but working documents incorporating national and lcoally agreed prescribing policies and 
guidelines. Where possible, formulary systems should be developed to promote therapeutic 
consistency across the local health economy; S29 (re. 'Influencing Prescribers') - IT solutions 
including 'decision support' should be sought where possible to provide all healthcare staff 
with timely and accurate information on the use fo medicines.  
Duerden 
and Walley, 
1999 
Prescribing 
at the 
Interface 
Between 
Primary and 
Secondary 
Care in the 
UK - 
Towards 
Joint 
Formularies 
UK Discussion paper 
Managing prescribing between primary and secondary care in UK arise from separate 
budgetary arrangements. Joint formularies argued as approach to improving overall care and 
raising awareness of the need to consider overall costs within a unified NHS. Written in 1999 
- paper acknowledges that local decisions around availability and use of drug therapies will 
increasingly be superseded by national decisions emanating from 'newly formed' NICE. 
Duerden and Walley defined formulary as  restricted lists of medicines to which prescribers 
are encouraged or 'required' to adhere - this is then handed down to junior doctors as a 
"managerial tool". "In practice, doctors work to a formulary i.e. a list of 'favoured medicines' 
whether it is written down or not - perhaps developed as a matter of habit without clear 
rational thought. the problem is that drs have difficulty working with a jointly defined list of 
drugs." 
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FAME, 
2005 
The FAME 
Manual, 
2005 - 
Working 
towards 
efficient 
management 
systems in 
primary and 
secondary 
care 
UK 
Summarised 
guidance from 
national forum for 
Formulary 
Pharmacists and 
Medicines Informatio 
Pharmacists 
Topics discussed: prescribing issues; the wider NHS environment; survery of formulary 
personnel (what is expected of a Formulary Pharmacist etc.); nature and function of a 
formulary; operational issues; professional and personal skills; evidence-based decision-
making and critical appraisal; health economics.  
Feely et al, 
1990 
Hospital 
formularies: 
need for 
continuous 
intervention 
Republic 
of Ireland  
Intervention study 
Study to investigation the effects of introducing a new hospital formulary (1) alone and (2) 
another with 'active intervetion' (feedback on prescribing babits; peer comparision; and 
information on drugs). In intervention group, generic prescribing rose by 50%; inappropriate 
prescribing and overall use of 3rd generation cephalosporins fell; compliance with 
recommended list of drugs was good. Drug costs fell (compared to projected). During the 
next year, when no intervention took place, previous gains were eroded and drug costs rose.  
Fitzpatrick 
et al, 2001 
A 
comprehensi
ve system for 
managing 
medicines in 
secondary 
care 
UK 
Broad spectrum 
article 
Paper describes a 'comprehensive' medicines management system set up to improve 
prescribing practice. In 1991 after the hospital became a trust, the drug budget was devolved 
to clinical directorates and expendiure on medicines became part of each directorate's 
budget reporting system. Trust management hoped that devolving the budget to directorates 
would encourage ownership of the issue and lead to more cost-effective prescribing. Four 
key components of 'comprehensive' strategy = (1) Managed entry of new drugs; (2) 
Pharmaceutical advice i.e. pharmacists were now interacting at ward level with doctors and 
nurses to promote safe and ration prescribing however ward pharmacists did not see cost-
related intervetions as part of their remit; (3) effective purchasing; (4) Close managerial 
attention based on improved information. The paper claims that as a result of this raft of 
measures it has been possible to control prescribing costs within the trust without 
compromising quality.  
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Furniss, 
2000 
Formularies 
in primary 
care 
UK 
Broad spectrum 
article 
Important statistic: 40% of primary care prescribing may be influenced by secondary care. 
Outlines that the evidence that quailty of prescribing imporves after the introduction of a 
formulary is limited but there are a number of studies that show cost savings. Formulary has 
traditionally been a way of attempting to rationalise the large number of drugs available and 
to help control costs. Discusses advantages and disadvantages of formularies.  Pharmacist is 
ideally placed to coordinate development of a local formulary. "Rationalisation of drug choices 
may enable disinvestment in one therapeutic area so that resources may be deployed in 
another."  
Goodwin, 
2003 
Impact of 
Formularies 
on Clinical 
Innovation 
US Discussion paper 
Argues that the initial step in the development of a new area in psychopharmacology has 
historically relied in large part on individual clinicians who pursued unconventional methods of 
treatment. When a set of guidelines such as a formulary ("a list of drugs eligible for 
reimbursement compiled by a managed care organisation") becomes restrictive it decreases 
clnician innovation. Restricted formularies are based on a naive interpretation of therapeutic 
equivalence may slow the advance of medical science without even achieving the only goal 
that could possible justify such restrictions - cost-control (points to cases in mental health 
where 'managed care' systems e.g. formulary have been penny-wise but pound foolish). If 
innovation is to flourish, formularies must be flexible and advisory not restrictive.  
Gosalakkal 
(2005) 
Hospital 
formularies 
restrict 
evidence 
based 
practice 
UK Letter 
Argues drug approvals are often based on bugets rather than deeper consideration for 
individal patient needs particularly in obscure specialist areas.  
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Greenfield 
et al, 2005 
Factors 
influencing 
clinicians' 
decisions to 
prescribe 
medication to 
prevent 
coronary 
heart disease 
UK 
Quantitative study of 
clinicans responses 
to postal 
questionnaire 
Used free-text sections of a postal questionnaire to identify what level of pretreatment risk 
clinicans would offer treatment. Clinicians' concerns centred on 5 key themes: the risks and 
benefits of treatment; the patient's role in treatment decisions; patient characteristics; costs to 
patients; costs to the health service. Concludes by saying: In addition to the use of risk 
assessment tools and guidelines, clinicians' actual prescribing behaviour may be influenced 
by more subjective factors. Advises there are also inter-professional variations. It is therefore 
important to identify and understand the influences and constraints which affect clinicians' 
recommendations. This study does not attribute 'professional' attitudes or a professional 
dimension to reflections on results but does point out the subjectivity of medical decision-
making. 
Groves et 
al, 2002 
Why 
physicians 
start or stop 
prescribing a 
drug: 
Literature 
review and 
formulary 
implications 
US Literature review 
Drug 'product life cycle' - affected by factors that influence the diffusion of a new drug into 
medical practice and its rate of adoption / relinquishment by individual physicians. These 
influences have 4 categories: (1) perceived attributes of new drug innovations; (2) 
communication channels; (3) nature of the social system; (4) phyician characteristics. This 
was a literature search identifying studies that have assesssed these factors' influence on 
diffusion, adoption and relinquishment. Discusses how these studies can help formulary 
'managers' better align prescribing behaviour with their fomrulary objectives. Outline the 
evoked set (or 'therapeutic armamentarium'). Discusses how knowledge of the evoked set 
and how it is accessed and what influences it can be exploited in order to achieve formulary 
objectives i.e. the adoption of formulary-approved durgs. E.g. "opinion leaders can be 
targeted to start the diffusion process, since they can help to create the local consensus that 
may be needed for acceptance...formulary managers should regularly meet with these 
individuals." Explains how pharmaceutical industry's strategy has generally been to try to 
incorporate a drug into the evoked set at an early stage in its life cycle, attain top-of-mind 
physician awareness, and ultimately maintain the product's first-choice status within the 
group of therapies to which physician regularly refers.  
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Healthcare 
Commissio
n, 2007 
The best 
medicine. 
The 
management 
of medicines 
in acute and 
specialist 
trusts 
UK 
Official publication 
from independent 
regulator for 
healthcare 
(Healthcare 
Commission, now 
Care Quality 
Commission) 
Formulary = preferred lists of medicines - contains medicines that the trust has identified as 
being necessary to meet the clinical needs of its patients. This contains medicines that the 
trust has identified as being necessary to meet the clinical needs of the patients. the trust 
builds up a knowledge-base of medicines in its formulary and where possible negotiates 
competitive prices for them. 173 trusts reviews - 152 had a formulary - 86 paper formulary 
(updated every 14 months) 111 trusts store in electronic format) 56 trusts have web-based 
format (updated every 5 months). Diagnosis-based guidance which supports the selection of 
medicines (i.e. clinical guidelines that link to the formulary) should drive best practice in 
prescribing and it is important that trusts' guidelines support effective prescribing. It is 
important that whose who prescribe comply with the formulary. The more medicines the 
formulary contains the easier it is to comply with but the benefits in terms of budget control 
and consistent clinical care lessen.  
Hemeryck 
et al, 1996 
Poor 
Utilisation 
and Limted 
Impact of 
Formularies 
on Quality of 
Prescribing 
by Hospital 
Doctors 
Republic 
of Ireland  
Quantitative study of 
non-consultant 
hospital doctors 
(using structured 
interview and chi-
squared analysis) 
Aim was to determine the utilisation and perceived value of formularies amongst 104 non-
consultant hospital doctors (NCHD). BNF (formulary) investigated. Structured interviews 
carried out over a 3 month period. 58% NCHDs carried the formulary. After distribution of 
'free' BNFs, significant improvements in quality of prescribing occured in surgical wards 
albeit, shortlived benefits. 
Hill, 2005 
Bridging the 
gap - joint 
formularies 
and 
leadership 
UK 
Broad spectrum 
article 
Definition of local formulary is provided. Development process and operation discussed. The 
author quotes a Formulary Pharmacist stating that although the formulary has been 
successful in terms of influencing prescribing practices, the further measures should be 
assessed. "we need to look at factors such as the impact on patient care and drug 
expenditure although these are difficult to measure." 
Hill-Smith, 
1996 
Sharing 
resources to 
create a 
district drug 
formulary: a 
countywide 
controlled 
trial 
UK 
Audit to determine 
the influence of a 
district primary care 
drug formulary 
Drug data extraction used to audit prescribing practice in order to determine impact of local 
formulary. "Creating a drug formulary takes considerable time, but merely adopting one lacks 
local perspective and ownership". Found that prescribing of formulary approved drugs 
increased and that costs significantly fell.  
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Humphries 
et al, 1997 
Audit of 
opioid 
prescribing: 
the effect of 
hospital 
guidelines 
UK 
Audit of prescriptions 
for opioids before 
and after 
implementation of 
hospital prescribing 
guidelines 
Opioid prescriptions collected by pharmacy department over a two week period. Following 
initial audit, analgesic prescribing guidelines were introduced. Statistically significant increase 
achieved in number of prescriptions that were correct for both dose and frequency according 
to both the BNF recommendations and local Acute Pain Service Guidelines. The use of 
accessible prescribing guidelines promotes demonstrable improvements in opioid 
prescribing.  
ISMP, 2005 
The truth 
about 
hospital 
formularies - 
Survery 
shows many 
myths STILL 
exist 15 
years later 
US 
Quantitative study to 
explore comments 
made by Pharmacy 
and Therapeutic 
Committee members 
(postal survey) 
All 11 of the original 'myths' (that were considered to thwart the full realisation of the potnetial 
of formulary to guide clinicans in choosing the safest, most effective drugs - the work of 
Rucker and Schiff, 1990) had been encountered by 19% of respondents to a survery. 
Concludes that fomrmulary deliberations today may still be centred less on the critical 
evaluation of scientific data, and more on misconceptions about formularies.  
Jenkins and 
Barber, 
2004 
What 
constitutes 
evidence in 
hospital new 
drug decision 
making? 
UK 
Qualitative 
ethnographic study 
of Drug and 
Therapeutic 
Committee meetings.  
DTCs at two general hospitals were observed, tape-recorded and analysed to determine 
what was considered evidence and how it was used in decision making. DTC meetings were 
attended by a non-participant observer and audio-recordings were made. Array of issues 
were discussed. Often this evidence was either inadequate or insufficient. EBM, while used in 
decision making was suplemented by local knowledge, although decisons were accounted for 
in the language of scientific rationality. Both abstract and scientific rationality and the local 
rationality of practical healthcare provision were present in the decisions of the DTCs on the 
adoption, or otherwise of new drugs into local formulary and healthcare. Authors suggest the 
coming together of local and abstract in local decision-making needs to be taken into account 
when formulating policy and providing decision support.  
Joshi et al, 
1994 
Hospital 
formularies in 
1993: Where, 
why and 
how? 
UK 
Quantitative study 
(postal 
questionnaire) to 
obtain an overall 
perspective on the 
management of 
hospital drug 
formularies in the UK 
Out-of-date paper but shows that in 1993 there were formularies operating in 90% of 
hospitals responding. Insights into DTC membership; reasons for the existence of the 
formulary and the basis for drug selection; type and format; content; distribution and 
introduction; policies; revision, monitoring and interventions. Some information also provided 
on "prescribers' attitudes and compliance" but this is vague.  
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Khan, 2002 
Using 
Medicines 
Wisely - The 
place of the 
formulary in 
medicines 
management 
UK Feature article  
Good introduction to hospital formularies (including some history). Article focuses on how 
best to develop and operate a formulary system locally.  
Kwan, 2005 
Hospital 
formularies 
restrict 
evidence 
based 
practice 
UK Letter 
Complains of his own local prescribing practice being "governed" by a "strict hosptial 
formulary".  Formulary has a limited number of drugs and is often determined "not by 
evidence but by cost per tablet". Critical of the drug approval process.  
Lanser, 
2002 
What should 
your 
formulary 
look like? 
US Feature article 
This is more relevant to US formularies and the insurance based drug benefit plans although 
the open / closed definitions of formularies has some application to UK conceptualisation of 
formularies. Main goal of formulary is to encourage physicians to use the most efficient drugs 
from a therapeutic and cost perspective. Based on the degree of inclusiveness of the PTC 
decisions, formulares tend to be grouped into two categories: open and closed. Open 
formularies - allow doctors to prescribe most medicines without penalty and place few 
limitations on adding new drugs to the list. Such formularies are viewed as guides to 
prescribing practice. Closed formularies - or 'restirictive formularies' limit the number of drugs 
stocked and available to be dispensed; while drugs not on formulary can still be prescribed 
they are usually more costly (this is to do with the insurance system). 
Malson and 
Wang, 
2009 
How Stoke-
on-Trent 
iskeeping its 
prescribing 
budget under 
control 
UK Feature article 
Incentive schemes are being used to change prescribing behaviour. The HoMM at NHS 
Stoke-on-Trent believes that the drug budget needs to broken down into manageable chunks 
to allow practices to deliver the most cost-effective prescribing. He says "overspending in one 
therapeutic area can be masked by underspending in another...so a lot can be hidden if 
you're dealing with a single figure like £60 million" (local budget it the region). 
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Maxwell, 
2005 
Evidence 
based 
prescribing 
(Editorial) 
US Feature article 
Good discussion around 'EBM' (or evidence-based prescribing): "Few areas of medical 
practice have felt the effects of this movement more clearly than prescribing. Until recently 
doctors could prescribe medicines without worrying that their choices might be judged against 
evidence accumulated in the world's literature. Now, prescribers are increasingly expected to 
back up their decisions with evidence. Enthusiasm for evidence based prescribing is 
welcome... But it also poses some real problems for prescribers. He suggests that one 
solution is to provide modern information technology systems in the consulting room or at the 
bedside...but even these may deliver too much unfiltered information including some original 
research, some guidance derived from research, and some unsubstantiated opinion" 
May et al, 
2005 
Technogover
nance: 
evidence, 
subjectivity, 
and the 
clinical 
encounter in 
primary care 
medicine.  
UK Discussion paper 
Technological solutions to problems of knowledge and practice are routinely used in 
healthcare. Systems are being employed as intermediaries in interactions between clinicians 
and patients. Identifies the apparent conflict between two important ways of organising ideas  
about practice in primary care - (1) a shift away from the objectification of the patient and 
towards patient-centred clinical practice in which patients' heterogeneous experiences / 
narratives of ill-health are qualitatively engaged in decisions about the management of of 
illness; and (2) the mobilisation of evidence about large populations of experimental subjects 
revealed through an impetus towards evidence-based medicine, in which quantitative 
knowledge is engaged to guide management of illness mediated through clinical guidelines. 
Both impulses are embodied in new technological solutions to the management of 
heterogenity of the clinical encounter. Technological solutions bring a new array of practices - 
'technogovernance' in which the heterogeneous narratives can be resituated. This paper 
appears to support the 'measured' (rational) use of 'technogovernance in the healthcare 
arena.  
Miller, 1973 
Prescirbing 
habits of 
physicians 
US Literature review 
Early paper that recognises the need to influence the adoption and relinquishment of drugs 
from doctors' own personal formularies. Describes in depth the process of adoption (adopting 
a new innovation e.g. drug). Although old paper, still relevant for a theoretical approach to 
understanding this aspect of prescribing practice.  
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NPC (2007) 
Managing 
medicines 
across a 
health 
community - 
Making area 
prescribing 
committees 
fit for 
purpose 
UK Official publication National collection of case studies - some of which describe local formulary operation.  
Oxman et 
al, 1995 
No magic 
bullets: a 
systematic 
review of 102 
trials of 
interventions 
to improve 
professional 
practice 
US Literature review 
Objective - to determine the effectiveness of different types of interventions in improving 
health professional performance and health outcomes. Literature analysis. disemination-only 
strategies such as conferences or mailing of unsolicitied matrials, demonstrated little or no 
change in healthcare professional behavioiur or health outcome when used alone. More 
complex intervetions e.g. use of outreach visits or local opinion leaders range from ineffective 
to highly effective but were most often moderately effective. Conclusions: "no magic bullets" 
for improving the quality of healthcare but there are wide range inteventions available that if 
used appropriately could lead to important improvements in professional practice or patient 
outcomes.  
Pearce and 
Begg, 1992 
A Review of 
Limted Lists 
and 
Formularies 
New 
Zealand 
Literature review Historical overview of formularies and models of formulary operation e.g. DTC advisable etc.  
Petrie and 
Scott, 1987 
Drug 
formularies in 
hospitals 
UK Feature article 
Autors writing in support of formularies (letters in response to this article offer insights in 
sentiments from doctors). Strong support for the utilisation of formularies to save money e.g. 
"operating a formulary will save 17% or more on overall drugs costs". Provides useful 
definition of formularies.  
Plumridge, 
1983 
A Review of 
Factors 
Influencing 
Drug 
Prescribing 
(Part 1) 
Australia Discussion paper Author provides largely own opinions of different influences on prescribing practice.  
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Plumridge 
et al, 1984 
Improving 
patient care 
and 
pharmacy 
managment: 
The effect of 
hospital 
formularies 
Australia 
Quantitative study 
using postal 
questionnaires to 
investigate the 
organisational 
features and 
implementation 
procedures 
associated with 
formularies.  
Out-dated - useful now for historical overview and also for the philosophy / rationale behind 
formulary implementation. Study of organisational features and implementation procedures 
associated with formulary use in major acutecare hospital throughout Austrailia. Data 
collected via qre mailed to 57 directors of pharmacy - 86% response rate. A high proportion 
of formularies was found to rate poorly in terms of organisation features (content; compilation; 
methods; format) and process variables (effectiveness as a communication document; 
prescribing aid; management tool). Methods of improving formulary effectiveness are outlined 
in the context of practical and normative research, incl improving the quality of drug therpay, 
use of formulary in cost control and improving user acceptance. Confirms that methods of 
improiving features and implementation procedures are neither widely applied or widely 
known. urgent need to reassess the usefulness of formularies and improve their effectiveness 
by adopting recommendations.  
Robertson 
et al, 2001 
Personal 
formularies 
Australia 
Prescription data 
extracted and 
analysed  
Aim was to determine the extent to which Australian GPs restrict the number of agents they 
prescribe within a drug class (personal formularies) and to assess concordance of these drug 
choices with standards based on established guidelines or recognised good prescribing 
practices. Conclusion: Australian GPs use 'personal formularies'. Formulary size varies with 
the drug class, can change over time as new agents become available, and its content can 
be influnced by promotional activities. Prescribing standards based on numbers of drugs 
used may not always reflect rational prescribing choices. Criteria based on specified drugs 
provide more rigorous prescribing standards but may give a misleading picture of prescribing 
quality in the absence of information on patients and indications for treatment. Personal 
formulary measures are potentially useful prescribing indicators but need to be carefully 
defined and interpreted. GPs should be encouraged to identify their personal formularies and 
review the drugs included in them. 
Rucker, 
1982 
Superior 
hospital 
formularies: 
a critical 
analysis 
US 
Descriptive analysis 
exploring the content 
of 8 "superior 
hosptial formularies" 
Out-dated and US-orientated. US definition of formulary useful.This is a study that looked at 
where 8 different formularies  
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Rucker and 
Schiff, 1990 
Drug 
Formularies: 
Myths-In-
Formation 
US 
Quantitative study 
investigating 
comments made at 
Pharmacy and 
Therapeutic 
Committee meetings 
Full realisation of formularies' potential has been hampered by insufficient comparative data 
on drug efficacy / safey and local resources for formulary development. Authors suggest that 
'misconceptions' concerning fundamental formulary concepts pose even more formidable 
obstacle. This paper identifies statements illustrating formulary misconceptions: (a) made by 
doctors attending PTCs during 3 yr period; (b) appearing in published sources. Critique 
assesses the role of opinions in influencing formulary construction. Statements compiled are 
assertions made by doctors attending PTC meetings as they debated the merits of adding 
drugs to or deleting them from the formulary at a large public hospital during a three year 
survey period. Claim that the discussions centred less on critical evaluation of scientific data 
and more on the purpose, design and need for the formulary per se. Rather than debating the 
relative merits of the drug being proposed the formulary concept itself was often subject to 
review. This lack of shared assumptions existed both within the Committee and in its 
interctions with staff physicians who came to a support additon / retention of a particular drug.  
Sacket et 
al, 1996 
Evidence 
based 
medicine: 
what it is and 
what it isn't 
UK / US / 
Canada 
Discussion paper 
Original definition and philosophy behind 'evidence-based medicine' outlined. Without clinical 
expertise, practice risks becoming tyrannised by evidence, for even excellent evidence may 
be inapplicable for an individual patient.  
Schumock 
et al, 2004 
Factors that 
Influence 
Prescribing 
Decisions 
US 
Quantitative study to 
describe and 
compare the 
opinions of doctors, 
pharmacists and 
formulary committee 
members 
"Strategies to control the quality and cost of medication use are largely dependent on the 
ability to alter selection of medications" (useful quote). Accepts that in hospital setting clinical 
pharmacists and formulary committee members are also key players. Authors state 
differences between doctors and pharmacists and formulary committee members have not 
been compared. Knowledge of these differences could have importance in predicting the 
effectiveness of strategies designed to influence drug use in this setting. Trained interviewer 
to adminster a standardised questionnaire designed to elicit opinons of participants regarding 
importance of factors thought to influence drug prescribing. 150 participants recruited to 
participate. Safety, effectiveness of drug, formulary status, restrictions on prescribing were all 
considerd highly influential by all participants. Doctors rated personal experience higher 
(more influential) than clinical pharmacists. Pharmacists consider recommendations by fellow 
pharmacists and prescribing guidelines and cost comparisons more influential than 
prescribers. Conclusion - should recognise and employ factors that are most influential in 
decision making process.  
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Sutters, 
1990 
The 
managment 
of a hospital 
formulary 
UK Discussion paper 
Paper describes the stages taken to set up a local hospital formulary. Following is discussed; 
philosophy behind the formulary project is outlined; mode of operation of DTC (membership 
etc.); contents and presentation; compilation of a formulary; operation of the formulary; 
integration of the formulary management system within pharmacy (i.e. working closely with 
pharmacy educators); internal marketing and publicity campaign 
Tan et al, 
2005 
Perspectives 
on DTC 
policy 
implementati
on 
Australia 
Qualitative study 
exploring the 
opinions of 
stakeholders with 
respect to DTC 
Focus group investigation of (1) the perceptions of barriers to DTC policy implementation and 
(2) ways to improve DTC policy implementation. Issues discovered were: lack of resources; 
lack of follow-up; lack of ownership; low DTC profile within the organisation; overreliance on 
pharmacy to implement policy. Highlights important considerations for formulary development 
/ implementation in resource-constrained NHS.  
Tugwell et 
al, 1984 
Design and 
preparation 
of a 
formulary - 
Guide to the 
prescribing of 
medicines 
UK Discussion paper Paper describes the stages taken to set up a local hospital formulary.  
Tugwell, 
2001 
Taking 
pharmacy 
services to a 
new level 
with the 
intranet 
UK 
Broad spectrum 
article 
Discusses the rise of information technology and pharmacy departments (centred around 
medicines information and formularies) can take advantage of this new innovation to help 
provide pharmacy services "faster and more comprehensively". In particular discusses: 
prescribing guidelines (including formulary); IV monographs; Pharmacy Bulletins; 
pharmaceutical care.  
Vickers, 
1987 
Drug 
formularies in 
hospitals 
UK Letter 
Expressing frustrations around formulary restrictions. Claims the "delusion" that drugs always 
account for such a large proportion of NHS expenditure, is actually a flawed rationale behind 
which new departments are being built in which specialists have to work with manufactuers 
(supporting their research) in order to get additional funding. Complains about the diminishing 
clinical freedom all this brings.  
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Walker et 
al, 2006 
Evidence 
Based Drug 
Formulary 
UK Feature article 
Authors state, intuitively a formulary is considered beneficial and thought to improve the 
qualtiy of prescribing, the quality of pt care and promote cost-effective prescribing. The 
evidence base for achieving any of these benefits is limited but this should not be surprising 
given the vagaries of prescribing, drug selection, drug budgets and the wishes of patients 
themselves. Discusses the application of a tool to promote rational formulary decision-making 
called SOJA (System of Objective Judgement Analysis) - includes thinking about clinical 
endpoints, safety, tolerability, dosage freq, drug interations, costs, and  a panel of 'experts' 
each given the drug a percentage for 'ideal properties' for each criterion.  
Williams 
and Bryan, 
2007 
Cost-
effectiveness 
analysis and 
formulary 
decision 
making in 
England: 
Findings 
from 
research 
UK Literature review 
Authors claim little is known about the information and processes used when making 
decisions on the inclusion of new treatments. The paper reports research on the use of 
economic evaluations in technology coverage decisions in England, although the findings 
have a relevance to other health care systems with devolved responsibility for resource 
allocation. It reports a study of four local formulary committees in which both qualitative and 
quantitative data were collected. The main research finding is that it is an exception for cost-
effectiveness analysis to inform technology coverage decisions. Barriers to use include 
access and expertise levels, concerns relating to the independence of analyses and 
problems with implementation of study recommendations. Further barriers derive from the 
constraints on decision makers, a lack of clarity over functions and aims of local committees, 
and the challenge of disinvestment in medical technologies. The relative weakness of the 
research-practice dynamics in this context suggests the need for a rethinking of the role of 
both analysts and decision makers. Authors claims the research supports the view that in 
order to be useful, analysis needs to better reflect the constraints of the local decision-making 
environment. Also recommend that local decision-making committees and bodies in the 
National Health Service more clearly identify the 'problems' which they are charged with 
solving and how their outputs contribute to broader finance and commissioning functions. 
This would help to establish the ways in which the routine use of cost-effectiveness analysis 
might become a reality. 
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APPENDIX 4 
INTERVIEW TOPIC GUIDE 
  
Title:       Grade: 
 
Note: This interview will be conducted using a semi-structured format based 
upon the questions shown below. The interviewer will encourage the pharmacist 
to describe their perceptions or experience and will use prompts to discuss 
specific issues only if the pharmacist has not already volunteered this 
information. The interviewer will use discretion with regard to the precise order 
of questions. The following is only a suggested order. 
 
 
Impressions of the Prescribing Guide 
 
Can you describe your views / perceptions of the Prescribing Guide? 
(prompt: convenience, relevance, evidence-based, ‘outside’ influence, 
perceived purpose) 
 
In your opinion, what is the purpose of a hospital drug formulary? 
(prompt: positive or negative view, necessary?) 
 
Does the Prescribing Guide meet your expectations of a formulary? 
 
Can you describe your experience of using the Prescribing Guide? 
 
Can you describe features of the Prescribing Guide you feel are working 
particularly well? 
(prompt: Health Topics – diagnosis-based, and why do you think that is?) 
 
How do you feel about the traffic light system of directing drug use? 
 
What features have you had difficulty with or do you feel are not useful? 
 
In terms of benefit to you, what features and / or information would you like to 
see on the Prescribing Guide?  
 
In your opinion does / will the Prescribing Guide have any impact or influence 
on prescribing practice? 
 
 
Influences on prescribing practice 
 
Can you describe the most influential forces on your practice of managing drug 
therapy? 
(prompt: senior colleagues, websites, personal experience, what makes them 
‘influential’ for you) 
 
On this spectrum (of influences), where do you feel the Prescribing Guide is 
placed? 
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What is your opinion of NICE guidance? 
 
Are you aware of the New Drugs and Formulary (NDF) Committee and its 
purpose? 
(prompt: what do your feel are its objectives?) 
 
 
Relationships with other healthcare professionals involved in drug 
therapy 
 
What are your perceptions of other healthcare professionals’ role in drug 
therapy? 
(prompt: doctors, NMPs) 
 
Can you describe any conflicts you may have had with another healthcare 
professional about prescribing? 
(prompt: and / or are there any experiences where you feel their contribution 
has been productive?) 
 
How do you feel about non-medical prescribing? 
 
 
 
 
Thank you for participating in this evaluation. 
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APPENDIX 5 
RESEARCH PARTICIPANT INFORMATION SHEET (COVERING LETTER) 
FOR PARTICIPANTS TAKING PART IN SEMI-STRUCTURED INTERVIEWS 
[East and North Hertfordshire NHS Trust headed paper] 
 
Dear Colleague, 
 
You are being invited to take part in a research project. Before you decide, it is 
important that you fully understand the purpose of the research and exactly 
what it will involve from you.  
 
The purpose of this research is to evaluate the recent development and 
implementation of the new online Prescribing Guide and ensure that it is 
developed in a manner that meets the needs of prescribers and other users 
within the Trust. The impact and influence of the Prescribing Guide on 
prescribing practice will be explored through semi-structured interviews, 
questionnaires and by analysing formulary adherence. Participants will include 
doctors, pharmacists and non-medical prescribers (NMP).  
 
You are therefore invited to discuss your views and perceptions related to drug 
therapy and the Prescribing Guide and any experiences you may have in using 
this service. The interview, lasting approximately 30 minutes, will be audio-
taped. It will be on an individual and once-only basis. I would, therefore, be 
grateful for your participation. Please inform me of your decision by replying to 
this letter (or see contact details below) by [2 week deadline]. You will be given 
a consent form to sign just prior to the start of the interview. 
 
The results of the research will be published in a scientific peer-reviewed journal 
and an internal report will also be produced. You will be notified of this with 
more details nearer the time. 
 
All information about you and the audio-recording arising from the interview will 
be kept strictly confidential and will not be shared with a third party. Similarly, 
any of your opinion statements that may be published or included in the internal 
report will have your name and other details removed so that you cannot be 
recognised from it. 
 
In the meantime, if you have any questions please do not hesitate to contact me 
by email (sandeep.bagga@nhs.net) or on Tel. 01438 314333 (ext. 4796).  
 
Many thanks for your assistance. 
 
Yours faithfully, 
 
 
Sandeep Bagga  
Senior Pharmacist – Formulary 
(Chief Investigator) 
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APPENDIX 6 
CONSENT FORM FOR SEMI-STRUCTURED INTERVIEWS 
 
 
Consent Form 
 
Title of project: 
Evaluation of the Impact and Influence of the Prescribing Guide on Prescribing 
Practice 
 
Name of Chief Investigator: 
Sandeep Bagga 
 
 
 
Please tick to 
confirm 
 I confirm that I have been given and have read and 
understood the information sheet (covering letter) for the 
above research project and have asked and received 
answers to any questions raised 
[      ] 
 I understand that my participation is voluntary and I am 
free to withdraw at any time 
[      ] 
 I understand that the Chief Investigator will hold all 
information and data collected in strict confidence and will 
not be shared by any third parties and every effort will be 
made to remove my name and other details so that I 
cannot be recognised and I give permission for the Chief 
Investigator to hold this data in their care 
[      ] 
 I agree to take part in the above research [      ] 
 
 
 
 
Name of participant 
 
Signature 
 
Date 
 
 
  
 
 
Name of person taking consent 
(Chief Investigator) 
 
Signature 
 
Date 
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APPENDIX 7 
AGENDA SHEET FOR STAKEHOLDERS MEETINGS 
 
Agenda Sheet for Stakeholders Meetings 
 
First Stakeholder Meeting (Week 1) 
 To determine the aims and objectives as perceived by the stakeholders. 
 To discuss which groups of drug to target for the analysis of formulary 
adherence (non-formulary prescribing) and on-formulary prescribing 
trends. 
 To provide feedback on content and structure of draft self-completion 
questionnaires. 
 
Second Stakeholder Meeting (Week 10) 
 Chief Investigator to present emerging themes and provisional findings 
from the evaluation. 
 To discuss the findings with all stakeholders. 
 To discuss potential modifications to the Prescribing Guide in order to 
overcome any recognised difficulties or problems identified with the 
delivery of the service. 
 
Third Stakeholder Meeting (Week 24) 
 Chief Investigator to present final provisional findings from the 
evaluation. 
 To discuss the emerging themes and any recommendations to further 
improve the service to inform report. 
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APPENDIX 8 - ONLINE SELF-COMPLETION QUESTIONNAIRE  
Prescribing Guide Questionnaire Pharmacists 
 
Title: Speciality: 
 
Question 1 
 
Please indicate below how frequently you use the prescribing guide (tick ONE 
box only).  
 
  More than once daily 
   
  Daily 
   
  Weekly 
   
  Monthly 
   
  Not at all   (but previously aware of Prescribing Guide) 
   
  Not at all   (NOT previously aware of the Prescribing Guide) 
  
If you have NOT used the Prescribing Guide please answer the next question, 
otherwise skip to Question 3.  
 
Question 2 
 
Do you know how to access the Prescribing Guide from the Trust Intranet 
(Knowledge Centre)? 
Yes   No  
 
Question 3 
 
Using the following rating scale, please indicate how important you consider the 
following factors in affecting your role in optimising drug therapy and medicines 
management: 
 
  Very 
important 
     Not 
important 
 
Senior members of your 
profession 
 3 2 1 0 -1 -2 -3  
          
NICE guidance  3 2 1 0 -1 -2 -3  
          
Pharmaceutical industry  3 2 1 0 -1 -2 -3  
          
Pharmacists  3 2 1 0 -1 -2 -3  
          
New Drugs & Formulary 
Committee 
 3 2 1 0 -1 -2 -3  
          
Prescribing Guide  3 2 1 0 -1 -2 -3  
          
Personal experience  3 2 1 0 -1 -2 -3  
Sandeep Bagga | Doctor of Pharmacy Practice 2012 296 
 
 
Question 4 
 
Using the following rating scale, please circle the number nearest the term that 
most closely matches your views about the Prescribing Guide: 
 
           
The Prescribing 
Guide is simple 
to use 
 
3 2 1 0 -1 -2 -3 
 The Prescribing 
Guide is 
complicated to 
use 
           
The Prescribing 
Guide is user 
friendly 
 
3 2 1 0 -1 -2 -3 
 The Prescribing 
Guide is NOT 
user friendly 
           
The Prescribing 
Guide is easily 
accessible 
 
3 2 1 0 -1 -2 -3 
 The Prescribing 
Guide is difficult 
to access 
           
The Prescribing 
Guide helps me 
decide what to 
prescribe  
 
3 2 1 0 -1 -2 -3 
 The Prescribing 
Guide is 
unhelpful in 
deciding what to 
prescribe 
           
The Prescribing 
Guide improves 
my professional 
autonomy 
 
3 2 1 0 -1 -2 -3 
 The Prescribing 
Guide damages 
my professional 
autonomy 
           
I find the 
Prescribing 
Guide  confirms 
my own 
preferences 
 
3 2 1 0 -1 -2 -3 
 I find the 
Prescribing 
Guide  
contradicts my 
own preferences 
           
I think the 
Prescribing 
Guide supports 
evidence based 
medicine 
 
3 2 1 0 -1 -2 -3 
 I think the 
Prescribing 
Guide 
contradicts 
evidence based 
medicine 
Question 5 
 
The Prescribing Guide is a continuously evolving service. The views and 
recommendations of users like yourself, are crucial in shaping the service to 
better meet the needs of both users and the Trust. Please comment, in the box 
below on any aspect of the Prescribing Guide.  
 
We are particularly interested to learn of any problems or difficulties you 
may be experiencing or improvements you feel could be made. 
 
 
 
 
Thank you for completing this questionnaire. 
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APPENDIX 9 
COVERING EMAIL FOR ONLINE QUESTIONNAIRES 
Email from Clinical Audit and Pharmacy Department 
 
At East & North Hertfordshire NHS Trust we are continually trying to improve the 
quality of care and service we provide for our patients. 
 
We now wish to look at the recently launched Trust Prescribing Guide to see if it is 
meeting the needs of both prescribers and the Trust and whether any changes are 
required to improve the service.  
 
Please click on the link below to access the short questionnaire. It is designed to be 
very easy to complete, so this should only take a few minutes.   
 
[Link placed here] 
 
The data collected will be accessible only to the Clinical Audit Team and the project 
lead.  All completed questionnaires will be treated in strict confidence and 
anonymity will be preserved.  
 
Thank you in advance for your co-operation 
 
Clinical Audit  
Clinical Governance 
East & North Hertfordshire NHS Trust 
 
Sandeep Bagga 
(Chief Investigator) 
Senior Pharmacist – Formulary 
East & North Hertfordshire NHS Trust 
Lister Hospital 
Ext 4796     Bleep 1477 
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APPENDIX 10 
LETTER FROM HERTFORDSHIRE RESEARCH ETHICS COMMITTEE 
(HREC) 
** Content removed for copyright reasons ** 
 
Reference: 
Hertforshire REC 
East of England REC Office No 3 
9th Floor, Terminus House 
The High 
Harlow 
Essex 
CM20 1XA 
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Essex 
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APPENDIX 11 
REFLEXIVE ACCOUNT 
As Section 5.10.1.1 outlines, this reflexive account is an attempt to 
explicitly discuss the researcher's views and attitudes towards aspects of 
the subject area. It is hoped such an approach can account for objectivity 
and impartiality. Additionally, this account was written prior to the 
phenomenological analysis and therefore contributes to the 'bracketing' 
of presuppositions and preconceptions required for such a philosophical 
approach.  
At the East and North Hertfordshire NHS Trust, my role as Senior Formulary 
Pharmacist was concerned with the entry of new drugs to the local hospital drug 
formulary; challenging non-formulary prescribing and; the development and 
implementation of the Prescribing Guide.  
A routine aspect of my work inevitably consisted of various forms of 
communication with doctors. In most of these cases, I liaised with senior 
doctors, typically consultants or specialist registrars. Responding to 'one-off' 
requests for non-formulary drugs, or to 'formal submissions' for a non-formulary 
drug to be added to the local formulary, I was required to conduct reviews on 
evidence-base behind the drug applications and evaluate the cost-implication to 
the Trust budget. In some instances these drugs were approved however in the 
majority of cases they were found to be unjustified since there was either an 
available formulary-approved drug that the doctor could have prescribed or 
there was a cheaper non-formulary drug that could be sourced for the 'one-off' 
scenario. Another common reason for rejection is that the drug has been 
deemed to be unsafe.  
In such scenarios, doctors often expressed frustration and resentment. In many 
cases the frustration was expressed in a few words and the communication 
came to an end, in other cases, doctors often insisted on the Pharmacy 
department making arrangement to buy the product and supply it to the patient. 
This was a point of varying degrees of divergence, often outright conflict. In 
these instances, my stance has never been to also adopt a similarly resistive 
attitude. Instead I made attempts to explain the rationale behind such decisions. 
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Therefore I would not categorise my approach to such circumstances as 
'intrinsically' aggressive, unnecessarily dictatorial or conflict-oriented.  
However, when 'conflict' scenarios as described above reach a point that I feel 
warranted a more assertive technique I would often adopt this approach and 
enforce the decision made to reject the drug in question.  
Similarly interactions have also occurred during my daily ward visits. On most 
occasions, doctors and I have managed to agree on suitable alternatives to 
challenges I have made to original drug selections. However there are also a 
number of incidents in which juniors have notably cited the authority of the 
senior doctor (consultant or registrar) and attempted to dismiss my advice. I 
have been conscious of such attempts and have attempted to see the challenge 
through by contacting the relevant 'authority'-figure. Once again I would not 
characterise my approach as ‘aggressive’ but view myself as the drug expert, 
certainly more so than junior doctors. In the capacity of Formulary Pharmacist, I 
acknowledge an authority also based on the fact that my input (based on drug 
reviews) ultimately contributed to requested drugs being approved or rejected.   
Therefore, in summary I would consider my professional demeanour to be well-
balanced. In terms of formulating any solidified attitudes or perspectives 
towards such scenarios, I feel I have yet to develop final conclusions. The 
principle reason for this is that I have been in my current post for three years 
and compared to many of my pharmacist and doctor colleagues who are also 
involved in similar communications, I feel I have a lot more to experience. In 
addition, my ward responsibilities as well as liaisons with senior doctors have 
become significantly more limited since I have been involved in the 
development of the Prescribing Guide.  
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APPENDIX 12 
MODIFICATIONS MADE TO THE PRESCRIBING GUIDE  
Modification Description 
Create new section 
on non-formulary 
drugs 
List of all drugs that have been discussed at the DTC and been 
subsequently rejected with rationale for decision 
Add DTC minutes 
Create a new section to house DTC minutes – increasing 
‘transparency’ of the review process 
Re-jig homepage 
Make the length narrower as users have missed that there is an 
‘Index Bar’ and add a new ‘Notice board’ 
Link ‘all’ drug-
related Trust 
guidelines / policies 
to drugs 
Precedent set for all newly approved Trust guidelines and policies 
to be communicated to the Formulary Team in Pharmacy (Clinical 
Audit secretary staff involved) 
Regular emails with 
links to junior 
doctors 
Precedent set for ‘regular’ emails to be sent to all junior doctors 
(relevant medical secretaries involved) 
Pharmacists to 
promote 
Prescribing Guide 
Pharmacists reminded regularly at department meetings to 
promote Prescribing Guide beyond the Pharmacy department 
Develop new 
extensive ‘How To 
Use’ section 
More explanations included along with ‘worked’ examples of how 
to use specific features on the Prescribing Guide. Links provided 
to the sections discussed. Prominent link inserted on homepage 
to ‘How to use’ section 
Bedford-PG 
discrepancy 
System put in place to communicate discrepancies between 
Pharmacy computer and Prescribing Guide to Formulary team 
Add search bar Simple search bar (simple HTML code) inserted on Index page 
Pharmacy Bulletin 
To inform all users of changes to Prescribing Guide as well as 
other important updates e.g. drug safety bulletins, DTC decision 
updates, common Medicines Information queries etc.  
Desktop icon 
To liaise with IT department regularly about possibility of placing 
an icon on the desktop screen of all Trust PC in clinical areas. In 
meantime, Pharmacy department reminded to manually create 
temporary icons when they attend their wards.  
Prescribing Guide 
leaflets (new) 
Original leaflets amended to include new changes and distributed. 
Posters 
New poster campaign to coincide with introduction of new junior 
doctors. Prominent locations discussed with Stakeholders (e.g. 
wards, doctors’ mess etc).  
Doctors induction 
Designated section of induction training (provided by pharmacists) 
to extensively cover Prescribing Guide. Demonstrations were key 
addition to existing content. 
Workshops / Stalls 
at Grand Rounds 
Arranged by coordinating effort with Stakeholders (particular 
consultant) at both hospital sites at the Trust. Using Trust laptop 
with wireless Intranet connection, four demonstrations made at 
Grand Rounds.  
Leaflets explaining 
DTC and formulary 
purpose 
Content of leaflet agreed with senior staff and members of DTC 
and distributed to all junior doctors and at induction training. 
Prescribing Guide 
screensaver 
Amended to include new changes. Booked in advance for August 
and September to coincide with arrival of new junior doctors. 
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APPENDIX 13 CLUSTERS OF 368 CODES GENERATED FROM QUALIATIVE ANALYSIS 
 
ACCESS-IT PI-INFLU MGT-RES-OTHER PG-BASIC PG-DEV-INT CONS-ALL-AW F=NICE F-NCOST JP-STRUCTURE 
IT-PREC PI-SUCC N-L-DRUGS PG-BR-OTHER PG-PH CONS-BUF-REG F-ACCOM F-NOTIDEAL PH-ALLINC 
IT-FUTURE PI-UNSUCC NMP-L-RESTRICT PG-COMP PG-P-HT CONS-DATA F-ADAPT 
 
PH-AMENAB 
IT-UPDATING PI-DISTRUST NMP-Q-SAFETY PG-CONS-AW PG-CHECK CONS-OWNER F-APPRO 
 
PH-CHAL 
IT-ORIENT 
 
NMP-RESORT PG-FOCAL PG-DISCREP CONS-RESIST F-AWARE 
 
PH-CLIN-FRUS 
IT-LOCATE 
 
N-PT-EXP PG-FREQ PG-NI-FRUSTR CONS-START F-BUREAU 
 
PH-CONTROL 
IT-PROBS AUTHORITY PROF-CRIT PG-FUTPRO PG-NEWSTAFF CONS-UNAFF F-CEP 
 
PH-COST 
 
CLIN-DIV PROF-CRITAPP PG-GUIDELINES PG-HELP-PX DR-SPECIAL F-COMM 
 
PH-CRIT 
CHANGE-PRACT CONFLICT PROF-DEMARC PG-HTU-DEMO PG-EVOL JD-APPREC F-CONSIS NICE-ADAPT PH-DEFICI 
COMPLEX-PRACT DIV-CAUSE PROF-DIV PG-IND-F PG-IMPACT JD-AUTO F-CONTROL NICE-ALLEBM PH-DEMAND 
DEFIANCE EXPERT PROF-ENCROACH PG-JUSTIFY PG-OPENMIND JD-DIFF-CONS F-COST NICE-AUTOCRAT PH-DISP 
DIALOGUE OLDER-NOTCH PROF-LIMIT PG-LACKCONFID PG-OTHER-PROBS JD-H-CONS F-DEMOCRAT NICE-BUREAU PH-DISSAT 
EBM-NA OTHER-INABIL PROF-OVERLAP PG-MANDATORY PG-EVERYG JD-L-CONFID F-DRUGS NICE-CON PH-DR-NC 
EBM-Q OTHER-STRUCT PROF-PEER PG-N-CONTROL PG-NOT-SURG JD-N-COST F-EBM NICE-CONSIS PH-DRUG-EXP 
EXP-HARD OTHER-TRAING NMP-Q-CLINIC PG-N-EFFORT PG-HABIT JD-STRUCTURE F-FLAW-DM NICE-COST PH-EBM 
GUIDEL-TIME OUT-SPHERE MGT-INSIGHT PG-N-INEFF PG-RES-PROM MED-TRAING F-HIGHER-A NICE-COVERT PH-EDUCAT 
LEGAL-IMPL PX-APPROACH NMP? PG-N-LOCATE PG-QUICK PX-ACCOUNT F-LACKKNOW NICE-EXPERTS PH-ENSURE 
LOCAL UND-OTHER RESIGN PG-NOTEBM PG-TRAING Px-AUTON F-LIMIT NICE-IND PH-EVOLVG 
OPTIM-PX PXR-PH-COST NMP-MAINT PG-NOT-PRACT PG-P-TLS PX-DIFF F-LIST NICE-LENIENT PH-EXP 
PREV-D-EXP UNST-RLSHPS NMP-EVOLVG PG-NOTSTART PG-MGT Px-Dr F-LOCAL NICE-N-COST PH-FRUSTR 
PRO-CONTROL FEW-DRUGS N-D-EXP PG-N-PT PG-EXP-THREAT Px-EXP F-MULTI NICE-N-DEC PH-INSIGHT 
STRUC-TIME RES-1STHAND 
 
PG-N-THINK PG-N-NMP PX-INAPP F-NATION NICE-N-PT PH-INTIM 
STRUCTURE BRAND-FAV 
 
PG-N-TIME PG-NOT1ST PX-INCONSIS F-N-EDUCAT NICE-N-UF PH-PG 
UNCERTAINTY HOSTILITY 
 
PG-N-UNFAM 
 
Px-MOT F-N-INEFFIC NICE-OVERR PH-PRAISE 
SPECIAL-IND PERSONAL WIDER-BENEF PG-OUTCLIN 
 
Px-NOT-CM F-N-OP NICE-OVERW PH-Q-THERAPY 
INCONSIS-PX DRUG-DM NATION-IMP PG-P-BNF 
 
Px-POWER F-NOT=NICE NICE-SAFETY PH-REPOS 
SPECIAL-PRACT STRUC-PXR PRIM-COST PG-P-COST PT-FOCUS Pxr-AMENAB F-NOTMOT NICE-STANDARDS PH-RETRO 
EXP-N-HARD CLOSER-PEERS 
 
PG-P-EBM PT-PERSP PXR-COND FP-BIAS NICE-SUCCUMB PH-RIGID 
 
RESEARCH-VS I-EDUCAT PG-P-EDUCAT PT-UNIQ Pxr-CONFID F-PHY NICE-SUM PH-ROLE 
OVER-RATIONAL 
 
I-EXP PG-P-EOU PT-URGENCY Pxr-EBM F-P-PHARMA NICE-UNFAM PH-SAFETY 
TIME-CONSTR 
 
I-PEERS PG-P-FORM PT-TO-F PX-REST-PRIM F-PT-FOCUS NICE-UTD PH-SIDELINED 
RESTRICT-AWARE R-DI I-PH PG-P-PRES 
 
Pxr-FRUSTR F-PURPOSE NICE-MORE PH-SKEPTIC 
ORG-CHANGE R-GUIDEL I-PHARMA PG-PROMOT 
 
PXR-INSIGHT F-RATION NICE-CEP PH-STOCKCON 
MULTI R-PROMOT I-MEDIA PG-P-UF BNF-REPUT Pxr-JUDGE F-REPRESENT NICE-JUST PH-STRUC-KNOW 
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GOOD-EXP R-TAILOR I-PG PG-REF OTHER-SOUR Pxr-LIMIT F-RESENT 
 
PH-SUPPLY 
MANAGE-RESO R-EBM I-NICE PG-STOCK GUIDANCE PXR-N-EX-PH F-RESO M-SEARCHB PH-TRAING 
CONSTR-RESO R-RENAL I-EBM PG-SUPERSEDE DUPLIC Pxr-PEERS F-RESTRICT M-PROMOT PH-UNDERM 
L-RESIS R-LOCATE I-COST PG-SUPPORTIVE 
 
PXR-PROBSOLV F-RIGID M-INFO PH-VARIETY 
BUDGETG R-MULTI I-AW-RESTR PG-THREAT 
 
PXR-PT F-SAFETY M-RECOG SP-INTERMED 
LACK-COMM R-EDUCAT I-GUIDEL PG-TOOMUCH RES-AMBIG PXR-R-Q F-SKEPTIC M-BLACK SP-RESP 
CRESO-UNSUST 
  
PG-UNFIN RES-EXP PXR-R-STRUCT F-START M-NDFLEAFLET TECH-SUPPLY 
CRESO-STIF-INNO 
  
PG-USAGE RES-NEWUND Pxr-TRUST F-T-FAILURE M-NDFMINS PH-OUT-ADV 
    
RES-Q Px-SUPER F-UNDERM 
 
PH-ALLPRS 
    
RES-RELUCT DR-FOCUS F-UTD 
 
PH-UPHOLDING 
    
PART-GRIEV 
 
F-WIDE PMGT-STRUCTURE PH-N-INFLU 
      
LFC-UNFAM PH-N-PT SP-COST 
      
F-RELUC PH-OBSTR PH-NEED? 
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APPENDIX 14 THE CONSTRUCTION OF GENERALISED 'STATEMENT 5'  
1. Formularies ensure 
management of constrained 
financial resources 
12. Pharmacists tend to justify 
the need for the DTC process 
23. Access to Prescribing Guide 
thwarted by IT issues 
34. Practitioners are interested 
in local DTC’s drug decisions 
45. Formulary recognised as a 
restrictive and largely unwanted 
influence on doctors prescribing 
practices 
56. Pharmacists are considered 
to be obstructive in prescribing 
practice 
2. Pharmacists more likely to 
speak about formularies in terms 
of clinical benefits to patients 
13. The formulary perceived as 
a threat to prescribing autonomy 
24. Access to Prescribing Guide 
thwarted by time constraints 
35. Recommendations to 
improve functionality of 
Prescribing Guide 
46. Pharmaceutical industry is 
considered highly biased and 
untrustworthy 
57. Doctors attempt to limit the 
prescribing powers of NMPs 
3. Doctors insistent on formulary 
being adaptable 
14. NMPs feel restricted by their 
own lists 
25. Prescribing Guide not 
appropriate for specialists (use 
value) 
36. Recommendation to 
increase training and awareness 
47. Junior doctors and 
pharmacists often adopt 
‘stepwise’ approach to drug 
therapy 
58. Pharmacists are too 
algorithm-driven 
4. Pharmacists unaware of 
restrictive language 
15. Prescribing Guide widely 
welcomed and praised as a new 
service 
26. Prescribing Guide praised 
for its comprehensive inclusion 
of a wide range of information 
sources within one local website 
37. Doctors highly influenced by 
their senior colleagues 
48. Pharmacists operate 
independently therefore more 
likely to require decision-support 
tools 
59. Pharmacists are too 
preoccupied with the supply 
function 
5. Doctors perceive formulary as 
restrictive 
16. Managers concerned with 
impact data 
27. Prescribing Guide on 
occasion supplanting advice of 
colleagues 
38. Pharmacists less influenced 
by senior colleagues 
49. Doctors recognised as open 
to  collaboration provided it is on 
their terms 
60. Pharmacists lack clinical 
expertise and opportunity to 
further cultivate a more clinical 
understanding 
6. Formulary restrictions 
generate opposition and 
resistance 
17. Vague conjecture regarding 
a perceived impact of the 
Prescribing Guide 
28. Prescribing Guide provides 
an awareness of local 
availabilities and priorities 
39. Doctors more likely to 
access primary sources of 
evidence-based medicine 
compared to pharmacists in 
routine practice 
50. Junior doctors more likely to 
adopt a collaborative approach 
than senior doctors 
61. Prescribers claim unique 
ability to deal with unusual and 
uncertain patient cases 
7. Prescribing practice should 
include being able to experiment 
with drugs and gain experience 
18. Resorting to the Prescribing 
Guide needs to become ‘habit’ 
29. Prescribing Guide has 
educational value 
40. Through experience 
pharmacists are more likely to 
develop an understanding of 
drug usage rather than 
individual clinical outcomes 
51. NMP expertise is recognised 
in multidisciplinary environment 
62. NMPs claim an evolution in 
clinical understanding that 
equips them with ability to 
manage ‘uncertainty’ in complex 
patient cases 
8. Only pharmacists and DTC 
members able to elaborate on 
DTCs’ importance and role 
19. Prescribing Guide is 
currently more supportive to 
junior doctors rather an 
immediate source of drug 
information 
30. Traffic light system causes 
confusion 
41. Doctors develop experience 
of individual clinical outcomes 
52. Pharmacists feeling 
marginalised by prescribers 
63. Doctors claim to be the only 
party who is entirely patient-
focused 
9. Doctors regard DTC as 
primarily concerned with cost-
containment 
20. Prescribing Guide now 
primary source of drug 
information for most pharmacists 
31. Prescribing Guide contains 
more information than is needed 
42. NICE useful in time 
constrained scenarios for 
pharmacists and junior doctors 
53. Prescribers are subject of 
pharmacists’ scrutiny Statement 5 - The local 
formulary symbolises a 'critical 
split' in approaches to resource 
management and patient care. 
The formulary is therefore 
central to many of the conflicts 
that take place within prescribing 
practice where the opponents 
take varying degrees of either a 
supportive or opposing view of 
the formulary decisions. 
10. Pharmacists tend to justify 
the cost-motivation behind the 
DTC 
21. Pharmacists and doctors 
differ in consideration of 
formulary status of drug 
32. Doctors concerned with 
patient’s impression of them 
using the Prescribing Guide 
43. Prescribers feel restricted by 
NICE because it impacts local 
decision-making 
54. Conflicts between 
pharmacists and prescribers 
centre around guidelines and 
experience / judgement 
(respectively) 
11. Doctors regard the DTC as 
excessively bureaucratic 
22. Prescribing Guide facilitates 
pharmacists’ retrospective 
challenging of prescribed drugs 
33. Recommendation to ensure 
more up-to-date links to local 
and national guidelines 
44. Formulary regarded as a 
supportive influence for 
pharmacists 
55. Participants reinforcing 
traditional divides and 
segregated working 
arrangements 
Sandeep Bagga | Doctor of Pharmacy Practice 2012 308 
 
APPENDIX 15 
SUMMARIES OF DISCUSSIONS DURING STAKEHOLDER MEETINGS 
Stakeholder Meeting 1 (i) 
Attendees: Senior Formulary Pharmacist and Senior Pharmacist 
Date: May 2009 
Venue: Senior Pharmacist’s office 
Summary: 
 
Study's proposed aim and objectives presented and agreed. This Stakeholder 
was particularly interested in the focus on 'attitudes' and 'perspectives' and was 
looking forward to the results. 
 
Design structure and content of online questionnaires discussed with 
Stakeholder. In particular, Job Title and Clinical Speciality for 'pharmacists' were 
checked and finalised.  
 
Wide-ranging discussion took place regarding the class of drugs to be targeted 
from 'formulary-adherence' quantitative data extraction. Pharmacist-Stakeholder 
recommended selecting drugs that were 'contentious' and would reveal 
information about expenditure of second-line, third-line (and more restricted 
drugs) compared to first-line options as a means to understand formulary 
deviance. Recommended in particular: Movicol (and other laxatives); statins; 
PPIs; antibiotics (in particular macrolides); and analgesics (later discussed 
Controlled Drugs such as oxycodone and Fentanyl and also commonly 
prescribed anti-inflammatories) (final list in Table 18). 
 
The pharmacist-Stakeholder also warned against the likely time-consuming 
nature of the data extraction process particularly the non-formulary data. After a 
brief discussion of how this may be possible using various functions within 
'Beford' (the Pharmacy computer system), he advised seeking the help of the IT 
Directorate Pharmacist at the Trust or an external individual who had originally 
setup 'Bedford' in the Pharmacy Department and routinely made visits to carry 
out updates to the system. 
 
Discussing potential participants for the semi-structured interviews (avoiding 
'names' and referring to 'category' of pharmacist e.g. "a Directorate Pharmacist 
or "a Junior Pharmacist who is currently doing a medical ward" in order to 
maintain confidentiality). The Stakeholder insisted on pursuing the Chief 
Pharmacist for interview as he believed that she could provide particularly 
interesting insights into the way 'managers' function and whether there was a 
visible difference between pharmacists who were 'practicing' on the wards and 
"in the field".  
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Stakeholder Meeting 1 (ii) 
Attendees: Senior Formulary Pharmacist and Consultant Doctor 
Date: May 2009 
Venue: Consultant Doctor’s office 
Summary: 
 
Study's proposed aim and objectives presented and agreed. 
 
Design structure and content of online questionnaires discussed with 
Stakeholder. In particular, Job Title and Clinical Speciality for 'doctors' were 
checked and finalised. 
 
Since this doctor-Stakeholder was an Elderly Care consultant, he initially 
proposed anti-parkinsonian drugs and 'drugs that cause renal failure'. However, 
the pharmacist-Stakeholder's recommendations of selecting more widely 
'contentious' drugs appealed to this Stakeholder therefore similar 
recommendations were made (final list in Table 18). 
 
Made recommendations about other consultants, registrars and junior doctors 
to interview.  
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Stakeholder Meeting 1 (iii) 
Attendees: Senior Formulary Pharmacist and NMP 
Date: May 2009 
Venue: NMP’s office 
Summary: 
 
Study's proposed aim and objectives presented and agreed. 
 
Design structure and content of online questionnaires discussed with 
Stakeholder. In particular, Job Title and Clinical Speciality for 'NMPs' were 
checked and finalised. NMP-Stakeholder also provided email address list of all 
NMPs at the Trust since, unlike with doctors and pharmacists, there were no 
administrative staff to facilitate the dissemination of online questionnaires (via 
email).  
 
Since this NMP-Stakeholder was a specialist 'Pain Nurse' and part of the Trust's 
'Pain Team', she was particularly interested in the use of Controlled Drugs. 
Since both the doctor- and pharmacist- Stakeholders expressed interest in this 
area, four Controlled Drugs (morphine, diamorphine, oxycodone and fentanyl) 
were specifically chosen with NMP-Stakeholder. She further discussed PPIs 
and anti-inflammatories since they were also drugs very familiar to her. She was 
not able to elaborate as readily as the doctor- and pharmacist- Stakeholders 
about other drug classes but agreed with the original list recommended by the 
pharmacist-Stakeholder. 
 
The NMP-Stakeholder stated that she understood the reason to have only one 
NMP in the interview list (sample population should correspond as closely as 
possible to the actual population) however she added that nurse NMPs would 
also provide useful insights and recommended having two instead of one NMPs 
interviewed in the next phase of semi-structured interviews. She also 
recommended particular nurses who had been qualified as 'prescriber' for some 
time. 
 
This Stakeholder also echoed the pharmacist-Stakeholder's advice to pursue 
the Chief Pharmacist for interview. 
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Stakeholder Meeting 2 
Attendees: Senior Formulary Pharmacist, Senior Pharmacist, Consultant 
Doctor and NMP 
Date: July 2009 
Venue: Consultant Doctor’s office 
Summary: 
 
All Stakeholders expressed disappointment at lack of use of Prescribing Guide 
by doctors. Doctor-Stakeholder stated "I'm not surprised" and explained that 
often others at the Trust are unable to understand the time-constraints that 
doctors are under emphasising junior doctors are particularly "stressed" and 
often do find the time to use it. The pharmacist-Stakeholder asked why doctors 
would not use a service designed to "help" them. The doctor-Stakeholder 
clarified "formularies are not thought to help them but help you" referring to the 
Pharmacy department and cost-saving priorities.  
 
The NMP-Stakeholder clarified that she has no need to refer to it because she 
has a small list of drugs that she adheres to and has become proficient at 
prescribing those drugs. She said she is aware of how to use it and "had a play 
around when it was launched" and found it very useful. She said she can see 
where doctors might benefit from using it and stressed that it should be 
"hammered home" to them.  
 
All Stakeholders were interested in the insights obtained from NMP1. In 
particular the clear transition from pharmacist to prescriber was a particular 
point of interest. The doctor-Stakeholder discussed the lack of patient-insight 
that some pharmacists (making the effort to exclude the pharmacist-
Stakeholder and acknowledging is specialist regard at the Trust and 
experience) inherently have especially when they do not make the effort to 
become involved in the process. The NMP at this point agrees that there are 
some pharmacists who seem as if they just want to make the supplies then "run 
off the ward". The doctor-Stakeholder resumes his original line of thought and 
states that NMP1 has demonstrated the development the ability to "think of the 
patient first" before "things like the drug budget or stock availabilities". The 
pharmacist-Stakeholder appeared to concede to this perspective, albeit 
reluctantly. He added though, that pharmacists "want" to do more "clinically" but 
have too many pressures of needing to be "down in dispensary for this slot" and 
expressed concern and empathy for junior pharmacists not receiving the 
training they need and he wants to provide because he himself is frequently 
having to cover extra wards and barely gets time to complete his "paperwork" 
for DTC meetings and his antimicrobial department commitments. Notably, both 
the NMP- and the doctor-Stakeholder refer to "prescribing powers" and the fact 
that the acquisition of this can lead to different "mode of thinking" as stated by 
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doctor-Stakeholder. 
All Stakeholders agreed (based on NMP-Stakeholder's suggestion) to increase 
the number of interviews with NMPs from one to two for the next phase of the 
data collection and recommended some names.  
 
Stakeholders contributed to the development of a list of potential modifications. 
Some suggested changes were immediately rejected (by the Formulary 
Pharmacist-Stakeholder) because they were deemed unrealistic or 
unachievable for example: the development of new features on the Prescribing 
Guide such as links to drug interactions, information on renal impairment 
caused by drugs. The modifications that were agreed to and were eventually 
implemented are listed with explanations in Appendix 12. Stakeholders helped 
to facilitate some of these modifications for example, the "Workshops / Stalls at 
Grand Rounds" were arranged by the doctor-Stakeholder and further offered to 
make regular presentations at Grand Round events (once a week for a month).  
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Stakeholder Meeting 3 
Attendees: Senior Formulary Pharmacist, Senior Pharmacist, Consultant 
Doctor and NMP 
Date: January 2010 
Venue: Consultant Doctor’s office 
Summary: 
 
After presentation of provisional findings, the notable 'emerging themes' 
discussed were: 
 
Prescribing Guide 'is' useful:  
All Stakeholders expressed praise for the Prescribing Guide focus on various 
different aspects of the final product. Particular attention was given to praise the 
"educational value" (doctor-Stakeholder) that it has for "juniors". It was also 
praised for its comprehensiveness and links to various different guidance. The 
availability of cost information was also considered useful, particularly 
emphasised by NMP-Stakeholder. However, doctor-Stakeholder mentioned that 
this could give doctors the impression that the Prescribing Guide is "actually to 
make prescribing cheaper". Pharmacist-Stakeholder added that "it is" to reduce 
the cost of drug prescribing but that the emphasis is on being "cost-effective" so 
that there is still high quality prescribing based on "robust clinical trial data" but 
also to ensure that an expensive drug is not being used when a cheaper drug 
could do the same thing.   
 
'Critical split': 
Pharmacist-Stakeholder stated there is "definitely a split" in views on the 
Prescribing Guide and more widely in prescribing practice. Stakeholders 
discussed the different approaches to resource management (drug budget) and 
patient care. Essentially Stakeholders agreed that doctors and NMPs are more 
likely to think about cost as low priority (with doctor-Stakeholder clarifying that 
junior doctors will probably not think about cost at all).  
 
Pharmacists appear to be 'subjugated': 
Pharmacist-Stakeholder and Formulary Pharmacist-Stakeholder discussed the 
various time-constraints that frustrate pharmacists and agreed that they impact 
on both junior and senior ward pharmacists. Pharmacist-Stakeholder stated that 
there is little that can be done about the concerns pharmacists have raised 
about supply-function because there are current staff-shortages which mean 
that often he has to ask all pharmacists to do additional ward rounds. He is 
concerned about the impact that this can have on the quality of clinical care 
given by pharmacists to patients i.e. not checking ward charts as accurately as 
they could.  
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A noticeable discrepancy between qualitative and quantitative findings in 
relation to senior colleagues as influence was specifically raised and discussed 
by Stakeholders. According to the results of Question 4 in the self-completion 
questionnaires, pharmacists indicated that seniors were 'important' influences to 
their role in drug therapy. However during the semi-structured interview, while 
discussing influences most pharmacists listed senior colleagues either very late 
or not at all. The pharmacist-Stakeholder attempted to provided a rationale for 
this discrepancy. He stated pharmacists invariably carry out their ward duties 
alone (unlike doctors who work in teams) and so although pharmacists certainly 
regard their senior colleagues as 'important' as indicated in the quantitative 
data, "they do the best they can on their own". Since he was often involved in 
educating junior pharmacists he also added that when pharmacists were unable 
to resolve an issue independently then they "always come up to me or whoever 
for direction". Therefore regarding this issue of senior colleagues, rather than 
the two sets of data conflicting or being discrepant, it would appear that in fact 
they provide a more comprehensive interpretation of pharmacists' regard for 
their senior colleagues. The NMP- and doctor- Stakeholder agreed with this 
rationale. 
 
Formulary regarded as a control measure / bureaucracy / cost-motivated: 
Extensive conversation about formulary being regarded as a control measure. 
All Stakeholders agree that ultimately it cannot be denied and does remove the 
autonomy from doctors and that this must cause frustrations. In particular 
doctor- and pharmacist-Stakeholder discussed the potential implications this 
has for doctor-pharmacists relations (pharmacist-Stakeholder mentions 
"strained" relationships at time). 
 
Pharmacists regarded as agents / supporters of restrictive practices: 
Notably NMP-Stakeholder agreed with participants making such statements. 
She claimed to have been in situations in which she was unhappy about the 
stance taken by a pharmacist. She stated she was often concerned by the 
delays caused by pharmacists because they were "following protocol rather 
than thinking of the sick patient in the hospital bed". There was a loose 
consensus that pharmacists (in general) follow and try to implement pre-
structured and algorithm-driven guidelines (often carried out by others) and lack 
the exercise of clinical judgement whereas doctors and NMPs are focused on 
the patient.  
 
NMP's experience an evolution of clinical thought process:  
The doctor-Stakeholder notably reminded the group of NMP1 "transformation" 
and stated that many pharmacists would benefit from getting a "closer look" at 
how patients are "really" managed instead "just phoning the doctor and saying 
oh no you can't have this".  
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APPENDIX 16 
FIGURES (A-H) SHOWING PRESCRIBING INFORMATION  
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Figure A. PPI usage at E&N Herts NHS Trust (July '08 to June '09) 
OMEPRAZOLE ISSUES LANSOPRAZOLE ISSUES ESOMEPRAZOLE ISSUES PANTOPROZOLE ISSUES 
OMEPRAZOLE COST LANSOPRAZOLE COST ESOMEPRAZOLE COST PANTOPROZOLE COST 
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Figure B. Laxatives expenditure at E&N Herts NHS Trust (July '08 to June '09) 
LACTULOSE COST SENNA COST MILPAR COST ISPAGHULA COST MOVICOL COST 
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Figure C. Statin usage at E&N Herts NHS Trust (July '08 to June '09)  
SIMVASTATIN ISSUES PRAVASTATIN ISSUES ATORVASTATIN ISSUES ROSUVASTATIN ISSUES 
SIMVASTATIN COST PRAVASTATIN COST ATORVASTATIN COST ROSUVASTATIN COST 
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Figure D. Analgesics usage at E&N Herts NHS Trust (July '08 to June '09) 
DIAMORHINE ISSUES MORPHINE ISSUES OXYCODONE ISSUES FENTANYL ISSUES 
DIAMORPHINE COST MORPHINE COST OXYCODONE COST FENTANYL COST 
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Figure E. Macrolide usage at E&N Herts NHS Trust (July '08 to June '09) 
ERYTHROMYCIN ISSUES CLARITHROMYCIN ISSUES AZITHROMYCIN ISSUES 
ERYTHROMYCIN COST CLARITHROMYCIN COST AZITHROMYCIN COST 
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Figure F. Drugs for urinary frequency at E&N Herts NHS Trust (July '08 to June '09) 
OXYBUTYNIN ISSUES TOLTERODINE ISSUES SOLIFENACIN ISSUES TROSPIUM ISSUES DULOXETINE ISSUES 
OXYBUTYNIN COST TOLTERODINE COST SOLIFENACIN COST TROSPIUM COST DULOXETINE COST 
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Figure G. NSAIDs usage at E&N Herts NHS Trust (July '08 to June '09)  
IBUPROFEN ISSUES DICLOFENAC ISSUES NAPROXEN ISSUES 
IBUPROFEN COST DICLOFENAC COST NAPROXEN COST 
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Figure H. Prostaglandin (ED) usage at E&N Herts NHS Trust (July '08 to June '09)  
BIMATOPROST ISSUES LATANOPROST ISSUES TRAVOPROST ISSUES 
BIMATOPROST COST LATANOPROST COST TRAVOPROST COST 
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APPENDIX 17  
THE PRISONER'S DILEMMA - ADAPTED FROM TARRANT ET AL (2004). 
Two people are arrested and charged with being involved in a serious crime. 
They are being held in isolated cells with no contact with each other. Since the 
police have insufficient evidence to convict them they seek incriminating 
information from the prisoners. Therefore each prisoner has a choice: (C) 
indicates 'concealing' information thereby 'cooperating' with the other prisoner; 
(D) indicates the prisoner 'defects' or 'discloses' the information to the police 
thereby demonstrating non-cooperation with the other prisoner. It is customary 
to use the (C) and (D) for 'cooperate' and 'defect' respectively. At this point the 
strategies that each prisoner can make can be described along with any 
consequent 'pay-offs' (benefits to the prisoner). If only one prisoner discloses 
the information, then that prisoner will be acquitted with a reward for helping the 
police (best possible scenario) and the other prisoner will receive a large prison 
sentence (worst possible scenario).  
  Prisoner 2 
  C D 
P
ri
s
o
n
e
r 
1
 
C CC CD 
D DC DD 
 
The 'Nash equilibrium' is a pair of strategies that are the best replies to each 
other. Tarrant et al (2004) clarify the best reply is the strategy that produces the 
best possible outcome given the other prisoner's strategy. In the Prisoner's 
Dilemma, the Nash equilibrium is joint defection (D, D), that is, both prisoner's 
disclosing information. In other words, there is overall stability if both prisoners 
opt 'not' to cooperate. This can be rationalised by considering that choosing (D) 
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(to disclose) is the best option for both prisoners regardless of the other's 
strategy (to disclose or to conceal). Although both prisoners would be better off 
if they 'both' choose to conceal (in effect cooperating with each other) but since 
they do not know what the other will choose the safest option is to defect 
(disclose). Crucially by choosing to conceal incriminating information, the 
prisoner 'exposes' himself to the risk of the worst possible scenario (C, D), that 
is, the other prisoner being tempted to disclose information. Therefore in this 
way game theory shows that cooperation is never a rational strategy.  
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APPENDIX 18  
EXAMPLE OF A TRANSCRIPT FROM A SEMI-STRUCTURED INTERVIEW 
Interviewee: CD2 
Duration of interview: 00:36:42 
Venue: Consultant's office  
Date: June 2009 
Interviewer: Okay so let me start with the hospital drug formulary, what do you 
think, or what is your perception of its purpose and its objectives? 
 
Consultant: To have a hospital drug formulary is, basically is for you to try and 
have a more limited supply of medication based on sort of local and 
regional priorities and therefore make, I’m sure logistically it makes 
sense to have a limited thing for the pharmacy to run because if you 
umm, if you run a service with the whole of the BNF then I’m sure 
logistically it’s much more difficult so where there are two or three 
different drugs which are of similar efficacy and stuff, it makes 
sense to have one which is the preferred agent again based on 
local priorities. So I understand the concept of having a hospital 
formulary and umm, you know I think that it’s a good idea so I don’t 
see any problems with that. 
 
Interviewer: And moving forward, just talking about the Prescribing Guide, what 
are your opinions of it, you know, what’s your general perceptions of 
it, as a final sort of product? 
 
Consultant: I think it’s umm, as all guidances, it has the value that when 
especially inexperienced juniors, especially if I’m doing a ward 
round and I tell them that I want a bronchodilator or I want an 
antibiotic or want something and then they ask okay sort of what 
dose, what drug, what and I say okay look it up. You know we have 
a formulary, we have a local Prescribing Guide, look it up and 
choose according to the preferences. So at least they have an 
understanding of where the drug stands and can do that. As far as 
my own practice is concerned, I know what drugs are on that so I 
don’t tend to look at it regularly unless someone tells me oh you 
said that and that is not in the formulary or something of that sort 
and I have to go back and look at it but I wouldn’t use it normally but 
that’s only because I know of the content of it as far as the drug I 
would prescribe. But obviously if I was going to prescribe a drug I 
don’t normally prescribe in my practice, I would say yeah like a 
newer form of insulin or something which I don’t normally prescribe I 
would look it up and look at the you know, current availability. 
Something outside my speciality would be very important for me to 
look up because I wouldn’t be fully aware of the latest preferred 
drugs in that area but within the drugs I would normally use, I don’t 
need to use it. 
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Interviewer: Hmm, and when you originally saw the Prescribing Guide, did it 
meet you perceptions of a hospital formulary, did it meet you 
expectations? 
 
Consultant: I think it’s an excellent device umm, to have, an excellent tool to 
have especially the Intranet availability of it. The only downside of it 
that the Intranet availability on the wards or in work areas is very 
limited and you know one computer and your fighting with radiology 
and pathology and all that they also deal with lack of time and to be 
able to go from the bedside back to the one computer on each ward 
which is available for hundreds of different purposes and including 
catering and admin stuff and nurses and other staff too is the main 
stumbling block. Say if we had, like in some areas in the hospital, 
you know you go on a ward round you have a laptop with you and, 
and you know you do your work on that and that’s much easier. So 
we can have these trolleys which have these laptops on them and 
can take them on the round and that makes life easier otherwise for 
me during a ward round from a bedside to go back to look at it is 
just practically impossible so I can’t say that it will make a big 
difference in day to day practice because of the lack of availability 
but when I send somebody away and say look you go and look it up 
now and then bring it back, that’s okay. 
 
Interviewer: I see, and when you do send one of your juniors away to look 
something up, what’s the feedback you’ve receive, are they 
satisfied with the Prescribing Guide? 
 
Consultant: Yes, they, they do get all the information they need from that. 
 
Interviewer: Okay and what about your own experiences of using it, I know you 
said you sometimes use it as well… 
 
Consultant: Oh yes. 
 
Interviewer: Can you perhaps describe your most successful attempt at using it? 
 
Consultant: I mean, at present I would say it still needs work. Because what I 
would be very interested in personally would be that, especially if 
it’s an area that I’m not particularly familiar with the literature and I 
don’t use it on a day to day practice and I see something in the 
formulary I would want it backed up by some national level or 
international level guidelines and I would also want links to the 
additional, you know the actual key papers in that area which would 
support the inclusion within the guideline within that, that formulary, 
and I don’t know, I haven’t sort of explored this very much in other 
areas where I don’t know the literature but that would be what I’d be 
looking for. Without that backing I would find it difficult to choose 
and prescribe a drug knowing that it’s on the formulary. Knowing 
that it’s on the formulary doesn’t automatically give it the evidence 
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guarantee that I would want to seek, you know for my own practice. 
 
Interviewer: Yes, okay. Okay what about the features that you feel might be 
working well, or elements of the Prescribing Guide you feel are 
particularly useful? 
 
Consultant: I think the simplification of medication down to the preferred agents 
is useful. I’m not sure the adverse events, because I’m sure there’s 
a BNF link, so that would be useful because, you know, when your 
prescribing a drug that you’re not normally aware of or not in your 
practice you want to know a couple of things, you want to know 
whether there are any contraindications, you want to know whether 
there are any adverse effects that you should make the patient 
aware of and you should be aware of and also whether there are 
any particular interactions and those are the typical bits that you 
would look up in a BNF. So we would want a formulary to provide 
what an eBNF would do, but in a much more, sort of, user-friendly 
way and locally what’s there otherwise the eBNF itself is there. 
 
Interviewer: Yes, that’s right. And do you feel with the Prescribing Guide as it is 
currently, do you feel that it has the potential to have a lasting, sort 
of sustained impact on prescribing practice? 
 
Consultant: I think to influence prescribing practices, you know you have to 
keep it updated at the frequency that the BNF is updated so almost 
three or four times a year and it would also have to believe in more 
evidence and especially more links to particular papers and other 
things where anybody who doesn’t know everything about a 
particular thing would want to be updated on and I think unless that 
is kept up-to-date which I’m sure involves a lot of work, will involve a 
lot of work, it would lose its impact. You know for me if I knew that it 
wasn’t updated more than once each year then I wouldn’t want to 
look at it again because you know that if I go on to any of these 
evidence-based websites or speciality college websites you can get 
to evidence which is much more advanced or recent and I like to, or 
we all like to sort of keep abreast of the developments in our areas 
so in order for it to be relevant in the future and not just a good idea 
in the beginning I would want it continuously updated. And the other 
feature… 
 
 TELEPHONE CALL – INTERVIEW PAUSED 
 
Consultant: Yes the bit I was going on to is that umm, you know if you open 
each section of the formulary, if on that section you had a, an alert, 
either alert or an update or change, say the NICE guidelines in that 
area had been updated or changed or current recommendations or 
there’s been an NPSA alert in that particular area, if that comes up 
as a, an item, you know, somewhere on that page, umm, that also 
gives it a sort of real time advantage. You see instead of being a 
repository of information that you refer to when in doubt, to make it 
more interactive or make it more reliable with something like if I log 
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in to it or if I open a page I would get an update of what’s happened 
in the last sort of couple of months in that particular area. So 
basically new evidence or new guidelines maybe new, I don’t mean 
new research but new sort of updates. 
 
Interviewer: So, not anecdotal things. 
 
Consultant: No not anecdotal. 
 
Interviewer: So do you mean finalised, approved and ratified guidelines whether 
that’s NICE then? 
 
Consultant: Yeah, could be NICE, could be speciality guidelines like the British 
Hypertensive Society, umm, other things like that. You know, every 
guideline has a page at the front which says you know, summary of 
changes which just highlight to you the bits you need to know about. 
So if the guidelines have changed, instead of me having to go 
through the whole guideline to understand what changes there are, 
if there’s a box on that page which says you know, asthma 
guidelines update, NICE and you know one, two, three four, these 
are the changes that are there. So you have to make it relevant you 
see, otherwise I would seek that information elsewhere. 
 
Interviewer: Right I see. So just going back to your earlier point, you’re saying 
that you want to know that it has evidence, umm, because that drug 
appears, even if it has a Pharmacist button, and you’ve seen those 
haven’t you, you click on those and they link to NICE guidelines and 
abstracts or summaries of meta-analyses for example? 
 
Consultant: Yes, I have seen those. 
 
Interviewer: But even if it didn’t have that, the drugs that appear on the 
formulary, they’ve been subjected to you know, evidence-based 
review so would… 
 
Consultant: Where, where would that evidence-based review have been done? 
 
Interviewer: Well, it would have been done by the formulary department with the 
New Drugs and Formulary Committee, so my question is, and just 
by seeing the drug on the formulary that would not… 
 
Consultant: I would not, I wouldn’t. I mean I have, seen nothing up till now in my 
practice that would give me the confidence that each drug, by 
appearing on the formulary is evidence-based. See, the problem is 
even NICE which has a very transparent process of approving, so 
everything NICE does, you can see and even there you will see that 
the amount of controversy that the NICE guidelines generate in 
different speciality areas when it comes down to it, because there 
are stakeholders in NICE compared to a meta-analysis which is 
pure evidence, scientific evidence, NICE fits in other factors like 
stakeholder factors so economy, logistics umm, management you 
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know other issues which, and affordability <<emphasis and use of 
hands as speech marks>> and other things which are not, so if you 
showed me a meta-analysis which is published in a front line 
journal, a top line journal, that would be pure evidence, that wouldn’t 
take in accounts of local people and their budgets so I would have a 
great trust in that, in a good journal obviously. 
 
Interviewer: So do you mean, you would have more trust in that than in NICE? 
 
Consultant: Oh yes, for sure <<emphasis, leaning forward>>. Because I know 
that the NICE process involves the logistics and economic factor. 
And the economic factors are thresholds which are set arbitrarily. 
So it not based on, it based on affordability and it’s not based on 
effectiveness. 
 
Interviewer: Okay, so is that perhaps how you feel about the New Drugs and 
Formulary committee? 
 
Consultant: I don’t know. What I feel about the New Drugs and Formulary 
Committee is that I don’t see any transparency, umm NICE I can 
see the transparency, NICE guidelines are published, NICE 
evidence and discussion is published, you can see it, the NDF 
Committee’s discussions there is no transparency, there is no 
publication of minutes of NDF Committee discussions on a website 
or somewhere everyone can see it and that doesn’t give me 
confidence in the process, you see, so I need you know, what I’m 
trying to say is even if NICE, you know NICE have their own set 
criteria for approval which is published for people to see, even that 
generates a huge amount of discussion and debate when NICE 
comes up with a guidelines. So how can you expect the, us, you 
know without any transparency, without any evidence being 
produced, if the NDF Committee comes up with something which I 
would believe not to be evidence-based based on my review of the 
literature which may not be a meta-analysis but you know I have to 
make a personal decision on that sort of thing, so I have to base it 
on my understanding of the literature, I have to base it on published 
reviews and, and other things like and, and international guidelines 
so from there the NDF Committee is like a black box, so doctors just 
don’t like black boxes, umm, you know I just can’t have a black box. 
You know, because we are continuously supposed to be evaluating 
and updating our decision making process and the decision making 
process depends on you know literature, depends upon your 
patient’s you know benefits, depends on your understanding of the 
literature and all that so, umm, it’s a diffuse process but my main 
contention is the lack of transparency, the lack of publication of 
minutes, I, I, don’t see why minutes are not published or if minutes 
are not published for everybody to see, they should be available 
internally you know within the Trust website, that would give me 
confidence, if I knew why the decision was taken if I knew what 
discussion actually happened, if there were minutes you could 
actually refer to which were then concrete and sent out, I would 
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have a trust in that system, without that, I don’t know what happens. 
I just can’t trust a black box. 
 
Interviewer: Okay, before we move on, you mention your views about hospital 
formularies and the Prescribing Guide, do you feel its patient 
focused? 
 
Consultant: I don’t see that formularies need to be patient focused. 
  
Interviewer: Right, are you saying they don’t need to be or that they are not? 
 
Consultant: You see, everything we do is patient focused. I don’t know what you 
mean by patient focused, like in research if I say patient focused I 
would include lay members or patients’ representatives within our 
decision making process. Umm, the problem here, is that you need 
to have pharmaceutical guidelines or formulary stuff depends on 
hard evidence, not only hard evidence on effectiveness, but also 
hard evidence of you know half-lives, and clearance and others, 
and that, I don’t see how patient focused comes in here. It’s all for 
patients, it’s all for the benefit of patients but beyond that I don’t 
know what else you mean.  
 
Interviewer: Well, I guess what I’m trying to get to is, do you feel the NDF 
decisions prioritise the patient or not? 
 
Consultant: I don’t know about that really. The problem is that I don’t know very 
much about what actually happens there because I just don’t see 
anything. So I wouldn’t want to judge it, but I would, umm, from my 
personal experience is that I find umm, practices or drugs which are 
licensed or evidence based and good practice units, big units 
around the world and around the country are not having the same 
treatment locally and umm, I cannot see why. I cannot see that it is 
down to evidence, umm, or the lack of it, because the evidence, we 
have supplied. But that’s a different issue, my main contention 
would be that would I trust everything that the NDF Committee 
approves as gold standard evidence, not at present. I would want to 
verify and check and verify again each of those information 
independently or from independent sources before I actually 
accepted that. 
 
Interviewer: Okay, I’ll move on to talking about prescribing practice in general 
and the influences on practice. What do you think are the main, or 
the top say few influences on prescribing for doctors? 
 
Consultant: I would say that the first, umm, I can’t, I can’t tell you one two three 
four five but I would say the most important are and I’ve looked at 
this before in my research and I found that peers, umm, or umm, it’s 
not called peer-pressure but it’s peer-usage, so if I knew of the 
drugs that are used by my peers in different parts of the country and 
by especially peers in tertiary centres where they are at a cutting 
edge of research, that make, that would be my sort of, I would rate it 
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as one of my highest reasons, umm, which would influence my 
practice so, which is why I always look at things like the Royal 
Brompton and all others, so whatever those units are doing umm, at 
the cutting edge I would consider that influential and when we 
looked at it for doctors that is one of the important factors. Second 
is obviously evidence from publications so the, we, all of us, we can 
produce a small list of publications that are key to our own area of 
practice and anything that comes up there for example the N-
acetylcysteine paper in the New England Journal of Medicine, now 
that’s a key paper and that’s a very good quality paper for umm, 
good quality evidence and that would change my practice so clear 
evidence in prime journals which we would be scanning regularly 
would make an influence. The third thing would be 
recommendations or new data presented at conferences and we all 
do one or two international conferences a year where you go and 
attend the sort of year-in review or update and sessions which is 
basically a synopsis of what the latest evidence is in the last year so 
I would be sitting there in asthma, and COPD and sleep and other 
areas then listening to you know the key presentations in those 
areas and I take back from there the key areas of development in, 
in that. So those are the three most important, umm influences. And 
then patient preferences always umm, come into this picture, say if 
a patient is on aminophylline, I know aminophylline does a great 
jobs but I know that patients hate it, so I would have to, I would 
encourage people but I would have to tailor my practice to that sort 
of thing. And after that I would put down representatives, umm, 
representatives coming and pushing… 
 
 TELEPHONE CALL – INTERVIEW PAUSED 
 
Consultant: Sorry about that. So, yeah what I was saying about representatives, 
you know there are drugs where you have a lot of pressure from 
representatives visiting, it has a, it has an effect of bringing that 
particular drug to the top of your list. 
 
Interviewer: Sorry, do you mean medical representatives? 
 
Consultant: Yes. If a medical representative of a particular drug that I don’t 
normally use for instance, comes along and umm, tries to tell me 
the advantages of that particular drug and all, it has an effect 
although you know, we never take that on face value and unless it’s 
supported by good quality evidence. It has the effect of bringing it to 
the top of your list in my, and you know, I’m sure this has been 
researched before. Umm, and the way to balance that like we all 
individuals do is by making sure that you have exposure to the 
whole range, rather than one particular agent and umm, you know, 
then sometimes as busy consultants do, and you know I personally 
don’t do it, but I know others do, which is to say that well if you think 
this particular drug is better than the other well present that 
information to the alternative representative and say well you know, 
produce the evidence. So you know, when I see somebody, I 
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always say you know, send me the actually papers which the 
medical information bits of the, generally send them and I like to 
read them and often you have access to some papers which you 
wouldn’t have otherwise, through our NHS system, so it’s an 
advantage in getting to look at the evidence. 
 
Interviewer: Okay, that’s interesting, you’ve mentioned quite a few influences 
there, where would you say the Prescribing Guide might slot in and 
have an impact? 
 
Consultant: I don’t think the Prescribing Guide would influence initiation of 
prescribing, I mean I don’t see it that way so I wouldn’t look at the 
Prescribing Guide as something to find out what I would do in this 
area, I wouldn’t look at it that way umm, I would look at it purely to 
see, okay I know, I need this particular drug let us see the offers 
from the family of drug, is available in this thing. So I would look at it 
at that step. 
 
Interviewer: So, because we have first line, second line, third line… 
 
Consultant: I would not look at it that way, you know which one is first line 
second line here, having made a decision about the family of drugs 
or the class of drugs previously but that decision of the class of 
drugs like say using an ACE inhibitor in somebody with 
hypertension, I wouldn’t get to that decision by looking at the 
formulary guide, that decision would come from the evidence base. 
I would just only purely look at that to see which particular agent we 
have on formulary. 
 
Interviewer: Let’s say for example, keeping with your example, say you’ve been 
to a conference and you’ve looked at papers and you’ve made your 
decision that out of all the ACE inhibitors you would like to use 
perindopril but our formulary says it’s amber and ramipril is first line, 
what would you use first? 
 
Consultant: I mean it depends on how good the evidence is, if the evidence 
shows that there is a clear advantage and that is a view that is held 
by my peers, you know and by the speciality society that you know, 
I belong to, the British Thoracic Society, if the BTS thinks that one is 
particularly better than the other then I, my view would be that I 
don’t care whether it’s there or not, I’ll prefer this agent because you 
would want to use the one that is best but if there was no sort of, set 
of clear guidelines from the speciality societies or the peers, so you 
know, the professors I bump into at the conferences or at 
presentations, umm, are not showing clear evidence or benefits for 
the other then I will choose the one that is available on the 
formulary. 
 
Interviewer: Okay, so have you ever requested a drug from formulary and hasn’t 
been approved? 
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Consultant: I can name you six, or seven umm or eight or ten <<laughs while 
shaking head>>.  
 
Interviewer: So the outcome with all these was that they were not approved? 
 
Consultant: Yes. I mean, that is always <<emphasis>> the case, it is always 
<<heavier emphasis>> the case and I’m sure this applies to other 
departments too. 
 
 TELEPHONE CALL – INTERVIEW PAUSED 
  
Interviewer: So I suppose we were touching on the issue of conflicts… 
 
Consultant: It’s, its’ not conflicts, I, I umm, I don’t think it’s a conflict, I think it’s 
just a hurdle you know, umm, and umm, and the difficulty is that the 
hurdles are not transparent and that makes it transparent. You see, 
so if it was an open process whereby evidence was presented, 
minutes were recorded, minutes which I could review, and umm I 
would have an opportunity to refute or support the application either 
in person or in writing and then it would be fine but because it’s a 
closed door system and perhaps it’s not intended to be, it just so 
happens that there is a lack of clarity in the process and that not 
sort of understanding why and when you talk to your colleagues in 
your speciality nobody can understand why, so that’s umm, umm, 
one factor. I mean, more recently, if I just take an example about 
one particular drug, the umm, say tiotropium and the latest advice 
from the NDF Committee was that tiotropium and combination 
drugs in patients with moderate to severe COPD should not be 
used together. Now, that’s come from our NDF Committee, in a 
letter from the Chief Pharmacist to me saying that is the NDF 
Committee’s view. Now, I would be alarmed by that view because 
internationally, COPD guidelines, evidence based guidelines, 
national guidelines, NICE guidelines all say something which our 
NDF Committee are coming out and saying, no. 
 
Interviewer: So why have the NDF Committee made this decision? 
 
Consultant: I don’t know. I would be alarmed by that and I don’t know why. I, I 
know that the constitution of the NDF Committee doesn’t include a 
respiratory person at all and I would be very worried if a committee 
is countering, counteracting something which appears in national 
and international guidelines and locally, without any local 
representation. Now I would have very little confidence in that 
committee for that reason so that’s one sort of, sort of glowing 
example of something that I particularly don’t understand and if that 
meant that our COPD patients in this particular area do not get the 
benefit of tiotropium combined with combination inhaler I would say 
that they are getting a very poor service and I would want to take 
that up, take that forward because I would say that is contravening 
standard national and international guidelines. Now obviously such 
examples are not going to be many, but I worry about the 
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constitution, I worry about the process of the NDF Committee’s 
decision making and I’d like really to see how the decision making is 
done, how robust is the decision making process and what are the 
conflicts of interest of the constitution, of the members of that 
committee. 
 
Interviewer: I understand, you said you wouldn’t class the Prescribing Guide in 
terms of influence, very highly, how do you feel about the NDF 
Committee in the same respect? 
 
Consultant: I wouldn’t be influenced in my prescribing practice by the NDF 
Committee, no. 
 
Interviewer: You feel it’s interfering with your practice? 
 
Consultant: If it does, as it does in many cases, the GMC’s position is quite 
clear, that you have to bring it up, that the your primary 
responsibility for a doctor is to make sure that your patient gets the 
best, umm, best medicine or best practice now it doesn’t 
necessarily mean the most expensive one, it means the one that is 
the most evidence based or in your opinion the current best 
evidence. Now the problem with guidelines is that if they are four 
years old or three years old and there is more overwhelming new 
evidence available or something it is your duty as a doctor to keep 
yourself updated and also provide your patients with the current 
best practice. So that’s the GMC’s duty and I would fall back on that 
if there was a conflict in a situation. 
 
Interviewer: But wouldn’t you assume, if there was a review carried out by the 
NDF Committee for a drug that you had requested which was to 
appear in a guideline that you feel was out-dated, and your saying 
that there is all this new, overwhelming evidence, wouldn’t you 
assume that the new evidence had been looked at and taken in to 
account? 
 
Consultant: I would hope so but cannot say that I have confidence that it has 
been done that way and primarily because that evidence is never 
produced and you have an inherent mistrust of something you 
cannot see. Simple as that. 
 
Interviewer: Okay, just want to know what your feelings are, your perceptions of 
other healthcare professionals involved in drug therapy, 
pharmacists and non-medical prescribers, what do you think about 
their role in drug therapy? 
 
Consultant: I think the main limitation of non-medical prescribers, umm, and this 
applies to even junior doctors or early prescribers in, in doctors, so 
if you look at our foundation level doctors umm, is that umm, the 
application, the knowledge base which is necessary to make clinical 
management decisions or choose appropriate agents is not always 
that robust and it’s not robust for F1s, it’s not robust for F2s and I 
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would say from senior registrar onwards it would be a much more 
robust process, but umm, say in the first five years of passing out of 
medicine, I would consider them to be non-robust so they wouldn’t 
particularly have the breadth of knowledge necessary or the depth 
of knowledge necessary to make the right decisions and so I 
wouldn’t leave them unsupervised in their decision making process. 
Now the problem with umm, non-medical prescribers is that the 
courses, that the basic courses which underpin their qualification 
are not necessarily aimed at the same process so if you’re a 
pharmacist, yes you know everything, ins and outs of particular 
drugs but you’re you know, diagnostic ability or your 
pathophysiology umm, knowledge will not be up to the standard of a 
doctors because of the different courses and same with nurses, you 
know, nursing courses are designed to produce nurses, they are not 
designed to produce doctors.  
 
Interviewer: What about pharmacists in general? 
 
Consultant: Pharmacists in general, I would say the same thing. Pharmacists in 
general are not designed to be diagnosticians so they wouldn’t be 
designed to understand the diagnostic process umm, make a 
diagnosis, understand the pathophysiology and then choose a drug. 
They would have a very good understanding of what a drug does in 
a particular situation once that particular diagnosis has been made. 
So if I tell you this is tuberculosis, then you would know which drugs 
you would use for that, but to get the diagnosis of tuberculosis is the 
bit that I wouldn’t expect a pharmacist or a non-medical prescriber 
to be able to make. 
 
Interviewer: In terms of advising on the right drug… 
 
Consultant: Advising on the right drug for a pharmacist, yes, that is always there 
and that is always welcome and units which umm, like in my training 
period, there are units where a pharmacist is present on a ward 
round and that is a fantastic combination and I always want that 
because having that expertise on your, when you’re making your 
decision is very very good but unfortunately logistics would mean 
that we don’t get that information and when we don’t get that 
information we have to fall back on the BNF, so if I had 
<<pharmacist named>> on my ward round, which I’ve had one day I 
sort of would tell her, I’d turn to her and say okay you tell me what 
are the interactions here, what should we be watching out for and 
she would have her BNF out and she would look at that, so, it’s 
good you know, because that is what multidisciplinary is all about 
and I would welcome that and same thing you know, if there was a 
drug or an interaction that I wasn’t sure about I would put it down 
and want to pick up and ask one of your New Drugs and umm, your 
umm Medicines advisor, information to say look up and umm, what 
because there are things like umm, post hoc reports and post like 
umm… 
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Interviewer: Yes, post-marketing surveillance. 
 
Consultant: Yes, which we don’t normally have in publications and I’ve often 
asked Medicines Information people or perhaps colleagues of 
yours, can you ring up the company and find out this post 
surveillance data and just tell me whether this is something that has 
changed so that is a useful tool to have. 
 
 KNOCK AT DOOR – INTERVIEW PAUSED 
  
Consultant: Sorry about that. Yes, so it would be a significant advantage to have 
that and which is why I always prefer to have an interactive process 
rather than a pharmacist telling me that you can’t give this because 
it’s not approved by NDF Committee which then is designed to 
increase your blood pressure, a good banter, an interaction, 
evidence exchange, colleague to colleague is good which is why I 
always tell my, whenever I get a call from pharmacy I tell them 
please can you get one of your senior pharmacists to talk to me 
because that way I can have a conversation, I can’t have a 
conversation with a junior pharmacist because they’re 
understanding is very low and they are very restricted and it just 
makes a mockery of the whole process. 
 
Interviewer: Okay, right, last question now. Could you describe a time when you 
experienced some, as you put it earlier, hurdles, somewhere when 
you felt your prescribing was limited and perhaps what could be 
done to improve the system? 
 
Consultant: Well, there are two clear examples. The first example is modafinil 
and the second example is ropinirole. Now both of these drugs are 
licensed, umm, fully licensed from the indications that they are used 
for, both these drugs are available in the formulary, in this Trust to 
other users and umm, something which is evidence based which 
has got a clear marketing license, umm, clear license to usage is 
not available to use for me, umm, and that I find absolutely 
appalling and I find it completely, absolutely impossible to, to accept 
the situation like that. If it was a drug which had never been used 
before and I was wanting to introduce that, yes I would go through 
that whole process, you know that whole application process for 
that and I would produce the evidence, umm, in situations where a 
drug is fully licensed, and a drug is available for use by others and 
I’m not allowed to use it, three years or four years into running a 
sleep service for example in this particular area, umm, I find it 
appalling. Now, if you look at the amount of work I have to do, in 
terms of clinical work, actual patient work, the time I have available 
to sit down and produce a voluminous application process for things 
which are done and dusted by others around the world and 
internationally, I mean I just don’t have that time and umm, okay 
you can understand there is a process and there is a protocol and 
you try and do that, you know three or four times and then to come 
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back and firstly not give me an evidence based answer and to come 
back and say we have never looked at it or we have looked at it and 
the Committee didn’t approve it, for what reason we don’t know and 
stuff is very frustrating. So I would say those two are clear conflicts 
<<emphasis using heavy intonation and hands>>. Now if I was 
introducing a drug which had never been used before, I would 
understand the process but what I do not understand is something 
which is approved, licensed, available in the, the thing is but not for 
this indication and there the reluctance of the Committee to approve 
that drug and producing hurdles and making it four years into 
approving modafinil, I mean I have been doing a sleep clinic for four 
years and modafinil is till not approved. Ropinirole, licensed, the 
only licensed drug in umm, in restless leg syndrome, I still cannot 
use it but others can use it, I don’t understand this. 
 
Interviewer: I think ropinirole has two licensed indications. 
 
Consultant: It is licensed for restless leg syndrome. 
 
Interviewer: Oh yes I know, but I think it’s only licensed for Parkinson’s here. 
 
Consultant: Why would it not be licensed for restless legs, you know when, 
internationally and nationally it’s licensed for that use and there are 
clear guidelines for how it should be used, I don’t understand. So 
you see, just by creating these hurdles my understanding is that it 
delays the whole process and it has done it successfully, four years 
into a sleep clinic I can’t still prescribe the drug I would consider 
essential.  
 
Interviewer: So do you mean that you actually requested this four years ago? 
 
Consultant: I’ve requested for it about three times and I don’t know what’s 
happened. Three months later you discover that it hasn’t happened 
and then you get a request to put in another one, then you get a 
request to put in a fast-track one, then you do it again, and do it 
again and then three years later you’re still in the same place and I 
still cannot use it. Melatonin, modafnil and ropinirole, I cannot use 
and I see 600 hundred patients in a clinic, new patients every year, 
why? Don’t understand <<emphasis then big (loud) sigh>>.  
 
Interviewer: Hmm, I see, so umm do you maybe umm not feel it necessary for 
the formulary to rationalise the use of drugs… 
 
Consultant: Well, I mean I don’t understand, you know, would you rationalise 
salbutamol in asthma? You know, and I don’t understand that, I 
mean what is the conflict? I mean are there five different drugs that 
are to be used in chrono-biological sleep disorders? No, it’s only 
melatonin. What other drug is available for day time sleepiness, 
okay there is modafinil and dexamphetamines they are available, 
but modafinil is the clear leader over the others because of side 
effects, do you understand and it is licensed and still <<forceful 
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hand and face gestures, leaning forward and emphasis in voice>> 
so, you know, I can’t understand it. And I don’t know where it stands 
now, I don’t know, what is the procedure? Every three months or so, 
I will give it a go and after that see if it has been approved but then 
it comes back to me, you know, saying sorry, you know it hasn’t 
been approved. 
 
Interviewer: So, are you saying that if there’s a drug you want to use and if it’s 
been licensed by the MHRA and whether it has… 
 
Consultant: If it has a clear presence in national guidelines, it shouldn’t require, 
or there should be no hurdles. If it’s a drug which is not in national 
guidelines, which is something which is new, which is not licensed 
for use in this particular area I can understand the position. What I 
cannot understand is, when the drugs which are licensed, which are 
in national guidelines, evidence based national guidelines, I don’t 
see why those drugs have to be fought for locally and I would 
question the integrity of the Committee and it’s constitution to see 
why it’s happening, you know, so I can’t understand that process at 
all. 
 
Interview: Right, Okay, I think I’ll leave it there, you’ve given me more than half 
an hour, thank you very much. 
 
 
 
